category	mir	disease	pmid	root_name	doid	icd10cm	mesh	omim	hpo	description
circulation_biomarker_diagnosis_down	hsa-mir-210	Acute Cerebral Infarction	25476086	cardiovascular system disease	DOID:3526	I63	D002544			The serum level of miR-210 in ACI was significantly lower than that in normal healthy persons, and it may be an important new serological marker in screening and diagnosis of ACI.
circulation_biomarker_diagnosis_down	hsa-mir-126	Acute Heart Failure	26580972			I50				Levels of miR-126  and miR-423-5p were lower in AHF and in non-AHF patients compared to stable CHF patients (both p<0.001).
circulation_biomarker_diagnosis_down	hsa-mir-27a	Acute Heart Failure	26569364			I50				The increase in creatinine during the first 3 days of hospitalization was significantly associated with lower levels of miR-199a-3p, miR-27a-3p, miR-652-3p, miR-423-5p, and miR-let-7i-5p
circulation_biomarker_diagnosis_down	hsa-mir-335	Acute Ischemic Stroke	27856935	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Decreased plasma miR-335 expression in patients with acute ischemic stroke and its association with calmodulin expression.
circulation_biomarker_diagnosis_down	hsa-mir-214	Acute Myocardial Infarction	25931214	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	The circulating level of miR-214 was significantly decreased in the AMI group, which might be correlated with the extent of the coronary lesion.Circulating miR-214 may be a promising biomarker for the diagnosis and prognosis of severe AMI.
circulation_biomarker_diagnosis_down	hsa-mir-181a	Allergic Rhinitis	27199509	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	The OPN protein and miR-181a levels may serve as predictors of disease severity in childhood AR and appear to be promising targets for modulating AR.
circulation_biomarker_diagnosis_down	hsa-let-7f	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-1285	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-107	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-103a	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-26b	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-26a	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-532	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_down	hsa-mir-143	Alzheimer Disease	26078483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Alzheimer Disease	26078483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls.
circulation_biomarker_diagnosis_down	hsa-mir-31	Alzheimer Disease	26078483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls.
circulation_biomarker_diagnosis_down	hsa-mir-590	Alzheimer Disease	21548758	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Decreased relative expression levels of hsa-miR-590-3p in blood cells was observed in patients with AD versus controls. hnRNP-A1 and its transcription regulatory factor miR-590-3p are disregulated in patients with AD, and the hnRNP-A1 rs7967622 C/C genotype is likely a risk factor for FTLD in male populations.
circulation_biomarker_diagnosis_down	hsa-mir-93	Alzheimer Disease	26078483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients'serum compared with controls.
circulation_biomarker_diagnosis_down	hsa-mir-4505	Anxiety Disorders	27423364	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	Results showed that the level of miR-4505 and miR-663 was negatively correlated with the  total HAMA scores in GAD patients (r=0.2228, r=0.264 P<0.05).
circulation_biomarker_diagnosis_down	hsa-mir-663	Anxiety Disorders	27423364	disease of mental health	DOID:2030	F41.9	D001008	607834	HP:0000739	esults showed that the level of miR-4505 and miR-663 was negatively correlated with the  total HAMA scores in GAD patients (r=0.2228, r=0.264 P<0.05).
circulation_biomarker_diagnosis_down	hsa-mir-106a	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-148a	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-204	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-211	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-30a	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-31	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-424	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-204	Aortic Valve Disease	28377507	cardiovascular system disease	DOID:62			PS109730		miR-486 inhibits Smurf2 expression to augment the miR-204 down-regulation
circulation_biomarker_diagnosis_down	hsa-mir-1	Arrhythmia	25625292			I49.9	D001145	600919	HP:0011675	patients with SVT had lower miR-1 expression levels while those with VT had higher miR-133 expression levels.
circulation_biomarker_diagnosis_down	hsa-mir-148a	Asthma	17847008	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Previously, we identified HLA-G as an asthma-susceptibility gene and discovered that the risk of asthma in a child was determined by both the child's HLA-G genotype and the mother's affection status. The activity of pluc-HLAG-G in the presence of each of the three miRNAs was significantly lower than those of pluc-HLAG-C and pluc-HLA-G-Del.
circulation_biomarker_diagnosis_down	hsa-mir-148b	Asthma	17847008	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Previously, we identified HLA-G as an asthma-susceptibility gene and discovered that the risk of asthma in a child was determined by both the child's HLA-G genotype and the mother's affection status. The activity of pluc-HLAG-G in the presence of each of the three miRNAs was significantly lower than those of pluc-HLAG-C and pluc-HLA-G-Del.
circulation_biomarker_diagnosis_down	hsa-mir-152	Asthma	17847008	respiratory system disease	DOID:2841	J45	D001249	600807	HP:0002099	Previously, we identified HLA-G as an asthma-susceptibility gene and discovered that the risk of asthma in a child was determined by both the child's HLA-G genotype and the mother's affection status. The activity of pluc-HLAG-G in the presence of each of the three miRNAs was significantly lower than those of pluc-HLAG-C and pluc-HLA-G-Del.
circulation_biomarker_diagnosis_down	hsa-mir-126	Atherosclerosis	25975504	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-126 and miR-223 platelets were reduced in the rabbit atherosclerotic plaque model group
circulation_biomarker_diagnosis_down	hsa-mir-145	Atherosclerosis	19744308	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	downregulated
circulation_biomarker_diagnosis_down	hsa-mir-181b	Atherosclerosis	26420120	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The serum miR-181b level was significantly reduced in patients with atherosclerosis. miR-181b may function as an atherosclerosis suppressor by interupting the NF-κB pathway in endothelial cells and inhibiting the proliferation and migration of vascular smooth muscle cells.
circulation_biomarker_diagnosis_down	hsa-mir-181b	Atherosclerosis	25896908	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Hyperlipidemia reduced the expression of miR-181b and increased  NT and N/M ratio.
circulation_biomarker_diagnosis_down	hsa-mir-182	Atherosclerosis	27199451	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Atherosclerotic lesions from patients with high asymmetrical dimethylarginine plasma levels exhibited decreased miR-182-3p expression levels and elevated MYADM expression levels.
circulation_biomarker_diagnosis_down	hsa-mir-30	Atherosclerosis	27379414	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	circulating miR-30 might be used as a biomarker for atherosclerosis
circulation_biomarker_diagnosis_down	hsa-mir-181b	Autism Spectrum Disorder	25126405	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	MiR-151a-3p, miR-181b-5p, miR-320a, miR-328, miR-433, miR-489, miR-572, and miR-663a were downregulated, while miR-101-3p, miR-106b-5p, miR-130a-3p, miR-195-5p, and miR-19b-3p were upregulated.
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Autistic Disorder	20868653	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-181b:deregulated
circulation_biomarker_diagnosis_down	hsa-mir-363	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-363: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-486	Autistic Disorder	20868653	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-486:deregulated
circulation_biomarker_diagnosis_down	hsa-mir-92a-1	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-92a-1: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-92a-2	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-92a-2: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-1	Bladder Neoplasms	25015192			C67	D001749	109800	HP:0009725	Hsa-miR-1 downregulates long non-coding RNA urothelial cancer associated 1 in bladder cancer.
circulation_biomarker_diagnosis_down	hsa-mir-107	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-10b	Breast Neoplasms	16466964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-125b-1	Breast Neoplasms	16466964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-125b-2	Breast Neoplasms	16466964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-143	Breast Neoplasms	17940623	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines.
circulation_biomarker_diagnosis_down	hsa-mir-145	Breast Neoplasms	16466964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-145	Breast Neoplasms	16885332	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Reduced expression in breast cancers
circulation_biomarker_diagnosis_down	hsa-mir-145	Breast Neoplasms	17940623	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines.
circulation_biomarker_diagnosis_down	hsa-mir-1469	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-1471	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-17	Breast Neoplasms	17442096	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In breast cancer cells, mir-17-5p expression is decreased.
circulation_biomarker_diagnosis_down	hsa-mir-17	Breast Neoplasms	17965831	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-17-5p was down-regulated in breast cancer cells, and enhanced expression decreased tumour cell proliferation.
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Breast Neoplasms	22692639	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Decreased serum miR-181a is a potential new tool for breast cancer screening.
circulation_biomarker_diagnosis_down	hsa-mir-182	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-1915	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-193a	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-193a-3p is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-195	Breast Neoplasms	25103018	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.
circulation_biomarker_diagnosis_down	hsa-mir-200c	Breast Neoplasms	27197674	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas  miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed.
circulation_biomarker_diagnosis_down	hsa-mir-21	Breast Neoplasms	23052693	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer
circulation_biomarker_diagnosis_down	hsa-mir-210	Breast Neoplasms	27197674	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas  miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed.
circulation_biomarker_diagnosis_down	hsa-mir-222	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-222: decreased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_down	hsa-mir-2355	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-24-1	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-24-2	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-30a	Breast Neoplasms	23389917	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	plasma; plasma miRNA-30a decreased in patients with BC and has great potential to use as novel biomarkers for BC diagnosis
circulation_biomarker_diagnosis_down	hsa-mir-3130-1	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-3130-2	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-3186	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-526a-1	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-526a-2	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-625	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-625* is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-718	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-874	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is down-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_down	hsa-mir-92a-1	Breast Neoplasms	23052693	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer
circulation_biomarker_diagnosis_down	hsa-mir-92a-2	Breast Neoplasms	23052693	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer
circulation_biomarker_diagnosis_down	hsa-mir-100	Carcinoma, Adrenocortical	21472710	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	miRs -100, -125b, and -195 were significantly down-regulated, whereas miR-483-5p was significantly up-regulated in malignant as compared with benign tumors.
circulation_biomarker_diagnosis_down	hsa-mir-218	Carcinoma, Esophageal	25812647	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The serum expression of miR-218 is downregulated in esophageal cancer patients and is correlated with tumor differentiation, stage, and lymph node metastasis. Serum miR-218 may be a potential biomarker for early detection and clinical evaluation in patient with esophageal cancer.
circulation_biomarker_diagnosis_down	hsa-let-7e	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Independent observations showed that the expression of miRNAs let-7e, 125a and 99b, located at 19q13.4, were considerably lower in HCC compared to nontumor liver [59] and [65]. Given that miRNA-125a targets expression of the mitochondrial tumor suppressor gene, MTSG1, and RAR|ив, chromosomal instability in and around FRA19A may extinguish expression of these tumor suppressor genes.
circulation_biomarker_diagnosis_down	hsa-mir-125a	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Independent observations showed that the expression of miRNAs let-7e, 125a and 99b, located at 19q13.4, were considerably lower in HCC compared to nontumor liver [59] and [65]. Given that miRNA-125a targets expression of the mitochondrial tumor suppressor gene, MTSG1, and RAR|ив, chromosomal instability in and around FRA19A may extinguish expression of these tumor suppressor genes.
circulation_biomarker_diagnosis_down	hsa-mir-127	Carcinoma, Hepatocellular	18942116	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-127: Down-regulation during hepatocarcinogenesis induced by a methyl-deficient diet
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Carcinoma, Hepatocellular	21278583	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-16-2	Carcinoma, Hepatocellular	21278583	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-199a-1	Carcinoma, Hepatocellular	21278583	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-199a-2	Carcinoma, Hepatocellular	21278583	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01).
circulation_biomarker_diagnosis_down	hsa-mir-200b	Carcinoma, Hepatocellular	18942116	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-200b: Down-regulation during hepatocarcinogenesis induced by a methyl-deficient diet
circulation_biomarker_diagnosis_down	hsa-mir-21	Carcinoma, Hepatocellular	21749846	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	In the 10-patient group, plasma microRNA-21 levels significantly diminished after surgery compared with the pre-operative values (p=0.0125). Plasma microRNA-21 level in the 126 patients with hepatocellular carcinoma was significantly higher than in patients with chronic hepatitis and healthy volunteers (p<0.0001, p<0.0001, respectively). ROC analysis of plasma microRNA-21 yielded an AUC of 0.773 with 61.1% sensitivity and 83.3% specificity when differentiating hepatocellular carcinoma from chronic hepatitis, and an AUC of 0.953 with 87.3% sensitivity and 92.0% specificity when differentiating hepatocellular carcinoma from healthy volunteers.
circulation_biomarker_diagnosis_down	hsa-mir-34a	Carcinoma, Hepatocellular	18942116	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-34a: Down-regulation during hepatocarcinogenesis induced by a methyl-deficient diet
circulation_biomarker_diagnosis_down	hsa-mir-99b	Carcinoma, Hepatocellular	17188425	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Independent observations showed that the expression of miRNAs let-7e, 125a and 99b, located at 19q13.4, were considerably lower in HCC compared to nontumor liver [59] and [65]. Given that miRNA-125a targets expression of the mitochondrial tumor suppressor gene, MTSG1, and RAR|ив, chromosomal instability in and around FRA19A may extinguish expression of these tumor suppressor genes.
circulation_biomarker_diagnosis_down	hsa-mir-125b	Carcinoma, Hepatocellular, HBV-Related	27152955							The levels of plasma miR-125b were remarkably decreased in HBV-HCC patients compared to healthy controls
circulation_biomarker_diagnosis_down	hsa-mir-106a	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-146b	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-17	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-223	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	Reduced plasma expression of let-7b was modestly associated with worse cancer-specific mortality in all patients and reduced serum expression of miR-223 was modestly associated with cancer-specific mortality in stage IA/B patients.
circulation_biomarker_diagnosis_down	hsa-mir-27a	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_down	hsa-mir-361	Carcinoma, Lung, Non-Small-Cell	22675530			C34.90	D002289		HP:0030358	Low levels of cell-free circulating miR-361-3p and miR-625* could be blood-based markers for discriminating malignant from benign lung tumors.
circulation_biomarker_diagnosis_down	hsa-mir-625	Carcinoma, Lung, Non-Small-Cell	22675530			C34.90	D002289		HP:0030358	Low levels of cell-free circulating miR-361-3p and miR-625* could be blood-based markers for discriminating malignant from benign lung tumors.
circulation_biomarker_diagnosis_down	hsa-let-7a-1	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7a-1	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-let-7a-2	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7a-2	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-let-7a-3	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7a-3	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-let-7b	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7c	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7d	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7e	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7f-1	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7f-1	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-let-7f-2	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7f-2	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-let-7g	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-let-7i	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-mir-141	Carcinoma, Renal Cell	18925646	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-141: down-regulation
circulation_biomarker_diagnosis_down	hsa-mir-142	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-142-5p: Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-150	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-19a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-200c	Carcinoma, Renal Cell	18925646	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-200c: down-regulation
circulation_biomarker_diagnosis_down	hsa-mir-219	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-219-5p: Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-26a-1	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-mir-26a-2	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-mir-302b	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-302c	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-30c-1	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-mir-30c-2	Carcinoma, Renal Cell	21229250	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	let-7 family, miR-30c, miR-26a are decreased in highly aggressive primary metastatic tumours.
circulation_biomarker_diagnosis_down	hsa-mir-367	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-381	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-451a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Down-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-508	Carcinoma, Renal Cell	22369946	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro.
circulation_biomarker_diagnosis_down	hsa-mir-509-1	Carcinoma, Renal Cell	22369946	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro.
circulation_biomarker_diagnosis_down	hsa-mir-509-2	Carcinoma, Renal Cell	22369946	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro.
circulation_biomarker_diagnosis_down	hsa-mir-509-3	Carcinoma, Renal Cell	22369946	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro.
circulation_biomarker_diagnosis_down	hsa-mir-1-1	Cardiomyopathy, Hypertrophic	17234972	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Significantly,the muscle-specific microRNA-1 (miR-1) was singularly downregulatedas early as day 1, persisting through day7, after aortic constriction Cinduced hypertrophy in a mouse model.
circulation_biomarker_diagnosis_down	hsa-mir-1-1	Cardiomyopathy, Hypertrophic	17468766	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-1-1	Cardiomyopathy, Hypertrophic	17479098	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue.
circulation_biomarker_diagnosis_down	hsa-mir-1-2	Cardiomyopathy, Hypertrophic	17234972	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Significantly,the muscle-specific microRNA-1 (miR-1) was singularly downregulatedas early as day 1, persisting through day7, after aortic constriction Cinduced hypertrophy in a mouse model.
circulation_biomarker_diagnosis_down	hsa-mir-1-2	Cardiomyopathy, Hypertrophic	17468766	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-1-2	Cardiomyopathy, Hypertrophic	17479098	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue.
circulation_biomarker_diagnosis_down	hsa-mir-133a-1	Cardiomyopathy, Hypertrophic	17468766	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-133a-1	Cardiomyopathy, Hypertrophic	17479098	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue.
circulation_biomarker_diagnosis_down	hsa-mir-133a-2	Cardiomyopathy, Hypertrophic	17468766	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-133a-2	Cardiomyopathy, Hypertrophic	17479098	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	The researchers showed that expression of miR-1 and another muscle-specific miRNA, miR-133, is decreased in human and mouse hypertrophic heart tissue.
circulation_biomarker_diagnosis_down	hsa-mir-126	Cardiovascular Diseases [unspecific]	28065883				D002318			Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy.
circulation_biomarker_diagnosis_down	hsa-mir-132	Cardiovascular Diseases [unspecific]	28065883				D002318			Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy.
circulation_biomarker_diagnosis_down	hsa-mir-320b	Carotid Artery Diseases	27460454			G45.1	D002340	147820	HP:0005344	Low serum miR-320b expression as a novel indicator of carotid atherosclerosis.
circulation_biomarker_diagnosis_down	hsa-mir-106b	Child Development Disorders, Pervasive	20374639			F84.9	D002659			down-regulation
circulation_biomarker_diagnosis_down	hsa-mir-106a	Cholangiocarcinoma	26534789	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Together, reduced expression of serum miR-106a is a powerful prognostic indicator for CCA patients. The dismal outcome of these CCA patients might correlate with a higher risk of lymph node metastasis.
circulation_biomarker_diagnosis_down	hsa-mir-150	Cholangiocarcinoma	27658773	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
circulation_biomarker_diagnosis_down	hsa-mir-194	Cholangiocarcinoma	26864161	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-483-5p and miR-194 showed deregulated expression in CC compared with controls.
circulation_biomarker_diagnosis_down	hsa-mir-483	Cholangiocarcinoma	26864161	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	whereas miR-483-5p and miR-194 showed deregulated expression in CC compared with controls
circulation_biomarker_diagnosis_down	hsa-mir-199b	Choriocarcinoma	19900756	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	miR-199b:Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma
circulation_biomarker_diagnosis_down	hsa-mir-155	Chronic Hepatitis B	27110261			B18.0-.1	D019694	610424		In the HBV-infected patients, the miR-155 levels were significantly lower than in the healthy controls
circulation_biomarker_diagnosis_down	hsa-mir-143	Colon Neoplasms	16195701			D12.6	D003110		HP:0100273	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-143	Colon Neoplasms	16885332			D12.6	D003110		HP:0100273	miR-143 and miR-145 expression is reduced.
circulation_biomarker_diagnosis_down	hsa-mir-143	Colon Neoplasms	16940181			D12.6	D003110		HP:0100273	Downregulation of Mir-143 and Mir-145 has been observed in colorectal cancer.
circulation_biomarker_diagnosis_down	hsa-mir-143	Colon Neoplasms	17940623			D12.6	D003110		HP:0100273	Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines.
circulation_biomarker_diagnosis_down	hsa-mir-145	Colon Neoplasms	16195701			D12.6	D003110		HP:0100273	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-145	Colon Neoplasms	16940181			D12.6	D003110		HP:0100273	Downregulation of Mir-143 and Mir-145 has beenobserved in colorectal cancer.
circulation_biomarker_diagnosis_down	hsa-mir-145	Colon Neoplasms	17940623			D12.6	D003110		HP:0100273	Studies have implicated other miRNAs in tumorigenesis. MiR-143 and miR-145, for instance, have been shown to be constantly down-regulated in colorectal tumors, and recent studies by Croce et al. also have shown that the downregulation of these miRNAs is a common occurrence in breast carcinomas and breast cancer lines.
circulation_biomarker_diagnosis_down	hsa-mir-221	Colorectal Carcinoma	29630521	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Following the overexpression of GAS5, the GAS5expressions was up-regulated and miR-221 expression was down-regulated; the rate  of cell proliferation, migration and invasion were decreased
circulation_biomarker_diagnosis_down	hsa-mir-143	Colorectal Carcinoma	16847880	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		reduced
circulation_biomarker_diagnosis_down	hsa-mir-143	Colorectal Carcinoma	19242066	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-143: only down-regulated in colon cancer but not in rectal cancer
circulation_biomarker_diagnosis_down	hsa-mir-145	Colorectal Carcinoma	16847880	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		reduced
circulation_biomarker_diagnosis_down	hsa-mir-145	Colorectal Carcinoma	19242066	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-145: down-regulated in both colon and rectal cancer
circulation_biomarker_diagnosis_down	hsa-mir-34a	Colorectal Carcinoma	22648208	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR-34a levels are reduced in colorectal cancer.
circulation_biomarker_diagnosis_down	hsa-mir-126	Coronary Artery Disease	29062343	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-126 expression was significantly down-regulated in the circulation of CAD patients compared with control subjects
circulation_biomarker_diagnosis_down	hsa-mir-126	Coronary Artery Disease	27321479	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		MiR-126 strongly associated with T2D and CAD
circulation_biomarker_diagnosis_down	hsa-mir-145	Coronary Artery Disease	25938589	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Lower plasma levels of miRNA-145 were significantly associated with the presence as well as severity of CAD. As a potential biomarker for CAD, plasma miRNA-145 may be useful in predicting CAD and its severity in patients presenting with chest pain.
circulation_biomarker_diagnosis_down	hsa-let-7b	Crohn Disease	24910152	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	Both inflamed and non-inflamed terminal ileal mucosa in adult patients with active CD have their distinct miRNA expression patterns compared with healthy controls. Dysregulated miRNAs may be responsible for pathogenesis of CD.
circulation_biomarker_diagnosis_down	hsa-mir-378	Dengue Virus Infection	26166761	disease by infectious agent	DOID:12205	A90	D003715	614371		This study found that miR-27a*, miR-30e, and miR-378 were down-regulated in DENV-infected patients
circulation_biomarker_diagnosis_down	hsa-mir-107	Diabetes Mellitus	24908639	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients.
circulation_biomarker_diagnosis_down	hsa-mir-126	Diabetes Mellitus	26299579	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Diabetes mellitus
circulation_biomarker_diagnosis_down	hsa-mir-126	Diabetes Mellitus	27005938	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Among those, miR-126 and miR-26a were significantly reduced in diabetic patients compared to non-diabetic patients.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Diabetes Mellitus	24908639	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients.
circulation_biomarker_diagnosis_down	hsa-mir-155	Diabetes Mellitus	26188366	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Downregulated microRNA-155 expression in peripheral blood mononuclear cells of type 2 diabetic patients is not correlated with increased inflammatory cytokine production.
circulation_biomarker_diagnosis_down	hsa-mir-15a	Diabetes Mellitus	26460159	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	These results demonstrated that peripheral blood miR-15a expression levels were significantly lower in patients with T2D and IFG/IGT individuals, compared with healthy individuals. Thus, miR-15a in peripheral whole blood may serve as a potential biomarker for T2D and pre-diabetes.
circulation_biomarker_diagnosis_down	hsa-mir-223	Diabetes Mellitus	24908639	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients.
circulation_biomarker_diagnosis_down	hsa-mir-375	Diabetes Mellitus	27383196	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	lower circulating levels of miR-192 and miR-375 compared to CD period
circulation_biomarker_diagnosis_down	hsa-mir-495	Diabetes Mellitus	24908639	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Hyperglycemia may downregulate the expressions of miR-223 and miR-146a, leading to subsequent platelet activation in patients with diabetes mellitus. Low platelet and plasma miR-223 and miR-146a expression is a risk factor for ischemic stroke in Chinese diabetes mellitus patients.
circulation_biomarker_diagnosis_down	hsa-mir-503	Diabetes Mellitus	21220732	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Deregulation of microRNA-503 Contributes to Diabetes Mellitus-Induced Impairment of Endothelial Function and Reparative Angiogenesis After Limb Ischemia.
circulation_biomarker_diagnosis_down	hsa-mir-146	Diabetes Mellitus, Type 1	24796653	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Decreased miR-146 expression in peripheral blood mononuclear cells is correlated  with ongoing islet autoimmunity in type 1 diabetes patients 1miR-146.
circulation_biomarker_diagnosis_down	hsa-mir-126	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-126	Diabetes Mellitus, Type 2	27321479	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	expression levels of circulating miR-126, determined by quantitative real time PCR, were decrease in peripheral blood of T2D patients and T2D with CAD compared  with healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Diabetes Mellitus, Type 2	25500583	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased serum anti-inflammatory miR-146a, increased pro-inflammatory IL-8 and increased HGF (a vascular/insular repair factor) as discriminating markers of failure of glucose control occurring on the  background of obesity and dyslipidemia.
circulation_biomarker_diagnosis_down	hsa-mir-155	Diabetes Mellitus, Type 2	25500583	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased serum anti-inflammatory miR-146a, increased pro-inflammatory IL-8 and increased HGF (a vascular/insular repair factor) as discriminating markers of failure of glucose control occurring on the  background of obesity and dyslipidemia.
circulation_biomarker_diagnosis_down	hsa-mir-15a	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-191	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-197	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-20b	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-21	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-223	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-24-1	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-24-2	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-320a	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-486	Diabetes Mellitus, Type 2	20651284	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	decreased in plasma
circulation_biomarker_diagnosis_down	hsa-mir-517a	Ectopic Pregnancy	22395025	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%).
circulation_biomarker_diagnosis_down	hsa-mir-519d	Ectopic Pregnancy	22395025	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%).
circulation_biomarker_diagnosis_down	hsa-mir-525	Ectopic Pregnancy	22395025	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%).
circulation_biomarker_diagnosis_down	hsa-mir-17	Endometriosis	23203215	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis
circulation_biomarker_diagnosis_down	hsa-mir-20a	Endometriosis	23203215	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis
circulation_biomarker_diagnosis_down	hsa-mir-20a	Endometriosis	27049094	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	For recurred cases, miR-199 showed a remarkably high expression and miR-17-5p and miR-20a expressed significantly low.
circulation_biomarker_diagnosis_down	hsa-mir-22	Endometriosis	23203215	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis
circulation_biomarker_diagnosis_down	hsa-let-7c	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-144	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-144*: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-193a	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-193a-5p and miR-193a-3p: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-193b	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-203	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-210	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-211	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-30a	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-30a-3p: downregulated
circulation_biomarker_diagnosis_down	hsa-mir-365a	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-375	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		The most downregulated miRNA, which strongly correlated with esophageal eosinophil levels.
circulation_biomarker_diagnosis_down	hsa-let-7d	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_down	hsa-mir-107	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_down	hsa-mir-148b	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_down	hsa-mir-146b	Fatty Liver, Non-Alcoholic	25232454	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miR-181d, miR-99a, miR-197 and miR-146b were significantly lower in biopsy-proven NAFLD patients than in the healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-155	Fatty Liver, Non-Alcoholic	27832630	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Decreased MiR-155 Level in the Peripheral Blood of Non-Alcoholic Fatty Liver Disease Patients may Serve as a Biomarker and may Influence LXR Activity.
circulation_biomarker_diagnosis_down	hsa-mir-29a	Fatty Liver, Non-Alcoholic	25232454	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miR-181d, miR-99a, miR-197 and miR-146b were significantly lower in biopsy-proven NAFLD patients than in the healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-203	Gastric Neoplasms	26233325	disease of cellular proliferation	DOID:10534	C16	D013274	137215		serum miR-203 levels were significantly lower in stage IV than stage I-III GC patients.
circulation_biomarker_diagnosis_down	hsa-mir-218-1	Gastric Neoplasms	22860003	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-218-2	Gastric Neoplasms	22860003	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-421	Gastric Neoplasms	22926798	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Gastric juice microRNA-421 is a new biomarker for screening gastric cancer.
circulation_biomarker_diagnosis_down	hsa-mir-101-1	Glioblastoma	21321380				D005909		HP:0100843	miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.
circulation_biomarker_diagnosis_down	hsa-mir-101-2	Glioblastoma	21321380				D005909		HP:0100843	miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.
circulation_biomarker_diagnosis_down	hsa-mir-342	Glioblastoma	21561454				D005909		HP:0100843	miR-342-3p: downregulated in the peripheral blood of glioblastoma patients.
circulation_biomarker_diagnosis_down	hsa-mir-205	Glioma	26230475	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
circulation_biomarker_diagnosis_down	hsa-mir-200a	Glomerulonephritis	20364043	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-200b	Glomerulonephritis	20364043	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-429	Glomerulonephritis	20364043	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-154	Graves Disease	22456620	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	The expression of miR-154*, miR-376b, and miR-431* were suppressed in PBMC (peripheral blood mononuclear cells) from initial GD patients. In addition, their expression levels were recovered in GD patients in remission.
circulation_biomarker_diagnosis_down	hsa-mir-376b	Graves Disease	22456620	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	The expression of miR-154*, miR-376b, and miR-431* were suppressed in PBMC (peripheral blood mononuclear cells) from initial GD patients. In addition, their expression levels were recovered in GD patients in remission.
circulation_biomarker_diagnosis_down	hsa-mir-431	Graves Disease	22456620	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	The expression of miR-154*, miR-376b, and miR-431* were suppressed in PBMC (peripheral blood mononuclear cells) from initial GD patients. In addition, their expression levels were recovered in GD patients in remission.
circulation_biomarker_diagnosis_down	hsa-mir-126	Heart Failure	21157109			I50	D006331		HP:0001635	The plasma concentration of miR-126 was negatively correlated with age and NYHA class, and could be a useful biomarker for heart failure
circulation_biomarker_diagnosis_down	hsa-mir-130b	Heart Failure	26211628			I50	D006331		HP:0001635	MiR-130b levels were reduced in obese HF patients compared with HF lean (P=0.036) and controls (P=0.025).
circulation_biomarker_diagnosis_down	hsa-mir-133	Heart Failure	23711953			I50	D006331		HP:0001635	In surgical CAD patients, a decreased miR-133 expression is associated with variables characteristic of heart failure.
circulation_biomarker_diagnosis_down	hsa-mir-16	Heart Failure	25033200			I50	D006331		HP:0001635	We provide evidence that miR-16 decreases in the circulation of end-stage HF patients and increases with a LVAD. Modeling studies suggest that miR-16 binds to and decreases expression of VPS4a. Overexpression of VPS4a decreases cell number. Together, these experiments suggest that miR-16 and VPS4a expression are altered in end-stage HF and in response to unloading with a LVAD. This signaling pathway may lead to reduced circulating cell number in HF.
circulation_biomarker_diagnosis_down	hsa-mir-27a	Heart Failure	28293796			I50	D006331		HP:0001635	Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations.
circulation_biomarker_diagnosis_down	hsa-mir-424	Hemangioma	21179471	disease of cellular proliferation	DOID:255	D18.0	D006391	602089		Down-Regulation of mir-424 Contributes to the Abnormal Angiogenesis via MEK1 and Cyclin E1 in Senile Hemangioma: Its Implications to Therapy.
circulation_biomarker_diagnosis_down	hsa-mir-155	Hepatitis C Virus Infection	22846613	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection.
circulation_biomarker_diagnosis_down	hsa-mir-106b	Human Immunodeficiency Virus Infection	26755399			B20	D015658	609423		we found that the miRNAs miR-106b and miR-20a that target p21  were specifically downregulated in HIV-1 infected CD4+ T cells.
circulation_biomarker_diagnosis_down	hsa-mir-125b-1	Human Immunodeficiency Virus Infection	21224041			B20	D015658	609423		heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects
circulation_biomarker_diagnosis_down	hsa-mir-125b-2	Human Immunodeficiency Virus Infection	21224041			B20	D015658	609423		heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects
circulation_biomarker_diagnosis_down	hsa-mir-150	Human Immunodeficiency Virus Infection	21224041			B20	D015658	609423		heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects
circulation_biomarker_diagnosis_down	hsa-mir-181a	Human Immunodeficiency Virus Infection	27171002			B20	D015658	609423		hsa-miR-155 and hsa-miR-181a were downregulated in VP whereas in the other groups, either an upregulation or no differences were observed after stimulation, respectively.
circulation_biomarker_diagnosis_down	hsa-mir-20a	Human Immunodeficiency Virus Infection	26755399			B20	D015658	609423		we found that the miRNAs miR-106b and miR-20a that target p21  were specifically downregulated in HIV-1 infected CD4+ T cells.
circulation_biomarker_diagnosis_down	hsa-mir-28	Human Immunodeficiency Virus Infection	21224041			B20	D015658	609423		heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects
circulation_biomarker_diagnosis_down	hsa-mir-382	Human Immunodeficiency Virus Infection	21224041			B20	D015658	609423		heroin-dependent subjects had significantly lower levels of anti-HIV miRNAs (miRNA-28, 125b, 150, and 382) in peripheral blood mononuclear cells than the healthy subjects
circulation_biomarker_diagnosis_down	hsa-mir-133b	Hypertension	21924071	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-296-5p (Fold change 0.47, P = 0.013) and miR-133b (Fold change 0.57, P = 0.033) were consistently down-regulated in the patient plasma, whereas let-7e (Fold change 1.62, P = 0.009) and hcmv-miR-UL112 (Fold change 2.72, P = 0.004), one human cytomegalovirus encoded microRNAs, were up-regulated in the patient samples.
circulation_biomarker_diagnosis_down	hsa-mir-296	Hypertension	21924071	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-296-5p (Fold change 0.47, P = 0.013) and miR-133b (Fold change 0.57, P = 0.033) were consistently down-regulated in the patient plasma, whereas let-7e (Fold change 1.62, P = 0.009) and hcmv-miR-UL112 (Fold change 2.72, P = 0.004), one human cytomegalovirus encoded microRNAs, were up-regulated in the patient samples.
circulation_biomarker_diagnosis_down	hsa-mir-1-1	Hypertrophy	21303526				D006984			The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF.
circulation_biomarker_diagnosis_down	hsa-mir-1-2	Hypertrophy	21303526				D006984			The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF.
circulation_biomarker_diagnosis_down	hsa-mir-133a-1	Hypertrophy	21303526				D006984			The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF.
circulation_biomarker_diagnosis_down	hsa-mir-133a-2	Hypertrophy	21303526				D006984			The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF.
circulation_biomarker_diagnosis_down	hsa-mir-374a	Hypoxic-Ischemic Encephalopathy	26001314			P91.60	D020925			We have shown a significant step-wise downregulation of hsa-miR-374a expression in cord blood of infants with perinatal asphyxia and subsequent HIE.
circulation_biomarker_diagnosis_down	hsa-mir-200b	Kideny Transplant Rejection	27521993			T86.11	D006084			our findings indicated that the aberrant urinary miR-21 and miR-200b expression levels were accompanied with renal allograft dysfunction and IFTA.
circulation_biomarker_diagnosis_down	hsa-mir-106	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-10a	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-10b	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-126	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-17	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-181a*: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_down	hsa-mir-199b	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-199b: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_down	hsa-mir-20	Leukemia	16549775			C95	D007938	613065	HP:0001909	we performed microRNA expression profiling of in vitro-differentiated megakaryocytes derived from CD34(+) hematopoietic progenitors. The main finding was down-regulation of miR-10a, miR-126, miR-106, miR-10b, miR-17 and miR-20.
circulation_biomarker_diagnosis_down	hsa-mir-21	Leukemia	24141112			C95	D007938	613065	HP:0001909	Moreover, the down-regulated expression of microRNA-21 in DF-1 chicken fibroblast cells infected with subgroup J avian leukemia virus (ALVs) was confirmed by the developed method, indicating that microRNA-21 might be a new biomarker for avian leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-27a	Leukemia	21070600			C95	D007938	613065	HP:0001909	Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.
circulation_biomarker_diagnosis_down	hsa-mir-331	Leukemia	21070600			C95	D007938	613065	HP:0001909	Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.
circulation_biomarker_diagnosis_down	hsa-mir-378a	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-378: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_down	hsa-mir-454	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-454-3p: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_down	hsa-mir-575	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-575: downregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_down	hsa-mir-663	Leukemia	27535859			C95	D007938	613065	HP:0001909	The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL.
circulation_biomarker_diagnosis_down	hsa-mir-223	Leukemia, Lymphoblastic	18056805	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML.
circulation_biomarker_diagnosis_down	hsa-mir-29a	Leukemia, Lymphoblastic	27535859	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL.
circulation_biomarker_diagnosis_down	hsa-mir-18a	Leukemia, Lymphoblastic, Acute	29068867	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Low Expression of miR-18a as a Characteristic of Pediatric Acute Lymphoblastic Leukemia.
circulation_biomarker_diagnosis_down	hsa-let-7f	Leukemia, Lymphoblastic, Acute, Childhood	28910942	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		The expression levels of let-7f-5p, miR-5100 and miR-25-3p in the cALL patients were  significantly lower than those of the controls
circulation_biomarker_diagnosis_down	hsa-mir-25	Leukemia, Lymphoblastic, Acute, Childhood	28910942	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		The expression levels of let-7f-5p, miR-5100 and miR-25-3p in the cALL patients were  significantly lower than those of the controls
circulation_biomarker_diagnosis_down	hsa-mir-5100	Leukemia, Lymphoblastic, Acute, Childhood	28910942	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		The expression levels of let-7f-5p, miR-5100 and miR-25-3p in the cALL patients were  significantly lower than those of the controls
circulation_biomarker_diagnosis_down	hsa-mir-103a-1	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-103a-2	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	26908869	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	18362358	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	lost or downregulated
circulation_biomarker_diagnosis_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	26908869	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	18362358	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	lost or downregulated
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181b:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	21636858	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	MiR-181b is a biomarker of disease progression in chronic lymphocytic leukemia
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181b:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulation
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	21636858	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	MiR-181b is a biomarker of disease progression in chronic lymphocytic leukemia
circulation_biomarker_diagnosis_down	hsa-mir-181c	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion
circulation_biomarker_diagnosis_down	hsa-mir-22	Leukemia, Lymphocytic, Chronic, B-Cell	19144983	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-22: downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification
circulation_biomarker_diagnosis_down	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulated
circulation_biomarker_diagnosis_down	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion
circulation_biomarker_diagnosis_down	hsa-mir-29a	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulated
circulation_biomarker_diagnosis_down	hsa-mir-29b-1	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-29b-2	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	low expression of the miR-223, miR-29c, miR-29b, and miR-181 family were strongly associated with disease progression in CLL cases harboring 17p deletion
circulation_biomarker_diagnosis_down	hsa-mir-29b-2	Leukemia, Lymphocytic, Chronic, B-Cell	21130495	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Downregulation
circulation_biomarker_diagnosis_down	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	downregulated
circulation_biomarker_diagnosis_down	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	19144983	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-29c: downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification
circulation_biomarker_diagnosis_down	hsa-mir-146b	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	28407516	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression.
circulation_biomarker_diagnosis_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	15737576	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Some human miRNAs are linked to leukemias: the miR-15a/miR-16 locus is frequently deleted or down-regulated in patients with B-cell chronic lymphocytic  leukemia and miR-142 is at a translocation site found in a case of aggressive B-cell leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_down	hsa-mir-16	Leukemia, Lymphocytic, Chronic, B-Cell	15737576	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Some human miRNAs are linked to leukemias: the miR-15a/miR-16 locus is frequently deleted or down-regulated in patients with B-cell chronic lymphocytic  leukemia and miR-142 is at a translocation site found in a case of aggressive B-cell leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-16	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_down	hsa-mir-186	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-19a	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-20a	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-223	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-324	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-484	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-mir-660	Leukemia, Lymphocytic, Chronic, B-Cell	23286334	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	we found that malignant B-cells from patients with CLL subsequently developing AIHA present nine down-regulated (i.e. miR-19a, miR-20a, miR-29c, miR-146b-5p, miR-186, miR-223, miR-324-3p, miR-484 and miR-660) miRNAs.
circulation_biomarker_diagnosis_down	hsa-let-7b	Leukemia, Myeloid, Acute	18056805	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML.
circulation_biomarker_diagnosis_down	hsa-mir-143	Leukemia, Myeloid, Acute	21678057	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29a and miR-142-3p show downregulation and diagnostic implication in human acute myeloid leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-148a	Leukemia, Myeloid, Acute	25924238	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	whilst anti-oncogenic microRNAsincluding miR-148a and miR-193a were down-regulated in MAPKBP1high patients with CN-AML
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Leukemia, Myeloid, Acute	22251480	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Myeloid, Acute	22251480	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Myeloid, Acute	22251480	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
circulation_biomarker_diagnosis_down	hsa-mir-181c	Leukemia, Myeloid, Acute	22251480	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
circulation_biomarker_diagnosis_down	hsa-mir-181d	Leukemia, Myeloid, Acute	22251480	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
circulation_biomarker_diagnosis_down	hsa-mir-199b	Leukemia, Myeloid, Acute	26848406	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Low miR-199b in AML patients correlates with worse overall survival and has prognostic significance for FAB-M5 subtype.
circulation_biomarker_diagnosis_down	hsa-mir-223	Leukemia, Myeloid, Acute	25793640	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MIR233 is genetically or epigenetically silenced in a subset of acute myeloid leukemia (AML).
circulation_biomarker_diagnosis_down	hsa-mir-29a	Leukemia, Myeloid, Acute	21678057	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-29a and miR-142-3p show downregulation and diagnostic implication in human acute myeloid leukemia.
circulation_biomarker_diagnosis_down	hsa-mir-29a	Leukemia, Myeloid, Acute	21818844	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Lower miR-29a expression was mainly observed in MLL-rearranged pediatric acute myeloid leukemia, specifically in cases carrying t(10;11).
circulation_biomarker_diagnosis_down	hsa-mir-29a	Leukemia, Myeloid, Acute	22981932	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our data indicate for the first time that the down-regulation of miR-29a was associated with advanced clinical features and poor prognosis of pediatric AML patients, suggesting that miR-29a down-regulation may be used as an unfavorable prognostic marker in pediatric AML.
circulation_biomarker_diagnosis_down	hsa-mir-96	Leukemia, Myeloid, Acute	24678958	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our data demonstrated that the expression of miR-96 was downregulated in newly diagnosed AML patients and associated with leukemic burden, as well as RFS and OS. This suggests that miR-96 detection might become a potential biomarker of prognosis and monitoring in AML.
circulation_biomarker_diagnosis_down	hsa-mir-34b	Leukemia, Myeloid, Acute, Pediatric	26861642			C92.0				miR鈥?4b levels in leukemia cell lines and primary leukemic cells were significantly lower than those in normal cells.
circulation_biomarker_diagnosis_down	hsa-mir-181a	Leukemia, Myeloid, Chronic	26722250	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression levels of miR-181a were significantly reduced in the patient with CML  and in the CML K562 cell line.
circulation_biomarker_diagnosis_down	hsa-mir-199b	Leukemia, Myeloid, Chronic	24680705	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
circulation_biomarker_diagnosis_down	hsa-mir-451a	Leukemia, Myeloid, Chronic	21511335	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	downregulated
circulation_biomarker_diagnosis_down	hsa-mir-10a	Leukemia, Myeloid, Chronic-Phase	19074828			C92.1	D015466			miR-10a: Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Leukemia, Promyelocytic, Acute	16847880	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells.
circulation_biomarker_diagnosis_down	hsa-mir-181b-1	Leukemia, Promyelocytic, Acute	16847880	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells.
circulation_biomarker_diagnosis_down	hsa-mir-181b-2	Leukemia, Promyelocytic, Acute	16847880	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells.
circulation_biomarker_diagnosis_down	hsa-mir-181d	Leukemia, Promyelocytic, Acute	16847880	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	miR-181 expression is decreased inTPA-induced differentiation of human promyelocytic leukemia cells.
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Leukemia-Lymphoma, Adult T-Cell	21441948			C91.51	D015459		HP:0005517	Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-kB activity and miR-16-1(*).
circulation_biomarker_diagnosis_down	hsa-mir-373	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	19206004	disease of cellular proliferation	DOID:7061	C83.5	D015452			miR-373*: down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-451a	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	19206004	disease of cellular proliferation	DOID:7061	C83.5	D015452			miR-451: down-regulated
circulation_biomarker_diagnosis_down	hsa-let-7b	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21242186	disease of cellular proliferation	DOID:5599	C83.5	D054218			aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002).
circulation_biomarker_diagnosis_down	hsa-mir-19a	Lung Fibrosis	27312312	respiratory system disease	DOID:3770	J84.10	D011658	178500		miR-19a in peripheral blood leukocyte could be used as an effective biomarker for silicosis
circulation_biomarker_diagnosis_down	hsa-let-7a-1	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7a-1	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7a-2	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7a-2	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7a-3	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7a-3	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7b	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7b	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7c	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7c	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7c	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-let-7d	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7d	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7d	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-let-7e	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7e	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7e	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-let-7f-1	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7f-1	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7f-2	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7f-2	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7g	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7g	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-let-7g	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-let-7i	Lung Neoplasms	16712479	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	downregulation
circulation_biomarker_diagnosis_down	hsa-let-7i	Lung Neoplasms	17096367	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Recent study demonstrated that the expression of let-7 was significantly reduced while the expression of RAS was dramatically increased in lung tumor tissues.
circulation_biomarker_diagnosis_down	hsa-mir-126	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-mir-145	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-mir-198	Lung Neoplasms	23354517	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Circulating;Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion
circulation_biomarker_diagnosis_down	hsa-mir-21	Lung Neoplasms	22782668	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In addition, miR-21 and miR-24 serum levels were lower in post-operative samples than those in pre-operative samples, suggesting they can potentially be used as biomarkers for disease recurrence after surgery operation.
circulation_biomarker_diagnosis_down	hsa-mir-24	Lung Neoplasms	22782668	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	In addition, miR-21 and miR-24 serum levels were lower in post-operative samples than those in pre-operative samples, suggesting they can potentially be used as biomarkers for disease recurrence after surgery operation.
circulation_biomarker_diagnosis_down	hsa-mir-98	Lung Neoplasms	22862169	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Some miRNAs as hsa-miR-126, hsa-miR-145, hsa-let-7g, hsa-let-7d, hsa-let-7c, hsa-let-7e and hsa-miR-98, which were lowly expressed in SPC-A1 cells, were not expressed in the pulmospheres.
circulation_biomarker_diagnosis_down	hsa-mir-150	Lupus Vulgaris	18998140			A18.4	D008177			miR-150: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-210	Lupus Vulgaris	18998140			A18.4	D008177			miR-210: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-223	Lupus Vulgaris	18998140			A18.4	D008177			miR-223: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-296	Lupus Vulgaris	18998140			A18.4	D008177			miR-296: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-30d	Lupus Vulgaris	18998140			A18.4	D008177			miR-30d: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-324	Lupus Vulgaris	18998140			A18.4	D008177			miR-324-3p: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-346	Lupus Vulgaris	18998140			A18.4	D008177			miR-346: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-365a	Lupus Vulgaris	18998140			A18.4	D008177			miR-365: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-365b	Lupus Vulgaris	18998140			A18.4	D008177			miR-365: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-423	Lupus Vulgaris	18998140			A18.4	D008177			miR-423: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-484	Lupus Vulgaris	18998140			A18.4	D008177			miR-484: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-486	Lupus Vulgaris	18998140			A18.4	D008177			miR-486: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-500a	Lupus Vulgaris	18998140			A18.4	D008177			miR-500: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-518b	Lupus Vulgaris	18998140			A18.4	D008177			miR-518b: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-557	Lupus Vulgaris	18998140			A18.4	D008177			miR-557: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-596	Lupus Vulgaris	18998140			A18.4	D008177			miR-596: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-602	Lupus Vulgaris	18998140			A18.4	D008177			miR-602: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-611	Lupus Vulgaris	18998140			A18.4	D008177			miR-611: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-615	Lupus Vulgaris	18998140			A18.4	D008177			miR-615: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-629	Lupus Vulgaris	18998140			A18.4	D008177			miR-629: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-637	Lupus Vulgaris	18998140			A18.4	D008177			miR-637: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-642a	Lupus Vulgaris	18998140			A18.4	D008177			miR-642: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-654	Lupus Vulgaris	18998140			A18.4	D008177			miR-654: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-663a	Lupus Vulgaris	18998140			A18.4	D008177			miR-663: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-769	Lupus Vulgaris	18998140			A18.4	D008177			miR-769-3p: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-99a	Lupus Vulgaris	18998140			A18.4	D008177			miR-99a: downregulation
circulation_biomarker_diagnosis_down	hsa-mir-17	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-17-5p: Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-181a-2	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-19a	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-19b-1	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-19b-2	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal cani   ne peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-203	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-218-1	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-218-2	Lymphoma	21910161	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level.
circulation_biomarker_diagnosis_down	hsa-mir-92a-1	Lymphoma	21383985	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma.
circulation_biomarker_diagnosis_down	hsa-mir-92a-2	Lymphoma	21383985	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma.
circulation_biomarker_diagnosis_down	hsa-mir-143	Lymphoma, B-Cell	17892514	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	Downregulation of microRNAs-143 and -145 in B-cell malignancies.
circulation_biomarker_diagnosis_down	hsa-mir-17	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-17: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-18a	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-18a: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-19a	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-19a: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-19b-1	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-19b: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-19b-2	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-19b: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-20a	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-20a: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-92a-1	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-92a: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-92a-2	Lymphoma, B-Cell	18941111	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-92a: down-regulates expression of distinct targets
circulation_biomarker_diagnosis_down	hsa-mir-128-1	Lymphoma, Hodgkin	18089852	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-128-2	Lymphoma, Hodgkin	18089852	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-96	Lymphoma, Hodgkin	18089852	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-101-1	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-101:miR-101 was down-regulated in all ALCL model systems
circulation_biomarker_diagnosis_down	hsa-mir-101-2	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-101:miR-101 was down-regulated in all ALCL model systems
circulation_biomarker_diagnosis_down	hsa-mir-150	Marek Disease	19297609				D008380			miR-150: down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-223	Marek Disease	19297609				D008380			miR-223: down-regulated
circulation_biomarker_diagnosis_down	hsa-let-7i	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7i*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-106b	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-106b:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-107	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-107:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-125b	Melanoma	24878024	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Exosomes can provide a suitable material to measure circulating miRNA in melanoma, and miR-16 can be used as an endogenous normalizer. Lower levels of miR-125b in exosomes obtained from serum are associated with advanced melanoma disease, probably reflecting the tumoral cell dysregulation.
circulation_biomarker_diagnosis_down	hsa-mir-16	Melanoma	24878024	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Exosomes can provide a suitable material to measure circulating miRNA in melanoma, and miR-16 can be used as an endogenous normalizer. Lower levels of miR-125b in exosomes obtained from serum are associated with advanced melanoma disease, probably reflecting the tumoral cell dysregulation.
circulation_biomarker_diagnosis_down	hsa-mir-17	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-17:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-20a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-20a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-20b	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-20b:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-214	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-214:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-216a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-216a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-217	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-217:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-221	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-221*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-330	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-330-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-452	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-452:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-509-3	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-509-3-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-517a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-517*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-518e	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-518e*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-519b	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-519b-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-593	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-593*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-621	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-621:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-646	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-646:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-767	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-767-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_down	hsa-mir-126	Mesothelioma	21483773	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Levels of miR-126 in serum, and its levels in patients' serum in association with a specific marker of MPM, SMRPs, correlate with subjects at high risk to develop malignant pleural mesothelioma (MPM).
circulation_biomarker_diagnosis_down	hsa-mir-126	Mesothelioma	22374169	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Kaplan-Meier analysis revealed that low level of circulating miR-126 in MM patients was strongly associated with worse prognosis.
circulation_biomarker_diagnosis_down	hsa-mir-9-1	Methylmalonic Acidemia	24927441	disease of metabolism	DOID:14749	E71.120	C537358	309541		Plasma miR-9-1 is significantly down-regulated in MMA patients, but it is significantly up-regulated after vitamin B12 treatment, suggesting that miR-9-1 may act as a biomarker in monitoring the progression of MMA.
circulation_biomarker_diagnosis_down	hsa-mir-33b	Multiple Myeloma	25975752	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma.
circulation_biomarker_diagnosis_down	hsa-mir-92a-1	Multiple Myeloma	22829237	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.
circulation_biomarker_diagnosis_down	hsa-mir-15b	Multiple Sclerosis	24277735	nervous system disease	DOID:2377	G35	D009103	PS126200		Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
circulation_biomarker_diagnosis_down	hsa-mir-223	Multiple Sclerosis	24277735	nervous system disease	DOID:2377	G35	D009103	PS126200		Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
circulation_biomarker_diagnosis_down	hsa-mir-23a	Multiple Sclerosis	24277735	nervous system disease	DOID:2377	G35	D009103	PS126200		Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
circulation_biomarker_diagnosis_down	hsa-mir-320a	Multiple Sclerosis	25468268	nervous system disease	DOID:2377	G35	D009103	PS126200		expression of miR-320a is decreased in B cells of MS patients and may contribute to increased blood-brain barrier permeability and neurological disability.
circulation_biomarker_diagnosis_down	hsa-mir-145	Myasthenia Gravis	24043548	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response.
circulation_biomarker_diagnosis_down	hsa-mir-181c	Myasthenia Gravis	25962782	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis.
circulation_biomarker_diagnosis_down	hsa-mir-125b-1	Myelodysplastic Syndromes	18936236	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-125b-1: Myeloid cell differentiation arrest by miR-125b-1
circulation_biomarker_diagnosis_down	hsa-mir-671	Myelodysplastic Syndromes	21649547	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	miR-671-5p: down-regulation
circulation_biomarker_diagnosis_down	hsa-mir-126	Myocardial Infarction	22719221	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased miR-1 and decreased miR-126 in plasma from patients with AMI after the onset of symptoms compared with healthy subjects were found.
circulation_biomarker_diagnosis_down	hsa-mir-133a	Myocardial Infarction	29324314	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Down-regulation of miR-133a/b in patients with myocardial infarction correlates with the presence of ventricular fibrillation
circulation_biomarker_diagnosis_down	hsa-mir-133b	Myocardial Infarction	29324314	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Down-regulation of miR-133a/b in patients with myocardial infarction correlates with the presence of ventricular fibrillation
circulation_biomarker_diagnosis_down	hsa-mir-155	Myocardial Infarction	28618412	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Failed Downregulation of Circulating MicroRNA-155 in the Early Phase after ST Elevation Myocardial Infarction Is Associated with Adverse Left Ventricular Remodeling.
circulation_biomarker_diagnosis_down	hsa-mir-29c	Nasopharyngeal Neoplasms	18390668			C11.9	D009303	607107	HP:0100630	down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-155	Neoplasms [unspecific]	16885332			C80.1	D009369			High expression of precursor miR-155/BIC in pediatric BL, but lack of BIC and miR-155 expression in adult BL
circulation_biomarker_diagnosis_down	hsa-mir-199a-1	Neoplasms [unspecific]	18430245			C80.1	D009369			decreased
circulation_biomarker_diagnosis_down	hsa-mir-337	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-337-3p: down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-338	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-338-3p: down-regulated
circulation_biomarker_diagnosis_down	hsa-mir-143	Obesity	26223376	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Circulating miR-335 (P鈥?鈥?.001), miR-143 (P鈥?鈥?.001) and miR-758 (P鈥?鈥?.006) in obese children were significantly lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-335	Obesity	26223376	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Circulating miR-335 (P鈥?鈥?.001), miR-143 (P鈥?鈥?.001) and miR-758 (P鈥?鈥?.006) in obese children were significantly lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-let-7a-3	Ovarian Neoplasms	17974952	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	decreased
circulation_biomarker_diagnosis_down	hsa-let-7e	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	let-7e: deregulated
circulation_biomarker_diagnosis_down	hsa-let-7d	Pancreatic Neoplasms	21139804	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-146a	Pancreatic Neoplasms	21139804	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		downregulated
circulation_biomarker_diagnosis_down	hsa-mir-29a	Parkinson Disease	24648008	nervous system disease	DOID:14330	G20	D010300	PS168600		We found four statistically significant miRNAs that were downregulated in either LRRK2 or IPD (miR-29a, miR-29c, miR-19a, and miR-19b).
circulation_biomarker_diagnosis_down	hsa-mir-15a	Pituitary Neoplasms	17028302	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas.
circulation_biomarker_diagnosis_down	hsa-mir-15b	Pituitary Neoplasms	17028302	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas.
circulation_biomarker_diagnosis_down	hsa-mir-16-1	Pituitary Neoplasms	17028302	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas.
circulation_biomarker_diagnosis_down	hsa-mir-16-2	Pituitary Neoplasms	17028302	disease of cellular proliferation	DOID:1785	C75.1	D010911		HP:0040277	Downregulation of miR-15 and miR-16 miRNAs also appears to be a feature of pituitary adenomas.
circulation_biomarker_diagnosis_down	hsa-mir-16	Plasmodium vivax Infection	25913668	disease by infectious agent	DOID:12978	B51	D016780	248310		Downregulation of plasma miR-451 and miR-16 in Plasmodium vivax infection.
circulation_biomarker_diagnosis_down	hsa-mir-451	Plasmodium vivax Infection	25913668	disease by infectious agent	DOID:12978	B51	D016780	248310		Downregulation of plasma miR-451 and miR-16 in Plasmodium vivax infection.
circulation_biomarker_diagnosis_down	hsa-mir-1	Polycystic Kidney Disease	24489795			Q61.19	D007690	PS173900	HP:0000113	We found that in ADPKD urine specimens, miRNA previously implicated as kidney tumor suppressors (miR-1 and miR-133), as well as miRNA of presumed inflammatory and fibroblast cell origin (miR-223/miR-199), are dysregulated when compared to other CKD patients. Concordant with findings in the primary tubule epithelial cell model, this suggests roles for dysregulated miRNA in ADPKD pathogenesis and potential use as biomarkers. We intend to assess prognostic potential of miRNA in a followup analysis.
circulation_biomarker_diagnosis_down	hsa-mir-199b	Polycystic Ovarian Syndrome	26860517	syndrome	DOID:11612	E28.2	D011085	184700		whereas that of miR-199b-5p was down-regulated.
circulation_biomarker_diagnosis_down	hsa-let-7a	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_down	hsa-mir-150	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_down	hsa-mir-150	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_down	hsa-mir-155	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_down	hsa-mir-221	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_down	hsa-mir-30b	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_down	hsa-mir-30c	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_down	hsa-mir-152	Preeclampsia	22095477	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Serum expression level of mir-152 was down-regulated in preeclampsia patients.
circulation_biomarker_diagnosis_down	hsa-mir-222	Preeclampsia	29381395	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	serum miR-222 expression levels showed a significant decrease in PE compared to GH and normotensive groups
circulation_biomarker_diagnosis_down	hsa-mir-22	Premature Ovarian Failure	25585503	endocrine system disease	DOID:5426	E28.3	D016649	PS311360		Mir-22-3p showed a lower expression level in POF and was modestly effective in distinguishing POF from control subjects. The decreased expression of miR-22-3p in plasma of POF may reflect the diminished ovarian reserve and be a consequence of the pathologic process of POF.
circulation_biomarker_diagnosis_down	hsa-mir-197	Primary Biliary Cirrhosis	23776611	immune system disease	DOID:12236	K74.5	D008105	PS109720	HP:0002613	Our results indicate that sera from patients with PBC have a unique mirNA expression profile and that the down-regulated expression of mir-505-3p and mir-197-3p can serve as clinical biomarkers of PBC.
circulation_biomarker_diagnosis_down	hsa-mir-505	Primary Biliary Cirrhosis	23776611	immune system disease	DOID:12236	K74.5	D008105	PS109720	HP:0002613	Our results indicate that sera from patients with PBC have a unique mirNA expression profile and that the down-regulated expression of mir-505-3p and mir-197-3p can serve as clinical biomarkers of PBC.
circulation_biomarker_diagnosis_down	hsa-let-7b	Prostate Neoplasms	22719071	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	downregulated in prostate cancer stem/progenitor cell.
circulation_biomarker_diagnosis_down	hsa-mir-125b	Prostate Neoplasms	22892455	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	An increase in serum miR-223 and a decrease in miR-125b and miR-146a were observed in group B.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Prostate Neoplasms	22892455	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	An increase in serum miR-223 and a decrease in miR-125b and miR-146a were observed in group B.
circulation_biomarker_diagnosis_down	hsa-mir-221	Prostate Neoplasms	26831660	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	downregulation of hsa-miR-221* (now hsa-miR-221-5p) and hsa-miR-708* (now hsa-miR-708-3p) in PCa compared to BPH.
circulation_biomarker_diagnosis_down	hsa-mir-409	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_down	hsa-mir-708	Prostate Neoplasms	26831660	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	downregulation of hsa-miR-221* (now hsa-miR-221-5p) and hsa-miR-708* (now hsa-miR-708-3p) in PCa compared to BPH.
circulation_biomarker_diagnosis_down	hsa-mir-182	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-182: decreased expression
circulation_biomarker_diagnosis_down	hsa-mir-183	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-183: decreased expression
circulation_biomarker_diagnosis_down	hsa-mir-96	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-96: decreased expression
circulation_biomarker_diagnosis_down	hsa-let-7e	Retinoblastoma	24748987	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Plasma miRNA (miR)-320, miR-let-7e and miR-21 levels were downregulated in the patient samples
circulation_biomarker_diagnosis_down	hsa-mir-21	Rheumatoid Arthritis	25164131	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis.
circulation_biomarker_diagnosis_down	hsa-mir-22	Rheumatoid Arthritis	25939484	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MiRNAs with a P-value <0.05 using three different normalizations were included in a multivariate model.After backwards elimination, the combination of low expression of miR-22 and high expression of miR-886.3p was associated with EULAR good response. Future studies to assess the utility of these miRNAs as predictive biomarkers are needed.
circulation_biomarker_diagnosis_down	hsa-mir-346	Schizophrenia	19264453	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-346: Expression of both miR-346 and GRID1 is lower in SZ patients than that in normal controls
circulation_biomarker_diagnosis_down	hsa-mir-146a	Sepsis	20188071			A41.9	D018805		HP:0100806	Serum miR-146a and miR-223 as potential new biomarkers for sepsis
circulation_biomarker_diagnosis_down	hsa-mir-150	Sepsis	19823581			A41.9	D018805		HP:0100806	miR-150 as a plasma prognostic marker in patients with sepsis
circulation_biomarker_diagnosis_down	hsa-mir-150	Sepsis	23372743			A41.9	D018805		HP:0100806	Circulating;Circulating MicroRNA-150 Serum Levels Predict Survival in Patients with Critical Illness and Sepsis
circulation_biomarker_diagnosis_down	hsa-mir-150	Sepsis	25394245			A41.9	D018805		HP:0100806	The expression of two miRNAs, that is, let-7a (P < 0.001) and miR-150 (P < 0.001), were confirmed to be significantly downregulated in GNB urosepsis patients compared with healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-223	Sepsis	20188071			A41.9	D018805		HP:0100806	Serum miR-146a and miR-223 as potential new biomarkers for sepsis
circulation_biomarker_diagnosis_down	hsa-mir-155	Sjogren Syndrome	24931100	immune system disease	DOID:12894	M35.00	D012859	270150		Our results demonstrated miR-146a overexpression and miR-155 underexpression in the peripheral mononuclear blood cells of the patients with pSS. Furthermore, the expression levels of these miRNAs correlated with the patients' clinical features. Our data suggest that miR-146a and miR-155 might play important roles in the pathogenesis of pSS and that their expression levels may be useful for diagnosing pSS and for predicting disease activity and therapeutic responses.
circulation_biomarker_diagnosis_down	hsa-mir-130a	Spinal Cord Injuries	25973054			S34.139A	D013119			Increased HDAC3 and decreased miRNA-130a expression in PBMCs through recruitment HDAC3 in patients with spinal cord injuries.
circulation_biomarker_diagnosis_down	hsa-mir-335	Spinal Muscular Atrophy	27483257	nervous system disease	DOID:12377	G12.9	D009134	253300	HP:0007269	The expression of miR-335-5p; already identified to control self-renewal or differentiation of mouse embryonic stem cells (mESCs); resulted to be reduced during the early steps of differentiation of SMA hiPSCs compared to wild type cells.
circulation_biomarker_diagnosis_down	hsa-mir-150	Spondylarthritis	26689798			M45-M49	D025241			miR-150 was downregulated in all of the samples
circulation_biomarker_diagnosis_down	hsa-mir-1297	Squamous Cell Carcinoma, Esophageal	27152453	disease of cellular proliferation	DOID:3748		C562729			It was statistically decreased in ESCC patients  compared with healthy controls.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Squamous Cell Carcinoma, Esophageal	26794279	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-146a is significantly reduced in cancerous tissue and serum samples of ESCC patients. It is an ideal biomarker for the prognosis and diagnosis of ESCC.
circulation_biomarker_diagnosis_down	hsa-mir-375	Squamous Cell Carcinoma, Esophageal	21673684	disease of cellular proliferation	DOID:3748		C562729			the plasma level of miR-21 was significantly higher (P=0.0218) and that of miR-375 (P=0.0052) was significantly lower in ESCC patients than controls. (2) The high plasma miR-21 levels reflected tumour levels in all cases (100%). The plasma level of miR-21 was significantly reduced in postoperative samples (P=0.0058). (3) On validation analysis, the plasma level of miR-21 tended to be higher in ESCC patients (P=0.0649), while that of miR-375 was significantly lower (P<0.0001) and the miR-21/miR-375 ratio was significantly higher (P<0.0001) in ESCC patients than in controls. The value of the area under the receiver-operating characteristic curve (AUC) was 0.816 for the miR-21/miR-375 ratio assay. Patients with a high plasma level of miR-21 tended to have greater vascular invasion (P=0.1554) and to show a high correlation with recurrence (P=0.0164).
circulation_biomarker_diagnosis_down	hsa-mir-122	Stroke	26661204			I64	D020521	601367	HP:0001297	our recent studies have demonstrated that miR-122 decreased in whole blood of patients and in whole blood of rats following ischemic stroke
circulation_biomarker_diagnosis_down	hsa-mir-124	Stroke	25257664			I64	D020521	601367	HP:0001297	serum miR-124 was significantly decreased within 24 hours after stroke onset and serum miR-9 was decreased in patients with larger stroke.
circulation_biomarker_diagnosis_down	hsa-mir-9	Stroke	25257664			I64	D020521	601367	HP:0001297	serum miR-124 was significantly decreased within 24 hours after stroke onset and serum miR-9 was decreased in patients with larger stroke.
circulation_biomarker_diagnosis_down	hsa-mir-146a	Stroke, Ischemic	26044809			I63.9			HP:0002140	miR-146a and miR-185 were present with quite low abundance in ISA compared with healthy individuals
circulation_biomarker_diagnosis_down	hsa-mir-106a	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_down	hsa-mir-141	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-145	Systemic Lupus Erythematosus	23199328	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis
circulation_biomarker_diagnosis_down	hsa-mir-17	Systemic Lupus Erythematosus	23129428	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Dual downregulation of microRNA 17-5p and E2F1 transcriptional factor in pediatric systemic lupus erythematosus patients
circulation_biomarker_diagnosis_down	hsa-mir-17	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_down	hsa-mir-192	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-200a	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-200b	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-200c	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-203	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_down	hsa-mir-205	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-20a	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_down	hsa-mir-31	Systemic Lupus Erythematosus	27510529	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The results revealed that miR-31 was lower expressed, while miR-21 was  high expressed in SLE patients compared to their first-degree relatives and controls.
circulation_biomarker_diagnosis_down	hsa-mir-429	Systemic Lupus Erythematosus	21372198	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls.
circulation_biomarker_diagnosis_down	hsa-mir-92a	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_down	hsa-mir-127	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	three miRNAs showed significantly more underexpression compared to the other downregulated miRNAs. These miRNAs are as follows mir-127, mir-130a and mir-144.
circulation_biomarker_diagnosis_down	hsa-mir-130a	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	three miRNAs showed significantly more underexpression compared to the other downregulated miRNAs. These miRNAs are as follows mir-127, mir-130a and mir-144.
circulation_biomarker_diagnosis_down	hsa-mir-144	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	three miRNAs showed significantly more underexpression compared to the other downregulated miRNAs. These miRNAs are as follows mir-127, mir-130a and mir-144.
circulation_biomarker_diagnosis_down	hsa-mir-218-1	Urinary Bladder Cancer	22237456	urinary system disease	DOID:11054	C67	D001749	109800		Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion.
circulation_biomarker_diagnosis_down	hsa-mir-218-2	Urinary Bladder Cancer	22237456	urinary system disease	DOID:11054	C67	D001749	109800		Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion.
circulation_biomarker_diagnosis_down	hsa-mir-133a	Vascular Hypertrophy	28772031							Local microRNA-133a downregulation is associated with hypertrophy in the dyssynchronous heart.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Acute Cerebral Infarction	27846323	cardiovascular system disease	DOID:3526	I63	D002544			Plasma MicroRNA-16 Is a Biomarker for Diagnosis, Stratification, and Prognosis of Hyperacute Cerebral Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Acute Cerebral Infarction	24841240	cardiovascular system disease	DOID:3526	I63	D002544			Identification of miRNA-21 and miRNA-24 in plasma as potential early stage markers of acute cerebral infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Acute Cerebral Infarction	24841240	cardiovascular system disease	DOID:3526	I63	D002544			Identification of miRNA-21 and miRNA-24 in plasma as potential early stage markers of acute cerebral infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Acute Cerebral Ischemia	21622133			I67.82			HP:0002637	MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Acute Coronary Syndrome	29350392			I24.9	D054058			although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events
circulation_biomarker_diagnosis_ns	hsa-mir-100	Acute Coronary Syndrome	25744750			I24.9	D054058			Plasma microRNA-100 as a biomarker of coronary plaque vulnerability – a new generation of biomarker for developing acute coronary syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Acute Coronary Syndrome	25933289			I24.9	D054058			Plasma miR-122, -140-3p, -720, -2861, and -3149 were associated with and potentially novel biomarkers for ACS.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Acute Coronary Syndrome	29350392			I24.9	D054058			although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Acute Coronary Syndrome	29350392			I24.9	D054058			although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events
circulation_biomarker_diagnosis_ns	hsa-mir-21	Acute Coronary Syndrome	27590242			I24.9	D054058			The role of serum levels of microRNA-21 and matrix metalloproteinase-9 in patients with acute coronary syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-3149	Acute Coronary Syndrome	25933289			I24.9	D054058			Plasma miR-122, -140-3p, -720, -2861, and -3149 were associated with and potentially novel biomarkers for ACS.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Acute Coronary Syndrome	29350392			I24.9	D054058			although most investigated miRs levels differ significantly between patients with ACS and CIE, similar levels of circulating miR-1-3p, miR-133a-3p, miR-133b, and miR-375 were observed; furthermore, we identified several common miRs as possible risk factors for recurrent cardiovascular events
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Acute Heart Failure	26345695			I50				Fifteen miRNAs found in the discovery phase to differ most significantly between healthy controls and patients with AHF
circulation_biomarker_diagnosis_ns	hsa-mir-145	Acute Ischemic Stroke	26096228	cardiovascular system disease	DOID:224	I63.9	D002546		HP:0002140	Circulating miR-145 is associated with plasma high-sensitivity C-reactive protein in acute ischemic stroke patients.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Acute Kidney Failure	21700819	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	Circulating miR-210 predicts survival in critically ill patients with acute kidney injury.
circulation_biomarker_diagnosis_ns	hsa-mir-494	Acute Kidney Failure	23160513	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	In conclusion, upregulation of microRNA-494 contributes to inflammatory or adhesion molecule-induced kidney injury after ischemia/reperfusion by inhibiting expression of ATF3. Furthermore, microRNA-494 may be a specific and noninvasive biomarker for AKI.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-194	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-200a	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-216a	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-216b	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-217	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-449a	Acute Kidney Failure	26106607	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	miR-200a/b/c, miR-145, miR-192, miR-194, miR-216a/b, miR-217, and miR-449a expression profiles are useful as biomarkers for identification of various kidney injuries.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Acute Myocardial Infarction	24253456	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Early in acute myocardial infarction the expression of miR-423-5p in plasma is significantly increased with subsequent normalization within 6 hours.Potentially it is an early marker of myocardial necrosis.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Acute Myocardial Infarction	26526403	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	In summary, we confirmed the predictive values of plasma miR-1,miR-208 and miR-499 in AMI. In contrast to miR-1, the cardiac-specific miR-208 and miR-499 were supposed to be more reliable as biomarkers in AMI screening and prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Acute Myocardial Infarction	27593229	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-122-5p/miR-133b Ratio Is a Specific Early Prognostic Biomarker in Acute Myocardial Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-124	Acute Myocardial Infarction	28338188	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Implication of peripheral blood miRNA-124 in predicting acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Acute Myocardial Infarction	24053180	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-133a may be a new biomarker for AMI and as a potential diagnostic tool. And increased miR-133a level may be used to predict both the presence and severity of coronary lesions in CHD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Acute Myocardial Infarction	27593229	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-122-5p/miR-133b Ratio Is a Specific Early Prognostic Biomarker in Acute Myocardial Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Acute Myocardial Infarction	20886220	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	In addition, we show that miR-30c and miR-145 levels correlate with infarct sizes estimated by Troponin T release. The here presented study shows that single miRNAs and especially miRNA signatures derived from peripheral blood, could be valuable novel biomarkers for cardiovascular diseases.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Acute Myocardial Infarction	28051023	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating MicroRNA-145 is Associated with Acute Myocardial Infarction and Heart Failure.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Acute Myocardial Infarction	27997916	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-181a as a Potential Novel Biomarker for Diagnosis of Acute Myocardial Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Acute Myocardial Infarction	25383678	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating microRNA-19a as a potential novel biomarker for diagnosis of acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Acute Myocardial Infarction	29085838	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	The miRNA Expression Profile in Acute Myocardial Infarct Using Sheep Model with Left Ventricular Assist Device Unloading.
circulation_biomarker_diagnosis_ns	hsa-mir-208	Acute Myocardial Infarction	26526403	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	In summary, we confirmed the predictive values of plasma miR-1,miR-208 and miR-499 in AMI. In contrast to miR-1, the cardiac-specific miR-208 and miR-499 were supposed to be more reliable as biomarkers in AMI screening and prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Acute Myocardial Infarction	28272696	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	A meta-analysis of the relations between blood microRNA-208b detection and acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Acute Myocardial Infarction	26875904	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Plasma miR-21 may be a novel biomarker for the diagnosis of AMI. Our study may also provide implications for the development of new biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Acute Myocardial Infarction	20886220	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	In addition, we show that miR-30c and miR-145 levels correlate with infarct sizes estimated by Troponin T release. The here presented study shows that single miRNAs and especially miRNA signatures derived from peripheral blood, could be valuable novel biomarkers for cardiovascular diseases.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Acute Myocardial Infarction	26526403	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	In summary, we confirmed the predictive values of plasma miR-1,miR-208 and miR-499 in AMI. In contrast to miR-1, the cardiac-specific miR-208 and miR-499 were supposed to be more reliable as biomarkers in AMI screening and prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Acute Myocardial Infarction	26547429	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	favorable sensitivity and selectivity,thus provides an alternative for the detection of miRNA. Most importantly, this effort may promote miRNA to work as an effective biomarker in the diagnosis of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-99a	Acute Myocardial Infarction	28051249	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	The clinical value of circulating miR-99a in plasma of patients with acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-126a	Acute Pancreatitis	26094040	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	Serum levels of unique miR-551-5p and endothelial-specific miR-126a-5p allow discrimination of patients in the early phase of acute pancreatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-551	Acute Pancreatitis	26094040	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	Serum levels of unique miR-551-5p and endothelial-specific miR-126a-6p allow discrimination of patients in the early phase of acute pancreatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Acute Respiratory Distress Syndrome	28856588	respiratory system disease	DOID:11394	J80	D012128			miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424 is a protective biomarker
circulation_biomarker_diagnosis_ns	hsa-mir-424	Acute Respiratory Distress Syndrome	28856588	respiratory system disease	DOID:11394	J80	D012128			miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424 is a protective biomarker
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Acute Respiratory Distress Syndrome	28856588	respiratory system disease	DOID:11394	J80	D012128			miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424 is a protective biomarker
circulation_biomarker_diagnosis_ns	hsa-mir-195	Adenocarcinoma, Lung	24282590	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Plasma levels of miR-195 and miR-122 expression were also associated with overall survival in the patients, especially in those with advanced stage (HR=0.23, 95%CI:0.07-0.84; and HR=0.22, 95%CI:0.06-0.77) and EGFR mutation (HR=0.27, 95%CI:0.08-0.96; and HR=0.23, 95%CI=0.06-0.81).
circulation_biomarker_diagnosis_ns	hsa-mir-21	Adenocarcinoma, Lung	29103767	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Circulating microRNA-339-5p and -21 in plasma as an early detection predictors of lung adenocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Adenocarcinoma, Lung	28123597	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Adenocarcinoma, Lung	28123597	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-339	Adenocarcinoma, Lung	29103767	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Circulating microRNA-339-5p and -21 in plasma as an early detection predictors of lung adenocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Adenocarcinoma, Lung	28449331	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Adenocarcinoma, Pancreatic Ductal	20614181	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Serum miR-196a could be a potential noninvasive marker for PDAC prognosis and selection of laparotomy.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	26262588	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Serum miR-21 and miR-34a are potentially useful diagnostic biomarkers of PDAC. In addition, our results suggest that these miRNAs are not differentially expressed in saliva, making them unsuitable for use as noninvasive biomarkers for diagnostic purposes.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Adenocarcinoma, Pancreatic Ductal	26262588	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Serum miR-21 and miR-34a are potentially useful diagnostic biomarkers of PDAC. In addition, our results suggest that these miRNAs are not differentially expressed in saliva, making them unsuitable for use as noninvasive biomarkers for diagnostic purposes.
circulation_biomarker_diagnosis_ns	hsa-mir-100	Adrenal Cortex Neoplasms	24336071	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	In contrast, of the selected eight miRNAs reported in the literature as differentially expressed in ACT tissues, five (hsa-miR-100, hsa-miR-181b, hsa-miR-184, hsa-miR-210 and hsa-miR-483-5p) showed a statistically significant overexpression in adrenocortical cancer vs adenoma when normalized on hsa-miR-16  as a reference gene.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Adrenal Cortex Neoplasms	24336071	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	In contrast, of the selected eight miRNAs reported in the literature as differentially expressed in ACT tissues, five (hsa-miR-100, hsa-miR-181b, hsa-miR-184, hsa-miR-210 and hsa-miR-483-5p) showed a statistically significant overexpression in adrenocortical cancer vs adenoma when normalized on hsa-miR-16  as a reference gene.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Adrenal Cortex Neoplasms	29029450	disease of cellular proliferation	DOID:0050891	C74.0	D000306		HP:0100641	we demonstrated that miR483-5p absolute plasma levels in ACC patients are powerful molecular markers that may help in the follow-up of patients after surgery and chemotherapy, and contribute to more accurately classify and predict tumor progression.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Age-Related Macular Degeneration	27658786	nervous system disease	DOID:10871	H35.30	D008268	PS603075		mir-17, miR-125b and miR-155 were dysregulated in multiple AMD mouse models as well as in human AMD plasma or retinae
circulation_biomarker_diagnosis_ns	hsa-mir-155	Age-Related Macular Degeneration	27658786	nervous system disease	DOID:10871	H35.30	D008268	PS603075		mir-17, miR-125b and miR-155 were dysregulated in multiple AMD mouse models as well as in human AMD plasma or retinae
circulation_biomarker_diagnosis_ns	hsa-mir-17	Age-Related Macular Degeneration	27658786	nervous system disease	DOID:10871	H35.30	D008268	PS603075		mir-17, miR-125b and miR-155 were dysregulated in multiple AMD mouse models as well as in human AMD plasma or retinae
circulation_biomarker_diagnosis_ns	hsa-mir-21	Allergic Asthma	25707810	immune system disease	DOID:9415	J45.909	C564133	600807		Serum MicroRNA-21 as a Biomarker for Allergic Inflammatory Disease in Children.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Allergic Rhinitis	25675113	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	Serum hsa-miR-223 was significantly up-regulated in postseason compared with preseason  samples.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Alzheimer Disease	24139697	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Our results indicate that serum miR-125b may serve as a useful noninvasive biomarker for AD.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Alzheimer Disease	26899870	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Dysregulation of miRNA isoform level at 5' end in Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-136	Alzheimer Disease	26899870	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Dysregulation of miRNA isoform level at 5' end in Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-137	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-137	Alzheimer Disease	26899870	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Dysregulation of miRNA isoform level at 5' end in Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-181c	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Alzheimer Disease	25119742	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's  disease.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-1	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-1	Alzheimer Disease	23435408	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	blood;Expression of the Transcription Factor Sp1 and its Regulatory hsa-miR-29b in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease
circulation_biomarker_diagnosis_ns	hsa-mir-29b-2	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-2	Alzheimer Disease	23435408	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	blood;Expression of the Transcription Factor Sp1 and its Regulatory hsa-miR-29b in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease
circulation_biomarker_diagnosis_ns	hsa-mir-301a	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-545	Alzheimer Disease	23922807	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Circulating miRNA biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-9-1	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-9-2	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-9-3	Alzheimer Disease	22155483	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-98	Alzheimer Disease	24577456	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Amyotrophic Lateral Sclerosis	29670510	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638
circulation_biomarker_diagnosis_ns	hsa-mir-124a	Amyotrophic Lateral Sclerosis	29670510	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638
circulation_biomarker_diagnosis_ns	hsa-mir-206	Amyotrophic Lateral Sclerosis	24586506	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Amyotrophic Lateral Sclerosis	29670510	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638
circulation_biomarker_diagnosis_ns	hsa-mir-638	Amyotrophic Lateral Sclerosis	29670510	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638
circulation_biomarker_diagnosis_ns	hsa-mir-9	Amyotrophic Lateral Sclerosis	29670510	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	We observed significant aberrant dysregulation across our patient cohort for miR-124a, miR-206, miR-9, let-7b, and miR-638
circulation_biomarker_diagnosis_ns	hsa-mir-126	Angiosarcoma	26512652	disease of cellular proliferation	DOID:0001816	C49.9	D006394		HP:0200058	Our findings suggest that these malignant endothelial proliferative diseases over-secreted miR-214 and miR-126, thus suggesting that these miRNAs have potential as diagnostic biomarkers for malignant endothelial proliferative diseases in canine and possible in human angiosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-214	Angiosarcoma	26512652	disease of cellular proliferation	DOID:0001816	C49.9	D006394		HP:0200058	Our findings suggest that these malignant endothelial proliferative diseases over-secreted miR-214 and miR-126, thus suggesting that these miRNAs have potential as diagnostic biomarkers for malignant endothelial proliferative diseases in canine and possible in human angiosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Aortic Aneurysm, Abdominal	28425970	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		Aneurysm-Specific miR-221 and miR-146a Participates in Human Thoracic and Abdominal Aortic Aneurysms.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Aortic Aneurysm, Abdominal	28425970	cardiovascular system disease	DOID:7693	I71.3-.4	D017544	PS100070		Aneurysm-Specific miR-221 and miR-146a Participates in Human Thoracic and Abdominal Aortic Aneurysms.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Aortic Stenosis	23948643	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Preoperative plasma levels of miR-133a reflect their myocardial pression and predict the regression potential of LV hypertrophy after AVR. The value of this bedside information for the surgical timing, particularly in asymptomatic aortic stenosis patients, deserves confirmation in further clinical studies.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Aplastic Anemia	27658437	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	A plasma microRNA signature as a biomarker for acquired aplastic anemia.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Aplastic Anemia	27658437	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	A plasma microRNA signature as a biomarker for acquired aplastic anemia.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Aplastic Anemia	27658437	hematopoietic system disease	DOID:12449	D61.9	D000741	609135	HP:0001915	A plasma microRNA signature as a biomarker for acquired aplastic anemia.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Arteriosclerosis Obliterans	27900989	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Negative Association of Circulating MicroRNA-126 with High-sensitive C-reactive Protein and Vascular Cell Adhesion Molecule-1 in Patients with Coronary Artery Disease Following Percutaneous Coronary Intervention.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-100	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-126	Atherosclerosis	28785651	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Circulating level of microRNA-126 may be a potential biomarker for recovery from smoking-related vascular damage in middle-aged habitual smokers.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Atherosclerosis	29531852	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-4p
circulation_biomarker_diagnosis_ns	hsa-mir-127	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-133a-1	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-145	Atherosclerosis	21817153	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-21	Atherosclerosis	27785570	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Atherosclerosis	29531852	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-3p
circulation_biomarker_diagnosis_ns	hsa-mir-210	Atherosclerosis	20888330	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The serum levels of miR-130a, miR-27b and miR-210 may serve as potential biomarkers for early stage ASO.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Atherosclerosis	28301500	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Atherosclerosis	20888330	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The serum levels of miR-130a, miR-27b and miR-210 may serve as potential biomarkers for early stage ASO.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Atherosclerosis	28301500	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Atherosclerosis	29531852	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-5p
circulation_biomarker_diagnosis_ns	hsa-mir-222	Atherosclerosis	20888330	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The serum levels of miR-130a, miR-27b and miR-210 may serve as potential biomarkers for early stage ASO.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Atherosclerosis	28301500	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-27b	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Atherosclerosis	27997904	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	The Relationship of Plasma miR-29a and Oxidized Low Density Lipoprotein with Atherosclerosis.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-30	Atherosclerosis	29531852	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A common microRNA profile to different atherosclerotic disease locations was identified, including deregulation of miR-21, miR-30, miR-126, and miR-221-3p
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Atherosclerosis	26333279	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-33a	Atherosclerosis	27664032	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Aberrant expression of plasma microRNA-33a in an atherosclerosis-risk group.
circulation_biomarker_diagnosis_ns	hsa-mir-1266	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-3149	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-3171	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-4279	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-4666a	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-892a	Atrial Fibrillation	27855199	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The Values of Coronary Circulating miRNAs in Patients with Atrial Fibrillation.
circulation_biomarker_diagnosis_ns	hsa-mir-103a	Autism Spectrum Disorder	26061495	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	this study provides the first global miRNA expression profile of ASD in China. The differentially expressed miR-34b may potentially explain the higher percentage of male ASD patients, and the aberrantly expressed miR-103a-3p may contribute to the abnormal ubiquitin-mediated proteolysis observed in ASD.
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Autism Spectrum Disorder	26061495	disease of mental health	DOID:0060041	F84.0	D000067877	209850	HP:0000729	this study provides the first global miRNA expression profile of ASD in China. The differentially expressed miR-34b may potentially explain the higher percentage of male ASD patients, and the aberrantly expressed miR-103a-3p may contribute to the abnormal ubiquitin-mediated proteolysis observed in ASD.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Autoimmune Lymphoproliferative Syndrome	27060458	immune system disease	DOID:6688	D89.82	D056735	PS308240		miR-21-3p was over-expressed significantly (P = 0路0313) in the son, with no significant change in the expression of miR-146a, miR-146a-3p and miR-21.
circulation_biomarker_diagnosis_ns	hsa-mir-139	Behcet Disease	26486198	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		miR199-3p and miR720 deserve further confirmation as biomarkers of BD in larger studies. PBMCs from active BD displayed a unique signature of microRNAs which may be implicated in regulation of innate immunity activation and T-cell function.
circulation_biomarker_diagnosis_ns	hsa-mir-720	Behcet Disease	26486198	cardiovascular system disease	DOID:13241	M35.2	D001528	109650		miR199-3p and miR720 deserve further confirmation as biomarkers of BD in larger studies. PBMCs from active BD displayed a unique signature of microRNAs which may be implicated in regulation of innate immunity activation and T-cell function.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Biliary Tract Neoplasms	24118467	disease of cellular proliferation	DOID:0050625	C24.9	D001661		HP:0100574	Plasma miR-21 is a novel diagnostic biomarker for BTC, and may be useful in distinguishing between BTC and BBD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Bladder Neoplasms	26489968			C67	D001749	109800	HP:0009725	MiRNAs detected in urine and serum/plasma will demonstrate their potentiality to describe the variegated scenario of BC and to become relevant clinical markers.
circulation_biomarker_diagnosis_ns	hsa-mir-152	Bladder Neoplasms	24961907			C67	D001749	109800	HP:0009725	expression level of serum miR-152 could provide information on the recurrence risk of NMIBC.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Bladder Neoplasms	26252880			C67	D001749	109800	HP:0009725	Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-497	Bladder Neoplasms	26014226			C67	D001749	109800	HP:0009725	Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-663a	Bladder Neoplasms	26014226			C67	D001749	109800	HP:0009725	Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Bladder Neoplasms	26489968			C67	D001749	109800	HP:0009725	MiRNAs detected in urine and serum/plasma will demonstrate their potentiality to describe the variegated scenario of BC and to become relevant clinical markers.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-32	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-744	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-mir-886	Brain Disease [unspecific]	25947950	nervous system disease	DOID:936	G93.40	D001927	608033		MiRNAs are detectable in cerebral microdialysate; a large group of miRNAs consistently showed a high RR in cerebral microdialysate. Measurement of cerebral interstitial miRNA concentrations may aid in the investigation of secondary brain injury in neurocritical conditions.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Breast Neoplasms	29683112	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of serum ncRNAs, including let-7a, miR-155, miR-574-5p, and MALAT1, was shown to be present in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-10	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-100	Breast Neoplasms	25722304	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.
circulation_biomarker_diagnosis_ns	hsa-mir-105	Breast Neoplasms	24735924	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-105 can be detected in the circulation at the premetastatic stage, and its levels in the blood and tumor are associated with ZO-1 expression and metastatic progression in early-stage breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Breast Neoplasms	26033453	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Breast Neoplasms	25004125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Breast Neoplasms	23238818	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers
circulation_biomarker_diagnosis_ns	hsa-mir-122	Breast Neoplasms	22400902	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Two circulating miRNAs, miR-375 and miR-122, exhibited strong correlations with clinical outcomes, including NCT response and relapse with metastatic disease.miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Breast Neoplasms	26749252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Novel combination of serum microRNA for detecting breast cancer in the early stage.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Breast Neoplasms	26056355	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-127	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1307	Breast Neoplasms	26749252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Novel combination of serum microRNA for detecting breast cancer in the early stage.
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Breast Neoplasms	26033453	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-140	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Breast Neoplasms	26124344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-146	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Breast Neoplasms	26033453	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Breast Neoplasms	25004125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-148b	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Breast Neoplasms	23071695	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum microRNA-155 as a potential biomarker to track disease in breast cancer
circulation_biomarker_diagnosis_ns	hsa-mir-155	Breast Neoplasms	23748853	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Breast Neoplasms	29683112	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of serum ncRNAs, including let-7a, miR-155, miR-574-5p, and MALAT1, was shown to be present in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Breast Neoplasms	26033453	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-16-1	Breast Neoplasms	22298638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-16-2	Breast Neoplasms	22298638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Breast Neoplasms	23748853	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-183	Breast Neoplasms	26124344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Breast Neoplasms	20576643	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A combination of three circulating miRNAs, including miR-195, further enhanced the discriminative power of this test for breast cancer to 94%.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Breast Neoplasms	26476723	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Breast Neoplasms	25516467	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 is a potential biomarker for early diagnosis of breast cancer with high sensitivity and specificity, and its clinical application warrants further investigation
circulation_biomarker_diagnosis_ns	hsa-mir-21	Breast Neoplasms	26056355	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Breast Neoplasms	26063582	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In conclusion, our findings demonstrate that serum miR-21 expression profile may serve as a potential non-invasive diagnostic and prognostic biomarker for breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Breast Neoplasms	27311114	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MicroRNA-21 (miR-21) is a promising diagnostic biomarker for breast cancer screening and disease progression
circulation_biomarker_diagnosis_ns	hsa-mir-210	Breast Neoplasms	22370716	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-215	Breast Neoplasms	22353773	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-221	Breast Neoplasms	22156446	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression level of miR-221 was significantly associated with hormone receptor (HR) status (p = 0.008). Patients with higher plasma miR-221 levels tended to be HR-negative. Patients with different miR-221 levels had significant differences in the overall response rate (p = 0.044) but not in the pathologic complete response rate (p = 0.477).
circulation_biomarker_diagnosis_ns	hsa-mir-222	Breast Neoplasms	22298638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Breast Neoplasms	25004125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Breast Neoplasms	22298638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-299	Breast Neoplasms	22353773	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Breast Neoplasms	26476723	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-301a	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-324	Breast Neoplasms	22298638	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-338	Breast Neoplasms	25004125	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Breast Neoplasms	23748853	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression.
circulation_biomarker_diagnosis_ns	hsa-mir-373	Breast Neoplasms	23238818	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers
circulation_biomarker_diagnosis_ns	hsa-mir-373	Breast Neoplasms	23748853	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Breast Neoplasms	22400902	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Two circulating miRNAs, miR-375 and miR-122, exhibited strong correlations with clinical outcomes, including NCT response and relapse with metastatic disease.miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients.
circulation_biomarker_diagnosis_ns	hsa-mir-376a	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-409	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-411	Breast Neoplasms	22353773	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-423	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-424	Breast Neoplasms	26476723	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-451	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Breast Neoplasms	26124344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-452	Breast Neoplasms	22353773	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-4634	Breast Neoplasms	26749252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Novel combination of serum microRNA for detecting breast cancer in the early stage.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Breast Neoplasms	26056355	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-520h	Breast Neoplasms	25982274	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-520h is crucial for DAPK2 regulation and breast cancer progression.
circulation_biomarker_diagnosis_ns	hsa-mir-574	Breast Neoplasms	29683112	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	A panel of serum ncRNAs, including let-7a, miR-155, miR-574-5p, and MALAT1, was shown to be present in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-652	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-652	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-6861	Breast Neoplasms	26749252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Novel combination of serum microRNA for detecting breast cancer in the early stage.
circulation_biomarker_diagnosis_ns	hsa-mir-6875	Breast Neoplasms	26749252	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Novel combination of serum microRNA for detecting breast cancer in the early stage.
circulation_biomarker_diagnosis_ns	hsa-mir-708	Breast Neoplasms	26124344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-801	Breast Neoplasms	24194846	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Plasma microRNA panel for minimally invasive detection of breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-92	Breast Neoplasms	24584717	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Breast Neoplasms	24498016	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.
circulation_biomarker_diagnosis_ns	hsa-mir-96	Breast Neoplasms	26056355	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Bronchopulmonary Dysplasia	26291337			P27.1	D001997			Our data are the first to demonstrate altered expression of the miR-17-92 cluster in bronchopulmonary dysplasia. The consistency between our autopsy and plasma findings further support our working hypothesis that the miR-17-92 cluster contributes to the molecular pathogenesis of bronchopulmonary dysplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Carcinoma, Adrenocortical	23756429	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Carcinoma, Adrenocortical	24238045	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	We show that dysregulated miRNAs in ACC are detectable in human serum samples. MiR-34a and miR-483-5p are candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Carcinoma, Adrenocortical	23756429	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Carcinoma, Adrenocortical	24238045	endocrine system disease	DOID:3948		D018268	202300	HP:0006744	We show that dysregulated miRNAs in ACC are detectable in human serum samples. MiR-34a and miR-483-5p are candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-4294	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-4476	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-4530	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-6075	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-6799	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-6836	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-6880	Carcinoma, Biliary Tract	25706130	disease of cellular proliferation	DOID:4897	K83.9	D001650		HP:0030153	Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Carcinoma, Bladder	28239818	urinary system disease	DOID:4007	D09.0	D001749	109800	HP:0002862	Identification of miR-146b-5p in tissues as a novel biomarker for prognosis of gallbladder carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Carcinoma, Breast	28058628			D05	D001943	114480	HP:0003002	A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Carcinoma, Breast	28359916			D05	D001943	114480	HP:0003002	Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Breast	25431259			D05	D001943	114480	HP:0003002	MiR-21 has a relatively high diagnostic value for detecting breast cancer, and miR-21 assays based on plasma, serum, and tissue achieved relatively higher accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Breast	28058628			D05	D001943	114480	HP:0003002	A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-27b	Carcinoma, Breast	28058628			D05	D001943	114480	HP:0003002	A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Carcinoma, Breast	28359916			D05	D001943	114480	HP:0003002	Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Carcinoma, Breast	28178621			D05	D001943	114480	HP:0003002	Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-374b	Carcinoma, Breast	28359916			D05	D001943	114480	HP:0003002	Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
circulation_biomarker_diagnosis_ns	hsa-mir-942	Carcinoma, Breast	28359916			D05	D001943	114480	HP:0003002	Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
circulation_biomarker_diagnosis_ns	hsa-mir-96	Carcinoma, Breast	28359916			D05	D001943	114480	HP:0003002	Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Breast, Triple Negative	28078851				D064726			Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-127	Carcinoma, Cervical	25701838	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Plasma miR-127 and miR-218 Might Serve as Potential Biomarkers for Cervical Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-16-2	Carcinoma, Cervical	26656154	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Carcinoma, Cervical	26656154	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Carcinoma, Cervical	26782446	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Clinical significance of serum miR-196a in cervical intraepithelial neoplasia and cervical cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-218	Carcinoma, Cervical	25701838	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Plasma miR-127 and miR-218 Might Serve as Potential Biomarkers for Cervical Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-2861	Carcinoma, Cervical	26656154	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-497	Carcinoma, Cervical	26656154	disease of cellular proliferation	DOID:2893	D06.9	D002583	603956	HP:0030159	Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Carcinoma, Colon	27485599	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Carcinoma, Colon	27798914	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Carcinoma, Colon	27872469	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Preoperative Serum MicroRNA-155 Expression Independently Predicts Postoperative Cognitive Dysfunction After Laparoscopic Surgery for Colon Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Colon	27798914	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Colon	27910062	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Plasma and saliva miR-21 expression in colorectal cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Colon	28376502	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Colon	27798914	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Carcinoma, Colon	27485599	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	A diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors with sensitivity of 89% and specificity of 81% (AUC = 0.922).
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Carcinoma, Colon	27485599	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	A diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors with sensitivity of 89% and specificity of 81% (AUC = 0.922).
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Carcinoma, Colon	25894979	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Carcinoma, Colon	25894979	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Carcinoma, Colon	27485599	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	A diagnostic four-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors with sensitivity of 89% and specificity of 81% (AUC = 0.922).
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Esophageal	24968850	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	Both salivary and plasmatic miR-21 can be sensitive biomarkers for EC, and salivary miR-21 detection has the potential to replace plasma detection for EC diagnosis.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-187	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-202	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Carcinoma, Gallbladder	25861754	disease of cellular proliferation	DOID:4948	C23	D005706			Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Carcinoma, Gastric	27909811	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Carcinoma, Gastric	27909811	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-125	Carcinoma, Gastric	27986464	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-194	Carcinoma, Gastric	27909811	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Carcinoma, Gastric	27614739	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Diagnostic and Prognostic Value of Serum MicroRNA-206 in Patients with Gastric Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Gastric	28121346	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	miR-21 can be used for the diagnosis of gastric cancer and prognosis of lymph node metastasis in gastric cancer
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Gastric	28641313	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331.
circulation_biomarker_diagnosis_ns	hsa-mir-331	Carcinoma, Gastric	28641313	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331.
circulation_biomarker_diagnosis_ns	hsa-mir-383	Carcinoma, Gastric	28243881	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	The Value of MiR-383, an Intronic MiRNA, as a Diagnostic and Prognostic Biomarker in Intestinal-Type Gastric Cancer.
circulation_biomarker_diagnosis_ns	hsa-let-7f	Carcinoma, Hepatocellular	24697119	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Carcinoma, Hepatocellular	23810247	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data indicate that serum miR-1 is a new independent parameter of OS in HCC patients and may therefore improve the predictive value of classical HCC staging scores.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Carcinoma, Hepatocellular	25894380	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We found that plasma miR-106b has clinical value in the detection of HCC from healthy people and CLD patients. Further large-scale study may be needed to validate our findings.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Carcinoma, Hepatocellular	29312570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA signatures and metabolomics have high diagnostic value in hepatocellular carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-107	Carcinoma, Hepatocellular	28079796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Carcinoma, Hepatocellular	28049231	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	23723713	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	23810247	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our data indicate that serum miR-1 is a new independent parameter of OS in HCC patients and may therefore improve the predictive value of classical HCC staging scores.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	26133725	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The combination of serum miR-16 and serum AFP is a significant improvement on the current best practice of serum AFP for HCC in HCVpositive patients. Serum miR-199a and miR-16 could be used as potential indicators of the progress of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	28750770	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-199a can help to differentiate HCC from CHC and LC
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Carcinoma, Hepatocellular	26637228	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A combination of serum miR-125b, miR-223, miR-27a, and miR-26a as a second-line tests could help detect  HCC in AFP (-) subjects.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Carcinoma, Hepatocellular	26756996	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-139	Carcinoma, Hepatocellular	27633066	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Reanalysis of microRNA expression profiles identifies novel biomarkers for hepatocellular carcinoma prognosis.
circulation_biomarker_diagnosis_ns	hsa-mir-139	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-200a can help to differentiate HCC from CHC and LC
circulation_biomarker_diagnosis_ns	hsa-mir-143	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-201a can help to differentiate HCC from CHC and LC
circulation_biomarker_diagnosis_ns	hsa-mir-155	Carcinoma, Hepatocellular	27751368	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Relationship Between Serum microRNA155 and Telomerase Expression in Hepatocellular Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Carcinoma, Hepatocellular	26119771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating miR-15b-5p, miR-338-5p, and miR-764 may be biomarkers for diagnosis of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Hepatocellular	24697119	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Hepatocellular	26133725	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The combination of serum miR-16 and serum AFP is a significant improvement on the current best practice of serum AFP for HCC in HCVpositive patients. Serum miR-199a and miR-18 could be used as potential indicators of the progress of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Hepatocellular	28079796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Carcinoma, Hepatocellular	25391771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-8p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at  cirrhosis stage of liver disease.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Carcinoma, Hepatocellular	29312570	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA signatures and metabolomics have high diagnostic value in hepatocellular carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-183	Carcinoma, Hepatocellular	26278140	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Sensitivity and specificity of miR-183 as a diagnostic marker of HCC were 57.9% and 76.2% in serum, and 78.9% and 81.0% in plasma
circulation_biomarker_diagnosis_ns	hsa-mir-192	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Carcinoma, Hepatocellular	25618599	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	circulating miR-199a-3p showed better predictive value in patients with long-term drinking. Our data suggested that circulating miR-375 and miR-199a-3p could be a novel serum biomarker for HCC. Nevertheless, further validating and improving study with larger sample should be conducted to confirm our results.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Carcinoma, Hepatocellular	26133725	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The combination of serum miR-16 and serum AFP is a significant improvement on the current best practice of serum AFP for HCC in HCVpositive patients. Serum miR-199a and miR-17 could be used as potential indicators of the progress of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	using miRNA panel of miR-22 and miR-199a-3p with AFP provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-202a can help to differentiate HCC from CHC and LC
circulation_biomarker_diagnosis_ns	hsa-mir-200	Carcinoma, Hepatocellular	26447841	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating microRNA-200 family members are significantly deregulated in patients with HCC and liver cirrhosis. Further studies are necessary to confirm the diagnostic value of the microRNA-200 family as accurate serum marker for cirrhosis-associated HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Carcinoma, Hepatocellular	25391771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-9p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at  cirrhosis stage of liver disease.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	24697119	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-16, let-7f, and miR-21 are related with the biological behavior of HCC, which means that they could be considered as the potential indicators to estimate the tumor size or the recurrence of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	24963487	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	26114756	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our current findings suggested that circulating miR-21 can serve as a potential co-biomarker for early-stage HCC diagnosis. Thorough large-scale studies are needed to confirm the generalizability of our findings.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	25973032	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC):clinical analyses of patients and an HCC rat model.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	29215815	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Combination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC
circulation_biomarker_diagnosis_ns	hsa-mir-22	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	using miRNA panel of miR-22 and miR-199a-3p with AFP provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	using miRNA panel of miR-122, miR-885-5p, miR-221, and miR-22 with AFP provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-223	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Carcinoma, Hepatocellular	25391771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-6p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at  cirrhosis stage of liver disease.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Carcinoma, Hepatocellular	26776075	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-30e and miR-224 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Carcinoma, Hepatocellular	28878865	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA 23a can be used as a screening test for early detection of HCC
circulation_biomarker_diagnosis_ns	hsa-mir-24	Carcinoma, Hepatocellular	25129312	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Carcinoma, Hepatocellular	29215815	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Combination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC
circulation_biomarker_diagnosis_ns	hsa-mir-26a-1	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-26a-2	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Carcinoma, Hepatocellular	22105822	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	We identified a microRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a and miR-801) that provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively). The satisfactory diagnostic performance of the microRNA panel persisted regardless of disease status (AUCs for Barcelona Clinic Liver Cancer stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively). The microRNA panel can also differentiate HCC from healthy (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Carcinoma, Hepatocellular	29215815	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Combination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-302c	Carcinoma, Hepatocellular	25391771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-7p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at  cirrhosis stage of liver disease.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Carcinoma, Hepatocellular	25391771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers of HCV-positive HCC in very early, even at  cirrhosis stage of liver disease.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Carcinoma, Hepatocellular	26776075	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-30e and miR-223 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-3126	Carcinoma, Hepatocellular	28079796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-338	Carcinoma, Hepatocellular	26119771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating miR-15b-5p, miR-338-5p, and miR-764 may be biomarkers for diagnosis of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Carcinoma, Hepatocellular	27893432	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Carcinoma, Hepatocellular	25618599	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	circulating miR-199a-3p showed better predictive value in patients with long-term drinking. Our data suggested that circulating miR-375 and miR-199a-3p could be a novel serum biomarker for HCC. Nevertheless, further validating and improving study with larger sample should be conducted to confirm our results.
circulation_biomarker_diagnosis_ns	hsa-mir-494	Carcinoma, Hepatocellular	26509672	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Carcinoma, Hepatocellular	26088272	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-519d	Carcinoma, Hepatocellular	26509672	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment.
circulation_biomarker_diagnosis_ns	hsa-mir-595	Carcinoma, Hepatocellular	26509672	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment.
circulation_biomarker_diagnosis_ns	hsa-mir-764	Carcinoma, Hepatocellular	26119771	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating miR-15b-5p, miR-338-5p, and miR-764 may be biomarkers for diagnosis of HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Carcinoma, Hepatocellular	27271989	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-92	Carcinoma, Hepatocellular	28079796	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-939	Carcinoma, Hepatocellular	26509672	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Therefore, we show that circulating microRNAs deserve attention as non-invasive biomarkers in the diagnostic setting of HCC and that exosomal secretion contributes to discharging a subset of microRNAs into the extracellular compartment.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Carcinoma, Hepatocellular, HBV-Related	25814782							These findings highlight the importance of validating reference genes before quantifying target miRNAs.Furthermore, our findings will improve studies that monitor hepatitis progression and will aid in the discovery of noninvasive biomarkers to diagnose early stage HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Carcinoma, Hepatocellular, HBV-Related	26267843							The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression.
circulation_biomarker_diagnosis_ns	hsa-mir-200a	Carcinoma, Hepatocellular, HBV-Related	25519019							only in the HCC group, miR-18a, miR-100, miR-145 and miR-223 were up-regulated 3.48-, 2.95-, 2.12- and 3.91-fold, respectively, and miR-200a and miR-222 were down-regulated 2.56- and 2.00-fold, respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular, HBV-Related	26267843							The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Carcinoma, Hepatocellular, HBV-Related	26267843							The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression.
circulation_biomarker_diagnosis_ns	hsa-mir-374a	Carcinoma, Hepatocellular, HBV-Related	26267843							The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression.
circulation_biomarker_diagnosis_ns	hsa-mir-542	Carcinoma, Hepatocellular, HBV-Related	26267843							The miRNA expression profile of PBMCs is altered in patients with HBV-ACLF, and a signature of six miRNAs may be a promising biomarker for HBV-ACLF progression.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Carcinoma, Hepatocellular, HCV-Related	26272105							This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Hepatocellular, HCV-Related	26272105							This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Hepatocellular, HCV-Related	26272105							This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Carcinoma, Hepatocellular, HCV-Related	26272105							This study shows that some microRNAs are differently expressed in peripheral blood mononuclear cells from hepatitis C virus patients who develop hepatocellular carcinoma or lymphoma, while others share a common behavior. Thus,analysis of the expression of microRNAs could be a noninvasive marker of hepatitis C virus-related carcinogenesis. This analysis could be a suitable tool for identifying the existence of a malignancy and also discriminating between these two hepatitis C virus-related cancers.
circulation_biomarker_diagnosis_ns	hsa-mir-183	Carcinoma, Lung	27768748	disease of cellular proliferation	DOID:3905	C34.90	D008175			Plasma miR-19b and miR-183 as Potential Biomarkers of Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Carcinoma, Lung	26146958	disease of cellular proliferation	DOID:3905	C34.90	D008175			The assessment of miRs-19b-3p and -29b-3p miRNAs may provide a new diagnostic approach for the early detection of non-small cell lung cancer
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Carcinoma, Lung	27768748	disease of cellular proliferation	DOID:3905	C34.90	D008175			Plasma miR-19b and miR-183 as Potential Biomarkers of Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Lung	24865991	disease of cellular proliferation	DOID:3905	C34.90	D008175			The current evidence suggests that serum miR-21 can be rapidly measured in lung carcinoma patients and has potential diagnostic value with moderate sensitivity and specificity. Further prospective studies to assess the early stage diagnostic value are needed in the future.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Carcinoma, Lung, Non-Small-Cell	28055956			C34.90	D002289		HP:0030358	Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	28253725			C34.90	D002289		HP:0030358	Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Carcinoma, Lung, Non-Small-Cell	28002496			C34.90	D002289		HP:0030358	a combination of miRs 21, 205, 155 and possibly other miRs as serum biomarkers for early detection of NSCLC
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Lung, Non-Small-Cell	28634901			C34.90	D002289		HP:0030358	Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Carcinoma, Lung, Non-Small-Cell	27733164			C34.90	D002289		HP:0030358	Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Carcinoma, Lung, Non-Small-Cell	23342174			C34.90	D002289		HP:0030358	a three-miRNA plasma panel (high miR-20a-5p, low miR-152-3p, and low miR-199a-5p) significantly predicted survival of squamous cell carcinoma patients. In conclusion, we identified two plasma miRNA expression profiles that may be useful for predicting the outcome of patients with resectable NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	28634901			C34.90	D002289		HP:0030358	Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	28002496			C34.90	D002289		HP:0030358	a combination of miRs 21, 205, 155 and possibly other miRs as serum biomarkers for early detection of NSCLC
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Carcinoma, Lung, Non-Small-Cell	26672767			C34.90	D002289		HP:0030358	Among the top markers that were concordant between both studies we found hsa-miR-20b-5p, hsa-miR-20a-5p, hsa-miR-17-5p, and hsa-miR-106a-5p.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	28055956			C34.90	D002289		HP:0030358	Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	28002496			C34.90	D002289		HP:0030358	a combination of miRs 21, 205, 155 and possibly other miRs as serum biomarkers for early detection of NSCLC
circulation_biomarker_diagnosis_ns	hsa-mir-22	Carcinoma, Lung, Non-Small-Cell	28253725			C34.90	D002289		HP:0030358	Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study.
circulation_biomarker_diagnosis_ns	hsa-mir-23b	Carcinoma, Lung, Non-Small-Cell	28055956			C34.90	D002289		HP:0030358	Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-372	Carcinoma, Lung, Non-Small-Cell	27122989			C34.90	D002289		HP:0030358	A sputum mir-21, mir-210, and mir-372 expression profile might provide a sensitive and highly specific means for detecting nsclc.
circulation_biomarker_diagnosis_ns	hsa-mir-10a	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Carcinoma, Lung, Non-Small-Cell	25755772			C34.90	D002289		HP:0030358	These preliminary data suggest that serum miR-125a-5p, miR-145 and miR-146a may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	22009180			C34.90	D002289		HP:0030358	There was statistical difference in the serum levels for hsa-miR-126, hsa-miR-183, and hsa-miR-222 between the controls and the Stage IV patients (metastatic non-small-cell lung cancer). It also showed statistical difference for hsa-miR-126 and hsa-miR-183 between the Stage I/II patients and Stage IV patients.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-141	Carcinoma, Lung, Non-Small-Cell	26202143			C34.90	D002289		HP:0030358	we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-145	Carcinoma, Lung, Non-Small-Cell	25755772			C34.90	D002289		HP:0030358	These preliminary data suggest that serum miR-125a-5p, miR-145 and miR-146a may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Carcinoma, Lung, Non-Small-Cell	25755772			C34.90	D002289		HP:0030358	These preliminary data suggest that serum miR-125a-5p, miR-145 and miR-146a may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-148	Carcinoma, Lung, Non-Small-Cell	25904302			C34.90	D002289		HP:0030358	The results of present study suggest that the expression levels of circulating miR-148/152 family may serve as biomarkers for NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-152	Carcinoma, Lung, Non-Small-Cell	25904302			C34.90	D002289		HP:0030358	The results of present study suggest that the expression levels of circulating miR-148/152 family may serve as biomarkers for NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-183	Carcinoma, Lung, Non-Small-Cell	22009180			C34.90	D002289		HP:0030358	There was statistical difference in the serum levels for hsa-miR-126, hsa-miR-183, and hsa-miR-222 between the controls and the Stage IV patients (metastatic non-small-cell lung cancer). It also showed statistical difference for hsa-miR-126 and hsa-miR-183 between the Stage I/II patients and Stage IV patients.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Carcinoma, Lung, Non-Small-Cell	26629532			C34.90	D002289		HP:0030358	This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Carcinoma, Lung, Non-Small-Cell	26202143			C34.90	D002289		HP:0030358	we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Carcinoma, Lung, Non-Small-Cell	26202143			C34.90	D002289		HP:0030358	we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Carcinoma, Lung, Non-Small-Cell	23881177			C34.90	D002289		HP:0030358	Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	23881177			C34.90	D002289		HP:0030358	Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Carcinoma, Lung, Non-Small-Cell	24065453			C34.90	D002289		HP:0030358	These findings suggest that serum miR-210 levels might be a novel diagnostic and prognostic marker of NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-214	Carcinoma, Lung, Non-Small-Cell	26629532			C34.90	D002289		HP:0030358	This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients
circulation_biomarker_diagnosis_ns	hsa-mir-222	Carcinoma, Lung, Non-Small-Cell	22009180			C34.90	D002289		HP:0030358	There was statistical difference in the serum levels for hsa-miR-126, hsa-miR-183, and hsa-miR-222 between the controls and the Stage IV patients (metastatic non-small-cell lung cancer). It also showed statistical difference for hsa-miR-126 and hsa-miR-183 between the Stage I/II patients and Stage IV patients.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Carcinoma, Lung, Non-Small-Cell	26629532			C34.90	D002289		HP:0030358	This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients
circulation_biomarker_diagnosis_ns	hsa-mir-301	Carcinoma, Lung, Non-Small-Cell	26202143			C34.90	D002289		HP:0030358	we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted.
circulation_biomarker_diagnosis_ns	hsa-mir-30d	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-451b	Carcinoma, Lung, Non-Small-Cell	23756108			C34.90	D002289		HP:0030358	Plasma miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed
circulation_biomarker_diagnosis_ns	hsa-mir-483	Carcinoma, Lung, Non-Small-Cell	26629532			C34.90	D002289		HP:0030358	This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients
circulation_biomarker_diagnosis_ns	hsa-mir-486	Carcinoma, Lung, Non-Small-Cell	26237047			C34.90	D002289		HP:0030358	The results suggest that miR-486 and miR-150 could be potential blood-based biomarkers for early diagnosis of NSCLC. Monitoring change of miR-486 expression in plasma might be an effective and non-invasive method for recurrence prediction of early-staged NSCLC patients.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Carcinoma, Lung, Non-Small-Cell	24549225			C34.90	D002289		HP:0030358	Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-7	Carcinoma, Lung, Non-Small-Cell	26629532			C34.90	D002289		HP:0030358	This serum miRNA panel holds the potential for diagnosing ethnically diverse NSCLC patients
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Carcinoma, Lung, Small-Cell	28106539			C34.90	D055752	182280	HP:0030357	Plasma miR-92a-2 as a biomarker for small cell lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Nasopharyngeal	24025417	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	plasma miRNA expression is a useful biomarker for NPC diagnosis but not for its prognosis. More importantly, it is simple, effective, and non-invasive. Combination of several plasma miRNAs can increase both NPC diagnostic sensitivity and specificity. miR-329,hsa-mir-487b,hsa-mir-494,hsa-mir-495
circulation_biomarker_diagnosis_ns	hsa-mir-24	Carcinoma, Nasopharyngeal	26018275	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Plasma miR-24 may serve as a novel molecular biomarker for early diagnosis and prognosis of NPC.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Carcinoma, Nasopharyngeal	24874644	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-548q	Carcinoma, Nasopharyngeal	24874644	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-9	Carcinoma, Nasopharyngeal	24327016	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Our study reports that plasma miR-9 may serve as a useful biomarker to predict NPC metastasis and to monitor tumour dynamics.
circulation_biomarker_diagnosis_ns	hsa-mir-27b	Carcinoma, Oral	22902387	gastrointestinal system disease	DOID:0050610					miR-27b-regulated TCTP as a novel plasma biomarker for oral cancer: From quantitative proteomics to post-transcriptional study.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Carcinoma, Ovarian	27092777	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Carcinoma, Ovarian	27062783	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Expression of MiR-130a in Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Carcinoma, Ovarian, Serous	28017893	endocrine system disease	DOID:0050933					Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Carcinoma, Pancreatic	28232049			C25.3	C562463	260350	HP:0002894	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Carcinoma, Pancreatic	28232049			C25.3	C562463	260350	HP:0002894	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Carcinoma, Pancreatic	28232049			C25.3	C562463	260350	HP:0002894	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-191	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Pancreatic	28232049			C25.3	C562463	260350	HP:0002894	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Carcinoma, Pancreatic	27631726			C25.3	C562463	260350	HP:0002894	Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-25	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-25	Carcinoma, Pancreatic	27639768			C25.3	C562463	260350	HP:0002894	Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Carcinoma, Pancreatic	28232049			C25.3	C562463	260350	HP:0002894	A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-323	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-345	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-483	Carcinoma, Pancreatic	27464352			C25.3	C562463	260350	HP:0002894	We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p,  -191, -323.3p, -345 and -483.5p).
circulation_biomarker_diagnosis_ns	hsa-mir-642b	Carcinoma, Pancreatic	27631726			C25.3	C562463	260350	HP:0002894	Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Carcinoma, Pancreatic	27631726			C25.3	C562463	260350	HP:0002894	Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Carcinoma, Prostate	28091918	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-297	Carcinoma, Prostate	28091918	disease of cellular proliferation	DOID:10286	D07.5	D011471	176807	HP:0012125	Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Rectal	20880178	disease of cellular proliferation	DOID:1993	C20	D012004			The direct amplification of plasma miR-221 can be used as a potential noninvasive molecular marker for diagnosis and prognosis of CRC and is correlated with p53 expression.
circulation_biomarker_diagnosis_ns	hsa-mir-106a	Carcinoma, Renal Cell	27814278	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-1233	Carcinoma, Renal Cell	29262564	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Renal Cell	27814278	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Carcinoma, Renal Cell	23064048	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-210	Carcinoma, Renal Cell	26426010	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Carcinoma, Renal Cell	29262564	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Renal Cell	25909813	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Renal Cell	29262564	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-222	Carcinoma, Renal Cell	25909813	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression.
circulation_biomarker_diagnosis_ns	hsa-mir-378	Carcinoma, Renal Cell	26426010	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-7	Carcinoma, Renal Cell	25909813	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Carcinoma, Renal Cell, Clear-Cell	24212760	disease of cellular proliferation	DOID:4467				HP:0006770	Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-148b	Carcinoma, Thyroid, Follicular	27473101	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	The best two-miRNA classifier (miR-484/miR-148b-3p) identified thyroid malignancy with a sensitivity of 89鈥? and a specificity of 87鈥?.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Carcinoma, Thyroid, Papillary	26341226	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-10a	Carcinoma, Thyroid, Papillary	26341226	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Carcinoma, Thyroid, Papillary	28288173	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Microarray profiling of circular RNAs in human papillary thyroid carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Carcinoma, Thyroid, Papillary	26341226	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Carcinoma, Thyroid, Papillary	24301304	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This study demonstrated that tumor levels of miR-222 and miR-146b are associated with PTC recurrence and that miR-222 and miR-146b levels in the circulation correspond to the presence of PTC. The potential of these miRNAs as tumor biomarkers to improve patient stratification according to the risk of recurrence and as circulating biomarkers for PTC surveillance warrants further study.
circulation_biomarker_diagnosis_ns	hsa-mir-199b	Carcinoma, Thyroid, Papillary	26341226	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-200a	Carcinoma, Thyroid, Papillary	28288173	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Microarray profiling of circular RNAs in human papillary thyroid carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Carcinoma, Thyroid, Papillary	28061868	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Carcinoma, Thyroid, Papillary	24301304	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	This study demonstrated that tumor levels of miR-222 and miR-146b are associated with PTC recurrence and that miR-222 and miR-146b levels in the circulation correspond to the presence of PTC. The potential of these miRNAs as tumor biomarkers to improve patient stratification according to the risk of recurrence and as circulating biomarkers for PTC surveillance warrants further study.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Carcinoma, Thyroid, Papillary	26168287	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Carcinoma, Thyroid, Papillary	26168287	disease of cellular proliferation	DOID:3969	C73	C536915	188550	HP:0002895	Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-let-7c	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-let-7f	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-10a	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-1244	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-135	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-33b	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-429	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-431	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-520b	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-664a	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Carcinoma, Urothelial, Upper Tract	26323574							Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection.
circulation_biomarker_diagnosis_ns	hsa-mir-96	Carcinoma, Urothelial, Upper Tract	25629698							MicroRNA expression is altered in UUTUC. The analysis of circulating miR-141 may be useful to identify patients with UUTUC.
circulation_biomarker_diagnosis_ns	hsa-mir-133	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-29	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Cardiomyopathy	27922664	cardiovascular system disease	DOID:0050700	I42	D009202			Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Cardiomyopathy, Dilated	25840506	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population.
circulation_biomarker_diagnosis_ns	hsa-mir-636	Cardiomyopathy, Dilated	25840506	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population.
circulation_biomarker_diagnosis_ns	hsa-mir-639	Cardiomyopathy, Dilated	25840506	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population.
circulation_biomarker_diagnosis_ns	hsa-mir-646	Cardiomyopathy, Dilated	25840506	cardiovascular system disease	DOID:12930	I42.0	D002311	115200	HP:0001644	We identified specific miRNAs that are differentially regulated between children with DCM who need a transplant compared with children with DCM who recover. A unique biomarker signature of miRNAs that are specific to children with DCM who have the potential to recover would be valuable in risk stratification of this challenging patient population.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Cardiomyopathy, Hypertrophic	26086795	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Cardiovascular Diseases [unspecific]	24874084				D002318			We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Cardiovascular Diseases [unspecific]	27924211				D002318			Circulating miR-126 and miR-499 reflect progression of cardiovascular disease; correlations with uric acid and ejection fraction.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-151	Cardiovascular Diseases [unspecific]	24874084				D002318			We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Cardiovascular Diseases [unspecific]	24573468				D002318			Smoking alters circulating plasma microvesicle pattern and microRNA signatures.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Cardiovascular Diseases [unspecific]	27725938				D002318			Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-26	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Cardiovascular Diseases [unspecific]	24573468				D002318			Smoking alters circulating plasma microvesicle pattern and microRNA signatures.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Cardiovascular Diseases [unspecific]	24874084				D002318			We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
circulation_biomarker_diagnosis_ns	hsa-mir-33	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Cardiovascular Diseases [unspecific]	27725938				D002318			Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-503	Cardiovascular Diseases [unspecific]	24874084				D002318			We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
circulation_biomarker_diagnosis_ns	hsa-mir-645	Cardiovascular Diseases [unspecific]	24874084				D002318			We have demonstrated that this panel of five serum miRNAs is expected to become potential non-invasive biomarkers for detection of MB.
circulation_biomarker_diagnosis_ns	hsa-mir-758	Cardiovascular Diseases [unspecific]	28379027				D002318			Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs.
circulation_biomarker_diagnosis_ns	hsa-mir-449a	Celiac Disease	28878141	immune system disease	DOID:10608	K90.0	D002446	PS212750	HP:0002608	Intestinal and Circulating MicroRNAs in Coeliac Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-150	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-205	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-215	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-467a	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-486	Cerebral Malaria	29747626	disease by infectious agent	DOID:14069	B50.0	D016779			The differential expression profiles of these selected miRNA (miR-146a, miR-150, miR-193b, miR-205, miR-215, miR-467a, and miR-486) were analyzed in mouse MV
circulation_biomarker_diagnosis_ns	hsa-mir-155	Cervical Neoplasms	28934937	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer
circulation_biomarker_diagnosis_ns	hsa-mir-21	Cervical Neoplasms	28934937	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer
circulation_biomarker_diagnosis_ns	hsa-mir-9	Cervical Neoplasms	28934937	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Chagas Disease	29559958	disease by infectious agent	DOID:12140	B57	D014355			Circulating Plasma MicroRNA-208a as Potential Biomarker of Chronic Indeterminate Phase of Chagas Disease
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Cholangiocarcinoma	26864161	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	miR-200c was found to be expressed differentially in PSC versus controls
circulation_biomarker_diagnosis_ns	hsa-mir-21	Cholangiocarcinoma	27685844	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Cholangiocarcinoma	27685844	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Cholangiocarcinoma	26864161	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	a difference in the expression of miR-222 and miR-483-5p in CC versus PSC
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Cholangiocarcinoma	26087181	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Choriocarcinoma	25202432	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Normalization of miR-98 expression levels to those of U6 snRNA, miR-192 or a combination of these  genes enabled the detection of a significant difference between BPE and LA-MPE samples.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Chronic Hepatitis	28368488			K75.9	D006521		HP:0200123	Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-10a	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Chronic Hepatitis B	24643113			B18.0-.1	D019694	610424		Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C.
circulation_biomarker_diagnosis_ns	hsa-mir-124	Chronic Hepatitis B	25131617			B18.0-.1	D019694	610424		Serum microRNA-124 is a novel biomarker for liver necroinflammation in patients with chronic hepatitis B virus infection.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Chronic Hepatitis B	26131144			B18.0-.1	D019694	610424		Positive correlation was found between the levels of hsa- miR-146a and ALT
circulation_biomarker_diagnosis_ns	hsa-mir-182	Chronic Hepatitis B	28562750			B18.0-.1	D019694	610424		Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Chronic Hepatitis B	26319884			B18.0-.1	D019694	610424		Serum miR-210 can be used as an indicator of HBV replication and translation, and a potential marker of necroinflammation in patients with CHB.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-29	Chronic Hepatitis B	25138057			B18.0-.1	D019694	610424		Serum miR-29 levels are negatively correlated with liver fibrotic stages and necroinflammation grades in patients with chronic HBV infection. miR-29 appears to be a novel biomarkers for predicting disease progression in these patients.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-511	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-574	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-98	Chronic Hepatitis B	26483130			B18.0-.1	D019694	610424		We constructed serum miRNA panels with considerable clinical value in diagnosing PNALT.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Chronic Hepatitis C	21070682			B18.2	D019698	609532		The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha
circulation_biomarker_diagnosis_ns	hsa-mir-122	Chronic Hepatitis C	24643113			B18.2	D019698	609532		Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Chronic Hepatitis C	28211229			B18.2	D019698	609532		Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.
circulation_biomarker_diagnosis_ns	hsa-mir-128	Chronic Hepatitis C	21070682			B18.2	D019698	609532		The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Chronic Hepatitis C	25877355			B18.2	D019698	609532		Involvement of TLR2-MyD88 in abnormal expression of miR-146a in peripheral blood monocytes of patients with chronic hepatitis C.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Chronic Hepatitis C	25505813			B18.2	D019698	609532		the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC.
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Chronic Hepatitis C	25505813			B18.2	D019698	609532		the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC.
circulation_biomarker_diagnosis_ns	hsa-mir-196	Chronic Hepatitis C	21070682			B18.2	D019698	609532		The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Chronic Hepatitis C	25738504			B18.2	D019698	609532		Circulating microRNA-196a as a candidate diagnostic biomarker for chronic hepatitis C.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Chronic Hepatitis C	25505813			B18.2	D019698	609532		the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Chronic Hepatitis C	25505813			B18.2	D019698	609532		the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC.
circulation_biomarker_diagnosis_ns	hsa-mir-296	Chronic Hepatitis C	21070682			B18.2	D019698	609532		The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha
circulation_biomarker_diagnosis_ns	hsa-mir-30	Chronic Hepatitis C	21070682			B18.2	D019698	609532		The main aim of this study was to evaluate the expression of several miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296) in peripheral blood mononuclear cells (PBMCs) from healthy individuals after in vitro IFN-treatment and in PBMCs from patients with chronic hepatitis C (CHC) before and 12 hours after the first injection of pegylated IFN alpha
circulation_biomarker_diagnosis_ns	hsa-mir-324	Chronic Hepatitis C	25505813			B18.2	D019698	609532		the expression levels of miR-16, miR-193b, miR-199a, miR-222, and miR-324 target miRNAs in PBMCs of CHC may act as significant risk biomarkers for the development of CHC.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Chronic Kidney Disease	28077372	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD
circulation_biomarker_diagnosis_ns	hsa-mir-126	Chronic Kidney Disease	26475583	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-1281	Chronic Kidney Disease	28077372	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Chronic Kidney Disease	28077372	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Chronic Kidney Disease	26475583	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Chronic Kidney Disease	26475583	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Chronic Kidney Disease	22512691	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Reduced Circulating miR-15b Is Correlated with Phosphate Metabolism in Patients with End-Stage Renal Disease on Maintenance Hemodialysis.
circulation_biomarker_diagnosis_ns	hsa-mir-1825	Chronic Kidney Disease	28077372	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD
circulation_biomarker_diagnosis_ns	hsa-mir-21	Chronic Kidney Disease	26475583	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Chronic Kidney Disease	26475583	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	Plasma levels of microRNA in chronic kidney disease: patterns in acute and chronic exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Chronic Kidney Disease	28077372	urinary system disease	DOID:784	N18.9	D007676		HP:0012622	miRNA are associated with kidney fibrosis, and specific urinary and plasma miRNA profile may have diagnostic and prognostic utility in CKD
circulation_biomarker_diagnosis_ns	hsa-mir-122	Chronic Obstructive Pulmonary Disease	23814167	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Plasma levels of individual myomiRs are altered in patients with COPD but alone do not predict muscle fibre size or proportion. Our findings are consistent with an increase in muscle wasting and turnover associated with the development of skeletal muscle dysfunction and fibre-type shift in patients with stable COPD.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Chronic Obstructive Pulmonary Disease	23814167	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	Plasma levels of individual myomiRs are altered in patients with COPD but alone do not predict muscle fibre size or proportion. Our findings are consistent with an increase in muscle wasting and turnover associated with the development of skeletal muscle dysfunction and fibre-type shift in patients with stable COPD.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-mir-4732	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-mir-491	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-mir-644b	Colitis, Ulcerative	26569605	gastrointestinal system disease	DOID:8577	K51	D003093			This is the first study to show the differential expression of miRNA involving different sites of colon in UC patients. Taking our data and previous reports into consideration, we propose that differential miRNA expression during UC perhaps contribute in the development of UC-associated CRC at the rectosigmoid area.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Colon Neoplasms	28415718			D12.6	D003110		HP:0100273	Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Colon Neoplasms	28415718			D12.6	D003110		HP:0100273	Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Colorectal Adenocarcinoma	25115394	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Colorectal Carcinoma	26134152	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Colorectal Carcinoma	27632639	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1229	Colorectal Carcinoma	29780253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Colorectal Carcinoma	29780253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs
circulation_biomarker_diagnosis_ns	hsa-mir-135a	Colorectal Carcinoma	27998467	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Expression and significance of serum microRNA-135a-5p level in colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-135b	Colorectal Carcinoma	24691020	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Stool-based miR-135b can be used as a noninvasive biomarker for the detection of CRC and advanced adenoma. 
circulation_biomarker_diagnosis_ns	hsa-mir-139	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Colorectal Carcinoma	25269744	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Colorectal Carcinoma	28177881	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A panel of microRNA signature in serum for colorectal cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-200	Colorectal Carcinoma	27632639	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-202	Colorectal Carcinoma	29780253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs
circulation_biomarker_diagnosis_ns	hsa-mir-203	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	24586105	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Re: Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	25524942	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR-21 may be a suitable diagnostic biomarker for CRC with moderate sensitivity and specificity. Further studies should evaluate the diagnostic value of miR-21 for CRC in the future.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	25683351	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The accuracy of circulating microRNA-21 in the diagnosis of colorectal cancer: a systematic review and meta-analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	28177881	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A panel of microRNA signature in serum for colorectal cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	29780253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Colorectal Carcinoma	23840538	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miRNA-29c shows anti-tumorigenesis activity, and preoperative circulating miRNA-29c levels can be used to predict postoperative early relapse of CRC.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Colorectal Carcinoma	24573638	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Colorectal Carcinoma	24573638	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Colorectal Carcinoma	24573638	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-378	Colorectal Carcinoma	24423916	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma levels of miR-378 could be used to discriminate CRC patients from healthy individuals, irrespective of the level of haemoglobin of plasma samples.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Colorectal Carcinoma	25807655	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-425	Colorectal Carcinoma	28177881	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A panel of microRNA signature in serum for colorectal cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-431	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-451	Colorectal Carcinoma	26271186	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Variability in microRNA recovery from plasma: Comparison of five commercial kits.
circulation_biomarker_diagnosis_ns	hsa-mir-484	Colorectal Carcinoma	25807655	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-532	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-532	Colorectal Carcinoma	29780253	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		A 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs
circulation_biomarker_diagnosis_ns	hsa-mir-652	Colorectal Carcinoma	24022433	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Plasma miRNAs are reliable, noninvasive, and inexpensive markers for CR adenomas. This miRNA panel warrants study in larger cohorts. Plasma-based assays could provide better screening compliance compared to fecal occult blood or endoscopic screening.
circulation_biomarker_diagnosis_ns	hsa-mir-720	Colorectal Carcinoma	26134152	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Colorectal Carcinoma	24709885	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Identification of a circulating microRNA signature for colorectal cancer detection.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Colorectal Carcinoma	25736690	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		All 3 miRNAs studied were positively inter-correlated.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Colorectal Carcinoma	25405754	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Colorectal Carcinoma	26038573	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Because serum levels of miR-21, miR-29a, and miR-125b discriminated patients with early colorectal neoplasm from healthy controls, our data highlight the potential clinical use of these molecular signatures for noninvasive screening of patients with colorectal neoplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Colorectal Carcinoma	24646542	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-15b and miR-17 Are Tumor-derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Colorectal Carcinoma	25405754	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Colorectal Carcinoma	24646542	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-15b and miR-17 Are Tumor-derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Colorectal Carcinoma	23673725	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-18a and miR-29a could be promising biomarkers for the screening and monitoring of CRC patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	25405754	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Colorectal Carcinoma	26038573	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Because serum levels of miR-21, miR-29a, and miR-125b discriminated patients with early colorectal neoplasm from healthy controls, our data highlight the potential clinical use of these molecular signatures for noninvasive screening of patients with colorectal neoplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	25405754	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The measured levels of miRNAs in serum and plasma from same patients varied in the presence of hemolysis, and since hemolysis and other factors affected miRNA expression, it is important to consider these confounders while developing miRNA-based diagnostic assays.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	26038573	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Because serum levels of miR-21, miR-29a, and miR-125b discriminated patients with early colorectal neoplasm from healthy controls, our data highlight the potential clinical use of these molecular signatures for noninvasive screening of patients with colorectal neoplasia.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	19876917	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-29a:plasma miR-29a and miR-92a have significant diagnostic value for advanced neoplasia
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	22018950	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Colorectal Carcinoma	23673725	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-18a and miR-29a could be promising biomarkers for the screening and monitoring of CRC patients.
circulation_biomarker_diagnosis_ns	hsa-mir-92a-1	Colorectal Carcinoma	19876917	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-92a:plasma miR-29a and miR-92a have significant diagnostic value for advanced neoplasia
circulation_biomarker_diagnosis_ns	hsa-mir-92a-2	Colorectal Carcinoma	19876917	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-92a:plasma miR-29a and miR-92a have significant diagnostic value for advanced neoplasia
circulation_biomarker_diagnosis_ns	hsa-mir-126	Coronary Artery Disease	25327597	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Plasma miR-126 level is positively correlated to the CCC formation and is an independent predictor of CCC development in patients with severely narrowed coronary arteries, suggesting that plasma miR-126 might be a useful new, stable blood biomarker for predicting CCC formation in patients with severely narrowed coronary arteries.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Coronary Artery Disease	20595655	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Consistent with the data obtained by the profile, circulating levels of miR-126, miR-17, miR-92a, and the inflammation-associated miR-155 were significantly reduced in patients with coronary artery disease compared with healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Coronary Artery Disease	25349183	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		In contrast, increased expression of miR-126 and miR-199a in circulating MVs was significantly associated with a lower major adverse CV event rate.
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Coronary Artery Disease	28628920	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Coronary Artery Disease	28205634	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Coronary Artery Disease	29357324	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Circulating MiR-146a May be a Potential Biomarker of Coronary Heart Disease in Patients with Subclinical Hypothyroidism.
circulation_biomarker_diagnosis_ns	hsa-mir-149	Coronary Artery Disease	25664324	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Circulating miR-765 and miR-149: potential noninvasive diagnostic biomarkers for geriatric coronary artery disease patients.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Coronary Artery Disease	29411649	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		serum miR-155 content may serve as a novel biomarker for evaluating severity of CHD
circulation_biomarker_diagnosis_ns	hsa-mir-155	Coronary Artery Disease	28628920	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Coronary Artery Disease	20595655	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Consistent with the data obtained by the profile, circulating levels of miR-126, miR-17, miR-92a, and the inflammation-associated miR-155 were significantly reduced in patients with coronary artery disease compared with healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Coronary Artery Disease	27602213	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Coronary Artery Disease	28628920	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China.
circulation_biomarker_diagnosis_ns	hsa-mir-370	Coronary Artery Disease	27602213	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease.
circulation_biomarker_diagnosis_ns	hsa-mir-765	Coronary Artery Disease	25664324	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Circulating miR-765 and miR-149: potential noninvasive diagnostic biomarkers for geriatric coronary artery disease patients.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Coronary Artery Disease	20595655	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Consistent with the data obtained by the profile, circulating levels of miR-126, miR-17, miR-92a, and the inflammation-associated miR-155 were significantly reduced in patients with coronary artery disease compared with healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-100	Coronary Atherosclerosis	26159918			I25.1	D003324		HP:0004929	miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation.
circulation_biomarker_diagnosis_ns	hsa-mir-1273	Coronary Atherosclerosis	26159918			I25.1	D003324		HP:0004929	miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Coronary Atherosclerosis	26159918			I25.1	D003324		HP:0004929	miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Coronary Atherosclerosis	26159918			I25.1	D003324		HP:0004929	miR-221, miR-155, miR-100 and hsa-miR-1273,expression level can be used as potential markersfor early coronary atherosclerotic plaque formation.
circulation_biomarker_diagnosis_ns	hsa-mir-598	Crohn Colitis	29272478	gastrointestinal system disease	DOID:0060192	K50.1	D003424			Two miRNAs (miR-598, miR-642) were consistently different between the patient groups
circulation_biomarker_diagnosis_ns	hsa-mir-642	Crohn Colitis	29272478	gastrointestinal system disease	DOID:0060192	K50.1	D003424			Two miRNAs (miR-598, miR-642) were consistently different between the patient groups
circulation_biomarker_diagnosis_ns	hsa-mir-19	Crohn Disease	25985247	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	These data identify miR-19-3p as a potential circulating marker of stricturing CD. Our data show that microRNAs have utility as noninvasive biomarkers of stricturing CD. Further longitudinal studies are required to determine the prognostic value of miR-19-3p at diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-149	Cutaneous Melanoma	28466785	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Cutaneous Melanoma	28466785	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Cutaneous Melanoma	28466785	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Cutaneous Melanoma	28466785	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-524	Cutaneous Melanoma	28466785	disease of cellular proliferation	DOID:8923	C43	C562393	PS155600	HP:0012056	Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Dementia	29559383	disease of mental health	DOID:1307	F03	D003704	127750	HP:0000726	Serum Exosomal miR-223 Serves as a Potential Diagnostic and Prognostic Biomarker for Dementia
circulation_biomarker_diagnosis_ns	hsa-let-7e	Dengue Virus Infection	29566761	disease by infectious agent	DOID:12205	A90	D003715	614371		six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Dengue Virus Infection	29566761	disease by infectious agent	DOID:12205	A90	D003715	614371		six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis
circulation_biomarker_diagnosis_ns	hsa-mir-132	Dengue Virus Infection	29566761	disease by infectious agent	DOID:12205	A90	D003715	614371		six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis
circulation_biomarker_diagnosis_ns	hsa-mir-155	Dengue Virus Infection	29566761	disease by infectious agent	DOID:12205	A90	D003715	614371		six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis
circulation_biomarker_diagnosis_ns	hsa-mir-184	Dengue Virus Infection	29566761	disease by infectious agent	DOID:12205	A90	D003715	614371		six significantly differentially expressed miRNAs, including hsa-miR-184, hsa-let-7e-5p, hsa-miR-132-3p, hsa-miR-155-5p, and hsa-miR-1246, were chosen for RT-qPCR analysis
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus	26498351	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells:relationship with type 2 diabetes complications.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus	24927146	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus	29452547	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Plasma miR-126 and miR-210 levels may be biomarkers for diabetes with or without CAD
circulation_biomarker_diagnosis_ns	hsa-mir-21	Diabetes Mellitus	26498351	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells:relationship with type 2 diabetes complications.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Diabetes Mellitus	25120598	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Compared with the miR-375 levels in patients with normal glucose tolerance (NGT; n=53), the samples from patients with IGT (n=44) exhibited downregulation of miR-375, while those from patients with T2DM (n=54) exhibited upregulation of miR-375 in the plasma.
circulation_biomarker_diagnosis_ns	hsa-mir-100	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-1275	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-150	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-21	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-210	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-24	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-342	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-375	Diabetes Mellitus, Type 1	28986402	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Regarding circulating miRNAs, 11 were consistently dysregulated in T1DM patients compared to controls: miR-21-5p,  miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275
circulation_biomarker_diagnosis_ns	hsa-mir-103	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus, Type 2	23144172	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	AngiomiR-126 expression and secretion from circulating CD34+ and CD14+ PBMCs:role for proangiogenic effects and alterations in type 2 diabetics
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus, Type 2	24455723	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-138	Diabetes Mellitus, Type 2	24204780	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Diabetes Mellitus, Type 2	18633110	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	miR-146: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-148	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Diabetes Mellitus, Type 2	24204780	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Diabetes Mellitus, Type 2	25530976	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	miR-182 can be a biomarker in diagnosis of the potential T2D that has benefits for medical purpose.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Diabetes Mellitus, Type 2	24981880	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-28	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-30d	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-320d	Diabetes Mellitus, Type 2	26554942	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Diabetes Mellitus, Type 2	29373500	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Evaluation of Two-Diabetes Related microRNAs Suitability as Earlier Blood Biomarkers for Detecting Prediabetes and type 2 Diabetes Mellitus
circulation_biomarker_diagnosis_ns	hsa-mir-376a	Diabetes Mellitus, Type 2	24204780	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-3960	Diabetes Mellitus, Type 2	26554942	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM.
circulation_biomarker_diagnosis_ns	hsa-mir-409	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Diabetes Mellitus, Type 2	26554942	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM.
circulation_biomarker_diagnosis_ns	hsa-mir-4534	Diabetes Mellitus, Type 2	26554942	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM.
circulation_biomarker_diagnosis_ns	hsa-mir-454	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-455	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-503	Diabetes Mellitus, Type 2	24204780	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study is the first to show a panel of serum miRNAs for obesity, and compare them with miRNAs identified in serum for diabetes and obesity with diabetes. Our results support the use of some miRNAs extracted from serum samples as potential predictive tools for obesity and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-572	Diabetes Mellitus, Type 2	26554942	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This study provided evidence that serum miRNAs had differential expressions between healthy controls and T2DM patients. These five differential expression miRNAs might be of help for subsequent study in T2DM.
circulation_biomarker_diagnosis_ns	hsa-mir-665	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-766	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Diabetes Mellitus, Type 2	25677225	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	This meta-analysis confirms that 40 miRNAs are significantly dysregulated in type 2 diabetes. miR-29a, miR-34a, miR-375,miR-103, miR-107, miR-132, miR-142-3p and miR-144 are potential circulating biomarkers of type 2 diabetes. In addition, miR-199a-3p and miR-223 are potential tissue biomarkers of type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Diabetes Mellitus, Type 2	27869909	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
circulation_biomarker_diagnosis_ns	hsa-mir-96	Diabetes Mellitus, Type 2	28260062	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Serum microRNA profiling and bioinformatics analysis of patients with type 2 diabetes mellitus in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Diabetic Cardiomyopathies	29044172				D058065			Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Diabetic Cardiomyopathies	29044172				D058065			Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy.
circulation_biomarker_diagnosis_ns	hsa-mir-130b	Diabetic Nephropathy	25952368			E10-11.21	D003928			Our findings suggest that serum miR-130b may be a new biomarker for the early diagnosis of DN in T2DM. Circulating miR-130b may possibly be involved  in the pathological mechanism of DN, such as lipid metabolic disorders, oxidative stress, extracellular matrix deposition and renal fibrosis.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Digestive System Neoplasms	26683919			D49.0	D004067			Potential Role of Circulating MiR-21 in the Diagnosis and Prognosis of Digestive System Cancer: A Systematic Review and Meta-Analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-139	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-365	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-425	Early-Stage Breast Carcinoma	24694649			D05.10	D001943	114480		We present herein a 9 miRNA signature capable of discriminating between ER-positive breast cancer and healthy controls. Using a specific algorithm based on the 9 miRNA signature, the risk for future individuals can be predicted. Since microRNAs are highly stable in blood components, this signature might be useful in the development of a blood-based multi-marker test to improve early detection of breast cancer. Such a test could potentially be used as a screening tool to identify individuals who would benefit from further diagnostic assessment.
circulation_biomarker_diagnosis_ns	hsa-mir-484	Early-Stage Breast Carcinoma	24641801			D05.10	D001943	114480		In this study, we found that miR-484 is significantly differentially expressed in serum of early breast cancer patients compared to healthy volunteers. We did not however find any correlation between miR-484 levels with histopathological parameters of the breast cancers. With further studies, miR-484 may prove useful as an adjunct to mammography for detection of early breast cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Early-Stage Cervical Squamous Cell Carcinoma	23799609							Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Early-Stage Cervical Squamous Cell Carcinoma	23799609							Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-2392	Early-Stage Cervical Squamous Cell Carcinoma	23799609							Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-3162	Early-Stage Cervical Squamous Cell Carcinoma	23799609							Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-4484	Early-Stage Cervical Squamous Cell Carcinoma	23799609							Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Early-Stage Gastric Carcinoma	24595006					613659		A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Early-Stage Gastric Carcinoma	24595006					613659		A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-451	Early-Stage Gastric Carcinoma	24595006					613659		A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Early-Stage Gastric Carcinoma	24595006					613659		A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Early-Stage Gastric Carcinoma	24595006					613659		A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Early-Stage Lung Carcinoma	24553369					211980		4-(Methylnitrosamino)-1-(3-pyridyl) -1-butanone induces circulating microRNA deregulation in early lung carcinogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Early-Stage Lung Carcinoma	24553369					211980		4-(Methylnitrosamino)-1-(3-pyridyl) -1-butanone induces circulating microRNA deregulation in early lung carcinogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Early-Stage Non-Small-Cell Lung Carcinoma	27093275			C34.90	D002289	211980		Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Early-Stage Non-Small-Cell Lung Carcinoma	27093275			C34.90	D002289	211980		Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-183	Early-Stage Non-Small-Cell Lung Carcinoma	27093275			C34.90	D002289	211980		Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Early-Stage Non-Small-Cell Lung Carcinoma	27093275			C34.90	D002289	211980		Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Early-Stage Non-Small-Cell Lung Carcinoma	24523873			C34.90	D002289	211980		The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel,non-invasive biomarker for early stage NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-429	Early-Stage Non-Small-Cell Lung Carcinoma	24523873			C34.90	D002289	211980		The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel,non-invasive biomarker for early stage NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Early-Stage Non-Small-Cell Lung Carcinoma	24523873			C34.90	D002289	211980		The results of the current study suggest that detection of serum miR-29c and miR-429 expression should be further evaluated as a novel,non-invasive biomarker for early stage NSCLC.
circulation_biomarker_diagnosis_ns	hsa-mir-873	Ectopic Pregnancy	28472791	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	MicroRNA-873 is a Potential Serum Biomarker for the Detection of Ectopic Pregnancy.
circulation_biomarker_diagnosis_ns	hsa-mir-199b	Endometrial Neoplasms	22920721	reproductive system disease	DOID:1380	C54.1	D016889	608089		Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-99a	Endometrial Neoplasms	22920721	reproductive system disease	DOID:1380	C54.1	D016889	608089		Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Endometriosis	19692421	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-145	Endometriosis	29308623	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis
circulation_biomarker_diagnosis_ns	hsa-mir-145	Endometriosis	29633787	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis
circulation_biomarker_diagnosis_ns	hsa-mir-200	Endometriosis	26206343	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	Circulating miR-200-family micro-RNAs have altered plasma levels in patients with endometriosis and vary with blood collection time.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Endometriosis	29308623	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis
circulation_biomarker_diagnosis_ns	hsa-mir-31	Endometriosis	29633787	reproductive system disease	DOID:289	N80.0	D004715	131200	HP:0030127	miR-31 and miR-145 as Potential Non-Invasive Regulatory Biomarkers in Patients with Endometriosis
circulation_biomarker_diagnosis_ns	hsa-mir-29	Endomyocardial Fibrosis	25457410	cardiovascular system disease	DOID:12932	I42.3	D004719		HP:0006685	Reply: MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Epilepsy	27840934	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure.
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Epilepsy	26382856	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Epilepsy	27840934	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure.
circulation_biomarker_diagnosis_ns	hsa-mir-181c	Epilepsy	26382856	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-194	Epilepsy	25825351	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Circulating miRNAs were differentially regulated in epilepsy patients as compared with controls. MiR-106b-5p may serve as a novel, noninvasive biomarker to improve the current diagnosis of epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Epilepsy	26382856	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Epilepsy	26382856	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Epilepsy	27840934	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure.
circulation_biomarker_diagnosis_ns	hsa-mir-378	Epilepsy	27840934	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Identification of serum miRNAs differentially expressed in human epilepsy at seizure onset and post-seizure.
circulation_biomarker_diagnosis_ns	hsa-mir-9a	Epilepsy	26382856	nervous system disease	DOID:1826	G40	D004827	PS601068	HP:0001250	Those miRNAs that are altered in plasma before the first spontaneous seizure,like miR-9a-3p, may be proposed as putative biomarkers of epileptogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Esophageal Neoplasms	23361059			C15.9	D004938	133239	HP:0100751	Serum;Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-155	Esophageal Neoplasms	22891887			C15.9	D004938	133239	HP:0100751	The relative expressions of miR-155, miR-183, and miR-20a in esophageal tissue were found to be significantly associated with increased risk for esophageal cancer. Circulating miR-155 showed significantly higher risk for esophageal cancer when adjusted by smoking status and alcohol use. Circulating miR-155 was found to have significant diagnostic value for esophageal cancer as evidenced by a receiver operating characteristic curve area of 66%.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-361	Essential Hypertension	28445253	cardiovascular system disease	DOID:10825	I10	C562386	145500		micro-RNA screening and prediction model construction for diagnosis of salt-sensitive essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-362	Essential Hypertension	28445253	cardiovascular system disease	DOID:10825	I10	C562386	145500		micro-RNA screening and prediction model construction for diagnosis of salt-sensitive essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Essential Hypertension	26358152	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension.
circulation_biomarker_diagnosis_ns	hsa-mir-34	Ewing Sarcoma	26659003	musculoskeletal system disease	DOID:3369		D012512	612219	HP:0012254	MicroRNA expression profiling may have some potential for prediction of disease progression and survival in Ewing sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Fatty Liver, Non-Alcoholic	24313922	disease of metabolism	DOID:0080208	K75.81	D065626	613282		We found that the hepatic and serum miR-122 levels were associated with hepatic steatosis and fibrosis. The serum miR-122 level can be a useful predictive marker of liver fibrosis in patients with NAFLD.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Fatty Liver, Non-Alcoholic	27077736	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Fatty Liver, Non-Alcoholic	27955628	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Fatty Liver, Non-Alcoholic	27077736	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Fatty Liver, Non-Alcoholic	27956809	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-1225	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-186	Focal Segmental Glomerulosclerosis	25218681	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Plasma miR-186 may be a biomarker for FSGS with nephrotic proteinuria.
circulation_biomarker_diagnosis_ns	hsa-mir-1915	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Focal Segmental Glomerulosclerosis	28246603	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Urinary Exosomal miR-193a Can Be a Potential Biomarker for the Diagnosis of Primary Focal Segmental Glomerulosclerosis in Children.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-663	Focal Segmental Glomerulosclerosis	25682967	urinary system disease	DOID:1312	N04.1	D005923	PS603278	HP:0000097	Patients with FSGS and minimal change disease (MCD) have a unique circulating and urinary miRNA profile. The diagnostic and prognostic potential of miRNAs in FSGS and minimal change disease (MCD) warrants further studies.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Foot-and-Mouth Disease	28388926				D005536			Proof-of-concept study: profile of circulating microRNAs in Bovine serum harvested during acute and persistent FMDV infection.
circulation_biomarker_diagnosis_ns	hsa-mir-424	Fragile X Syndrome	23790110	genetic disease	DOID:14261	Q99.2	D005600	300624		MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients.
circulation_biomarker_diagnosis_ns	hsa-mir-574	Fragile X Syndrome	23790110	genetic disease	DOID:14261	Q99.2	D005600	300624		MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients.
circulation_biomarker_diagnosis_ns	hsa-mir-128	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-130b	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-142	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-151a	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-323a	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-330	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-mir-625	Friedreich Ataxia	29509186	nervous system disease	DOID:12705	G11.1	D005621	229300		We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects
circulation_biomarker_diagnosis_ns	hsa-let-7a	Gastric Neoplasms	23519840	disease of cellular proliferation	DOID:10534	C16	D013274	137215		High CCR7 protein expression may be caused by the loss of Dicer 1 protein expression and reduced let-7a miRNA level in gastric cancer. The serum let-7a level might be a marker for the diagnosis of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-106a	Gastric Neoplasms	20349219	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-106a:detection of miRNA in peripheral blood may be a novel tool for monitoring circulating tumor cells in patients with gastric cancers
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Gastric Neoplasms	25218271	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Gastric Neoplasms	24481716	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-129-1	Gastric Neoplasms	23307240	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Gastric juice miR-129 as a potential biomarker for screening gastric cancer
circulation_biomarker_diagnosis_ns	hsa-mir-129-2	Gastric Neoplasms	23307240	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Gastric juice miR-129 as a potential biomarker for screening gastric cancer
circulation_biomarker_diagnosis_ns	hsa-mir-140	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Gastric Neoplasms	20349219	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-17:detection of miRNA in peripheral blood may be a novel tool for monitoring circulating tumor cells in patients with gastric cancers
circulation_biomarker_diagnosis_ns	hsa-mir-185	Gastric Neoplasms	26059512	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Gastric Neoplasms	24626859	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Circulating miR-18a could be a useful biomarker for screening GC and monitoring tumor dynamics.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Gastric Neoplasms	24481716	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Gastric Neoplasms	29535809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		circulating miRNA-196a is a novel biomarker for detection of early gastric cancer and its precursor
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-199a-1	Gastric Neoplasms	23733518	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiRNA-199a-3p: A Potential Circulating Diagnostic Biomarker for Early Gastric Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-199a-2	Gastric Neoplasms	23733518	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiRNA-199a-3p: A Potential Circulating Diagnostic Biomarker for Early Gastric Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Gastric Neoplasms	24947260	disease of cellular proliferation	DOID:10534	C16	D013274	137215		GDF15 and MMP7 serum levels have diagnostic value for GC. The combination marker formed by GDF15, MMP7 and miR-200c is indicative of adverse evolution in GC patients.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Gastric Neoplasms	26059512	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Gastric Neoplasms	23521833	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The levels of serum miR-20a-5p, let-7a and miR-320a were positively correlated with PGA/PGC, which may indirectly reflect the functional status of the gastric mucosa.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Gastric Neoplasms	28413641	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Serum miR-20a is a promising biomarker for gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Gastric Neoplasms	26509997	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In summary, we verified the diagnostic and prognostic value of tissue hsa-miR-21hsa-miR-21 and hsa-miR-29 in GC. Both of them can be potentially applied as novel and non-invasive biomarkers for GC.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Gastric Neoplasms	26720919	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Two-stage cyclic enzymatic amplification method for ultrasensitive electrochemical assay of microRNA-21 in the blood serum of gastric cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Gastric Neoplasms	26059512	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Gastric Neoplasms	22432036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Three serum miRNAs (miR-221, miR-744, and miR-376c) as potential biomarkers for GC detection
circulation_biomarker_diagnosis_ns	hsa-mir-222	Gastric Neoplasms	25129310	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Gastric Neoplasms	27010210	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-29	Gastric Neoplasms	26509997	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In summary, we verified the diagnostic and prognostic value of tissue hsa-miR-21hsa-miR-21 and hsa-miR-29 in GC. Both of them can be potentially applied as novel and non-invasive biomarkers for GC.
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Gastric Neoplasms	23521833	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The levels of serum miR-20a-5p, let-7a and miR-320a were positively correlated with PGA/PGC, which may indirectly reflect the functional status of the gastric mucosa.
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Gastric Neoplasms	22432036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Three serum miRNAs (miR-221, miR-744, and miR-376c) as potential biomarkers for GC detection
circulation_biomarker_diagnosis_ns	hsa-mir-421	Gastric Neoplasms	22263628	disease of cellular proliferation	DOID:10534	C16	D013274	137215		MiR-421 is a functional marker of circulating tumor cells in gastric cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-425	Gastric Neoplasms	24603541	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Taken together, our results revealed the oncogenic roles of miR-191 and miR-425 in gastric carcinogenesis, and indicated the potential use of serum miR-191 as a novel and stable biomarker for GC diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-433	Gastric Neoplasms	23806809	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-627	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-629	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-652	Gastric Neoplasms	26607322	disease of cellular proliferation	DOID:10534	C16	D013274	137215		This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-744	Gastric Neoplasms	22432036	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Three serum miRNAs (miR-221, miR-744, and miR-376c) as potential biomarkers for GC detection
circulation_biomarker_diagnosis_ns	hsa-mir-92b	Gastric Neoplasms	26059512	disease of cellular proliferation	DOID:10534	C16	D013274	137215		In conclusion, we identified a five-miRNA signature in the peripheral plasma which could serve as a non-invasive biomarker in detection of GC.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Gastrointestinal Neoplasms	22198701			D37.9	D005770			The algorithms revealed miR-16 and miR-93 were the most stably expressed reference genes, with stability values of 1.778 and 2.213, respectively, for serum microRNA analysis across all the patients and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Gastrointestinal Neoplasms	22198701			D37.9	D005770			The algorithms revealed miR-16 and miR-93 were the most stably expressed reference genes, with stability values of 1.778 and 2.213, respectively, for serum microRNA analysis across all the patients and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-367	Germ Cell Tumor	26671749	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
circulation_biomarker_diagnosis_ns	hsa-mir-371a	Germ Cell Tumor	25187505	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
circulation_biomarker_diagnosis_ns	hsa-mir-371a	Germ Cell Tumor	26671749	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
circulation_biomarker_diagnosis_ns	hsa-mir-372	Germ Cell Tumor	26671749	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
circulation_biomarker_diagnosis_ns	hsa-mir-373	Germ Cell Tumor	26671749	disease of cellular proliferation	DOID:2994	Z85.43	D009373	273300		A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
circulation_biomarker_diagnosis_ns	hsa-mir-224	Giant Cell Tumor of Bone	22326282	disease of cellular proliferation	DOID:4305		D018212		HP:0011847	altered expression
circulation_biomarker_diagnosis_ns	hsa-mir-144	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-184	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-202	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-3074	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-30d	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-4448	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-451a	Glaucoma	27064390	nervous system disease	DOID:1686	H40	D005901	137750		Our data illustrate the feasibility of miRNA analysis by NGS in small individual aqueous humor samples. Intraocular cells as well as blood plasma contribute to the extracellular aqueous humor miRNome. The data suggest possible roles of miRNA in intraocular cell adhesion and signaling by TGF-β and Wnt, which are important in intraocular pressure regulation and glaucoma.
circulation_biomarker_diagnosis_ns	hsa-mir-128	Glioblastoma	23174013				D005909		HP:0100843	The plasma levels of miR-21, miR-128 and miR-342-3p were significantly altered in GBM patients compared to normal controls and could discriminate glioma from healthy controls with high specificity and sensitivity
circulation_biomarker_diagnosis_ns	hsa-mir-21	Glioblastoma	23174013				D005909		HP:0100843	The plasma levels of miR-21, miR-128 and miR-342-3p were significantly altered in GBM patients compared to normal controls and could discriminate glioma from healthy controls with high specificity and sensitivity
circulation_biomarker_diagnosis_ns	hsa-mir-221	Glioblastoma	28381184				D005909		HP:0100843	microRNA expression levels was built, which has the potential to be used in clinics and thus to improve the survival status of glioblastoma multiforme patients
circulation_biomarker_diagnosis_ns	hsa-mir-222	Glioblastoma	28381184				D005909		HP:0100843	microRNA expression levels was built, which has the potential to be used in clinics and thus to improve the survival status of glioblastoma multiforme patients
circulation_biomarker_diagnosis_ns	hsa-mir-342	Glioblastoma	23174013				D005909		HP:0100843	The plasma levels of miR-21, miR-128 and miR-342-3p were significantly altered in GBM patients compared to normal controls and could discriminate glioma from healthy controls with high specificity and sensitivity
circulation_biomarker_diagnosis_ns	hsa-let-7g	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-124	Glioma	23936026	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These results suggest that miR-124 may function as anti-migration and anti-invasion influence in glioma and provides a potential approach for developing miR-124-based therapeutic strategies for malignant glioma therapy.
circulation_biomarker_diagnosis_ns	hsa-mir-1825	Glioma	28475008	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A novel serum microRNA-based identification and classification biomarker of human glioma.
circulation_biomarker_diagnosis_ns	hsa-mir-185	Glioma	26458593	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	These findings suggest that plasma miR-185 has become potential biomarkers for glioma and may be useful in clinical management for glioma patients.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Glioma	27981547	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Circulating miR-199a-3p in plasma and its potential diagnostic and prognostic value in glioma.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Glioma	26284486	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Therefore, we concluded that the exosomal miR-21 levels could be demonstrated as a promising indicator for glioma diagnosis and prognosis, particularly with values to predict tumor recurrence or metastasis.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Glioma	25756397	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Serum miR-210 is a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.
circulation_biomarker_diagnosis_ns	hsa-mir-29	Glioma	25367878	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Identification and Evaluation of Serum MicroRNA-29 Family for Glioma Screening.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Glioma	26620922	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miR-29b and VEGFA in blood were significantly different compared with the control group
circulation_biomarker_diagnosis_ns	hsa-mir-320	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-340	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-454	Glioma	28815332	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A signature composed of miR-93, miR-590-3p, and miR-454 enabled to nearly perfectly separate patients from controls
circulation_biomarker_diagnosis_ns	hsa-mir-576	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-590	Glioma	28815332	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A signature composed of miR-93, miR-590-3p, and miR-454 enabled to nearly perfectly separate patients from controls
circulation_biomarker_diagnosis_ns	hsa-mir-626	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-7	Glioma	24858071	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	miRNA profile of the peripheral blood may serve as a new biomarker for glioma diagnosis with high specificity and sensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Glioma	28815332	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	A signature composed of miR-93, miR-590-3p, and miR-454 enabled to nearly perfectly separate patients from controls
circulation_biomarker_diagnosis_ns	hsa-mir-21	Glomerulonephritis	25468389	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	Furthermore, the glomerular and serum levels of miR-21, a putative microRNA ligand of TLR8, were higher in BXSB-Yaa mice than in BXSB mice.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-28	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-374a	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-377	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-411	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-489	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-586	Graft-Versus-Host Disease	26051902			D89.813	D006086	614395		Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-671	Graft-Versus-Host Disease	27553380			D89.813	D006086	614395		The predictive value of selected serum microRNAs for acute GVHD by TaqMan MicroRNA arrays.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Graft-Versus-Host Disease	24041574			D89.813	D006086	614395		Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Head And Neck Neoplasms	19043531	disease of cellular proliferation	DOID:11934	C76.0	D006258		HP:0012288	mir-205: a marker of metastatic
circulation_biomarker_diagnosis_ns	hsa-let-7b	Heart Failure	25763857			I50	D006331		HP:0001635	Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells.
circulation_biomarker_diagnosis_ns	hsa-let-7i	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Heart Failure	26498537			I50	D006331		HP:0001635	Dysregulation of miR-1 and miR-21 expression may be essential for the development of HF; miR-1 might become a biomarker for predicting HF exacerbation.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Heart Failure	28052002			I50	D006331		HP:0001635	Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Heart Failure	23696613			I50	D006331		HP:0001635	Four microRNAs, miR-103, miR-142-3p, miR-30b, and miR-342-3p, were differentially expressed between HF and controls
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Heart Failure	23247724			I50	D006331		HP:0001635	We identified new circulating miRNAs (miR-454, miR-500, miR-1246, miR-142-3p) which showed distinct patterns of expression in patients with diastolic dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Heart Failure	25619197			I50	D006331		HP:0001635	Of these, miR-1233, -183-3p, -190a, -193b-3p, -193b-5p, -211-5p, -494, and -671-5p distinguished HF from controls.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-129	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Heart Failure	28666417			I50	D006331		HP:0001635	Identifying differential miR and gene consensus patterns in peripheral blood of patients with cardiovascular diseases from literature data.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Heart Failure	23247724			I50	D006331		HP:0001635	We identified new circulating miRNAs (miR-454, miR-500, miR-1246, miR-142-3p) which showed distinct patterns of expression in patients with diastolic dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Heart Failure	23696613			I50	D006331		HP:0001635	Four microRNAs, miR-103, miR-142-3p, miR-30b, and miR-342-3p, were differentially expressed between HF and controls
circulation_biomarker_diagnosis_ns	hsa-mir-145	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Heart Failure	25739750			I50	D006331		HP:0001635	This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Heart Failure	29258606			I50	D006331		HP:0001635	Inflammation-associated microRNA changes in circulating exosomes of heart failure patients
circulation_biomarker_diagnosis_ns	hsa-mir-155	Heart Failure	22939041			I50	D006331		HP:0001635	Angiotensin Receptor Type 1 Single Nucleotide Polymorphism 1166A/C is Associated With Malignant Arrhythmias and Altered Circulating miR-155 Levels in Patients With Chronic Heart Failure.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Heart Failure	29258606			I50	D006331		HP:0001635	Inflammation-associated microRNA changes in circulating exosomes of heart failure patients
circulation_biomarker_diagnosis_ns	hsa-mir-182	Heart Failure	25985726			I50	D006331		HP:0001635	miR-182 (p = 0.04), miR-200a* (p = 0.019), and miR-568 (p = 0.023) were found to be inversely  correlated with LVM index (LVMI), while miR-155 (p = 0.019) and miR-595 (p = 0.04) were determined to be positively correlated with LVMI.
circulation_biomarker_diagnosis_ns	hsa-mir-199	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-208	Heart Failure	23676496			I50	D006331		HP:0001635	Gain-of-function and loss-of-function strategies in mice, together with assessment of muscle biopsies from humans, demonstrated that type I muscle fiber proportion is increased via the stimulatory actions of ERRγ on the expression of miR-499 and miR-208b.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Heart Failure	26498537			I50	D006331		HP:0001635	Dysregulation of miR-1 and miR-21 expression may be essential for the development of HF; miR-1 might become a biomarker for predicting HF exacerbation.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Heart Failure	26498537			I50	D006331		HP:0001635	Dysregulation of miR-1 and miR-21 expression may be essential for the development of HF; miR-1 might become a biomarker for predicting HF exacerbation.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Heart Failure	26211628			I50	D006331		HP:0001635	MiR-21 levels were not different among the groups.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-211	Heart Failure	25619197			I50	D006331		HP:0001635	Of these, miR-1233, -183-3p, -190a, -193b-3p, -193b-5p, -211-5p, -494, and -671-5p distinguished HF from controls.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Heart Failure	25739750			I50	D006331		HP:0001635	This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Heart Failure	25364765			I50	D006331		HP:0001635	miR-24 and miR-214 are bi-functional cardio-miRs.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Heart Failure	29499204			I50	D006331		HP:0001635	miR-25 expression during different stages of heart disease, offers a new perspective for the role of miR-25 function in heart failure
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Heart Failure	28475616			I50	D006331		HP:0001635	Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Heart Failure	23696613			I50	D006331		HP:0001635	Four microRNAs, miR-103, miR-142-3p, miR-30b, and miR-342-3p, were differentially expressed between HF and controls
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Heart Failure	25739750			I50	D006331		HP:0001635	This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
circulation_biomarker_diagnosis_ns	hsa-mir-30d	Heart Failure	25995320			I50	D006331		HP:0001635	Baseline plasma miR-30d level is associated with response to CRT in HFDYS in this translational pilot study. MiR-30d increase in cardiomyocytes correlates with areas of increased wall stress in HFDYS and is protective against deleterious tumor necrosis factor signaling.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-328	Heart Failure	25739750			I50	D006331		HP:0001635	This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Heart Failure	23696613			I50	D006331		HP:0001635	Four microRNAs, miR-103, miR-142-3p, miR-30b, and miR-342-3p, were differentially expressed between HF and controls
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-375	Heart Failure	25739750			I50	D006331		HP:0001635	This study has shown for the first time that various miRNA combinations are useful biomarkers for HF, and also in the differentiation of HFpEF from HFrEF. The utility of these biomarker combinations can be altered by inclusion of natriuretic peptide. MiRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF.
circulation_biomarker_diagnosis_ns	hsa-mir-378	Heart Failure	26430739			I50	D006331		HP:0001635	Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each  device do not relate to differences in miR expression levels.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Heart Failure	29314582			I50	D006331		HP:0001635	A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups
circulation_biomarker_diagnosis_ns	hsa-mir-454	Heart Failure	23247724			I50	D006331		HP:0001635	We identified new circulating miRNAs (miR-454, miR-500, miR-1246, miR-142-3p) which showed distinct patterns of expression in patients with diastolic dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Heart Failure	23676496			I50	D006331		HP:0001635	Gain-of-function and loss-of-function strategies in mice, together with assessment of muscle biopsies from humans, demonstrated that type I muscle fiber proportion is increased via the stimulatory actions of ERRγ on the expression of miR-499 and miR-208b.
circulation_biomarker_diagnosis_ns	hsa-mir-500	Heart Failure	23247724			I50	D006331		HP:0001635	We identified new circulating miRNAs (miR-454, miR-500, miR-1246, miR-142-3p) which showed distinct patterns of expression in patients with diastolic dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-92a-1	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-92a-2	Heart Failure	23736534			I50	D006331		HP:0001635	Changed circulating miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p
circulation_biomarker_diagnosis_ns	hsa-mir-122	HELLP Syndrome	24304191	cardiovascular system disease	DOID:13133	O14.2	D017359	614985		In our proof of principle study, we demonstrated that patients with HELLP syndrome showed alterations of serum miRNA expression patterns. Data analysis goes along with the hypothesis that HELLP syndrome is regarded to be a heterogeneous disease.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	HELLP Syndrome	24304191	cardiovascular system disease	DOID:13133	O14.2	D017359	614985		In our proof of principle study, we demonstrated that patients with HELLP syndrome showed alterations of serum miRNA expression patterns. Data analysis goes along with the hypothesis that HELLP syndrome is regarded to be a heterogeneous disease.
circulation_biomarker_diagnosis_ns	hsa-mir-758	HELLP Syndrome	24304191	cardiovascular system disease	DOID:13133	O14.2	D017359	614985		In our proof of principle study, we demonstrated that patients with HELLP syndrome showed alterations of serum miRNA expression patterns. Data analysis goes along with the hypothesis that HELLP syndrome is regarded to be a heterogeneous disease.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Hematologic Neoplasms	27761889	disease of cellular proliferation	DOID:2531	C96.9	D019337		HP:0004377	EV miR155 may serve as an attractive new, non-invasive diagnostic biomarker in human hematologic malignancies
circulation_biomarker_diagnosis_ns	hsa-let-7c	Hepatitis B Virus Infection	22392036	disease by infectious agent	DOID:2043	B16/18	D006509	610424		After screening 13 previously identified HBV-specific serum miRNAs, we obtained four miRNAs, let-7c, miR-23b, miR-122, and miR-150, which are differentially expressed in OBI sera compared to healthy control sera. This 4-serum miRNA signature shows a high level of accuracy in discriminating both OBI (AUC = 0.999) and HBV (AUC = 0.989) cases from the non-infected controls.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis B Virus Infection	22239527	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum miR-122 levels are strongly correlated with HBs antigen.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis B Virus Infection	22392036	disease by infectious agent	DOID:2043	B16/18	D006509	610424		After screening 13 previously identified HBV-specific serum miRNAs, we obtained four miRNAs, let-7c, miR-23b, miR-122, and miR-150, which are differentially expressed in OBI sera compared to healthy control sera. This 4-serum miRNA signature shows a high level of accuracy in discriminating both OBI (AUC = 0.999) and HBV (AUC = 0.989) cases from the non-infected controls.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis B Virus Infection	21606975	disease by infectious agent	DOID:2043	B16/18	D006509	610424		The serum level of miR-122 strongly correlates with serum ALT activity and with necroinflammatory activity in patients with CHC and elevated ALT levels, but not with fibrosis stage and functional capacity of the liver
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Hepatitis B Virus Infection	24595450	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-1275	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Hepatitis B Virus Infection	22392036	disease by infectious agent	DOID:2043	B16/18	D006509	610424		After screening 13 previously identified HBV-specific serum miRNAs, we obtained four miRNAs, let-7c, miR-23b, miR-122, and miR-150, which are differentially expressed in OBI sera compared to healthy control sera. This 4-serum miRNA signature shows a high level of accuracy in discriminating both OBI (AUC = 0.999) and HBV (AUC = 0.989) cases from the non-infected controls.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Hepatitis B Virus Infection	25976622	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum miR-181b is correlated with liver and serum HBV DNA levels as well as disease progression in CHB.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Hepatitis B Virus Infection	24595450	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-23b	Hepatitis B Virus Infection	22392036	disease by infectious agent	DOID:2043	B16/18	D006509	610424		After screening 13 previously identified HBV-specific serum miRNAs, we obtained four miRNAs, let-7c, miR-23b, miR-122, and miR-150, which are differentially expressed in OBI sera compared to healthy control sera. This 4-serum miRNA signature shows a high level of accuracy in discriminating both OBI (AUC = 0.999) and HBV (AUC = 0.989) cases from the non-infected controls.
circulation_biomarker_diagnosis_ns	hsa-mir-583	Hepatitis B Virus Infection	23554832	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Circulating miR-583 and miR-663 Refer to ZHENG Differentiation in Chronic Hepatitis B
circulation_biomarker_diagnosis_ns	hsa-mir-663	Hepatitis B Virus Infection	23554832	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Circulating miR-583 and miR-663 Refer to ZHENG Differentiation in Chronic Hepatitis B
circulation_biomarker_diagnosis_ns	hsa-mir-720	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-mir-99a	Hepatitis B Virus Infection	25452043	disease by infectious agent	DOID:2043	B16/18	D006509	610424		Serum microRNA levels reflect differences in the etiology and stage of viral hepatitis.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	27239848	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Evaluation of miR-122 level in the plasma of chronically HCV infected patients.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	23085648	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	23383654	disease by infectious agent	DOID:1883	B19.2	D006526	609532		circulating;Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	26283876	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	25065618	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122, miR-126, miR-136 and miR-181a have been  shown to be involved in HCV infection with different genotypes. Their expression  has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Hepatitis C Virus Infection	28232800	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Circulating ECV-Associated miRNAs as Potential Clinical Biomarkers in Early Stage HBV and HCV Induced Liver Fibrosis.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Hepatitis C Virus Infection	25065618	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122, miR-126, miR-136 and miR-181a have been  shown to be involved in HCV infection with different genotypes. Their expression  has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis.
circulation_biomarker_diagnosis_ns	hsa-mir-134	Hepatitis C Virus Infection	26283876	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-136	Hepatitis C Virus Infection	25065618	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122, miR-126, miR-136 and miR-181a have been  shown to be involved in HCV infection with different genotypes. Their expression  has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-155	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-16	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Hepatitis C Virus Infection	25065618	disease by infectious agent	DOID:1883	B19.2	D006526	609532		miR-122, miR-126, miR-136 and miR-181a have been  shown to be involved in HCV infection with different genotypes. Their expression  has been associated with the gender, stage and grade of liver disease, mode of transmission, serum HCV load and the presence of steatosis.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Hepatitis C Virus Infection	28232800	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Circulating ECV-Associated miRNAs as Potential Clinical Biomarkers in Early Stage HBV and HCV Induced Liver Fibrosis.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Hepatitis C Virus Infection	23390075	disease by infectious agent	DOID:1883	B19.2	D006526	609532		circulating;The circulating miR-20a may serve as a potential for predictive biomarker in HCV mediated fibrosis
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hepatitis C Virus Infection	22066022	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The serum miR-21 level is a marker for necroinflammatory activity, but does not differ between patients with HCV and HCV-induced HCC.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Hepatitis C Virus Infection	23650540	disease by infectious agent	DOID:1883	B19.2	D006526	609532		PBMC expression of miR-Let-7d, miR-16, miR-21, miR-26b, miR-146a and miR-155 was evaluated by real-time PCR in 167 HCV patients 
circulation_biomarker_diagnosis_ns	hsa-mir-424	Hepatitis C Virus Infection	26283876	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-629	Hepatitis C Virus Infection	26283876	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hepatoblastoma	27601233	disease of cellular proliferation	DOID:687	C22.2	D018197		HP:0002884	Diagnostic and prognostic values of serum exosomal microRNA-21 in children with hepatoblastoma: a Chinese population-based study.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Hereditary Breast Carcinoma	24129975			D05	D001943	114480		miR-4417 and miR-423-3p expressions differentiated 70.1 % of hereditary and non-hereditary BCs. Array miR expression profiles can differentiate the four study groups using FFPE BC.
circulation_biomarker_diagnosis_ns	hsa-mir-4417	Hereditary Breast Carcinoma	24129975			D05	D001943	114480		miR-4417 and miR-423-3p expressions differentiated 70.1 % of hereditary and non-hereditary BCs. Array miR expression profiles can differentiate the four study groups using FFPE BC.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-369	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-429	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-638	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-938	Hirschsprung Disease	26933947	gastrointestinal system disease	DOID:10487	Q43.1	D006627	600156	HP:0002251	miRNA Profiling Reveals Dysregulation of RET and RET-Regulating Pathways in Hirschsprung's Disease.
circulation_biomarker_diagnosis_ns	hsa-mir-183	Human Immunodeficiency Virus Infection	25997625			B20	D015658	609423		We show for the first time a joint miRNA and mRNA expression profile related to a HIV-1 latency phenotype, outline a dynamic network of potential regulators involving in HIV-1 latency or replication state, and gain new insights into the source messages for affecting HIV-1 latency.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Human Immunodeficiency Virus Infection	28955339			B20	D015658	609423		Deregulated MicroRNA-21 Expression in Monocytes from HIV-Infected Patients Contributes to Elevated IP-10 Secretion in HIV Infection.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Huntington Disease	25889241	nervous system disease	DOID:12858	G10	D006816	143100		These results demonstrate that miRNA expression in cortical BA9 provides insight into striatal involvement and support a role for these miRNAs,particularly miR-10b-5p, in HD pathogenicity. The miRNAs identified in our studies of postmortem brain tissue may be detectable in peripheral fluids and thus warrant consideration as accessible biomarkers for disease stage, rate of progression, and other important clinical characteristics of HD.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Hyperactivity Disorder	25724585	disease of mental health	DOID:1094	F90	D001289	143465	HP:0007018	Circulating MicroRNA Let-7d in Attention-Deficit/Hyperactivity Disorder.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Hyperhomocysteinemia	28633641				D020138			Expression levels of atherosclerosis-associated miR-143 and miR-145 in the plasma of patients with hyperhomocysteinaemia.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Hyperhomocysteinemia	28633641				D020138			Expression levels of atherosclerosis-associated miR-143 and miR-145 in the plasma of patients with hyperhomocysteinaemia.
circulation_biomarker_diagnosis_ns	hsa-mir-33a	Hyperlipoproteinemia Type III	28811385	disease of metabolism	DOID:3145		D006952	617347	HP:0010980	Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: implication of a ZEB1-dependent mechanism.
circulation_biomarker_diagnosis_ns	hsa-mir-33b	Hyperlipoproteinemia Type III	28811385	disease of metabolism	DOID:3145		D006952	617347	HP:0010980	Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: implication of a ZEB1-dependent mechanism.
circulation_biomarker_diagnosis_ns	hsa-mir-1-1	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-1: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-1-2	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-1: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-126	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-126	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-154 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Hypertension	26984682	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miRNA-208b and miRNA-133a show distinct profiling in peripheral blood cells isolated from untreated patients
circulation_biomarker_diagnosis_ns	hsa-mir-133a-1	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-133a: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-133a: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-143	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-145	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-145	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-155 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-156 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-155	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-155: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-155	Hypertension	29057982	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Characterization of serum miRNAs as molecular biomarkers for acute Stanford type A aortic dissection diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-157	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-157 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-17	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-150 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Hypertension	18690400	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miR-208: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Hypertension	26984682	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	miRNA-208b and miRNA-133a show distinct profiling in peripheral blood cells isolated from untreated patients
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hypertension	26114349	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The decreased levels of NOx and eNOS found in this study indicate the co-existence of endothelial dysfunction and hypertension once more. In the absence of microalbuminuria, the increased miR-21 expression in patients with iCIMT made us conclude that this miRNA might be involved in the early stages of atherosclerotic process in hypertensive patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-21	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-151 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-221	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-223	Hypertension	29186297	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Cardiovascular morbidity is associated with differential expression of myriad miRNAs; miR-21, miR-155, miR-126, miR-146a/b, miR-143/145, miR-223, and miR-221 are the top 9 most reported miRNAs in hypertension and atherosclerotic disease
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-152 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-505	Hypertension	25449503	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	hsa-mir-505 is a novel circulating signature of hypertension, which may play a role in angiogenesis. Our results provide mechanistic insights into hypertension-associated pathogenesis and point 
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Hypertension	29615793	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Specifically, altered circulating expression of miR-17, miR-21, miR-34a, miR-92a, miR-126, miR-145, miR-146a, and miR-153 has  been linked with the pathogenesis and progression of cardiovascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-122	Idiopathic Asthenospermia	27264812			R86.9			HP:0012207	Seminal plasma miR-122-3p and miR-141-5p stability and its diagnosis value for idiopathic asthenospermia.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Idiopathic Asthenospermia	27264812			R86.9			HP:0012207	Seminal plasma miR-122-3p and miR-141-5p stability and its diagnosis value for idiopathic asthenospermia.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-302a	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-302c	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-3620	Immune Thrombocytopenic Purpura	24851893	immune system disease	DOID:8924	D69.3	D016553	188030		The plasma differential miRNA profiles are identified in ITP patients. And miRNA is involved in calcium signaling pathway and T cell receptor signaling pathway may be associated with ITP pathogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-378i	Immune Thrombocytopenic Purpura	24851893	immune system disease	DOID:8924	D69.3	D016553	188030		The plasma differential miRNA profiles are identified in ITP patients. And miRNA is involved in calcium signaling pathway and T cell receptor signaling pathway may be associated with ITP pathogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-410	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-4721	Immune Thrombocytopenic Purpura	24851893	immune system disease	DOID:8924	D69.3	D016553	188030		The plasma differential miRNA profiles are identified in ITP patients. And miRNA is involved in calcium signaling pathway and T cell receptor signaling pathway may be associated with ITP pathogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-544a	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-597	Immune Thrombocytopenic Purpura	24418947	immune system disease	DOID:8924	D69.3	D016553	188030		Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Inflammation	26083362				D007249			The expression profile of microRNAs/mRNAs in monocytes of T2D patients indicates an altered adhesion, differentiation, and shape change potential. Monocyte inflammatory activation was only found in patients with normal serum lipids. Abnormal lipid values coincided with a reduced monocyte inflammatory state.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Influenza	24699363	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Influenza	24699363	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans.
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Influenza	24699363	respiratory system disease	DOID:8469	J09-J11	D007251	614680		Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans.
circulation_biomarker_diagnosis_ns	hsa-mir-3663	Inherited Hemoglobin Disease	26837891							Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume.
circulation_biomarker_diagnosis_ns	hsa-mir-4726	Inherited Hemoglobin Disease	26837891							Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume.
circulation_biomarker_diagnosis_ns	hsa-mir-7109	Inherited Hemoglobin Disease	26837891							Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume.
circulation_biomarker_diagnosis_ns	hsa-mir-940	Inherited Hemoglobin Disease	26837891							Discussion Five of these microRNAs including U101, hsa-miR-4726-5p, hsa-miR7109 5p, hsa-miR3663, and hsa-miR940 had significant changes in expression and volume.
circulation_biomarker_diagnosis_ns	hsa-mir-125b-1	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-125b-2	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-128-1	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-128-2	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-20b	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Interstitial Lung Disease	22512273	respiratory system disease	DOID:3082	J84	D017563	614748	HP:0006530	(miR-125b-5p, miR-128, miR-30e, and miR-20b) were significantly changed, both in the lung tissue and in plasma, and exhibited mainstream (MS) exposure duration-dependent pathological changes in the lung.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Intestinal Schistosomiasis	26230095	disease by infectious agent	DOID:0050597	B65.1	D012554	181460		The inconsistent levels of the host circulating miRNAs, miR-122, miR-21 and miR-34a in serum were confirmed in the two murine models during infection
circulation_biomarker_diagnosis_ns	hsa-mir-1275	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Intrahepatic Cholangiocarcinoma	25482320	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		combination of these two markers improved the power of screening ICC. Moreover, on the basis of the plasma miR-150 level, 15 ICC patients were divided into a low or high expression group. We found that plasma miR-150 is a potential diagnostic biomarker for ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-199b	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-874	Intrahepatic Cholangiocarcinoma	25903557	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		The association of unique miRNA profiles with different ICC subtypes suggests the involvement of specific miRNAs during ICC tumor progression. In plasma, an eight-miRNA signature associated with ICC could form the foundation of an accessible (plasma-based) miRNA-based biomarker for the early detection of ICC.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Irritable Bowel Syndrome	24768587	syndrome	DOID:9778	K58	D043183			This preliminary study reports the association of two miRNAs,detected in whole blood, with IBS. These miRNAs link to pain and inflammatory pathways both of which are thought to be dysregulated in IBS. Larger sample sizes are needed to confirm their importance and potential as biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Irritable Bowel Syndrome	24768587	syndrome	DOID:9778	K58	D043183			This preliminary study reports the association of two miRNAs,detected in whole blood, with IBS. These miRNAs link to pain and inflammatory pathways both of which are thought to be dysregulated in IBS. Larger sample sizes are needed to confirm their importance and potential as biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Ischemia-Reperfusion Injury	27760486				D015427			Micro RNA-320 as a novel potential biomarker in renal ischemia reperfusion.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Ischemia-Reperfusion Injury	27979484				D015427			MicroRNA-125b as a new potential biomarker on diagnosis of renal ischemia-reperfusion injury.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-142	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Ischemic Heart Disease	28768728			I25.9/I24.9	D017202			six miRNA mimics (miR-34a, -122, -133a, -142, -146a, and -208a) induced cytokine production in a dose-dependent manner
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Kideny Transplant Rejection	28577875			T86.11	D006084			Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Kideny Transplant Rejection	28577875			T86.11	D006084			Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Kideny Transplant Rejection	28577875			T86.11	D006084			Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Kideny Transplant Rejection	28577875			T86.11	D006084			Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Kideny Transplant Rejection	28577875			T86.11	D006084			Circulating miR-150, miR-192, miR-200b, and miR-423-3p as Non-invasive Biomarkers of Chronic Allograft Dysfunction.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Kidney Diseases [unspecific]	28522697			N18.9	D007674			Circulating MicroRNA-125b Predicts the Presence and Progression of Uremic Vascular Calcification.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Kidney Diseases [unspecific]	23070235			N18.9	D007674			Circulating levels of inflammation-associated miR-155 and endothelial-enriched miR-126 in patients with end-stage renal disease
circulation_biomarker_diagnosis_ns	hsa-mir-192	Kidney Injury	28056546			S37.0	D058186			Urinary MicroRNA-30c-5p and MicroRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Kidney Injury	28056546			S37.0	D058186			Urinary MicroRNA-30c-5p and MicroRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Kidney Neoplasms	22429968	disease of cellular proliferation	DOID:263	C64	D007680			MicroRNA 15a, Inversely Correlated to PKC, Is a Potential Marker to Differentiate between Benign and Malignant Renal Tumors in Biopsy and Urine Samples.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Leukemia	22209839			C95	D007938	613065	HP:0001909	These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML.
circulation_biomarker_diagnosis_ns	hsa-mir-128	Leukemia	22209839			C95	D007938	613065	HP:0001909	These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Leukemia	22431542			C95	D007938	613065	HP:0001909	Analyzed retrospectively, miR-15a levels differ among the del(13q) groups.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Leukemia	21176349			C95	D007938	613065	HP:0001909	The results showed that the expression levels of miRNA-17-19b in K562 cells and white blood cells of peripheral blood from CML patients were higher than those in mobilized white blood cells of peripheral blood from normal person.
circulation_biomarker_diagnosis_ns	hsa-mir-18	Leukemia	21176349			C95	D007938	613065	HP:0001909	The results showed that the expression levels of miRNA-17-19b in K562 cells and white blood cells of peripheral blood from CML patients were higher than those in mobilized white blood cells of peripheral blood from normal person.
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Leukemia	23998571			C95	D007938	613065	HP:0001909	MicroRNA-193b expression in newly diagnosed leukemia patients and its significance.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Leukemia	21176349			C95	D007938	613065	HP:0001909	The results showed that the expression levels of miRNA-17-19b in K562 cells and white blood cells of peripheral blood from CML patients were higher than those in mobilized white blood cells of peripheral blood from normal person.
circulation_biomarker_diagnosis_ns	hsa-mir-19b-1	Leukemia	21176349			C95	D007938	613065	HP:0001909	The results showed that the expression levels of miRNA-17-19b in K562 cells and white blood cells of peripheral blood from CML patients were higher than those in mobilized white blood cells of peripheral blood from normal person.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Leukemia	22209839			C95	D007938	613065	HP:0001909	These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Leukemia	24153013			C95	D007938	613065	HP:0001909	Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells.
circulation_biomarker_diagnosis_ns	hsa-mir-365	Leukemia	24153013			C95	D007938	613065	HP:0001909	Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells.
circulation_biomarker_diagnosis_ns	hsa-mir-638	Leukemia	19440243			C95	D007938	613065	HP:0001909	The ratio of miR-92a/miR-638 in plasma has strong potential for clinical application as a novel biomarker for detection of leukemia.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Leukemia	19440243			C95	D007938	613065	HP:0001909	The ratio of miR-92a/miR-638 in plasma has strong potential for clinical application as a novel biomarker for detection of leukemia.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Leukemia, Acute	20561445	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-128-1	Leukemia, Acute	20561445	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Acute	20561445	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Leukemia, Acute	20561445	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Leukemia, Acute	20561445	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-101-2	Leukemia, Lymphoblastic, Acute	22456238	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	As for the most differentially expressed miRNAs, they included 8 upregulated and 14 downregulated miRNAs, of which miR-148a at 7p15.2, miR-22 at 17p13.3, miR-223 at Xq12, as well as miR-101-2 at 9p24.1 exhibited recurrent CNAs or CNN LOH.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Leukemia, Lymphoblastic, Acute	24955371	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	these miRNAs not only may be used as biomarkers in diagnosis of ALL and monitoring the disease but also provide new insights into the potential roles of them in leukemogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Leukemia, Lymphoblastic, Acute	22456238	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	As for the most differentially expressed miRNAs, they included 8 upregulated and 14 downregulated miRNAs, of which miR-148a at 7p15.2, miR-22 at 17p13.3, miR-223 at Xq12, as well as miR-101-2 at 9p24.1 exhibited recurrent CNAs or CNN LOH.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Lymphoblastic, Acute	24955371	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	these miRNAs not only may be used as biomarkers in diagnosis of ALL and monitoring the disease but also provide new insights into the potential roles of them in leukemogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Leukemia, Lymphoblastic, Acute	24955371	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	these miRNAs not only may be used as biomarkers in diagnosis of ALL and monitoring the disease but also provide new insights into the potential roles of them in leukemogenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Leukemia, Lymphoblastic, Acute	22456238	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	As for the most differentially expressed miRNAs, they included 8 upregulated and 14 downregulated miRNAs, of which miR-148a at 7p15.2, miR-22 at 17p13.3, miR-223 at Xq12, as well as miR-101-2 at 9p24.1 exhibited recurrent CNAs or CNN LOH.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Leukemia, Lymphoblastic, Acute	22456238	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	As for the most differentially expressed miRNAs, they included 8 upregulated and 14 downregulated miRNAs, of which miR-148a at 7p15.2, miR-22 at 17p13.3, miR-223 at Xq12, as well as miR-101-2 at 9p24.1 exhibited recurrent CNAs or CNN LOH.
circulation_biomarker_diagnosis_ns	hsa-mir-708	Leukemia, Lymphoblastic, Acute, Childhood	25214155	disease of cellular proliferation	DOID:0080144	C91.0	D054198	613065		MiR-708-5p is differentially expressed in childhood acute lymphoblastic leukemia but not strongly associated to clinical features.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Leukemia, Lymphoblastic, Acute, T-Cell	21642990	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Cross-comparison of miRNA expression profiles in human T-ALL with the results of an unbiased miRNA library screen allowed us to identify five miRNAs (miR-19b, miR-20a, miR-26a, miR-92 and miR-223) that are capable of promoting T-ALL development in a mouse model and which account for the majority of miRNA expression in human T-ALL.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Leukemia, Lymphoblastic, Acute, T-Cell	21642990	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Cross-comparison of miRNA expression profiles in human T-ALL with the results of an unbiased miRNA library screen allowed us to identify five miRNAs (miR-19b, miR-20a, miR-26a, miR-92 and miR-223) that are capable of promoting T-ALL development in a mouse model and which account for the majority of miRNA expression in human T-ALL.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Leukemia, Lymphoblastic, Acute, T-Cell	21642990	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Cross-comparison of miRNA expression profiles in human T-ALL with the results of an unbiased miRNA library screen allowed us to identify five miRNAs (miR-19b, miR-20a, miR-26a, miR-92 and miR-223) that are capable of promoting T-ALL development in a mouse model and which account for the majority of miRNA expression in human T-ALL.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Leukemia, Lymphoblastic, Acute, T-Cell	21642990	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Cross-comparison of miRNA expression profiles in human T-ALL with the results of an unbiased miRNA library screen allowed us to identify five miRNAs (miR-19b, miR-20a, miR-26a, miR-92 and miR-223) that are capable of promoting T-ALL development in a mouse model and which account for the majority of miRNA expression in human T-ALL.
circulation_biomarker_diagnosis_ns	hsa-mir-92	Leukemia, Lymphoblastic, Acute, T-Cell	21642990	disease of cellular proliferation	DOID:5602	C91.0		613065	HP:0006727	Cross-comparison of miRNA expression profiles in human T-ALL with the results of an unbiased miRNA library screen allowed us to identify five miRNAs (miR-19b, miR-20a, miR-26a, miR-92 and miR-223) that are capable of promoting T-ALL development in a mouse model and which account for the majority of miRNA expression in human T-ALL.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-155:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-15a:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases
circulation_biomarker_diagnosis_ns	hsa-mir-181b-1	Leukemia, Lymphocytic, Chronic, B-Cell	22350310	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181b is a biomarker for the progression of this disease from indolent to aggressive.
circulation_biomarker_diagnosis_ns	hsa-mir-181b-2	Leukemia, Lymphocytic, Chronic, B-Cell	22350310	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181b is a biomarker for the progression of this disease from indolent to aggressive.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Leukemia, Lymphocytic, Chronic, B-Cell	21460253	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	circulating miR-20a correlates reliably with diagnosis-to-treatment time.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-34a:We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases
circulation_biomarker_diagnosis_ns	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_ns	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	20561445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	20561445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Leukemia, Lymphocytic, Chronic, B-Cell	20561445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Leukemia, Lymphocytic, Chronic, B-Cell	28830603	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Leukemia, Lymphocytic, Chronic, B-Cell	20561445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Leukemia, Lymphocytic, Chronic, B-Cell	20561445	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, miR-29b, miR-181a and miR-181b in patients with CLL, while miR-128-1, miR-223, let-7b, miR-155 and miR-181a in patients with AL were analyzed by 2((-DeltaDeltaCT)) method.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	27730344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
circulation_biomarker_diagnosis_ns	hsa-mir-92	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Leukemia, Myeloid, Acute	26067326	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We propose development of serum exosome miRNA as a platform for a novel,sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Leukemia, Myeloid, Acute	24477595	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
circulation_biomarker_diagnosis_ns	hsa-mir-127	Leukemia, Myeloid, Acute	18478077	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-135a	Leukemia, Myeloid, Acute	24072101	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Leukemia, Myeloid, Acute	28890884	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-150	Leukemia, Myeloid, Acute	23391324	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	plasma;Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-154	Leukemia, Myeloid, Acute	18478077	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Myeloid, Acute	26067326	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We propose development of serum exosome miRNA as a platform for a novel,sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.
circulation_biomarker_diagnosis_ns	hsa-mir-181a-2	Leukemia, Myeloid, Acute	18450603	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-181c	Leukemia, Myeloid, Acute	18450603	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-181d	Leukemia, Myeloid, Acute	18450603	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-196b	Leukemia, Myeloid, Acute	24072101	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups.
circulation_biomarker_diagnosis_ns	hsa-mir-196b	Leukemia, Myeloid, Acute	26317787	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	These results suggest that microRNA-155 is a potential diagnostic biomarker for all subgroups of paediatric AML, whereas microRNA-196b is specific for subgroups M4-M5.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Leukemia, Myeloid, Acute	28987820	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo.
circulation_biomarker_diagnosis_ns	hsa-mir-299	Leukemia, Myeloid, Acute	18478077	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-3151	Leukemia, Myeloid, Acute	26430723	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
circulation_biomarker_diagnosis_ns	hsa-mir-323a	Leukemia, Myeloid, Acute	18478077	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-335	Leukemia, Myeloid, Acute	25301405	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our data offer the convincing evidence for the first time that serum miR-335 level may be markedly and consistently increased in pediatric AML patients. Serum miR-335 may serve as a promising marker for monitoring the progression and predicting the clinical outcome of patients with this disease.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Leukemia, Myeloid, Acute	23391324	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	plasma;Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-342	Leukemia, Myeloid, Acute	28890884	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-370	Leukemia, Myeloid, Acute	18478077	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-377	Leukemia, Myeloid, Acute	25502508	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	a miRNA signature in human cord blood stem and progenitor cells with a potential role in hematopoietic stemness properties and possibly in leukemogenesis of specific AML subtypes.
circulation_biomarker_diagnosis_ns	hsa-mir-409	Leukemia, Myeloid, Acute	24072101	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups.
circulation_biomarker_diagnosis_ns	hsa-mir-4739	Leukemia, Myeloid, Acute	25502508	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	a miRNA signature in human cord blood stem and progenitor cells with a potential role in hematopoietic stemness properties and possibly in leukemogenesis of specific AML subtypes.
circulation_biomarker_diagnosis_ns	hsa-mir-644	Leukemia, Myeloid, Acute	24072101	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-409-3p, miR-135a, miR-196b and mir-644 arose as prognostic markers for IR-AML, both overall and within specific molecular subgroups.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Leukemia, Myeloid, Acute	28890884	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia
circulation_biomarker_diagnosis_ns	hsa-mir-103	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-1827	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-1973	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Leukemia, Myeloid, Chronic	21501493	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	The expression deregulation of miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was confirmed by real-time quantitative PCR.
circulation_biomarker_diagnosis_ns	hsa-mir-298	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-299	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-3201	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-3611	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-3646	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-3686	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-3915	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-4268	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-4279	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-4290	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-498	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-518b	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-525	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-612	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-665	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-711	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-943	Leukemia, Myeloid, Chronic	24460325	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Selective miRNA expression profile in chronic myeloid leukemia K562 cell-derived  exosomes.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	24598659	disease of cellular proliferation	DOID:5599	C83.5	D054218			Expression of miR-16 in patients with T lymphoblastic lymphoma/acute lymphoblastic leukemia.
circulation_biomarker_diagnosis_ns	hsa-mir-3613	Liposarcoma	29689704	disease of cellular proliferation	DOID:3382	C49.9	D008080	613488	HP:0012034	Whole blood miRNA expression analysis reveals miR-3613-3p as a potential biomarker for dedifferentiated liposarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-513a-1	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-mir-513a-2	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-mir-513b	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-mir-513c	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-mir-571	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-mir-652	Liver Cirrhosis	22412969	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	significant alterations in serum levels of miR-513-3p, miR-571 and miR-652. Up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue.
circulation_biomarker_diagnosis_ns	hsa-let-7f	Liver Diseases [unspecific]	27639178			K76.9	D008107			Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Liver Diseases [unspecific]	22427142			K76.9	D008107			The results showed a positive correlation between serum miR-122 and alanine aminotransferase, a clinical biomarker for liver function.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Liver Diseases [unspecific]	28070111			K76.9	D008107			circulating liver-specific miR-122 and miR-192 levels also increased 24 hr or later compared with ALT, suggesting that circulating miR-122 and miR-192 may serve as potential biomarkers to detect hepatotoxicity in cynomolgus monkeys
circulation_biomarker_diagnosis_ns	hsa-mir-122	Liver Diseases [unspecific]	29636028			K76.9	D008107			Comprehensive analysis of blood cells and plasma identifies tissue-specific miRNAs as potential novel circulating biomarkers
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Liver Diseases [unspecific]	25815788			K76.9	D008107			Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Liver Diseases [unspecific]	23886700			K76.9	D008107			Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Liver Diseases [unspecific]	28070111			K76.9	D008107			circulating liver-specific miR-122 and miR-192 levels also increased 24 hr or later compared with ALT, suggesting that circulating miR-122 and miR-192 may serve as potential biomarkers to detect hepatotoxicity in cynomolgus monkeys
circulation_biomarker_diagnosis_ns	hsa-mir-223	Liver Diseases [unspecific]	23886700			K76.9	D008107			Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Liver Diseases [unspecific]	27639178			K76.9	D008107			Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.
circulation_biomarker_diagnosis_ns	hsa-mir-340	Liver Diseases [unspecific]	27639178			K76.9	D008107			Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Liver Injury	24086271			S36.11	D056486			serum miR-122 has strong potential as a novel, specific and noninvasive biomarker for diagnosis of cholestasis-induced liver injury.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Liver Injury	24287929			S36.11	D056486			Plasma miR-122 expression is correlated with hepatectomy-induced liver injury in patients with HCC. Increase in miR-122 expression could be used as an index of such injury before and after hepatectomy in these patients.
circulation_biomarker_diagnosis_ns	hsa-let-7a	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-451	Liver Neoplasms	26082194	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in liver carcinoma resection studies.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-146	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-212	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-340	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-425	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Lofgren Syndrome	28050119			D86.9				The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren's Syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Lung Disease [unspecific]	23338559	respiratory system disease	DOID:850	J98.4	D008171	606963		plasma;Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease
circulation_biomarker_diagnosis_ns	hsa-let-7f	Lung Neoplasms	20595154	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	NSCLC patients and healthy controls differ in vesicle-related miRNAs in plasma. Levels of let-7f and miR-30e-3p in NSCLC patients are associated with poor outcome.
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Lung Neoplasms	25639977	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the panel of miRNA biomarkers had the potential for the early detection of lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Lung Neoplasms	25639977	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the panel of miRNA biomarkers had the potential for the early detection of lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Lung Neoplasms	23337359	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	serum;Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
circulation_biomarker_diagnosis_ns	hsa-mir-142	Lung Neoplasms	23410826	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Serum: miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Lung Neoplasms	25501703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results.
circulation_biomarker_diagnosis_ns	hsa-mir-148b	Lung Neoplasms	25501703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results.
circulation_biomarker_diagnosis_ns	hsa-mir-152	Lung Neoplasms	25501703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Lung Neoplasms	23337359	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	serum;Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lung Neoplasms	25501703	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNAs have great potential to serve as promising novel biomarkers in NSCLC screening. Further large-scale studies are needed to validate our results.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lung Neoplasms	26109362	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	MiR-21 expression levels in whole blood and peripheral blood cells did not show significant differences between lung cancer patients and healthy controls, and it might be ineffective to measure miR-21 expression to achieve an  early diagnosis of lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Lung Neoplasms	25639977	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	the panel of miRNA biomarkers had the potential for the early detection of lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Lung Neoplasms	20595154	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	NSCLC patients and healthy controls differ in vesicle-related miRNAs in plasma. Levels of let-7f and miR-30e-3p in NSCLC patients are associated with poor outcome.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Lung Neoplasms	25765717	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miRNA-31 may be a molecular marker for the diagnostic and prognostic evaluation of primary lung cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-3662	Lung Neoplasms	26079400	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-944	Lung Neoplasms	26079400	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-1224	Lupus Nephritis	20485490	urinary system disease	DOID:0080162	M32.14	D008181			miR-1224-3P:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested
circulation_biomarker_diagnosis_ns	hsa-mir-371a	Lupus Nephritis	20485490	urinary system disease	DOID:0080162	M32.14	D008181			miR-371-5P:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested
circulation_biomarker_diagnosis_ns	hsa-mir-423	Lupus Nephritis	20485490	urinary system disease	DOID:0080162	M32.14	D008181			miR-423-5P:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested
circulation_biomarker_diagnosis_ns	hsa-mir-638	Lupus Nephritis	20485490	urinary system disease	DOID:0080162	M32.14	D008181			miR-638:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested
circulation_biomarker_diagnosis_ns	hsa-mir-663a	Lupus Nephritis	20485490	urinary system disease	DOID:0080162	M32.14	D008181			miR-663:hsa-miR-371-5P, hsa-miR-423-5P, hsa-miR-638, hsa-miR-1224-3P and hsa-miR-663 that were differentially expressed in lupus nephritis across different racial groups and all specimen types tested
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Lymphoma, Burkitt	27991481	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lymphoma, Burkitt	27991481	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Lymphoma, Burkitt	27991481	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-18	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-19b-1	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lymphoma, Large B-Cell, Diffuse	24400911	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-92-1	Lymphoma, Large B-Cell, Diffuse	22964854	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-17-92 cluster could represent a reliable, standardizable diagnostic tool for the sub-classification of large B-cell lymphoid neoplasm.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Lymphoma, Non-Hodgkin	24675587	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	Altered serum levels of miR-21, miR-122, and miR-223 are seen in HIV-infected individuals.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Lymphoma, T-Cell	25503151	disease of cellular proliferation	DOID:0050749	C84.4	D016399	186960	HP:0012190	miR profiling in CTCL may be a key to improving both diagnosis and risk prediction.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Machado-Joseph Disease	23879331	nervous system disease	DOID:1440	G11.1	D017827	109150		MicroRNA profiling in the serums of SCA3/MJD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Machado-Joseph Disease	23879331	nervous system disease	DOID:1440	G11.1	D017827	109150		MicroRNA profiling in the serums of SCA3/MJD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Machado-Joseph Disease	23879331	nervous system disease	DOID:1440	G11.1	D017827	109150		MicroRNA profiling in the serums of SCA3/MJD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Machado-Joseph Disease	23879331	nervous system disease	DOID:1440	G11.1	D017827	109150		MicroRNA profiling in the serums of SCA3/MJD patients.
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Macroglobulinemia	25428891	disease of metabolism	DOID:9080	Q38.2	D008258	153600		Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia.
circulation_biomarker_diagnosis_ns	hsa-mir-320b	Macroglobulinemia	25428891	disease of metabolism	DOID:9080	Q38.2	D008258	153600		Combination of serum microRNA-320a and microRNA-321b as a marker for Waldenström macroglobulinemia.
circulation_biomarker_diagnosis_ns	hsa-mir-34b	Major Depressive Disorder	26807671	disease of mental health	DOID:1470	F32	D003865	608520		Differentially Notch-associated miRNAs expressions in peripheral blood might be involved in MDD, and the miR-34b-5p and miR-34c-5p levels in peripheral blood leukocytes are closely related to MDD, suicide idea and cognitive function, further studies with large sample size are warranted to test the feasibility of these miRNAs serving as biomarkers for MDD.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Major Depressive Disorder	26807671	disease of mental health	DOID:1470	F32	D003865	608520		Differentially Notch-associated miRNAs expressions in peripheral blood might be involved in MDD, and the miR-34b-5p and miR-34c-5p levels in peripheral blood leukocytes are closely related to MDD, suicide idea and cognitive function, further studies with large sample size are warranted to test the feasibility of these miRNAs serving as biomarkers for MDD.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Male Infertility	25740880	reproductive system disease	DOID:12336	N46.9	D007248		HP:0003251	Serum miR-155 as a potential biomarker of male fertility.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Melanoma	26208390	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Melanoma	26039581	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A profile of 2 miRNAs (miR-1246 and miR-185) significantly associated with metastatic melanoma with a sensitivity of 90.5% and a specificity of 89.1% was identified. This plasma miRNA profile may become an accurate non-invasive biomarker for melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-155	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-185	Melanoma	26039581	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A profile of 2 miRNAs (miR-1246 and miR-185) significantly associated with metastatic melanoma with a sensitivity of 90.5% and a specificity of 89.1% was identified. This plasma miRNA profile may become an accurate non-invasive biomarker for melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Melanoma	26208390	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
circulation_biomarker_diagnosis_ns	hsa-mir-203	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Melanoma	26045823	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Our results offer the convincing evidence that miR-206 may be implicated in aggressive progression of melanoma. More importantly, the serum level of miR-206 may be a noninvasive prognostic biomarker for the patients with melanoma.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Melanoma	26208390	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
circulation_biomarker_diagnosis_ns	hsa-mir-211	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-33a	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-373	Melanoma	26208390	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
circulation_biomarker_diagnosis_ns	hsa-mir-424	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-4487	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-4706	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-4731	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-506	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-509	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-514	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-514a	Melanoma	26288839	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	This panel was found to be superior to currently used serological markers for melanoma progression
circulation_biomarker_diagnosis_ns	hsa-mir-520c	Melanoma	26208390	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
circulation_biomarker_diagnosis_ns	hsa-mir-9	Melanoma	23863473	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
circulation_biomarker_diagnosis_ns	hsa-mir-134	Mesial Temporal Lobe Epilepsy	28384161			G40.209	D004833	608096		MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Mesial Temporal Lobe Epilepsy	27833019			G40.209	D004833	608096		Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Mesial Temporal Lobe Epilepsy	27833019			G40.209	D004833	608096		Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-365a	Mesial Temporal Lobe Epilepsy	27833019			G40.209	D004833	608096		Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-532	Mesial Temporal Lobe Epilepsy	27833019			G40.209	D004833	608096		Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-663b	Mesial Temporal Lobe Epilepsy	27833019			G40.209	D004833	608096		Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Mesothelioma	28321148	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.
circulation_biomarker_diagnosis_ns	hsa-mir-1207	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Metabolic Syndrome	23922812	disease of metabolism	DOID:14221	E88.81	D024821	605552		These findings cast new light on the regulation of miR-33a and miR-122 in a dyslipidemic model of obese rats and the way these miRNAs are modulated by dietary components in the liver and in PBMCs.
circulation_biomarker_diagnosis_ns	hsa-mir-1237	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-1288	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-129-1	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-129-2	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-130b	Metabolic Syndrome	23868745	disease of metabolism	DOID:14221	E88.81	D024821	605552		Circulating miR-130b reflects the degree of obesity and could serve as a potential biomarker for hypertriacylglycerolaemia and metabolic syndrome. Circulating miR-130b could function as a metabolic mediator for adipose muscle crosstalk and might be involved in the pathogenesis of obesity associated metabolic diseases.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-331	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-33a	Metabolic Syndrome	23922812	disease of metabolism	DOID:14221	E88.81	D024821	605552		These findings cast new light on the regulation of miR-33a and miR-122 in a dyslipidemic model of obese rats and the way these miRNAs are modulated by dietary components in the liver and in PBMCs.
circulation_biomarker_diagnosis_ns	hsa-mir-484	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-625	Metabolic Syndrome	24784704	disease of metabolism	DOID:14221	E88.81	D024821	605552		Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways  underlying metabolic syndrome: the cardiovascular risk in Young Finns Study.
circulation_biomarker_diagnosis_ns	hsa-mir-128	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-134	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-323	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-370	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-382	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-491	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-mir-874	Mild Cognitive Impairment	24368295			G31.84	D060825	614306		Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.
circulation_biomarker_diagnosis_ns	hsa-let-7c	Multiple Myeloma	23424776	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Five miRNAs (let-7c, miR-16, miR- 449, miR-181a and miR-181b) were found to exhibit similar expression patterns (p < 0.05) in peripheral blood when compared to data obtained by using bone marrow aspirates from MM patients in other studies.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Multiple Myeloma	26516702	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Therefore, our data suggest that the expression patterns of miR-15a/16-1 are different in MM patients, and miR-15a seems to be linked with disease progression and prognosis while miR-16-1 acts as a valuable diagnostic marker.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Multiple Myeloma	23424776	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Five miRNAs (let-7c, miR-16, miR- 449, miR-181a and miR-181b) were found to exhibit similar expression patterns (p < 0.05) in peripheral blood when compared to data obtained by using bone marrow aspirates from MM patients in other studies.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Multiple Myeloma	28446295	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Circulating Serum MicroRNA as Diagnostic Biomarkers for Multiple Myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-16-1	Multiple Myeloma	26516702	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Therefore, our data suggest that the expression patterns of miR-15a/16-1 are different in MM patients, and miR-15a seems to be linked with disease progression and prognosis while miR-16-1 acts as a valuable diagnostic marker.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Multiple Myeloma	23424776	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Five miRNAs (let-7c, miR-16, miR- 449, miR-181a and miR-181b) were found to exhibit similar expression patterns (p < 0.05) in peripheral blood when compared to data obtained by using bone marrow aspirates from MM patients in other studies.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Multiple Myeloma	23424776	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Five miRNAs (let-7c, miR-16, miR- 449, miR-181a and miR-181b) were found to exhibit similar expression patterns (p < 0.05) in peripheral blood when compared to data obtained by using bone marrow aspirates from MM patients in other studies.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-331	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Multiple Myeloma	18700954	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-335: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-342	Multiple Myeloma	18700954	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-342: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-449	Multiple Myeloma	23424776	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Five miRNAs (let-7c, miR-16, miR- 449, miR-181a and miR-181b) were found to exhibit similar expression patterns (p < 0.05) in peripheral blood when compared to data obtained by using bone marrow aspirates from MM patients in other studies.
circulation_biomarker_diagnosis_ns	hsa-mir-561	Multiple Myeloma	18700954	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	miR-561: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-660	Multiple Myeloma	25593199	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Multiple Sclerosis	22108567	nervous system disease	DOID:2377	G35	D009103	PS126200		deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-128	Multiple Sclerosis	29527713	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Multiple Sclerosis	23773985	nervous system disease	DOID:2377	G35	D009103	PS126200		RRMS patients in remission had altered expression of mirNAs. We validated mir-145 as a potential diagnostic biomarker for the diagnosis of MS in blood, plasma and serum.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Multiple Sclerosis	29246612	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-150	Multiple Sclerosis	22108567	nervous system disease	DOID:2377	G35	D009103	PS126200		deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-191	Multiple Sclerosis	29527713	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Multiple Sclerosis	29246612	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-24	Multiple Sclerosis	29527713	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Multiple Sclerosis	27606352	nervous system disease	DOID:2377	G35	D009103	PS126200		Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis.
circulation_biomarker_diagnosis_ns	hsa-mir-326	Multiple Sclerosis	21949733	nervous system disease	DOID:2377	G35	D009103	PS126200		Four miRNAs (miR-326, miR-155, miR-146a, miR-142-3p) were aberrantly expressed in peripheral blood mononuclear cells from RRMS (relapsing remitting multiple sclerosis) patients compared to healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-326	Multiple Sclerosis	25642434	nervous system disease	DOID:2377	G35	D009103	PS126200		Our longitudinal analysis revealed that miR-18a, miR-20b, miR-29a, and miR-103 were upregulated and predominantly expressed by CD4(+) T cells, whereas miR-326 was downregulated upon natalizumab treatment.
circulation_biomarker_diagnosis_ns	hsa-mir-326	Multiple Sclerosis	29246612	nervous system disease	DOID:2377	G35	D009103	PS126200		miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Multiple Sclerosis	29527713	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-572	Multiple Sclerosis	25947625	nervous system disease	DOID:2377	G35	D009103	PS126200		Evaluation of miR-572 may serve as a non-invasive biomarker for remyelination.
circulation_biomarker_diagnosis_ns	hsa-let-7c	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-let-7e	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-let-7i	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-100	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-103a-1	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-103a-2	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-107	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-126	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-132	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-140	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-143	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-145	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-151a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-154	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-155	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-195	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-199a-1	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-199a-2	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-199b	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-19b-1	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-19b-2	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-21	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-210	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-214	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-22	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-221	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-222	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-223	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-28	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-299	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-335	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-362	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-376c	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-379	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	Ten different miRNAs showing distinct expression patterns in the 10 different diseases (miR-21, miR-22, miR-29c, miR-30a-3p, miR-146b, miR-221, miR-368, miR-379, Ambi-miR-693, and Ambi-miR-11040).
circulation_biomarker_diagnosis_ns	hsa-mir-381	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-432	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-452	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-487b	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-495	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-497	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-501	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-99b	Muscle Atrophy	17942673			M62.5	D009133		HP:0100295	dysregulation
circulation_biomarker_diagnosis_ns	hsa-mir-1	Muscle Diseases [unspecific]	25146754			M63.80	D009135			These miRNAs are potential biomarkers of muscle damage or adaptation to exercise.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Muscular Dystrophy	27529242			G71.0	D009136	310200	HP:0003560	miR-206 has  potential as a "liquid biopsy" for carrier detection and genetic counseling in DMD.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Muscular Dystrophy, Duchenne	25150707	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Taken together, our data demonstrate that levels of miR-1, miR-133a, and miR-206 in serum of BMD and miR-1 in sera of LGMD and FSHD patients showed no significant differences compared with those of controls by Bonferroni correction. However, the results might need increase in sample sizes to evaluate these three miRNAs as variable biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Muscular Dystrophy, Duchenne	24460924	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
circulation_biomarker_diagnosis_ns	hsa-mir-1-1	Muscular Dystrophy, Duchenne	21425469	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans
circulation_biomarker_diagnosis_ns	hsa-mir-1-2	Muscular Dystrophy, Duchenne	21425469	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans
circulation_biomarker_diagnosis_ns	hsa-mir-133	Muscular Dystrophy, Duchenne	24460924	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Muscular Dystrophy, Duchenne	25150707	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Taken together, our data demonstrate that levels of miR-1, miR-133a, and miR-206 in serum of BMD and miR-1 in sera of LGMD and FSHD patients showed no significant differences compared with those of controls by Bonferroni correction. However, the results might need increase in sample sizes to evaluate these three miRNAs as variable biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-133a-1	Muscular Dystrophy, Duchenne	21425469	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Muscular Dystrophy, Duchenne	21425469	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans
circulation_biomarker_diagnosis_ns	hsa-mir-133b	Muscular Dystrophy, Duchenne	21425469	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		miR-1, miR-133, and miR-206 are new and valuable biomarkers for the diagnosis of DMD and possibly also for monitoring the outcomes of therapeutic interventions in humans
circulation_biomarker_diagnosis_ns	hsa-mir-206	Muscular Dystrophy, Duchenne	25150707	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Taken together, our data demonstrate that levels of miR-1, miR-133a, and miR-206 in serum of BMD and miR-1 in sera of LGMD and FSHD patients showed no significant differences compared with those of controls by Bonferroni correction. However, the results might need increase in sample sizes to evaluate these three miRNAs as variable biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Muscular Dystrophy, Duchenne	24460924	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-140	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-185	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-20b	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Myasthenia Gravis	24637658	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Analysis of serum miRNA profiles of myasthenia gravis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-101	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-140	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-296	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-mir-485	Mycobacterium tuberculosis Infection	26053546			A18	D014376	607948		A unique signature of 11 microRNAs in human macrophages was identified to differentiate active MTB disease from LTBI and healthy controls.
circulation_biomarker_diagnosis_ns	hsa-let-7a-1	Myelodysplastic Syndromes	21602527	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
circulation_biomarker_diagnosis_ns	hsa-let-7a-2	Myelodysplastic Syndromes	21602527	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
circulation_biomarker_diagnosis_ns	hsa-let-7a-3	Myelodysplastic Syndromes	21602527	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-16-1	Myelodysplastic Syndromes	21602527	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-16-2	Myelodysplastic Syndromes	21602527	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
circulation_biomarker_diagnosis_ns	hsa-mir-194	Myelodysplastic Syndromes	25975751	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	MicroRNA-194-5p could serve as a diagnostic and prognostic biomarker in myelodysplastic syndromes.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Myelodysplastic Syndromes	24503739	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Myeloma	25216866			C90.0	D009101	254500		Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma.
circulation_biomarker_diagnosis_ns	hsa-mir-10a	Myeloproliferative Neoplasms	18773208	disease of cellular proliferation	DOID:2226	D47.1		616871		miR-10a: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-126	Myeloproliferative Neoplasms	18773208	disease of cellular proliferation	DOID:2226	D47.1		616871		miR-126: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-155	Myeloproliferative Neoplasms	18299402	disease of cellular proliferation	DOID:2226	D47.1		616871		Sustained expression
circulation_biomarker_diagnosis_ns	hsa-mir-17	Myeloproliferative Neoplasms	18773208	disease of cellular proliferation	DOID:2226	D47.1		616871		miR-17-5p: deregulation
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Myeloproliferative Neoplasms	18773208	disease of cellular proliferation	DOID:2226	D47.1		616871		miR-20a: deregulation
circulation_biomarker_diagnosis_ns	hsa-let-7b	Myocardial Infarction	24284400	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The circulating let-7b is suspected to be the biomarker of acute MI and let-7i, the biomarker of DCM.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we identified several miRs associated with future AMI
circulation_biomarker_diagnosis_ns	hsa-mir-1	Myocardial Infarction	23630629	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	the levels of miR-1 in serum and urine from patients after open-heart surgeries and CPB were significant increased at all observed time points.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Myocardial Infarction	23641832	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186, miR-208, miR-223 and miR-499) as AMI biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-1	Myocardial Infarction	28663047	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction
circulation_biomarker_diagnosis_ns	hsa-mir-1	Myocardial Infarction	29030746	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Platelet microRNA for predicting acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-106a	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we identified several miRs associated with future AMI
circulation_biomarker_diagnosis_ns	hsa-mir-1-1	Myocardial Infarction	23747779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-1-2	Myocardial Infarction	23747779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Myocardial Infarction	22813605	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-126 showed a positive association , whereas miR-223 and miR-197 were inversely associated with disease risk.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Myocardial Infarction	29030746	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Platelet microRNA for predicting acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-133a-1	Myocardial Infarction	23747779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Myocardial Infarction	23347612	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating;Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Myocardial Infarction	23747779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-134	Myocardial Infarction	23641832	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186, miR-208, miR-223 and miR-499) as AMI biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-144	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we identified several miRs associated with future AMI
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Myocardial Infarction	26337652	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-146a and miR-21 may be novel biomarkers predictive of LVR after acute MI. Their combination may better predict LVR than either alone.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Myocardial Infarction	29030746	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Platelet microRNA for predicting acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-186	Myocardial Infarction	23641832	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186, miR-208, miR-223 and miR-499) as AMI biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-186	Myocardial Infarction	24727883	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	In a validation phase, a miRNA panel including miR-132, miR-150, and miR-186 showed the highest discriminatory power
circulation_biomarker_diagnosis_ns	hsa-mir-195	Myocardial Infarction	23236408	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our results imply that the plasma concentration of miR-30a, miR-195 and let-7b can be potential indicators for AMI
circulation_biomarker_diagnosis_ns	hsa-mir-197	Myocardial Infarction	22813605	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-126 showed a positive association , whereas miR-223 and miR-197 were inversely associated with disease risk.
circulation_biomarker_diagnosis_ns	hsa-mir-208	Myocardial Infarction	23641832	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186, miR-208, miR-223 and miR-499) as AMI biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Myocardial Infarction	23747779	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-1, miR-208a, and miR-133a continuously rose during the first 4 h after induction of AMI.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Myocardial Infarction	23168198	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Serum miR-208a may be a new biomarker the early diagnosis of STEAMI patients.
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Myocardial Infarction	28164501	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-208b: A Potentially Sensitive and Reliable Biomarker for the Diagnosis and Prognosis of Acute Myocardial Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-208b	Myocardial Infarction	29475914	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	plasma levels of circulating miR-208b and miR-499 could serve as potential AMI biomarkers
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Myocardial Infarction	21949348	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	deregulated between blood of patients with Unstable Angina and patients with Myocardial Infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Myocardial Infarction	26337652	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-146a and miR-21 may be novel biomarkers predictive of LVR after acute MI. Their combination may better predict LVR than either alone.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Myocardial Infarction	29030746	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Platelet microRNA for predicting acute myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Myocardial Infarction	29188800	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients
circulation_biomarker_diagnosis_ns	hsa-mir-223	Myocardial Infarction	22813605	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating miR-126 showed a positive association , whereas miR-223 and miR-197 were inversely associated with disease risk.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-424-5p and miR-26a-5p were associated exclusively with risk in men and women
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Myocardial Infarction	28663047	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Myocardial Infarction	23236408	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Our results imply that the plasma concentration of miR-30a, miR-195 and let-7b can be potential indicators for AMI
circulation_biomarker_diagnosis_ns	hsa-mir-423	Myocardial Infarction	23347612	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Circulating;Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction
circulation_biomarker_diagnosis_ns	hsa-mir-424	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we identified several miRs associated with future AMI
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Infarction	23641832	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	RT-qPCR analysis identified a profile of six serum miRNAs (miR-1, miR-134, miR-186, miR-208, miR-223 and miR-499) as AMI biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Infarction	24533109	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	MiRNAs, especially miR-499 and miR-133a, may be suitable for use as diagnostic biomarkers of myocardial infarction.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Infarction	28614255	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	 miRNA-499 had better diagnostic accuracy over other miRNAs
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Infarction	29188800	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Infarction	29475914	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	plasma levels of circulating miR-208b and miR-500 could serve as potential AMI biomarkers
circulation_biomarker_diagnosis_ns	hsa-mir-499a	Myocardial Infarction	22252325	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Serum miR-499 and hs-cTnT provided comparable diagnostic value with areas under the ROC curves of 0.97. The reclassification index of miR-499 to a clinical model including several risk factors and hs-cTnT was not significant (P = 0.15).
circulation_biomarker_diagnosis_ns	hsa-mir-660	Myocardial Infarction	27192016	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	we identified several miRs associated with future AMI
circulation_biomarker_diagnosis_ns	hsa-mir-1	Myocardial Ischemic-Reperfusion Injury	25791720				D015428			A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Myocardial Ischemic-Reperfusion Injury	25791720				D015428			A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery.
circulation_biomarker_diagnosis_ns	hsa-mir-208a	Myocardial Ischemic-Reperfusion Injury	20395621				D015428			miR-208:plasma miR-208 is a biomarker of myocardial injury
circulation_biomarker_diagnosis_ns	hsa-mir-21	Myocardial Ischemic-Reperfusion Injury	25791720				D015428			A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery.
circulation_biomarker_diagnosis_ns	hsa-mir-499	Myocardial Ischemic-Reperfusion Injury	25791720				D015428			A time-dependent change in miR-1/208a/499 levels occurred during open-heart surgery, and these were associated with levels of cTnI and CK-MB.These results reveal that miRNAs may be sensitive biomarkers for I/R injury during open-heart surgery.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Myotonic Dystrophy Type 1	26919350	musculoskeletal system disease	DOID:11722	G71.11	D009223	PS160900		a selection of six candidate miRNAs, miR-103, miR-107, miR-21, miR-29a, miR-30c, and miR-652 all failed to show consistent differences in serum expression in subsequent validation experiments.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Myotonic Dystrophy Type 1	26919350	musculoskeletal system disease	DOID:11722	G71.11	D009223	PS160900		a selection of six candidate miRNAs, miR-103, miR-107, miR-21, miR-29a, miR-30c, and miR-652 all failed to show consistent differences in serum expression in subsequent validation experiments.
circulation_biomarker_diagnosis_ns	hsa-mir-17	Nasopharyngeal Neoplasms	23056289			C11.9	D009303	607107	HP:0100630	Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Nasopharyngeal Neoplasms	23056289			C11.9	D009303	607107	HP:0100630	Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-223	Nasopharyngeal Neoplasms	23056289			C11.9	D009303	607107	HP:0100630	Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Nasopharyngeal Neoplasms	23056289			C11.9	D009303	607107	HP:0100630	Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma
circulation_biomarker_diagnosis_ns	hsa-let-7	Neoplasms [unspecific]	25856466			C80.1	D009369			Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia [corrected].
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Neoplasms [unspecific]	26522916			C80.1	D009369			Heterogeneity of miR-10b expression in circulating tumor cells.
circulation_biomarker_diagnosis_ns	hsa-mir-124	Neoplasms [unspecific]	25416717			C80.1	D009369			This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles  for prospective testing.
circulation_biomarker_diagnosis_ns	hsa-mir-140	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-1538	Neoplasms [unspecific]	25416717			C80.1	D009369			This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles  for prospective testing.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Neoplasms [unspecific]	26765436			C80.1	D009369			Appraising MicroRNA-155 as a Noninvasive Diagnostic Biomarker for Cancer Detection: A Meta-Analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-185	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Neoplasms [unspecific]	24815829			C80.1	D009369			Circulating miR-18a: a sensitive cancer screening biomarker in human cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-191	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Neoplasms [unspecific]	26035744			C80.1	D009369			in clinicopathology analysis,miR-200c expression in blood was significantly associated with TNM stage, lymph node metastasis and distant metastasis. MiR-200c may have the potential to become a new blood biomarker to monitor cancer prognosis and progression.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Neoplasms [unspecific]	25907045			C80.1	D009369			we selectively detected cancer cell-derived exosomal miRNA-21 among heterogeneous exosome mixtures and in human serum. The method developed in the article is simple, fast, and sensitive, so it will offer great opportunities for the high-throughput diagnosis and prognosis of diseases.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Neoplasms [unspecific]	25777797			C80.1	D009369			Finally, the protocol was applied to monitor miRNA-21 expression in epithelial to mesenchymal transition (EMT)-induced MCF-7 cells, an epithelial tumor cell line. CK expression was lost in these cells,whereas miRNA-21 was still expressed, suggesting that miRNA-21 might be a good marker for detecting CTCs with an EMT phenotype.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Neoplasms [unspecific]	25431259			C80.1	D009369			MiR-21 has a relatively high diagnostic value for detecting breast cancer, and miR-21 assays based on plasma, serum, and tissue achieved relatively higher accuracy
circulation_biomarker_diagnosis_ns	hsa-mir-21	Neoplasms [unspecific]	25527152			C80.1	D009369			the circulating miR-21 may be a potential biomarker as diagnostic tool for early-stage cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-218	Neoplasms [unspecific]	25416717			C80.1	D009369			This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles  for prospective testing.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Neoplasms [unspecific]	27859748			C80.1	D009369			Use of Serum MicroRNAs as Biomarker for Hepatobiliary Diseases in Dogs.
circulation_biomarker_diagnosis_ns	hsa-mir-302a	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-302b	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-302c	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-302d	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-30d	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-367	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-367	Neoplasms [unspecific]	26306513			C80.1	D009369			Targeted miRNA-based blood tests for miR-371-3 and miR-367 clusters are currently under development and hold a great promise for the future.
circulation_biomarker_diagnosis_ns	hsa-mir-371a	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-372	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-373	Neoplasms [unspecific]	21173133			C80.1	D009369			Identification of MicroRNAs From the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Neoplasms [unspecific]	28638226			C80.1	D009369			Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients.
circulation_biomarker_diagnosis_ns	hsa-mir-425	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-490	Neoplasms [unspecific]	25416717			C80.1	D009369			This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles  for prospective testing.
circulation_biomarker_diagnosis_ns	hsa-mir-520d	Neoplasms [unspecific]	26094174			C80.1	D009369			Among HKGs that were expressed in all samples, we suggest that RNU6 and miR-520d-5p were the best candidates for HKGs for studies of plasma miRNA because of the consistent and high Ct in all samples and a very narrow,reproducible SD.
circulation_biomarker_diagnosis_ns	hsa-mir-9	Neoplasms [unspecific]	25416717			C80.1	D009369			This study describes a pipeline for robust diagnostic serum miRNA profiling in childhood solid tumors, and has identified candidate miRNA profiles  for prospective testing.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Neoplasms [unspecific]	23874370			C80.1	D009369			Principal component analysis based feature extraction approach to identify circulating microRNA biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Nephrotic Syndrome	26261628	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Nephrotic Syndrome	26261628	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Nephrotic Syndrome	26261628	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-586	Nephrotic Syndrome	26261628	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-942	Nephrotic Syndrome	26261628	urinary system disease	DOID:1184	N04	D009404	PS256300	HP:0000100	Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Neuralgia, Postherpetic	28225487			B02.29	D051474			Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-127	Neuralgia, Postherpetic	28225487			B02.29	D051474			Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Neuralgia, Postherpetic	28225487			B02.29	D051474			Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Neuralgia, Postherpetic	28225487			B02.29	D051474			Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-892b	Neuralgia, Postherpetic	28225487			B02.29	D051474			Comparing serum microRNA levels of acute herpes zoster patients with those of postherpetic neuralgia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Non-Neoplastic Diseases	24586876							Only a subset of reported blood-based microRNA biomarkers have specificity for a particular disease. The remainder of the reported non-neoplastic biomarkers are either biologically implausible, non-specific, or uninterpretable due to limitations of our current understanding of microRNA expression.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Obesity	29607782	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Obesity	21367929	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Expression of two miRNAs (miR-17-5p and miR-132) differed significantly between obese and nonobese omental fat (P = 0.048 and P = 0.016).
circulation_biomarker_diagnosis_ns	hsa-mir-143	Obesity	25637573	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Obesity leads to alterations in miRNA expressions and miRNA-143 and -223s can be used as biomarkers for the metabolic changes in obesity.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Obesity	29607782	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity
circulation_biomarker_diagnosis_ns	hsa-mir-150	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Obesity	29607782	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity
circulation_biomarker_diagnosis_ns	hsa-mir-17	Obesity	21367929	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Expression of two miRNAs (miR-17-5p and miR-132) differed significantly between obese and nonobese omental fat (P = 0.048 and P = 0.016).
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Obesity	29607782	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity
circulation_biomarker_diagnosis_ns	hsa-mir-221	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Obesity	25637573	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Obesity leads to alterations in miRNA expressions and miRNA-143 and -223s can be used as biomarkers for the metabolic changes in obesity.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-324	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-340	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Obesity	29607782	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	Dysregulation of circulating miRs may contribute mechanistically to the heightened inflammatory state associated with overweight and obesity
circulation_biomarker_diagnosis_ns	hsa-mir-375	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-652	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-99b	Obesity	26406295	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	This study provides the first identification of altered circulating  miRNAs in maternal obesity and suggests a possible role of such miRNAS as markers for pre- and postnatal growth.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Oral Neoplasms	25485932			C06.9	D009062		HP:0100649	Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-196b	Oral Neoplasms	25485932			C06.9	D009062		HP:0100649	Combined determination of circulating miR-196a and miR-196b levels may serve as panel plasma biomarkers for the early detection of oral cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Osteoarthritis	28647559	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miRNA-146a, miRNA-155 and JNK expression levels in peripheral blood mononuclear cells according to grade of knee osteoarthritis.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Osteoarthritis	28647559	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	miRNA-146a, miRNA-155 and JNK expression levels in peripheral blood mononuclear cells according to grade of knee osteoarthritis.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Osteoporosis	26026730	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	In total 6 miRNAs, miR-10a-5p, miR-10b-5p, miR-133b, miR-22-3p, miR-328-3p, and let-7g-5p exhibited  significantly different serum levels in response to fracture
circulation_biomarker_diagnosis_ns	hsa-mir-133a-1	Osteoporosis	22506038	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	miR-133a in circulating monocytes is a potential biomarker for postmenopausal osteoporosis.
circulation_biomarker_diagnosis_ns	hsa-mir-133a-2	Osteoporosis	22506038	musculoskeletal system disease	DOID:11476	M80	D010024	166710	HP:0000939	miR-133a in circulating monocytes is a potential biomarker for postmenopausal osteoporosis.
circulation_biomarker_diagnosis_ns	hsa-mir-148a	Osteosarcoma	25185654	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Osteosarcoma	25775010	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Osteosarcoma	25775010	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-199a	Osteosarcoma	26069101	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Identification of miR-199a-5p in serum as noninvasive biomarkers for detecting and monitoring osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Osteosarcoma	27922432	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-21 predicts poor prognosis in patients with osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Osteosarcoma	28742209	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Osteosarcoma	26377680	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	In conclusion, our findings suggested that expression level of miR-26a and miR-27a contributes to aggressive progression of this malignancy.Therefore, may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Osteosarcoma	25960240	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-27a expression may be elevated in sera of osteosarcoma patients and in turn contributes to aggressive progression of this malignancy. Detection of serum miR-27a levels may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Osteosarcoma	26377680	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	In conclusion, our findings suggested that expression level of miR-26a and miR-27a contributes to aggressive progression of this malignancy.Therefore, may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients.
circulation_biomarker_diagnosis_ns	hsa-mir-320a	Osteosarcoma	25775010	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-374a	Osteosarcoma	25775010	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our data suggest that altered levels of circulating miRNAs might have great potential to serve as novel, non-invasive biomarkers for osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-497	Osteosarcoma	27735043	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	miR-497 as a potential serum biomarker for the diagnosis and prognosis of osteosarcoma.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Ovarian Neoplasms	23542579	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Serum miR-132, miR-26a, let-7b, and miR-145 could be considered aspotential candidates as novel biomarkers in serous ovarian cancer. 
circulation_biomarker_diagnosis_ns	hsa-mir-106b	Ovarian Neoplasms	24641401	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-125b-1	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-125b: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-125b-2	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-125b: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-130a: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-132	Ovarian Neoplasms	23542579	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Serum miR-132, miR-26a, let-7b, and miR-145 could be considered aspotential candidates as novel biomarkers in serous ovarian cancer. 
circulation_biomarker_diagnosis_ns	hsa-mir-138	Ovarian Neoplasms	24911418	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	our study suggests that detecting these ovarian cancer specific miRNAs in plasma might serve as novel non-invasive biomarkers for ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Ovarian Neoplasms	25722112	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Serum microRNA-145 as a novel biomarker in human ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Ovarian Neoplasms	23542579	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Serum miR-132, miR-26a, let-7b, and miR-145 could be considered aspotential candidates as novel biomarkers in serous ovarian cancer. 
circulation_biomarker_diagnosis_ns	hsa-mir-200a	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-200b	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-203	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-214	Ovarian Neoplasms	18589210	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Ovarian Neoplasms	24641401	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Ovarian Neoplasms	18442408	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	dysregulated
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Ovarian Neoplasms	23542579	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Serum miR-132, miR-26a, let-7b, and miR-145 could be considered aspotential candidates as novel biomarkers in serous ovarian cancer. 
circulation_biomarker_diagnosis_ns	hsa-mir-30c-1	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-30c: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-30c-2	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-30c: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-335	Ovarian Neoplasms	18823650	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-335: deregulated
circulation_biomarker_diagnosis_ns	hsa-mir-339	Ovarian Neoplasms	26485143	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	10 miRNAs (miR-193a-5p, miR-375, miR-339-3p, miR-340-5p, miR-532-3p, miR-133a-3p, miR-25-3p, miR-10a-5p, miR-616-5p, and miR-148b-5p) displayed fold changes in concentration ranging from -2.9 to 4 (p<0.05), in recurrent platinum resistant ovarian cancer patients
circulation_biomarker_diagnosis_ns	hsa-mir-451	Ovarian Neoplasms	24641401	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Ovarian Neoplasms	24641401	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-92	Ovary Mixed Epithelial Carcinoma	23963852	endocrine system disease	DOID:6898					The detection of miR-92 levels in the serum might serve as a new tumour biomarker in the diagnosis and assessment of prognosis of EOC.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Pancreatic Adenocarcinoma	19723895	disease of cellular proliferation	DOID:4074	C25.3				miR-155 has recently been identified as a candidate biomarker of early pancreatic neoplasia
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Pancreatic Adenocarcinoma	28466015	disease of cellular proliferation	DOID:4074	C25.3				Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-204	Pancreatic Adenocarcinoma	26807325	disease of cellular proliferation	DOID:4074	C25.3				miR-223 and miR-204 were able to distinguish patients with early stage cancer from patients with CP
circulation_biomarker_diagnosis_ns	hsa-mir-21	Pancreatic Adenocarcinoma	19723895	disease of cellular proliferation	DOID:4074	C25.3				profiled four miRNAs, miR-21, miR-210, miR-155, and miR-196a, all implicated in the development of pancreatic cancer with either proven or predicted target genes involved in critical cancer-associated cellular pathways.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Pancreatic Adenocarcinoma	19723895	disease of cellular proliferation	DOID:4074	C25.3				profiled four miRNAs, miR-21, miR-210, miR-155, and miR-196a, all implicated in the development of pancreatic cancer with either proven or predicted target genes involved in critical cancer-associated cellular pathways.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Pancreatic Adenocarcinoma	28466015	disease of cellular proliferation	DOID:4074	C25.3				Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively.
circulation_biomarker_diagnosis_ns	hsa-mir-107	Pancreatic Neoplasms	23834149	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		At last, we have also explained the role of miRNAs in diagnostic marker (miR- 200, miR-21, miR-103, miR-107, and miR-155) and as a therapeutic modulator (miR-34, miR-21, miR-221, and miR-101) in pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1246	Pancreatic Neoplasms	29100367	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-134	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Pancreatic Neoplasms	19106647	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-155: miR-155 is a biomarker of early pancreatic neoplasia
circulation_biomarker_diagnosis_ns	hsa-mir-182	Pancreatic Neoplasms	25326859	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating microRNA-182 in plasma and its potential diagnostic and prognostic value for pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1825	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Pancreatic Neoplasms	27380024	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Patients with PDAC or IPMN showed significantly higher amounts of serum MAPK-associated miRNAs than those with AIP (p<0.009 for miR-7, p<0.002 for miR-34a, p<0.001 for miR-181d, p<0.002 for miR-193b).
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Pancreatic Neoplasms	29100367	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-211	Pancreatic Neoplasms	23329235	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer
circulation_biomarker_diagnosis_ns	hsa-mir-221	Pancreatic Neoplasms	27539232	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Pancreatic Neoplasms	25819175	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Plasma miR-223 might be a clinically useful biomarker for screening PCa, and predicting malignant potential of IPMN and the invasiveness of PCa.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Pancreatic Neoplasms	25030590	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Plasma miR-21, miR-155, miR-25, miR-210 have diagnostic value for pancreatic cancer, and deserve further study.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Pancreatic Neoplasms	23430754	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		blood;Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Pancreatic Neoplasms	23782250	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Pancreatic Neoplasms	27380024	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Patients with PDAC or IPMN showed significantly higher amounts of serum MAPK-associated miRNAs than those with AIP (p<0.009 for miR-7, p<0.002 for miR-34a, p<0.001 for miR-181d, p<0.002 for miR-193b).
circulation_biomarker_diagnosis_ns	hsa-mir-378	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-484	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-628	Pancreatic Neoplasms	23697990	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825.
circulation_biomarker_diagnosis_ns	hsa-mir-636	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-7	Pancreatic Neoplasms	27380024	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Patients with PDAC or IPMN showed significantly higher amounts of serum MAPK-associated miRNAs than those with AIP (p<0.009 for miR-7, p<0.002 for miR-34a, p<0.001 for miR-181d, p<0.002 for miR-193b).
circulation_biomarker_diagnosis_ns	hsa-mir-744	Pancreatic Neoplasms	26505678	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Plasma miR-744 might be useful biomarker for screening PCa,monitoring, and predicting poor prognosis and chemoresistance in PCa patients.
circulation_biomarker_diagnosis_ns	hsa-mir-885	Pancreatic Neoplasms	24449318	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-96	Pancreatic Neoplasms	27539232	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-1-1	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-1-2	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-126*: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-147a	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-147: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-151a	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-151-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-16-2	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-199a-1	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-199a-3p/miR-199b-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-199a-2	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-199a-3p/miR-199b-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-199b	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-199a-3p/miR-199b-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-19b-1	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-19b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-19b-2	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-19b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Parkinson Disease	27748571	nervous system disease	DOID:14330	G20	D010300	PS168600		Serum miR-221 serves as a biomarker for Parkinson's disease.
circulation_biomarker_diagnosis_ns	hsa-mir-26a-1	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-26a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-26a-2	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-26a-2	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-26a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-28	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-28-5p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-1	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-1	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-29b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-2	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29b-2	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-29b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-29c: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-301a	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-301a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Parkinson Disease	21295623	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-30b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-30c-1	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-30c: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-30c-2	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-30c: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-335: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-374a	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-374a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-374b	Parkinson Disease	22003392	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-374b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Peripheral Nervous System Diseases	28870579	nervous system disease	DOID:574	G64	D010523			Aberrant microRNA expression in patients with painful peripheral neuropathies.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Peripheral Nervous System Diseases	28870579	nervous system disease	DOID:574	G64	D010523			Aberrant microRNA expression in patients with painful peripheral neuropathies.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Peripheral Nervous System Diseases	28870579	nervous system disease	DOID:574	G64	D010523			Aberrant microRNA expression in patients with painful peripheral neuropathies.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Peripheral Vascular Disease	24129591	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.miR-16, miR-363, and miR-15b had the best predictive values
circulation_biomarker_diagnosis_ns	hsa-mir-15b	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Peripheral Vascular Disease	24129591	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.miR-16, miR-363, and miR-15b had the best predictive values
circulation_biomarker_diagnosis_ns	hsa-mir-16	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-181a-2	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-20b	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-27b	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-28	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-363	Peripheral Vascular Disease	24129591	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.miR-16, miR-363, and miR-15b had the best predictive values
circulation_biomarker_diagnosis_ns	hsa-mir-363	Peripheral Vascular Disease	24129592	cardiovascular system disease	DOID:341	I73.9	D016491			A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b,-27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Polycystic Ovarian Syndrome	28193283	syndrome	DOID:11612	E28.2	D011085	184700		Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-23b	Polycystic Ovarian Syndrome	28193283	syndrome	DOID:11612	E28.2	D011085	184700		Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population.
circulation_biomarker_diagnosis_ns	hsa-mir-125	Polycythemia Vera	26011312	hematopoietic system disease	DOID:8997	D45	D011087	263300		In conclusion, our data indicate that other factors such as aberrant miR-125 expression may influence on the disease phenotype in patients with PV and ET.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Prediabetes	26164754	disease of metabolism	DOID:11716	R73.03	D011236			Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Prediabetes	26164754	disease of metabolism	DOID:11716	R73.03	D011236			Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Prediabetes	25532038	disease of metabolism	DOID:11716	R73.03	D011236			the pattern of circulating miRNAs is modified by defects in glucose metabolism in a similar manner in mice and humans. This circulating miRNA signature for prediabetes could be used as a new diagnostic tool, as well as to monitor response to intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-193b	Prediabetes	25532038	disease of metabolism	DOID:11716	R73.03	D011236			the pattern of circulating miRNAs is modified by defects in glucose metabolism in a similar manner in mice and humans. This circulating miRNA signature for prediabetes could be used as a new diagnostic tool, as well as to monitor response to intervention.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-1301	Preeclampsia	25064070	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-1301 is dysregulated in early-onset preeclampsia and could possibly play a role in the regulation of leptin during pregnancy.
circulation_biomarker_diagnosis_ns	hsa-mir-130a	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-135b	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-149	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Preeclampsia	28700503	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MiR-210 and miR-155 as potential diagnostic markers for pre-eclampsia pregnancies.
circulation_biomarker_diagnosis_ns	hsa-mir-188	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-18b	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-203	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Preeclampsia	24035613	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Hence, we conclude that aberrant expression of miR-210 may contribute to trophoblast function and that miR-210 is a novel predictive serum biomarker for preeclampsia that can help in identifying at-risk women for monitoring and treatment.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Preeclampsia	28700503	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	MiR-210 and miR-155 as potential diagnostic markers for pre-eclampsia pregnancies.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Preeclampsia	25064070	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-1301 is dysregulated in early-onset preeclampsia and could possibly play a role in the regulation of leptin during pregnancy.
circulation_biomarker_diagnosis_ns	hsa-mir-224	Preeclampsia	25064070	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-1301 is dysregulated in early-onset preeclampsia and could possibly play a role in the regulation of leptin during pregnancy.
circulation_biomarker_diagnosis_ns	hsa-mir-224	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-27a	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-296	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-301a	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-517c	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-518	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-518e	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-519d	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Preeclampsia	25738738	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	the miRNAs identified in this study as being abnormally expressed in PE, may be useful as non-invasive diagnostic biomarkers. Co-regulated mRNAs and possible causal pathways involved in the pathogenesis of PE were also identified.
circulation_biomarker_diagnosis_ns	hsa-mir-98	Preeclampsia	25981845	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
circulation_biomarker_diagnosis_ns	hsa-mir-1179	Proliferative Diabetic Retinopathy	25427542	nervous system disease	DOID:13207	E11.3599				serum miRNAs have the potential to be sensitive, cost-effective biomarkers for the early detection of PDR. These biomarkers could serve as a dynamic monitoring factor for detecting the progression of PDR from NPDR.
circulation_biomarker_diagnosis_ns	hsa-mir-181c	Proliferative Diabetic Retinopathy	25427542	nervous system disease	DOID:13207	E11.3599				serum miRNAs have the potential to be sensitive, cost-effective biomarkers for the early detection of PDR. These biomarkers could serve as a dynamic monitoring factor for detecting the progression of PDR from NPDR.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Proliferative Diabetic Retinopathy	25427542	nervous system disease	DOID:13207	E11.3599				serum miRNAs have the potential to be sensitive, cost-effective biomarkers for the early detection of PDR. These biomarkers could serve as a dynamic monitoring factor for detecting the progression of PDR from NPDR.
circulation_biomarker_diagnosis_ns	hsa-mir-106a	Proliferative Glomerulonephritis	29748623	urinary system disease	DOID:4778				HP:0000793	Plasma microRNA panel is a novel biomarker for focal segmental glomerulosclerosis and associated with podocyte apoptosis.
circulation_biomarker_diagnosis_ns	hsa-let-7c	Prostate Neoplasms	25521481	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone.
circulation_biomarker_diagnosis_ns	hsa-mir-103	Prostate Neoplasms	24583788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Prostate Neoplasms	24583788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Prostate Neoplasms	23935962	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Prostate Neoplasms	25521481	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone.
circulation_biomarker_diagnosis_ns	hsa-mir-141	Prostate Neoplasms	22240788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating miR-141 and miR-375 have association with metastatic prostate cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-19	Prostate Neoplasms	24893170	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.
circulation_biomarker_diagnosis_ns	hsa-mir-200a	Prostate Neoplasms	23935962	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Prostate Neoplasms	23935962	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Prostate Neoplasms	23574937	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results demonstrate that plasma levels of selected miRNAs are potential biomarkers to differentiate localized PCa and mCRPC.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Prostate Neoplasms	23935962	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
circulation_biomarker_diagnosis_ns	hsa-mir-222	Prostate Neoplasms	24583788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients.
circulation_biomarker_diagnosis_ns	hsa-mir-30c	Prostate Neoplasms	25521481	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone.
circulation_biomarker_diagnosis_ns	hsa-mir-345	Prostate Neoplasms	24893170	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.
circulation_biomarker_diagnosis_ns	hsa-mir-34c	Prostate Neoplasms	18668526	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-34c: Significant changes in Radiation modulation
circulation_biomarker_diagnosis_ns	hsa-mir-375	Prostate Neoplasms	23935962	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Prostate Neoplasms	25521481	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the combination of the studied circulating plasma miRNAs and serum PSA has the potential to be used as a noninvasive diagnostic biomarker for PC screening outperforming the PSA testing alone.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Prostate Neoplasms	25754273	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Prostate Neoplasms	22240788	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Circulating miR-141 and miR-375 have association with metastatic prostate cancer.
circulation_biomarker_diagnosis_ns	hsa-mir-519c	Prostate Neoplasms	24893170	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance.
circulation_biomarker_diagnosis_ns	hsa-mir-521-1	Prostate Neoplasms	18668526	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-521: Significant changes in Radiation modulation
circulation_biomarker_diagnosis_ns	hsa-mir-521-2	Prostate Neoplasms	18668526	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-521: Significant changes in Radiation modulation
circulation_biomarker_diagnosis_ns	hsa-mir-628	Prostate Neoplasms	24477576	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our results demonstrate that the three miRNAs, particularly miR-628-5p, may be further developed as a biomarker, which can serve as novel noninvasive biomarker for PCa diagnosis and prognosis.
circulation_biomarker_diagnosis_ns	hsa-mir-143	Psoriasis	24909097	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Psoriasis	24909097	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles.
circulation_biomarker_diagnosis_ns	hsa-mir-33	Psoriasis	24656994	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	In psoriasis patients plasma levels of lipid and glucose metabolism-related miRNA-33 are increased and correlated with insulin. The study of circulating miRNA-33 in psoriasis may provide new insights about the associated systemic inflammatory abnormalities.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Pulmonary Hypertension	28554172	cardiovascular system disease	DOID:6432	I27.20	D006976	PS178600	HP:0002092	The Circulating MicroRNA-206 Level Predicts the Severity of Pulmonary Hypertension in Patients with Left Heart Diseases.
circulation_biomarker_diagnosis_ns	hsa-mir-18b	Rectal Neoplasms	25990502	disease of cellular proliferation	DOID:1984		D012004			MicroRNA expression in patient plasma changes during preoperative CRT. The alteration is not continuous and the meaning requires additional analysis on a larger patient cohort. The co-occurrence of reduced miR-18b and miR-20a expression with lymph node negativity after preoperative CRT could help to stratify the surgical procedure with respect to total mesorectal excision and LR if validated prospectively.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Rectal Neoplasms	25990502	disease of cellular proliferation	DOID:1984		D012004			MicroRNA expression in patient plasma changes during preoperative CRT. The alteration is not continuous and the meaning requires additional analysis on a larger patient cohort. The co-occurrence of reduced miR-18b and miR-20a expression with lymph node negativity after preoperative CRT could help to stratify the surgical procedure with respect to total mesorectal excision and LR if validated prospectively.
circulation_biomarker_diagnosis_ns	hsa-mir-1183	Rheumatic Heart Diseases	26539505	cardiovascular system disease	DOID:0050827	I09.9	D012214			Detection of Differentially Expressed MicroRNAs in Rheumatic Heart Disease:miR-1183 and miR-1299 as Potential Diagnostic Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-1299	Rheumatic Heart Diseases	26539505	cardiovascular system disease	DOID:0050827	I09.9	D012214			Detection of Differentially Expressed MicroRNAs in Rheumatic Heart Disease:miR-1183 and miR-1299 as Potential Diagnostic Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-125a	Rheumatoid Arthritis	23874885	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Rheumatoid Arthritis	28782994	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Serum miR-210 and miR-155 expression levels as novel biomarkers for rheumatoid arthritis diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Rheumatoid Arthritis	28560518	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Rheumatoid Arthritis	28782994	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Serum miR-210 and miR-155 expression levels as novel biomarkers for rheumatoid arthritis diagnosis.
circulation_biomarker_diagnosis_ns	hsa-mir-219-2	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-24	Rheumatoid Arthritis	23874885	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-3925	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-3926	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-4634	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-4764	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-mir-9	Rheumatoid Arthritis	26637811	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	In conclusion, this study identified 9-plasma miRNAs signature in Chinese patients with RA which may serve as noninvasive biomarkers for the diagnosis of RA.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-103a-1	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-103a-2	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-103b-1	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-103b-2	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Schizophrenia	25985888	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of schizophrenia patients.
circulation_biomarker_diagnosis_ns	hsa-mir-137	Schizophrenia	29684772	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia
circulation_biomarker_diagnosis_ns	hsa-mir-17	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-181b	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-181b-1	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-181b-2	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-212	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-212	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-219-2	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-22	Schizophrenia	29684772	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-346	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-346	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-346	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-346	Schizophrenia	29127368	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Diagnostic value of blood-derived microRNAs for schizophrenia: results of a meta-analysis and validation.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Schizophrenia	21738743	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	peripheral blood miR-34a was differentially expressed between cases and controls in both the learning and the testing set.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-432	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-432	Schizophrenia	25656957	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-7	Schizophrenia	25487174	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miRNA expression is more significant in plasma than in PBMC, and suggest that miR-30e in plasma may be a more sensitive biomarker for schizophrenia diagnosis, although its aberrant expression can be detected in both plasma and PBMC.
circulation_biomarker_diagnosis_ns	hsa-mir-9	Schizophrenia	28877483	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Dysregulation of miRNA-9 in a Subset of Schizophrenia Patient-Derived Neural Progenitor Cells.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Schizophrenia	29684772	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia
circulation_biomarker_diagnosis_ns	hsa-mir-92a-1	Schizophrenia	22094284	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	miR-181b, miR-219-2-3p, miR-346, miR-195, miR-1308, miR-92a, miR-17, miR-103 and let-7g are the key players to reflect the schizophrenia illnesses status and may serve as candidate biomarkers for diagnosis of schizophrenia. In addition, we also found that the risperidone improved the serum miR-346 level of schizophrenia significantly, and therefore may not be an effective drug in regulating serum miR-346 level of schizophrenia.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Scleroderma, Localized	25152444	musculoskeletal system disease	DOID:8472	L94.0	D012594			Down-regulation of miR-196a and subsequent overexpression of type 1 collagen in dermal fibroblasts may play a key role in the pathogenesis of LSc. The serum levels of miR-196a may be useful as a diagnostic marker of LSc.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Scleroderma, Localized	21129921	musculoskeletal system disease	DOID:8472	L94.0	D012594			Circulating miR-29a levels in patients with scleroderma spectrum disorder
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Scleroderma, Systemic	21129921	musculoskeletal system disease	DOID:418	M34	D012595	181750		Circulating miR-29a levels in patients with scleroderma spectrum disorder
circulation_biomarker_diagnosis_ns	hsa-mir-122	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Sepsis	24421215			A41.9	D018805		HP:0100806	Serum miR-122 levels are related to coagulation disorders in sepsis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Sepsis	24413579			A41.9	D018805		HP:0100806	Levels of circulating miR-133a are elevated in sepsis and predict mortality in critically ill patients.
circulation_biomarker_diagnosis_ns	hsa-mir-133a	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Sepsis	25086335			A41.9	D018805		HP:0100806	So far, miR-223, miR-146a and miR-150 have been identified to have promising prognostic and diagnostic value to sepsis.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Sepsis	25265569			A41.9	D018805		HP:0100806	miR-182, miR-143, miR-145, miR-146a, miR-150, and miR-155 were dysregulated in sepsis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Sepsis	28164567			A41.9	D018805		HP:0100806	The Prognostic Value of Plasma MicroRNA-155 and MicroRNA-146a Level in Severe Sepsis and Sepsis-Induced Acute Lung Injury Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Sepsis	28552958			A41.9	D018805		HP:0100806	Characterization of basal and lipopolysaccharide-induced microRNA expression in equine peripheral blood mononuclear cells using Next-Generation Sequencing.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Sepsis	24146790			A41.9	D018805		HP:0100806	microRNA miR-150 and miR-4772-5p-iso were able to discriminate between patients who have systemic inflammatory response syndrome and patients with sepsis.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Sepsis	25086335			A41.9	D018805		HP:0100806	So far, miR-223, miR-146a and miR-150 have been identified to have promising prognostic and diagnostic value to sepsis.
circulation_biomarker_diagnosis_ns	hsa-mir-150	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Sepsis	28164567			A41.9	D018805		HP:0100806	The Prognostic Value of Plasma MicroRNA-155 and MicroRNA-146a Level in Severe Sepsis and Sepsis-Induced Acute Lung Injury Patients.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Sepsis	28552958			A41.9	D018805		HP:0100806	Characterization of basal and lipopolysaccharide-induced microRNA expression in equine peripheral blood mononuclear cells using Next-Generation Sequencing.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-16-1	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-16-2	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-182	Sepsis	19823581			A41.9	D018805		HP:0100806	we found that miR-150, miR-182, miR-342-5p, and miR-486 expression profiles differentiated sepsis patients from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-193a	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Sepsis	25810564			A41.9	D018805		HP:0100806	Recent reports on alterations in miR-223 serum levels during sepsis revealed contradictory results, preventing a potential use of this miRNA in clinical routine. We clearly show that miR-223 serum levels do not reflect the presence of sepsis neither in mouse models nor in a large cohort of ICU patients and do not indicate clinical outcome of critically ill patients. Thus miR-223 serum levels should not be used as a biomarker in this setting.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Sepsis	23026916			A41.9	D018805		HP:0100806	only miR-223 (p = 0.035) and miR-499-5p (p < 0.001) were significantly different between patients with mild sepsis and patients with severe sepsis and septic shock.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-297	Sepsis	22344312			A41.9	D018805		HP:0100806	Microarray analysis showed that serum miR-297 and miR-574-5p were differentially expressed in sepsis survivors and nonsurvivors. Upon validation with 118 sepsis patients' samples, these two miRNA expressions were significantly different, with P < 0.001. miR-297 was more closely associated with survival from sepsis, whereas miR-574-5p was associated with death from sepsis.
circulation_biomarker_diagnosis_ns	hsa-mir-297	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-342	Sepsis	19823581			A41.9	D018805		HP:0100806	we found that miR-150, miR-182, miR-342-5p, and miR-486 expression profiles differentiated sepsis patients from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-4772	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-483	Sepsis	22719975			A41.9	D018805		HP:0100806	Serum miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p were significantly differentially expressed.
circulation_biomarker_diagnosis_ns	hsa-mir-486	Sepsis	19823581			A41.9	D018805		HP:0100806	we found that miR-150, miR-182, miR-342-5p, and miR-486 expression profiles differentiated sepsis patients from healthy controls
circulation_biomarker_diagnosis_ns	hsa-mir-499	Sepsis	23026916			A41.9	D018805		HP:0100806	only miR-223 (p = 0.035) and miR-499-5p (p < 0.001) were significantly different between patients with mild sepsis and patients with severe sepsis and septic shock.
circulation_biomarker_diagnosis_ns	hsa-mir-574	Sepsis	22344312			A41.9	D018805		HP:0100806	Microarray analysis showed that serum miR-297 and miR-574-5p were differentially expressed in sepsis survivors and nonsurvivors. Upon validation with 118 sepsis patients' samples, these two miRNA expressions were significantly different, with P < 0.001. miR-297 was more closely associated with survival from sepsis, whereas miR-574-5p was associated with death from sepsis.
circulation_biomarker_diagnosis_ns	hsa-mir-574	Sepsis	27434572			A41.9	D018805		HP:0100806	The researches regarding circulating miRNA as biomarkers of sepsis were collected to analyze the characteristics of differential expression of miRNAs including miR-150, miR-133a, miR-122, miR-223,  miR-4772, miR-297 and miR-574-5p etc.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Spinal Muscular Atrophy	27377135	nervous system disease	DOID:12377	G12.9	D009134	253300	HP:0007269	confirmed a significant alteration of miR-9 and miR-132 level in serum samples from SMA patients.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Spondylarthritis	26689798			M45-M49	D025241			The most repressed miRNA was miR-16 and is predicted to regulate the expression of activin A receptor
circulation_biomarker_diagnosis_ns	hsa-let-7a	Squamous Cell Carcinoma, Esophageal	25914476	disease of cellular proliferation	DOID:3748		C562729			Plasma miR-20a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC.
circulation_biomarker_diagnosis_ns	hsa-mir-10b	Squamous Cell Carcinoma, Esophageal	26554762	disease of cellular proliferation	DOID:3748		C562729			Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening.
circulation_biomarker_diagnosis_ns	hsa-mir-15a	Squamous Cell Carcinoma, Esophageal	27802201	disease of cellular proliferation	DOID:3748		C562729			Serum microRNA-15a level acts as a potential diagnostic and prognostic biomarker for human esophageal squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-185	Squamous Cell Carcinoma, Esophageal	26316588	disease of cellular proliferation	DOID:3748		C562729			In conclusion, our findings shed novel light on the role of miR-185/RAGE in ESCC metastasis, and plasma miR-185 has potential as a novel diagnostic biomarker in ESCC.
circulation_biomarker_diagnosis_ns	hsa-mir-18a	Squamous Cell Carcinoma, Esophageal	23579215	disease of cellular proliferation	DOID:3748		C562729			Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Squamous Cell Carcinoma, Esophageal	28095062	disease of cellular proliferation	DOID:3748		C562729			MicroRNA-196a as a Potential Diagnostic Biomarker for Esophageal Squamous Cell Carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Squamous Cell Carcinoma, Esophageal	26554762	disease of cellular proliferation	DOID:3748		C562729			Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Squamous Cell Carcinoma, Esophageal	25914476	disease of cellular proliferation	DOID:3748		C562729			Plasma miR-20a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC.
circulation_biomarker_diagnosis_ns	hsa-mir-23a	Squamous Cell Carcinoma, Esophageal	27566562	disease of cellular proliferation	DOID:3748		C562729			Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-25	Squamous Cell Carcinoma, Esophageal	25117812	disease of cellular proliferation	DOID:3748		C562729			Plasma miR-25 might be a clinically useful biomarker for cancer detection and the monitoring of tumour dynamics in ESCC patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Squamous Cell Carcinoma, Esophageal	26554762	disease of cellular proliferation	DOID:3748		C562729			Predictive Value of Serum miR-10b, miR-29c, and miR-205 as Promising Biomarkers in Esophageal Squamous Cell Carcinoma Screening.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Squamous Cell Carcinoma, Head and Neck	22094257	disease of cellular proliferation	DOID:5520	C76.0	C535575			Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	25099764	disease of cellular proliferation	DOID:2876					Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-378	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	28051256	disease of cellular proliferation	DOID:2876					Expression of serum microRNA-378 and its clinical significance in laryngeal squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-19a	Squamous Cell Carcinoma, Lung	24130905	disease of cellular proliferation	DOID:3907	C34.91				Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-19b	Squamous Cell Carcinoma, Lung	24130905	disease of cellular proliferation	DOID:3907	C34.91				Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Squamous Cell Carcinoma, Lung	24130905	disease of cellular proliferation	DOID:3907	C34.91				Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Squamous Cell Carcinoma, Lung	24130905	disease of cellular proliferation	DOID:3907	C34.91				Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Squamous Cell Carcinoma, Lung	24130905	disease of cellular proliferation	DOID:3907	C34.91				Tumor cells secrete miRNA-containing exosomes into circulation, and that miRNA profiling of the exosomal plasma fraction may reveal powerful cancer biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Squamous Cell Carcinoma, Oral	25858373	disease of cellular proliferation	DOID:0050866					Due to the satisfactory diagnostic performance, plasma miR-125b can  be used as a promising biomarker in OSCC.
circulation_biomarker_diagnosis_ns	hsa-mir-186	Squamous Cell Carcinoma, Oral	24452363	disease of cellular proliferation	DOID:0050866					miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Squamous Cell Carcinoma, Oral	25174622	disease of cellular proliferation	DOID:0050866					Circulating microRNA-21 (MIR-21) and phosphatase and tensin homolog (PTEN) are promising novel biomarkers for detection of oral squamous cell carcinoma.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Squamous Cell Carcinoma, Oral	20233326	disease of cellular proliferation	DOID:0050866					plasma miR-31 could be validated a marker of OSCC for diagnostic uses
circulation_biomarker_diagnosis_ns	hsa-mir-3651	Squamous Cell Carcinoma, Oral	24452363	disease of cellular proliferation	DOID:0050866					miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood.
circulation_biomarker_diagnosis_ns	hsa-mir-375	Squamous Cell Carcinoma, Oral	28030794	disease of cellular proliferation	DOID:0050866					Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients.
circulation_biomarker_diagnosis_ns	hsa-mir-494	Squamous Cell Carcinoma, Oral	24452363	disease of cellular proliferation	DOID:0050866					miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood.
circulation_biomarker_diagnosis_ns	hsa-let-7b	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-132	Stroke	26806865			I64	D020521	601367	HP:0001297	These results indicated that there was a substantial correlation between serum miR-132 expression and post-stroke cognitive functionality,suggesting that miR-132 may be a risk marker for PSCI. Because of the limitations of this study, the results should be treated with caution. cel-mir-39
circulation_biomarker_diagnosis_ns	hsa-mir-145	Stroke	23860376			I64	D020521	601367	HP:0001297	Serum miR-145 was not detected in over 50% of the patients and it may not be an ideal marker to predict stroke. MiR-21 and miR-221 are novel biomarkers for atherosclerosis and stroke.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Stroke	19724284			I64	D020521	601367	HP:0001297	correlate(upregulated or downregulated)
circulation_biomarker_diagnosis_ns	hsa-mir-22	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Stroke	23860376			I64	D020521	601367	HP:0001297	Serum miR-145 was not detected in over 50% of the patients and it may not be an ideal marker to predict stroke. MiR-21 and miR-221 are novel biomarkers for atherosclerosis and stroke.
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-26b	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-27b	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-298	Stroke	19724284			I64	D020521	601367	HP:0001297	correlate(upregulated or downregulated)
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-30e	Stroke	26333279			I64	D020521	601367	HP:0001297	A specific circulating miRNAs profile is associated with migraine without aura. Remarkably, the same miRNAs are known to be modulated in the setting of atherosclerosis and stroke in humans. This study represents a first step towards further characterization of MO diagnosis/pathophysiology, also in relation to its link with cardiovascular risk.
circulation_biomarker_diagnosis_ns	hsa-mir-362	Stroke	19724284			I64	D020521	601367	HP:0001297	miR-362-3p correlate(pregulated or downregulated)
circulation_biomarker_diagnosis_ns	hsa-let-7b	Stroke, Ischemic	24237608			I63.9			HP:0002140	These data suggest that miR-30a, miR-126 and let-7b might be useful biomarkers for ischemic stroke in humans.
circulation_biomarker_diagnosis_ns	hsa-let-7e	Stroke, Ischemic	26415639			I63.9			HP:0002140	MicroRNA let-7e Is a Potential Circulating Biomarker of Acute Stage Ischemic Stroke.
circulation_biomarker_diagnosis_ns	hsa-let-7e	Stroke, Ischemic	27776139			I63.9			HP:0002140	Identification of Blood Let-7e-5p as a Biomarker for Ischemic Stroke.
circulation_biomarker_diagnosis_ns	hsa-mir-122	Stroke, Ischemic	27151415			I63.9			HP:0002140	Two miRNAs (miR-145 and miR-122) may represent potential biomarkers in ischemic stroke
circulation_biomarker_diagnosis_ns	hsa-mir-126	Stroke, Ischemic	24237608			I63.9			HP:0002140	These data suggest that miR-30a, miR-126 and let-7b might be useful biomarkers for ischemic stroke in humans.
circulation_biomarker_diagnosis_ns	hsa-mir-30a	Stroke, Ischemic	24237608			I63.9			HP:0002140	These data suggest that miR-30a, miR-126 and let-7b might be useful biomarkers for ischemic stroke in humans.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-148b	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-195	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-500b	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-505	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-mir-99a	Synovial Sarcoma	26250552	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	Our results have identified a specific whole blood miRNA signature that may serve as an independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for synovial sarcoma.
circulation_biomarker_diagnosis_ns	hsa-let-7d	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-let-7e	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Systemic Lupus Erythematosus	25399392	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling andfibrosis, but need to be validated in independent studies.
circulation_biomarker_diagnosis_ns	hsa-mir-145	Systemic Lupus Erythematosus	29246612	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-150	Systemic Lupus Erythematosus	25399392	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling andfibrosis, but need to be validated in independent studies.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Systemic Lupus Erythematosus	25253569	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Systemic Lupus Erythematosus	25399392	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling andfibrosis, but need to be validated in independent studies.
circulation_biomarker_diagnosis_ns	hsa-mir-181a	Systemic Lupus Erythematosus	27816459	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-181c	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-18b	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-196a	Systemic Lupus Erythematosus	27816459	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Systemic Lupus Erythematosus	27816459	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-210	Systemic Lupus Erythematosus	28560518	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-210 expression in PBMCs from patients with systemic lupus erythematosus and rheumatoid arthritis.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Systemic Lupus Erythematosus	27835701	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Systemic Lupus Erythematosus	25399392	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling andfibrosis, but need to be validated in independent studies.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Systemic Lupus Erythematosus	29246612	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-26a	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-29b	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-29c	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-3074	Systemic Lupus Erythematosus	27835701	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-324	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-326	Systemic Lupus Erythematosus	29246612	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-145, miR-223 and miR-326 expression profile is a promising diagnostic biomarker for MS and NPSLE, but not for NMOSD
circulation_biomarker_diagnosis_ns	hsa-mir-328	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-335	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-345	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-362	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-365	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-380	Systemic Lupus Erythematosus	27835701	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-494	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-532	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-556	Systemic Lupus Erythematosus	27835701	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-579	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-629	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-638	Systemic Lupus Erythematosus	25399392	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling andfibrosis, but need to be validated in independent studies.
circulation_biomarker_diagnosis_ns	hsa-mir-744	Systemic Lupus Erythematosus	26225955	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers.
circulation_biomarker_diagnosis_ns	hsa-mir-758	Systemic Lupus Erythematosus	27835701	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_ns	hsa-mir-371a	Testicular Neoplasms	23059743	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours
circulation_biomarker_diagnosis_ns	hsa-mir-141	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	A unique miRNA expression signature differentiated between PTC cell lines with BRAF mutations and a normal thyroid cell line. 15 miRNAs were found to be upregulated and 23 miRNAs were downregulated.
circulation_biomarker_diagnosis_ns	hsa-mir-146b	Thyroid Neoplasms	25456009	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b and miR-155 helped to discriminate between benign and malignant lesions. Circulating miRNA is likely a useful alternate serological marker for PTC. This preliminary study suggested that circulating miRNAs may be useful as follow-up tools as well as diagnostic tools.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Thyroid Neoplasms	25456009	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	miR-146b and miR-155 helped to discriminate between benign and malignant lesions. Circulating miRNA is likely a useful alternate serological marker for PTC. This preliminary study suggested that circulating miRNAs may be useful as follow-up tools as well as diagnostic tools.
circulation_biomarker_diagnosis_ns	hsa-mir-181a-1	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Another miRNA these two groups found to be upregulated albeit less significantly was miR-213, our study also found miR-213 to be upregulated in BRAF mutated cell lines [25 fold].
circulation_biomarker_diagnosis_ns	hsa-mir-16	Transitional Cell Carcinoma	29141625	disease of cellular proliferation	DOID:2671		D002295			MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Transitional Cell Carcinoma	29141625	disease of cellular proliferation	DOID:2671		D002295			MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples.
circulation_biomarker_diagnosis_ns	hsa-mir-142	Traumatic Brain Injury	28117263			S06.2	D000070642			Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study.
circulation_biomarker_diagnosis_ns	hsa-mir-423	Traumatic Brain Injury	28117263			S06.2	D000070642			Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study.
circulation_biomarker_diagnosis_ns	hsa-mir-93	Tuberculosis	25753045	disease by infectious agent	DOID:399	A15-A19	D014376			Identification of miR-93 as a suitable miR for normalizing miRNA in plasma of tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-let-7g	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-16	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-192	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-200c	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-204	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-206	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Tuberculosis, Pulmonary	21998423	disease by infectious agent	DOID:2957	A15	D014397			Circulating miR-29a might have great potential to serve as a marker for detection of active pulmonary tuberculosis infection.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-30b	Tuberculosis, Pulmonary	27682490	disease by infectious agent	DOID:2957	A15	D014397			The expression of serum miRNAs in pneumoconiosis complicated with pulmonary tuberculosis patients.
circulation_biomarker_diagnosis_ns	hsa-mir-31	Tuberculosis, Pulmonary	26681217	disease by infectious agent	DOID:2957	A15	D014397			Therefore, miR-31 has the potential to be a diagnostic marker in pediatric TB patients.
circulation_biomarker_diagnosis_ns	hsa-mir-28	Unstable Angina	25704294	cardiovascular system disease	DOID:8805	I20.0	D000789			Our findings suggest that circulating miR-28-5p, involved in LXRα-ABCA1 pathway, may be a potential biomarker for diagnosis and prognosis of unstable angina.
circulation_biomarker_diagnosis_ns	hsa-mir-205	Urinary Bladder Cancer	18799331	urinary system disease	DOID:11054	C67	D001749	109800		miR-205: miR-21/miR-205 expression ratio that has the ability to distinguish between invasive and noninvasive bladder tumors
circulation_biomarker_diagnosis_ns	hsa-mir-21	Urinary Bladder Cancer	18799331	urinary system disease	DOID:11054	C67	D001749	109800		miR-21: miR-21/miR-205 expression ratio that has the ability to distinguish between invasive and noninvasive bladder tumors
circulation_biomarker_diagnosis_ns	hsa-mir-93	Uterine Cancer	29844841	disease of cellular proliferation	DOID:363	C55	D014594			Expression of serum Hsa-miR-93 in uterine cancer and its clinical significance.
circulation_biomarker_diagnosis_ns	hsa-mir-125b	Uveal Melanoma	24370793				C536494	155720	HP:0007716	The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Uveal Melanoma	24370793				C536494	155720	HP:0007716	The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
circulation_biomarker_diagnosis_ns	hsa-mir-146a	Uveal Melanoma	25951497				C536494	155720	HP:0007716	Our findings suggest the possibility to detect in VH and serum of UM patients diagnostic miRNAs released by the affected eye: based on this,miR-146a could be considered a potential circulating marker of UM.
circulation_biomarker_diagnosis_ns	hsa-mir-155	Uveal Melanoma	24370793				C536494	155720	HP:0007716	The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Uveal Melanoma	24370793				C536494	155720	HP:0007716	The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
circulation_biomarker_diagnosis_ns	hsa-mir-21	Uveal Melanoma	25951497				C536494	155720	HP:0007716	Our findings suggest the possibility to detect in VH and serum of UM patients diagnostic miRNAs released by the affected eye: based on this,miR-146a could be considered a potential circulating marker of UM.
circulation_biomarker_diagnosis_ns	hsa-mir-223	Uveal Melanoma	24370793				C536494	155720	HP:0007716	The development of metastasis in uveal melanoma is associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Uveal Melanoma	25951497				C536494	155720	HP:0007716	Our findings suggest the possibility to detect in VH and serum of UM patients diagnostic miRNAs released by the affected eye: based on this,miR-146a could be considered a potential circulating marker of UM.
circulation_biomarker_diagnosis_ns	hsa-mir-126	Vascular Disease [unspecific]	23386708	cardiovascular system disease	DOID:178	I72.9	D000783			plasma;Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease
circulation_biomarker_diagnosis_ns	hsa-mir-142	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-20a	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-221	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-29a	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-34a	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-383	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_ns	hsa-mir-92a	Vasculitis	26016752	cardiovascular system disease	DOID:865	I77.6	D014657		HP:0002633	In this first study ever on circulating miRNA profiles in AAV, we find clear indication of their potential as biomarkers for diagnosis and classification, but more studies are needed to identify the best markers as well as the mechanisms responsible for variations.
circulation_biomarker_diagnosis_up	hsa-mir-124-1	Acute Cerebral Infarction	21551949	cardiovascular system disease	DOID:3526	I63	D002544			Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction.
circulation_biomarker_diagnosis_up	hsa-mir-124-2	Acute Cerebral Infarction	21551949	cardiovascular system disease	DOID:3526	I63	D002544			Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction.
circulation_biomarker_diagnosis_up	hsa-mir-124-3	Acute Cerebral Infarction	21551949	cardiovascular system disease	DOID:3526	I63	D002544			Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction.
circulation_biomarker_diagnosis_up	hsa-mir-210	Acute Cerebral Infarction	29434712	cardiovascular system disease	DOID:3526	I63	D002544			miR-210 is upregulated in the serum of patients with ACI, and miR-210 may be involved in the pathogenesis of ACI through regulating the proliferation and apoptosis of endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-122	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-125a	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-223	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-323	Acute Coronary Syndrome	25124998			I24.9	D054058			Our study identifies miR-652 as a novel candidate biomarker for post-ACS prognosis beyond existing biomarkers of LVEF and NT-proBNP. Moreover circulating miR-323-3p was markedly elevated in patients for at least a year post-ACS and may be a stable biomarker for ACS.
circulation_biomarker_diagnosis_up	hsa-mir-486	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-499	Acute Coronary Syndrome	27346801			I24.9	D054058			miRNA-499 and miRNA-210 expression levels were significantly increased
circulation_biomarker_diagnosis_up	hsa-mir-652	Acute Coronary Syndrome	25124998			I24.9	D054058			Our study identifies miR-652 as a novel candidate biomarker for post-ACS prognosis beyond existing biomarkers of LVEF and NT-proBNP. Moreover circulating miR-323-3p was markedly elevated in patients for at least a year post-ACS and may be a stable biomarker for ACS.
circulation_biomarker_diagnosis_up	hsa-mir-92a	Acute Coronary Syndrome	27519051			I24.9	D054058			MiR-223, miR-92a, miR-486, miR-122, miR-125a and miR-146a levels were higher in the hyperglycemic ACS compared to normoglycemic sera.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Acute Kidney Failure	27400799	urinary system disease	DOID:3021	N17.9	D058186		HP:0001919	The results showed that in acute kidney injury induced by cisplatin, miR-146b in serum increased more quickly than did the usual indexes of kidney injury and decreased with restoration of MSCs.
circulation_biomarker_diagnosis_up	hsa-mir-133a	Acute Myocardial Infarction	27124025	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	circulating miR-133a is upregulated in AMI patients,
circulation_biomarker_diagnosis_up	hsa-mir-208a	Acute Myocardial Infarction	24253456	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Early in acute myocardial infarction the expression of miR-423-5p in plasma is significantly increased with subsequent normalization within 6 hours.Potentially it is an early marker of myocardial necrosis.
circulation_biomarker_diagnosis_up	hsa-mir-221	Acute Myocardial Infarction	27374153	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Circulating miR-221-3p as a novel marker for early prediction of acute myocardial infarction.
circulation_biomarker_diagnosis_up	hsa-mir-30d	Acute Myocardial Infarction	27176713	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	miR-125b-5p and miR-30d-5p presented a diagnostic value for early diagnosis of AMI, and miR鈥?0d鈥?p may have a higher diagnostic value than cTnI.
circulation_biomarker_diagnosis_up	hsa-mir-423	Acute Myocardial Infarction	24253456	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Early in acute myocardial infarction the expression of miR-423-5p in plasma is significantly increased with subsequent normalization within 6 hours.Potentially it is an early marker of myocardial necrosis.
circulation_biomarker_diagnosis_up	hsa-mir-499	Acute Myocardial Infarction	26101645	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	miR-499 expression levels were significantly higher in the 53 AMI patients
circulation_biomarker_diagnosis_up	hsa-mir-499	Acute Myocardial Infarction	27162785	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	the circulating levels of miRNA-499 was increased in AMI patients.
circulation_biomarker_diagnosis_up	hsa-mir-122	Acute Pancreatitis	27477940	endocrine system disease	DOID:2913	K85	D019283	167800	HP:0001735	In mice, we found that LPS-induced inflammation increases blood levels of MIR122, which reduces expression of Epo in the kidney;
circulation_biomarker_diagnosis_up	hsa-mir-155	Adenocarcinoma, Lung	24190459	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	endogenous miR-155 stably existed in patient serum and could be sensitively and specifically measured. Overexpression of miR-155 in serum specimens could constitute a diagnostic marker for the early detection of lung adenocarcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-155	Adenocarcinoma, Pancreatic Ductal	22513294	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Quantification by real-time quantitative polymerase chain reaction revealed that miR-155, miR-21, and miR-210 were higher in serum of PDAC rats,similar to plasma of patients with PDAC
circulation_biomarker_diagnosis_up	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	22513294	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Quantification by real-time quantitative polymerase chain reaction revealed that miR-155, miR-21, and miR-210 were higher in serum of PDAC rats,similar to plasma of patients with PDAC
circulation_biomarker_diagnosis_up	hsa-mir-210	Adenocarcinoma, Pancreatic Ductal	22513294	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Quantification by real-time quantitative polymerase chain reaction revealed that miR-155, miR-21, and miR-210 were higher in serum of PDAC rats,similar to plasma of patients with PDAC
circulation_biomarker_diagnosis_up	hsa-mir-375	Adenocarcinoma, Pancreatic Ductal	24048453	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		In the plasma-miRNA population, we find miRNA-375, which is selectively expressed in the endocrine pancreas under normal conditions, increased in PDAC cases compared with patients with other pancreatic or gastrointestinal diseases. The miRNA-375 does not outperform CA-19-9 diagnostically in the present cohort.
circulation_biomarker_diagnosis_up	hsa-mir-19a	Allergic Rhinitis	27491928	respiratory system disease	DOID:4481	J30.9	D065631	607154	HP:0003193	The results showed that the levels of miR-19a, but not the rest of the 5 members (miR-17, miR-18a, miR-19b, miR-20a, and miR-92a), were significantly higher in peripheral B cells from AR patients as than in B cells from healthy participants.
circulation_biomarker_diagnosis_up	hsa-mir-151a	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_up	hsa-mir-161	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_up	hsa-let-7d	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_up	hsa-mir-5010	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_up	hsa-mir-112	Alzheimer Disease	23895045	nervous system disease	DOID:10652	G30.9	D000544	104300	HP:0002511	A blood based 12-miRNA signature of Alzheimer disease patients.
circulation_biomarker_diagnosis_up	hsa-mir-338	Amyotrophic Lateral Sclerosis	25130371	nervous system disease	DOID:332	G12.21	D000690	PS105400	HP:0007354	miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients.
circulation_biomarker_diagnosis_up	hsa-mir-21	Ankylosing Spondylitis	24786924	musculoskeletal system disease	DOID:7147	M45.9	D013167			Higher expression of whole blood microRNA-21 in patients with ankylosing spondylitis associated with programmed cell death 4 mRNA expression and collagen cross-linked C-telopeptide concentration.
circulation_biomarker_diagnosis_up	hsa-mir-29a	Ankylosing Spondylitis	24593209	musculoskeletal system disease	DOID:7147	M45.9	D013167			We report for the first time elevated miR-29a expression in PBMCs of patients with ankylosing spondylitis, and miR-29a might be used as a useful diagnostic marker in new bone formation but cannot reflect disease activity.
circulation_biomarker_diagnosis_up	hsa-mir-21	Aortic Stenosis	22882958	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	The myocardial and plasma levels of miR-21 were significantly higher in the AS patients compared with the controls and correlated directly with the echocardiographic mean transvalvular gradients.
circulation_biomarker_diagnosis_up	hsa-mir-30c	Aortic Stenosis	27129184	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Levels of miR-30c were higher in the AS group than in the controls (P<0.01), whereas levels of miR-106a, miR-148a, miR-204, miR-211, miR-31 and miR-424 were lower in the AS group than in the controls (P<0.01).
circulation_biomarker_diagnosis_up	hsa-mir-133	Arrhythmia	25625292			I49.9	D001145	600919	HP:0011675	patients with SVT had lower miR-1 expression levels while those with VT had higher miR-133 expression levels.
circulation_biomarker_diagnosis_up	hsa-mir-126	Arteriosclerosis Obliterans	27766047	cardiovascular system disease	DOID:5160		D001162		HP:0002634	In smokers who completely attained smoking cessation, both RH-PAT index and plasma miR-126 values were increased
circulation_biomarker_diagnosis_up	hsa-mir-126	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-126:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-126	Atherosclerosis	25697638	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	and the levels of miR-126 had positive correlation with cerebral atherosclerosis
circulation_biomarker_diagnosis_up	hsa-mir-146a	Atherosclerosis	21820659	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Atherosclerosis	27502756	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	In monocytes, miR124a and -125a were low, while miR-146a and miR-155 appeared elevated.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Atherosclerosis	21820659	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study.
circulation_biomarker_diagnosis_up	hsa-mir-17	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-17-5p:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-17	Atherosclerosis	25697638	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	he levels of miR-17 were significantly increased in acute stroke patients
circulation_biomarker_diagnosis_up	hsa-mir-21	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-21	Atherosclerosis	21820659	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study.
circulation_biomarker_diagnosis_up	hsa-mir-21	Atherosclerosis	24848278	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	In atherosclerosis, miR-21, 122, 130a, and 211 were significantly increased whereas miR-92a, 126, and 222 were markedly decreased.
circulation_biomarker_diagnosis_up	hsa-mir-210	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-210:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-210	Atherosclerosis	21820659	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study.
circulation_biomarker_diagnosis_up	hsa-mir-221	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-221:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-222	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-222:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-296	Atherosclerosis	20489169	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-296:found high levels of expression for all of them in quiescent endothelial cells
circulation_biomarker_diagnosis_up	hsa-mir-29a	Atherosclerosis	28250354	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	Elevated Plasma miR-29a Levels Are Associated with Increased Carotid Intima-Media Thickness in Atherosclerosis Patients.
circulation_biomarker_diagnosis_up	hsa-mir-34a	Atherosclerosis	21820659	cardiovascular system disease	DOID:1936	I70	D050197	108725	HP:0002621	miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques (compared to non-atherosclerotic left internal thoracic arteries (LITA)) in the Tampere Vascular Study.
circulation_biomarker_diagnosis_up	hsa-mir-203	Atopic Dermatitis	25531302	integumentary system disease	DOID:3310	L20	D003876	PS603165	HP:0001047	miR-203 and miR-483-5p were significantly up-regulated in serum of children with AD compared with healthy children.
circulation_biomarker_diagnosis_up	hsa-mir-328	Atrial Fibrillation	26987792	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Plasma levels of miR-328 were higher in patients with AF than in control subjects.
circulation_biomarker_diagnosis_up	hsa-mir-132	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-132: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-146a	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-146a: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-146b	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		mir-146b: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-23a	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-23a: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-23b	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-23b: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-663a	Autistic Disorder	19360674	disease of mental health	DOID:12849	F84.0	D001321	209850		miR-663: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-301a	Autoimmune Diseases [unspecific]	26338824				D001327	607836	HP:0002960	Our data reveal a novel mechanism in which the elevated miR-301a in  PBMC and inflamed mucosa of IBD promotes Th17 cell differentiation through downregulation of SNIP1.
circulation_biomarker_diagnosis_up	hsa-mir-21	Autoimmune Lymphoproliferative Syndrome	27060458	immune system disease	DOID:6688	D89.82	D056735	PS308240		miR-21-3p was over-expressed significantly (P = 0路0313) in the son, with no significant change in the expression of miR-146a, miR-146a-3p and miR-21.
circulation_biomarker_diagnosis_up	hsa-mir-21	Brain Neoplasms	16466964	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	overexpressed
circulation_biomarker_diagnosis_up	hsa-let-7a-1	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a* is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-let-7a-2	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a* is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-let-7a-3	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	let-7a* is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-let-7b	Breast Neoplasms	22821209	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours.
circulation_biomarker_diagnosis_up	hsa-let-7g	Breast Neoplasms	22821209	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours.
circulation_biomarker_diagnosis_up	hsa-mir-103a-1	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-103a-1	Breast Neoplasms	22588912	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05).
circulation_biomarker_diagnosis_up	hsa-mir-103a-2	Breast Neoplasms	22588912	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05).
circulation_biomarker_diagnosis_up	hsa-mir-103b-1	Breast Neoplasms	22588912	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05).
circulation_biomarker_diagnosis_up	hsa-mir-103b-2	Breast Neoplasms	22588912	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05).
circulation_biomarker_diagnosis_up	hsa-mir-106b	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-10b	Breast Neoplasms	22906258	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Serum Overexpression of MicroRNA-10b in Patients with Bone Metastatic Primary Breast Cancer.
circulation_biomarker_diagnosis_up	hsa-mir-127	Breast Neoplasms	16766263	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	upregulation
circulation_biomarker_diagnosis_up	hsa-mir-132	Breast Neoplasms	17447837	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-1323	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-141	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-146a	Breast Neoplasms	23898484	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Breast Neoplasms	27197674	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas  miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed.
circulation_biomarker_diagnosis_up	hsa-mir-148b	Breast Neoplasms	22927033	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Four miRNAs (miR-148b, miR-376c, miR-409-3p and miR-801) were shown to be significantly upregulated in the plasma of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-155	Breast Neoplasms	16466964	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-155	Breast Neoplasms	16885332	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression in breast cancers
circulation_biomarker_diagnosis_up	hsa-mir-155	Breast Neoplasms	23372341	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	serum;miR-205 was down-regulated and miR-155 was up-regulated in BC patient serum
circulation_biomarker_diagnosis_up	hsa-mir-18b	Breast Neoplasms	22821209	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours.
circulation_biomarker_diagnosis_up	hsa-mir-197	Breast Neoplasms	25644077	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The expression level of miR-29b-2, -155, -197 and -205 was significantly increased in the serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-200a	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-200b	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-200c	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-202	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-203	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-205	Breast Neoplasms	23372341	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	serum;miR-205 was down-regulated and miR-155 was up-regulated in BC patient serum
circulation_biomarker_diagnosis_up	hsa-mir-20a	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-20a: increased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_up	hsa-mir-20a	Breast Neoplasms	22350790	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-20b	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-20b: increased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	23898484	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	16885332	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Overexpression in breast cancers
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	22350790	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	26827795	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the serum levels of miR-21 and miR-221 were significantly overexpressed in breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	27197674	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas  miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed.
circulation_biomarker_diagnosis_up	hsa-mir-21	Breast Neoplasms	29679553	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Assessment of miRNAs in serum samples can be applied as minimally non-invasive markers for early detection of breast cancer, and as discriminator between different clinicopathological characters
circulation_biomarker_diagnosis_up	hsa-mir-210	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-214	Breast Neoplasms	22350790	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-221	Breast Neoplasms	26827795	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the serum levels of miR-21 and miR-221 were significantly overexpressed in breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-222	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-222	Breast Neoplasms	29679553	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Assessment of miRNAs in serum samples can be applied as minimally non-invasive markers for early detection of breast cancer, and as discriminator between different clinicopathological characters
circulation_biomarker_diagnosis_up	hsa-mir-23a	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-23b	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-24-1	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-25	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-29a	Breast Neoplasms	22387599	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	significantly increased in serum of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-335	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-373	Breast Neoplasms	25333260	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-373	Breast Neoplasms	29679553	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Assessment of miRNAs in serum samples can be applied as minimally non-invasive markers for early detection of breast cancer, and as discriminator between different clinicopathological characters
circulation_biomarker_diagnosis_up	hsa-mir-375	Breast Neoplasms	22952344	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-376c	Breast Neoplasms	22927033	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Four miRNAs (miR-148b, miR-376c, miR-409-3p and miR-801) were shown to be significantly upregulated in the plasma of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-409	Breast Neoplasms	22927033	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Four miRNAs (miR-148b, miR-376c, miR-409-3p and miR-801) were shown to be significantly upregulated in the plasma of breast cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-4257	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-4306	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-497	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-516b-1	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-516b-2	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-9-1	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-9: increased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_up	hsa-mir-9-2	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-9: increased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_up	hsa-mir-922	Breast Neoplasms	22242178	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The miRNA is up-regulated in whole blood of breast cancer patients
circulation_biomarker_diagnosis_up	hsa-mir-9-3	Breast Neoplasms	18777135	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-9: increased expression in c-Myc induced mouse mammary tumors
circulation_biomarker_diagnosis_up	hsa-mir-127	Carcinoma, Breast	27983524			D05	D001943	114480	HP:0003002	Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer.
circulation_biomarker_diagnosis_up	hsa-mir-372	Carcinoma, Embryonal	19057917	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	miR-372: highly up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-373	Carcinoma, Embryonal	19057917	disease of cellular proliferation	DOID:3308		D018236		HP:0002898	miR-373: highly up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-122	Carcinoma, Hepatocellular	21229610	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC.
circulation_biomarker_diagnosis_up	hsa-mir-130b	Carcinoma, Hepatocellular	22403344	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity).
circulation_biomarker_diagnosis_up	hsa-mir-15b	Carcinoma, Hepatocellular	22403344	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity).
circulation_biomarker_diagnosis_up	hsa-mir-17	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-17: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-182	Carcinoma, Hepatocellular	25903466	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	our present study indicates that serum miR-182 and miR-331-3p, upregulated in HCC, can provide positive diagnostic and prognostic values for HCC
circulation_biomarker_diagnosis_up	hsa-mir-183	Carcinoma, Hepatocellular	22403344	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity).
circulation_biomarker_diagnosis_up	hsa-mir-18a	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-18a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-18a	Carcinoma, Hepatocellular	22865399	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-18a was significantly higher in HBV patients with HCC than healthy controls (p < 0.01).
circulation_biomarker_diagnosis_up	hsa-mir-19a	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-19a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-19b: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-19b-2	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-19b: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-20a	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-20a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Hepatocellular	18223217	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	increased
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-21: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Hepatocellular	21229610	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC.
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Hepatocellular	22403344	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-15b, miR-21, miR-130b and miR-183 highly expressed in tumours. Combined miR-15b and miR-130b demonstrated as a classifier for HCC detection, yielding a receiver operating characteristic curve area of 0.98 (98.2% sensitivity and 91.5% specificity).
circulation_biomarker_diagnosis_up	hsa-mir-210	Carcinoma, Hepatocellular	22387901	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro.
circulation_biomarker_diagnosis_up	hsa-mir-222	Carcinoma, Hepatocellular	26380927	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	The serum levels of exosomal miR-18a, miR-221, miR-222 and miR-224 were significantly higher in patients with HCC
circulation_biomarker_diagnosis_up	hsa-mir-223	Carcinoma, Hepatocellular	21229610	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC.
circulation_biomarker_diagnosis_up	hsa-mir-331	Carcinoma, Hepatocellular	25903466	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-92a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Carcinoma, Hepatocellular	18688024	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	miR-92a: Elevated expression of the miR-17-92 polycistron and miR-21 contributes to the malignant phenotype
circulation_biomarker_diagnosis_up	hsa-mir-96	Carcinoma, Hepatocellular	26770453	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-96 levels in the HCC patients were remarkably higher than in the other groups
circulation_biomarker_diagnosis_up	hsa-mir-100	Carcinoma, Lung, Non-Small-Cell	22937028			C34.90	D002289		HP:0030358	High expression of miR-100 and low expression of miRNA-93, miRNA-134, miRNA-151 and miRNA-345 were associated with poor survival in both the training and validation cohort.
circulation_biomarker_diagnosis_up	hsa-mir-10b	Carcinoma, Lung, Non-Small-Cell	25869877			C34.90	D002289		HP:0030358	Prognostic value of microRNA-10b overexpression in peripheral blood mononuclear cells of nonsmall-cell lung cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-1254-1	Carcinoma, Lung, Non-Small-Cell	21258252			C34.90	D002289		HP:0030358	miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer. The expression of hsa-miR-1254 and hsa-miR-574-5p was significantly increased in the early-stage NSCLC samples with respect to the controls.  The utility of miR-1254 and miR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation.
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	21627863			C34.90	D002289		HP:0030358	Plasma miR-21 was significantly higher in NSCLC patients than in age- and sex-matched controls (P < 0.001). miR-21 was related to TNM stage (P < 0.001), but not related to age, sex, smoking status, histological classification, lymph node status, and metastasis (all P > 0.05).
circulation_biomarker_diagnosis_up	hsa-mir-21	Carcinoma, Lung, Non-Small-Cell	21721011			C34.90	D002289		HP:0030358	serum miR-21 expression was an independent prognostic factor for NSCLC patients.
circulation_biomarker_diagnosis_up	hsa-mir-29c	Carcinoma, Lung, Non-Small-Cell	21544802			C34.90	D002289		HP:0030358	The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased.
circulation_biomarker_diagnosis_up	hsa-mir-574	Carcinoma, Lung, Non-Small-Cell	21258252			C34.90	D002289		HP:0030358	miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer. The expression of hsa-miR-1254 and hsa-miR-574-5p was significantly increased in the early-stage NSCLC samples with respect to the controls.  The utility of miR-1254 and miR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation.
circulation_biomarker_diagnosis_up	hsa-mir-200b	Carcinoma, Ovarian	26416421	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Plasma miR-200b proved to have a greater average concentration in OvCa samples
circulation_biomarker_diagnosis_up	hsa-mir-106b	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-1233-1	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-1233-2	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-126	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-126*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-1290	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-134	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-144	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-144*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-151a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-151-30: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-151b	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-151-30: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-203	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-210	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-26b	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-26b*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-29c	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-29c*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-320a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-320b-1	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-320b-2	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-339	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-339-3p: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-365a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-365b	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-378a	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-378a	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378b	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378c	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378d-1	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378d-2	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378e	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378f	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378g	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378h	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-378i	Carcinoma, Renal Cell	22542158	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	The level of miR-378 was significantly increased in serum of ccRCC patients.
circulation_biomarker_diagnosis_up	hsa-mir-425	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-425*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-454	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-454*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-571	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-625	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	miR-625*: Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-629	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-655	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-7-1	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-760	Carcinoma, Renal Cell	22440013	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulated in the blook serum of patients with renal cell carcinoma compared to healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-93	Carcinoma, Renal Cell	21984948	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Cardiac Allograft Vasculopathy	26198441			T86.290	D014652			Median plasma levels of miR-210-5p, miR-92a-3p, miR-126-3p, and miR-126-5p were higher in patients with CAV than in patients without CAV.
circulation_biomarker_diagnosis_up	hsa-mir-208	Cardiomegaly	26622415			I51.7	D006332		HP:0001640	miR-208 expression levels are increased in the peripheral blood of patients with cardiac hypertrophy.
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Cardiomyopathy, Hypertrophic	17965831	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue.
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Cardiomyopathy, Hypertrophic	17965831	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue.
circulation_biomarker_diagnosis_up	hsa-mir-195	Cardiomyopathy, Hypertrophic	17786230	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	Cardiac-specific overexpression of miRNA-195 (miR-195), which is consistently upregulated in rodent and human hypertrophic hearts, for example, results in dilated cardiomyopathy and heart failure in mice as early as two weeks of age, implying that upregulation of miR-195 during cardiac hypertrophy actively contributes to the disease process.
circulation_biomarker_diagnosis_up	hsa-mir-29a	Cardiomyopathy, Hypertrophic	24161319	cardiovascular system disease	DOID:11984	I42.2	D002312	192600	HP:0001639	cardiac remodeling associated with HCM determines a significant release of miRNAs into the bloodstream: the circulating levels of both cardiac- and non-cardiac-specific miRNAs are significantly increased in the plasma of HCM patients. However, correlation with left ventricular hypertrophy parameters holds true for only a few miRNAs (i.e.,miR-199a-5p, -27a, and -29a), whereas only miR-29a is significantly associated with both hypertrophy and fibrosis, identifying it as a potential biomarker for myocardial remodeling assessment in HCM.
circulation_biomarker_diagnosis_up	hsa-mir-1	Cardiovascular Diseases [unspecific]	22135162				D002318			miR-1 and miR-133 are highly expressed in cardiomyocytes and their precursors and regulate cardiomyogenesis. 
circulation_biomarker_diagnosis_up	hsa-mir-1	Cardiovascular Diseases [unspecific]	29506853				D002318			Plasma microRNAs reflecting cardiac and inflammatory injury in coronary artery bypass grafting surgery
circulation_biomarker_diagnosis_up	hsa-mir-133	Cardiovascular Diseases [unspecific]	22135162				D002318			miR-1 and miR-133 are highly expressed in cardiomyocytes and their precursors and regulate cardiomyogenesis. 
circulation_biomarker_diagnosis_up	hsa-mir-133a	Cardiovascular Diseases [unspecific]	29506853				D002318			Plasma microRNAs reflecting cardiac and inflammatory injury in coronary artery bypass grafting surgery
circulation_biomarker_diagnosis_up	hsa-mir-208a	Cardiovascular Diseases [unspecific]	29506853				D002318			Plasma microRNAs reflecting cardiac and inflammatory injury in coronary artery bypass grafting surgery
circulation_biomarker_diagnosis_up	hsa-mir-423	Cardiovascular Diseases [unspecific]	26562412				D002318			Our results suggested that miR-423-5p is enriched in PF, and serum miR-423-5p may be associate with uAP. Its expression pattern was different to that of muscle- and vascular-enriched miRNAs, miR-133a, miR-126, and miR-92a.
circulation_biomarker_diagnosis_up	hsa-mir-372	Cerebellum Cancer	19057917	nervous system disease	DOID:4205	C71.6	D002528			miR-372: highly up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-373	Cerebellum Cancer	19057917	nervous system disease	DOID:4205	C71.6	D002528			miR-373: highly up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-145	Cerebral Ischemia	22370881	cardiovascular system disease	DOID:2316	I67.82	D002545		HP:0002637	Circulatory microRNA-145 expression is increased in cerebral ischemia.
circulation_biomarker_diagnosis_up	hsa-mir-200a	Cervical Neoplasms	26171195	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	The Solexa sequencing results revealed 12 markedly upregulated serum miRNAs in cervical cancer patients compared with controls
circulation_biomarker_diagnosis_up	hsa-mir-23a	Child Development Disorders, Pervasive	20374639			F84.9	D002659			up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-141	Cholangiocarcinoma	17355635	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-192	Cholangiocarcinoma	26456596	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	We found that miR-192 was significantly higher in O. viverrini infected, PDF and also CCA groups (p<0.05) than in healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-200b	Cholangiocarcinoma	17355635	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-21	Cholangiocarcinoma	26456596	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	MiR-21 was significantly higher in PDF and CCA groups (p<0.05) than in healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-21	Cholangiocarcinoma	29516989	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	serum miR-21 was a promising biomarker for diagnosing the late stage CCA and would have potential to be a useful prognostic biomarker of CCA
circulation_biomarker_diagnosis_up	hsa-mir-21	Cholesteatoma	28224282	integumentary system disease	DOID:869	H71.9	D002781	604183	HP:0009797	The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-mir-10b	Choriocarcinoma	23933230	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	we observed that miR-21 was significantly overexpressed in PDAC, and miR-10b was highly expressed in PanIN II-III.
circulation_biomarker_diagnosis_up	hsa-mir-223	Choriocarcinoma	26807325	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Three miRNAs (miR-143, miR-223, and  miR-30e) were significantly over-expressed in patients with Stage I cancer when compared with age-matched healthy individuals
circulation_biomarker_diagnosis_up	hsa-mir-99b	Chronic Fatigue Syndrome	26967895	syndrome	DOID:8544	G93.3	D015673		HP:0012432	Microarray analysis identified differential expression of 34 miRNA, all  of which were up-regulated.
circulation_biomarker_diagnosis_up	hsa-mir-125b	Chronic Hepatitis B	26802212			B18.0-.1	D019694	610424		serum miRNA-125b was positively correlated with the  serum HBV DNA level.
circulation_biomarker_diagnosis_up	hsa-mir-122	Chronic Hepatitis C	25461662			B18.2	D019698	609532		serum microRNA-122 was elevated in acute and chronic hepatitis patients. However, this biomarker for acute liver injury did not reflect the liver inflammation activity in CHC patients.
circulation_biomarker_diagnosis_up	hsa-mir-122	Chronic Hepatitis C	26812693			B18.2	D019698	609532		serum levels of miR-122 and miR-222 were significantly elevated in HCV patients
circulation_biomarker_diagnosis_up	hsa-mir-222	Chronic Hepatitis C	26812693			B18.2	D019698	609532		the serum levels of miR-122 and miR-222 were significantly elevated in HCV patients
circulation_biomarker_diagnosis_up	hsa-mir-296	Chronic Hepatitis C	25790297			B18.2	D019698	609532		Serum miR-34a, miR-130a, miR-19a, miR-192, miR-195, and miR-296 were upregulated, whereas serum miR-146a was downregulated in CHC compared to controls.
circulation_biomarker_diagnosis_up	hsa-mir-21	Chronic Obstructive Pulmonary Disease	24556821	respiratory system disease	DOID:3083	J44.9	D029424	606963	HP:0006510	An increased ratio of serum miR-21 to miR-181a levels is associated with the early pathogenic process of chronic obstructive pulmonary disease in asymptomatic heavy smokers.
circulation_biomarker_diagnosis_up	hsa-mir-106a	Colon Neoplasms	17442096			D12.6	D003110		HP:0100273	Indeed, in human solid tumors, mir-106a expression is increased in colon, pancreas, and prostate tumors.
circulation_biomarker_diagnosis_up	hsa-mir-132	Colon Neoplasms	17447837			D12.6	D003110		HP:0100273	miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-141	Colon Neoplasms	17355635			D12.6	D003110		HP:0100273	These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-145	Colon Neoplasms	16885332			D12.6	D003110		HP:0100273	Reduced accumulation in colon adenomas and carcinomas
circulation_biomarker_diagnosis_up	hsa-mir-200b	Colon Neoplasms	17355635			D12.6	D003110		HP:0100273	These include miR-200b and miR-141 which have been shown to be highly overexpressed in malignant cholangiocytes and in colon carcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-96	Colorectal Adenocarcinoma	27044381	disease of cellular proliferation	DOID:0050861	C19	C000599423	114500		miR-96 is significantly upregulated in colorectal adenocarcinoma specimens compared to their non-cancerous counterparts
circulation_biomarker_diagnosis_up	hsa-mir-135a	Colorectal Carcinoma	27126269	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-135a-5p expression in colorectal cancer patients was higher than that in patients with colorectal polyps and healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-21	Colorectal Carcinoma	25178939	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Elevated level of microRNA-21 in the serum of patients with colorectal cancer.
circulation_biomarker_diagnosis_up	hsa-mir-29a	Colorectal Carcinoma	25736690	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Significant upregulation of miR-29a in CRC was reported when compared to normal
circulation_biomarker_diagnosis_up	hsa-mir-145	Colorectal Carcinoma	19047896	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-145: increased expression
circulation_biomarker_diagnosis_up	hsa-mir-181b-1	Colorectal Carcinoma	19047896	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-181b: increased expression
circulation_biomarker_diagnosis_up	hsa-mir-203	Colorectal Carcinoma	19047896	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-203: increased expression
circulation_biomarker_diagnosis_up	hsa-mir-20a	Colorectal Carcinoma	19047896	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-20a: increased expression
circulation_biomarker_diagnosis_up	hsa-mir-21	Colorectal Carcinoma	19047896	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-21: increased expression
circulation_biomarker_diagnosis_up	hsa-mir-21	Colorectal Carcinoma	22868372	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		In the plasma group, miR-21 differentiated CRC patients from controls with 90% specificity and sensitivity.
circulation_biomarker_diagnosis_up	hsa-mir-31	Colorectal Carcinoma	19242066	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		miR-31: up-regulated compared with normal control
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Coronary Artery Disease	17919180	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		elevated expression
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Coronary Artery Disease	17965831	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue.
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Coronary Artery Disease	17919180	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		elevated expression
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Coronary Artery Disease	17965831	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miR-1 is overexpressed in patients with coronary artery disease and that overexpression of miR-1 in a rat model of cardiac infarction exacerbated arrhythmogenesis. Cardiac hypertrophy may also be regulated by miR-1, which is significantly down-regulated in hypertrophic tissue.
circulation_biomarker_diagnosis_up	hsa-mir-122	Coronary Artery Disease	22587332	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-mir-126	Coronary Artery Disease	28751542	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		patients with stenosis showed an increase of circulating miRNA-21, miRNA-126-3p, and miRNA-222 in response to cardiac stress
circulation_biomarker_diagnosis_up	hsa-mir-206	Coronary Artery Disease	26685009	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-mir-21	Coronary Artery Disease	26248417	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miRNA-21 was significantly elevated in acute myocardial infarction subgroup than the control group. The level of miRNA-21 associates with the degree of coronary artery stenosis, and might be a potential marker for the diagnosis of acute myocardial infarction. miRNA-21 may play an important role in protecting myocardium from ischemia/reperfusion injury.
circulation_biomarker_diagnosis_up	hsa-mir-21	Coronary Artery Disease	28751542	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		patients with stenosis showed an increase of circulating miRNA-21, miRNA-126-3p, and miRNA-222 in response to cardiac stress
circulation_biomarker_diagnosis_up	hsa-mir-222	Coronary Artery Disease	28751542	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		patients with stenosis showed an increase of circulating miRNA-21, miRNA-126-3p, and miRNA-222 in response to cardiac stress
circulation_biomarker_diagnosis_up	hsa-mir-370	Coronary Artery Disease	22587332	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-mir-574	Coronary Artery Disease	26685009	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-mir-106a	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-107	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-126	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-16-2	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-191	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-199a-1	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-199a-2	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-200c	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-23a	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-29a	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-362	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-532	Crohn Disease	22386737	gastrointestinal system disease	DOID:8778	K50	D003424	266600	HP:0100280	The miRNA showed significantly higher levels in the blood from patients with CD compared with the healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-124	Depression Disorder	27078210	disease of mental health	DOID:1596	F32.9	D003866			expression levels of miR-124 from PBMCs in MDD patients were significantly higher than those in healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-147	Diabetes Mellitus	27518498	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Analysis for serum microRNAs expression showed the distinctive and synergistic upregulation of miR-147 with periodontitis-induced effects in rats
circulation_biomarker_diagnosis_up	hsa-mir-326	Diabetes Mellitus, Type 1	22069274	disease of metabolism	DOID:9744	E10	D003922	222100	HP:0100651	Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity.
circulation_biomarker_diagnosis_up	hsa-mir-101	Diabetes Mellitus, Type 2	25726255	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The present findings demonstrated that the circulating miR-101, miR-375 and miR-802 levels are significantly increased in T2D patients versus NGT subjects and they may become the new biomarkers for type 2 diabetes.
circulation_biomarker_diagnosis_up	hsa-mir-143	Diabetes Mellitus, Type 2	24927876	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function.
circulation_biomarker_diagnosis_up	hsa-mir-145	Diabetes Mellitus, Type 2	24927876	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Diabetes Mellitus, Type 2	24023848	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	circulating miRNA-146a levels were significantly elevated in new-T2DM patients compared with healthy controls. Whether expression of circulating miRNA-146a holds predictive value for T2DM warrants further investigations.
circulation_biomarker_diagnosis_up	hsa-mir-217	Diabetes Mellitus, Type 2	27522360	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	Compared with control, serum microRNA-217 levels were significantly increased in type 2 diabetes patients
circulation_biomarker_diagnosis_up	hsa-mir-33b	Diabetes Mellitus, Type 2	27301461	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	plasma miRNA33b may be useful as a new metabolic biomarker of dyslipidemia in patients with T2DM
circulation_biomarker_diagnosis_up	hsa-mir-375	Diabetes Mellitus, Type 2	25726255	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The present findings demonstrated that the circulating miR-101, miR-375 and miR-802 levels are significantly increased in T2D patients versus NGT subjects and they may become the new biomarkers for type 2 diabetes.
circulation_biomarker_diagnosis_up	hsa-mir-802	Diabetes Mellitus, Type 2	25726255	disease of metabolism	DOID:9352	E11	D003924	125853	HP:0005978	The present findings demonstrated that the circulating miR-101, miR-375 and miR-802 levels are significantly increased in T2D patients versus NGT subjects and they may become the new biomarkers for type 2 diabetes.
circulation_biomarker_diagnosis_up	hsa-mir-30	Diabetic Nephropathy	27470555			E10-11.21	D003928			We found urinary exosomalmiR-133b, miR-342, and miR-30a were expressed at significantly elevated levels in T2DN patients (P<0.001) compared to normal.
circulation_biomarker_diagnosis_up	hsa-mir-342	Diabetic Nephropathy	27470555			E10-11.21	D003928			We found urinary exosomalmiR-133b, miR-342, and miR-30a were expressed at significantly elevated levels in T2DN patients (P<0.001) compared to normal.
circulation_biomarker_diagnosis_up	hsa-mir-377	Diabetic Nephropathy	18716028			E10-11.21	D003928			miR-377: MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy
circulation_biomarker_diagnosis_up	hsa-mir-27b	Diabetic Retinopathy	26395742	nervous system disease	DOID:8947	E10-11.31	D003930			miR-27b and miR-320a, were associated with incidence and with progression of retinopathy
circulation_biomarker_diagnosis_up	hsa-let-7c	Down Syndrome	27323694	genetic disease	DOID:14250	Q90	D004314	190685		Seven miRNAs were verified as upregulated in DS placentas (miR-99a, miR-542-5p, miR-10b, miR-125b, miR-615, let-7c and miR-654)
circulation_biomarker_diagnosis_up	hsa-mir-323a	Ectopic Pregnancy	22395025	reproductive system disease	DOID:0060329	O00.9	D011271		HP:0031456	Concentrations of serum hCG, progesterone, miR-517a, miR-519d, and miR-525-3p were significantly lower in EP and SA cases than in VIP cases. In contrast, the concentration of miR-323-3p was significantly increased in EP cases, compared with SA and VIP cases. As a single marker, miR-323-3p had the highest sensitivity of 37.0% (at a fixed specificity of 90%).
circulation_biomarker_diagnosis_up	hsa-mir-146a	Eczema Herpeticum	18419608	disease by infectious agent	DOID:9123	B00.0	D007617			upregulation
circulation_biomarker_diagnosis_up	hsa-mir-106b	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-106b*: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-132	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-142	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-146a	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		Plasma analysis of the most upregulated esophageal miRNAs identified miR-146a, miR-146b, and miR-223 as the most differentially expressed miRNAs in the plasma.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		Plasma analysis of the most upregulated esophageal miRNAs identified miR-146a, miR-146b, and miR-223 as the most differentially expressed miRNAs in the plasma.
circulation_biomarker_diagnosis_up	hsa-mir-21	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		One of the most upregulated miRNA, which strongly correlated with esophageal eosinophil levels.
circulation_biomarker_diagnosis_up	hsa-mir-212	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-222	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-222*: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-223	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		One of the most upregulated miRNA, which strongly correlated with esophageal eosinophil levels. And miR-223 is one of the most differentially expressed miRNAs in the plasma.
circulation_biomarker_diagnosis_up	hsa-mir-29b-1	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-29b-2	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-339	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-339-5p: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-592	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-7-1	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-7-2	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-7-3	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		upregulated
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Eosinophilic Esophagitis	22391115	gastrointestinal system disease	DOID:13922	K20.0	D057765	610247		miR-92a-1*: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-21	Esophageal Neoplasms	22354855			C15.9	D004938	133239	HP:0100751	Serum concentration of miRNA-21 in ESCC patients was significantly higher than that in healthy controls (P<0.001). A significant reduction in the serum miR-21 levels was observed in the postoperative samples versus the preoperative samples (P=0.003). Furthermore, miRNA-21 levels were significantly reduced in ESCC patients who responded to chemotherapy (P=0.003), whereas no significant change was observed in the non-responders.
circulation_biomarker_diagnosis_up	hsa-mir-21	Esophageal Neoplasms	22799367			C15.9	D004938	133239	HP:0100751	Serum miR-21 expression in ESCC samples was significantly higher than in paired cancer-free samples (P <0.05). Metastasis was associated with mir-21 expression in serum (P <0.05), ESCC patients with metastasis having 8.4-fold higher serum miR-21 concentrations than healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-21	Esophageal Neoplasms	23224754			C15.9	D004938	133239	HP:0100751	Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma
circulation_biomarker_diagnosis_up	hsa-mir-1	Essential Hypertension	24284386	cardiovascular system disease	DOID:10825	I10	C562386	145500		Hypertensive patients showed lower miR-143, miR-145 and miR-133 and higher miR-21 and miR-1 expression levels compared with controls
circulation_biomarker_diagnosis_up	hsa-mir-144	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_up	hsa-mir-21	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_up	hsa-mir-4454	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_up	hsa-mir-451a	Familial Mediterranean Fever	29787577	immune system disease	DOID:2987	M04.1	D010505	134610		four miRNAs were upregulated (miR-144-3p, miR-21-5p, miR-4454, and miR-451a), and three were downregulated (miR-107, let-7d-5p, and miR-148b-3p)
circulation_biomarker_diagnosis_up	hsa-mir-15b	Fatty Liver [unspecific]	23287814	disease of metabolism	DOID:9452	K76.0	D005234	613282	HP:0001397	Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease
circulation_biomarker_diagnosis_up	hsa-mir-122	Fatty Liver, Alcoholic	21886843			K70.0	D005235			Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis.
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Fatty Liver, Alcoholic	21886843			K70.0	D005235			Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis.
circulation_biomarker_diagnosis_up	hsa-mir-16-2	Fatty Liver, Alcoholic	21886843			K70.0	D005235			Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis.
circulation_biomarker_diagnosis_up	hsa-mir-34a	Fatty Liver, Alcoholic	21886843			K70.0	D005235			Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis.
circulation_biomarker_diagnosis_up	hsa-mir-122	Fatty Liver, Non-Alcoholic	23727030	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis.
circulation_biomarker_diagnosis_up	hsa-mir-21	Fatty Liver, Non-Alcoholic	23727030	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis.
circulation_biomarker_diagnosis_up	hsa-mir-34a	Fatty Liver, Non-Alcoholic	23727030	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis.
circulation_biomarker_diagnosis_up	hsa-mir-451	Fatty Liver, Non-Alcoholic	23727030	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis.
circulation_biomarker_diagnosis_up	hsa-mir-21	Focal Epithelial Hyperplasia	17478730	disease by infectious agent	DOID:5362	K13.29	D017573	229045		We found that miR-21 was one of the most upregulated miRNAs in the vascular wall after balloon injury. Our results strongly indicate that miR-21 is an important regulator for neointimal hyperplasia.
circulation_biomarker_diagnosis_up	hsa-mir-107	Gastric Neoplasms	26406411	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The overexpression of miR-107 in tumors and serum of gastric cancer patients and its correlation with HIF-1α expression in tumor tissues was indicated that miR-107 may have a potential to use as a biomarker for detection of gastric cancer patients and hypoxia in gastric cancer tumor.
circulation_biomarker_diagnosis_up	hsa-mir-132	Gastric Neoplasms	17447837	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-151a	Gastric Neoplasms	22956063	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-151b	Gastric Neoplasms	22956063	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-199a-1	Gastric Neoplasms	22956063	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-199a-2	Gastric Neoplasms	22956063	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients.
circulation_biomarker_diagnosis_up	hsa-mir-200c	Gastric Neoplasms	22954417	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The miR-200c blood expression levels in GC patients were significantly higher than in normal controls (p = 0.018). increased miR-200c levels are detected in the blood of gastric cancer patients. MiR-200c has the potential to be a predictor of progression and survival.
circulation_biomarker_diagnosis_up	hsa-mir-21	Gastric Neoplasms	22860003	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-223	Gastric Neoplasms	22860003	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The plasma levels of miR-223 (P<0.001) and miR-21 (P<0.001) were significantly higher in GC patients than in healthy controls, while miR-218 (P<0.001) was significantly lower. The ROC analyses yielded the AUC values of 0.9089 for miR-223, 0.7944 for miR-21 and 0.7432 for miR-218, and combined ROC analysis revealed the highest AUC value of 0.9531 in discriminating GC patients from healthy controls.
circulation_biomarker_diagnosis_up	hsa-mir-421	Gastric Neoplasms	25510566	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-421 increased significantly in GC patients than in controls. miR-421 in either serum or PBMCs had higher sensitivity and specificity than CEA and CA-125 in GC diagnosis.
circulation_biomarker_diagnosis_up	hsa-mir-92a	Gastric Neoplasms	26790436	disease of cellular proliferation	DOID:10534	C16	D013274	137215		High expression of miR-92a compared with adjacent normal tissues was associated with shorter OS.
circulation_biomarker_diagnosis_up	hsa-mir-128-1	Glioblastoma	21561454				D005909		HP:0100843	upregulated in the peripheral blood of glioblastoma patients.
circulation_biomarker_diagnosis_up	hsa-mir-128-2	Glioblastoma	21561454				D005909		HP:0100843	upregulated in the peripheral blood of glioblastoma patients.
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioblastoma	16466964				D005909		HP:0100843	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioblastoma	16885332				D005909		HP:0100843	Elevated levels in glioblastoma primary tumors and cell lines
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioblastoma	17028302				D005909		HP:0100843	miR-21 is strongly overexpressed in this highly malignant brain tumor type, while knockdown of miR-21 in glioblastoma cells by an antisense-oligonucleotide triggered activation of caspases and led to increased apoptotic cell death, suggesting that miR-21 overexpression may contribute to the malignant phenotype by suppressing critical apoptosis-related genes.
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioblastoma	22891879				D005909		HP:0100843	Plasma MicroRNA-21 in glioblastoma was significantly higher than controls (p = .02) and decreased significantly in 9 patients (p = .05). One patient with increasing microRNA-21 developed a histopathologically proven recurrence after the second sample collection.
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioblastoma	27047250				D005909		HP:0100843	we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas
circulation_biomarker_diagnosis_up	hsa-mir-15b	Glioma	27047250	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas
circulation_biomarker_diagnosis_up	hsa-mir-16	Glioma	27047250	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas
circulation_biomarker_diagnosis_up	hsa-mir-182	Glioma	26978735	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our findings showed that the level of circulating miR-182 in glioma patients was higher than that in healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioma	27047250	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	we identified significantly increased levels of two candidate biomarkers, miR-15b and miR-21, in blood of patients affected by gliomas
circulation_biomarker_diagnosis_up	hsa-mir-21	Glioma	27166186	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	CSF-based miR-21 might serve as a potential biomarker for  diagnosing brain cancer
circulation_biomarker_diagnosis_up	hsa-mir-146a	Glomerulonephritis	21694443	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	The expression levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy were elevated.
circulation_biomarker_diagnosis_up	hsa-mir-155	Glomerulonephritis	21694443	urinary system disease	DOID:2921	N05	D005921	305800	HP:0000099	The expression levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy were elevated.
circulation_biomarker_diagnosis_up	hsa-mir-199a	Graft-Versus-Host Disease	27342518			D89.813	D006086	614395		The expression of miR-423, miR-199a-3p, miR-93* are upregulated in aGVHD group, which can be used as biomarkes to monitor and to diagnose aGVHD.
circulation_biomarker_diagnosis_up	hsa-mir-423	Graft-Versus-Host Disease	27342518			D89.813	D006086	614395		The expression of miR-423, miR-199a-3p, miR-93* are upregulated in aGVHD group, which can be used as biomarkes to monitor and to diagnose aGVHD.
circulation_biomarker_diagnosis_up	hsa-mir-93	Graft-Versus-Host Disease	27342518			D89.813	D006086	614395		The expression of miR-423, miR-199a-3p, miR-93* are upregulated in aGVHD group, which can be used as biomarkes to monitor and to diagnose aGVHD.
circulation_biomarker_diagnosis_up	hsa-mir-22	Graves Disease	24533739	immune system disease	DOID:12361	E05.00	D006111	275000	HP:0100647	Further analysis consistently showed that serum levels of miR-22, miR-375 and miR-451 were increased in patients with HT. On the other hand, the serum levels of miR-16, miR-22, miR-375 and miR-451 were increased in patients with GD compared with healthy subjects.
circulation_biomarker_diagnosis_up	hsa-mir-16	Hearing Loss	28224282			H91.93	D034381			The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-mir-185	Hearing Loss	28224282			H91.93	D034381			The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-mir-24	Hearing Loss	28224282			H91.93	D034381			The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-mir-451a	Hearing Loss	28224282			H91.93	D034381			The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-mir-106b	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-155	Heart Failure	28319523			I50	D006331		HP:0001635	Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support.
circulation_biomarker_diagnosis_up	hsa-mir-16	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-182	Heart Failure	25643195			I50	D006331		HP:0001635	Microarray profiling revealed an increase in the expression of miR-21, miR-650, miR-744, miR-516-5p, miR-1292, miR-182, miR-1228, miR-595, miR-663b, miR-1296, miR-1825, miR-299-3p, miR-662 miR-122, miR-3148 and miR-518e and a decrease in the expression of miR-129-3p, miR-3155, miR-3175, miR-583, miR-568, miR-30d, miR-200a-star, miR-1979, miR-371-3p, miR-155-star and miR-502-5p in sera of CHF patients.
circulation_biomarker_diagnosis_up	hsa-mir-192	Heart Failure	23743335			I50	D006331		HP:0001635	Among the 377 examined microRNAs, the serum level of only miR-192 was significantly upregulated in AMI patients with development of ischemic HF
circulation_biomarker_diagnosis_up	hsa-mir-195	Heart Failure	25364765			I50	D006331		HP:0001635	Circulating miR-195 is elevated in acute myocardial infarction, breast cancer, prostate cancer and colorectal adenoma.
circulation_biomarker_diagnosis_up	hsa-mir-208a	Heart Failure	17379774			I50	D006331		HP:0001635	upregulation
circulation_biomarker_diagnosis_up	hsa-mir-208a	Heart Failure	29559958			I50	D006331		HP:0001635	miR-208a, a microRNA that is a key factor in promoting cardiovascular dysfunction during cardiac hypertrophy processes of heart failure, has its circulating levels increased during chronic indeterminate  phase when compared to cardiac (CARD) clinical forms in patients with Chagas disease
circulation_biomarker_diagnosis_up	hsa-mir-20b	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-22	Heart Failure	22120965			I50	D006331		HP:0001635	significantly increased serum level
circulation_biomarker_diagnosis_up	hsa-mir-223	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-299	Heart Failure	25643195			I50	D006331		HP:0001635	Microarray profiling revealed an increase in the expression of miR-21, miR-650, miR-744, miR-516-5p, miR-1292, miR-182, miR-1228, miR-595, miR-663b, miR-1296, miR-1825, miR-299-3p, miR-662 miR-122, miR-3148 and miR-518e and a decrease in the expression of miR-129-3p, miR-3155, miR-3175, miR-583, miR-568, miR-30d, miR-200a-star, miR-1979, miR-371-3p, miR-155-star and miR-502-5p in sera of CHF patients.
circulation_biomarker_diagnosis_up	hsa-mir-320a	Heart Failure	22120965			I50	D006331		HP:0001635	significantly increased serum level
circulation_biomarker_diagnosis_up	hsa-mir-423	Heart Failure	20185794			I50	D006331		HP:0001635	MiR423-5p as a circulating biomarker for heart failure
circulation_biomarker_diagnosis_up	hsa-mir-423	Heart Failure	22120965			I50	D006331		HP:0001635	miR-423-5p: significantly increased serum level
circulation_biomarker_diagnosis_up	hsa-mir-423	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-423-5p	Heart Failure	23438607			I50	D006331		HP:0001635	Patients with DCM have elevated plasma miR-423-5p levels. The plasma concentration of miR-423-5p was positively correlated with the level of NT-proBNP. Circulating levels of miR-423-5p could be served as a diagnostic biomarker for heart failure caused by DCM. 
circulation_biomarker_diagnosis_up	hsa-mir-499	Heart Failure	27162785			I50	D006331		HP:0001635	the circulating levels of miRNA-499 was increased in AMI patients.
circulation_biomarker_diagnosis_up	hsa-mir-499a	Heart Failure	20921333			I50	D006331		HP:0001635	miR-499 was significantly elevated
circulation_biomarker_diagnosis_up	hsa-mir-92b	Heart Failure	22120965			I50	D006331		HP:0001635	significantly increased serum level
circulation_biomarker_diagnosis_up	hsa-mir-93	Heart Failure	23388090			I50	D006331		HP:0001635	Quantitative real-time polymerase chain reaction (PCR) analysis for a selected panel of miRNAs indicated that circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and miR-423-5p were significantly increased in response to hypertension-induced heart failure
circulation_biomarker_diagnosis_up	hsa-mir-122	Hepatitis C Virus Infection	21886843	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection.
circulation_biomarker_diagnosis_up	hsa-mir-122	Hepatitis C Virus Infection	26157120	disease by infectious agent	DOID:1883	B19.2	D006526	609532		During acute HCV infection, increases in miR-122 (P < 0.01) and miR-885-5p (Pcorrected < 0.05) and a decrease in miR-494 (Pcorrected <  0.05) were observed at the earliest time points after virus detection.
circulation_biomarker_diagnosis_up	hsa-mir-155	Hepatitis C Virus Infection	29528577	disease by infectious agent	DOID:1883	B19.2	D006526	609532		MicroRNA-155 is a relatively reliable marker for HCC detection
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Hepatitis C Virus Infection	21886843	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection.
circulation_biomarker_diagnosis_up	hsa-mir-16-2	Hepatitis C Virus Infection	21886843	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection.
circulation_biomarker_diagnosis_up	hsa-mir-221	Hepatitis C Virus Infection	25433287	disease by infectious agent	DOID:1883	B19.2	D006526	609532		HCVcc infection could upregulate the expression of miR-221 in NF-κB dependent manner.
circulation_biomarker_diagnosis_up	hsa-mir-34a	Hepatitis C Virus Infection	21886843	disease by infectious agent	DOID:1883	B19.2	D006526	609532		Extracellular levels of circulating miRNAs, miR-122, miR-34a and to a lesser extent miR-16, steadily increased during the course of HCV infection.
circulation_biomarker_diagnosis_up	hsa-mir-155	Human Immunodeficiency Virus Infection	28627655			B20	D015658	609423		Elevated expression of miR-155 is associated with the differentiation of CD8+ T cells in patients with HIV-1.
circulation_biomarker_diagnosis_up	hsa-mir-21	Human Immunodeficiency Virus Infection	28968466			B20	D015658	609423		upregulation of hsa-miR-21 and hsa-miR-222 by Tat may contribute to protect against apoptosis and to anergy observed in HIV-infected CD4+ T cells
circulation_biomarker_diagnosis_up	hsa-mir-222	Human Immunodeficiency Virus Infection	28968466			B20	D015658	609423		upregulation of hsa-miR-21 and hsa-miR-222 by Tat may contribute to protect against apoptosis and to anergy observed in HIV-infected CD4+ T cells
circulation_biomarker_diagnosis_up	hsa-mir-34b	Huntington Disease	21421997	nervous system disease	DOID:12858	G10	D006816	143100		Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.
circulation_biomarker_diagnosis_up	hsa-mir-33a	Hypercholesterolaemia	26229086			E78.3	D006937	143890		Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age.
circulation_biomarker_diagnosis_up	hsa-mir-33b	Hypercholesterolaemia	26229086			E78.3	D006937	143890		Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age.
circulation_biomarker_diagnosis_up	hsa-mir-122	Hyperlipidemia	22587332			E78.4	D006949		HP:0003077	Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-mir-370	Hyperlipidemia	22587332			E78.4	D006949		HP:0003077	Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease.
circulation_biomarker_diagnosis_up	hsa-let-7e	Hypertension	21924071	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-296-5p (Fold change 0.47, P = 0.013) and miR-133b (Fold change 0.57, P = 0.033) were consistently down-regulated in the patient plasma, whereas let-7e (Fold change 1.62, P = 0.009) and hcmv-miR-UL112 (Fold change 2.72, P = 0.004), one human cytomegalovirus encoded microRNAs, were up-regulated in the patient samples.
circulation_biomarker_diagnosis_up	hsa-mir-122	Hypertension	25837765	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	MiR-122 and miR-637 expressions were also significantly upregulated in the WCH group compared with the NT group
circulation_biomarker_diagnosis_up	hsa-mir-132	Hypertension	23712358	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The miR-132 and miR-212 are highly increased in the heart, aortic wall and kidney of rats with hypertension (159 ± 12 mm Hg) and cardiac hypertrophy following chronic AngII infusion.
circulation_biomarker_diagnosis_up	hsa-mir-145	Hypertension	23339529	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients
circulation_biomarker_diagnosis_up	hsa-mir-212	Hypertension	23712358	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The miR-132 and miR-212 are highly increased in the heart, aortic wall and kidney of rats with hypertension (159 ± 12 mm Hg) and cardiac hypertrophy following chronic AngII infusion.
circulation_biomarker_diagnosis_up	hsa-mir-21	Hypertrophy	21303526				D006984			The downregulation of miR-1, miR-133a, and upregulation of miR-21 can be reversed by one single upstream regulator, SRF.
circulation_biomarker_diagnosis_up	hsa-mir-185	Idiopathic Short Stature	24342208			R62.56	C565805	300582		plasma miR-185 expression was significantly up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-132	Inflammation	23264652				D007249			In peptidoglycan (PGN)/TLR2-stimulated THP-1 monocytes, PBMCs, and primary macrophages showed rapid and dramatic miR-132 and miR-212 (miR-132/-212) upregulation.
circulation_biomarker_diagnosis_up	hsa-mir-212	Inflammation	23264652				D007249			In peptidoglycan (PGN)/TLR2-stimulated THP-1 monocytes, PBMCs, and primary macrophages showed rapid and dramatic miR-132 and miR-212 (miR-132/-212) upregulation.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Intrahepatic Cholangiocarcinoma	29095255	disease of cellular proliferation	DOID:4928	C22.1	D018281	615619		Both plasma and tumor tissue miR-146a high expression correlates with prolonged overall survival of surgical patients with intrahepatic cholangiocarcinoma.
circulation_biomarker_diagnosis_up	hsa-mir-16	Ischemia-Reperfusion Injury	27297958				D015427			urinary miR-16 was 100-fold higher in AKI patients.
circulation_biomarker_diagnosis_up	hsa-mir-192	Ischemia-Reperfusion Injury	24553149				D015427			However, miR-10a, miR-192, and miR-194 were significantly increased in plasma of rats with renal ischemia-reperfusion injury, among which miR-10a was elevated within 1 h after reperfusion, whereas miR-192 and miR-194 were elevated at 6 h after injury.
circulation_biomarker_diagnosis_up	hsa-mir-194	Ischemia-Reperfusion Injury	24553149				D015427			However, miR-10a, miR-192, and miR-194 were significantly increased in plasma of rats with renal ischemia-reperfusion injury, among which miR-10a was elevated within 1 h after reperfusion, whereas miR-192 and miR-194 were elevated at 6 h after injury.
circulation_biomarker_diagnosis_up	hsa-mir-210	Ischemic Diseases [unspecific]	21360638				D007511	601367		High levels of miR-210 have been linked to an in vivo hypoxic signature and associated with adverse prognosis in cancer patients. A wide spectrum of miR-210 targets have been identified, with roles in mitochondrial metabolism, angiogenesis, DNA repair, and cell survival.
circulation_biomarker_diagnosis_up	hsa-mir-200c	Kawasaki Syndrome	24259014	immune system disease	DOID:13378	M30.3	D009080	611775		Elevated serum level of microRNA (miRNA)-200c and miRNA-371-5p in children with Kawasaki disease.
circulation_biomarker_diagnosis_up	hsa-mir-371	Kawasaki Syndrome	24259014	immune system disease	DOID:13378	M30.3	D009080	611775		Elevated serum level of microRNA (miRNA)-200c and miRNA-371-5p in children with Kawasaki disease.
circulation_biomarker_diagnosis_up	hsa-mir-142	Kideny Transplant Rejection	28380212			T86.11	D006084			Upregulation of microRNA 142-3p in the peripheral blood and urinary cells of kidney transplant recipients with post-transplant graft dysfunction.
circulation_biomarker_diagnosis_up	hsa-mir-21	Kideny Transplant Rejection	27521993			T86.11	D006084			our findings indicated that the aberrant urinary miR-21 and miR-200b expression levels were accompanied with renal allograft dysfunction and IFTA.
circulation_biomarker_diagnosis_up	hsa-mir-126	Kidney Diseases [unspecific]	23070235			N18.9	D007674			Circulating levels of inflammation-associated miR-155 and endothelial-enriched miR-126 in patients with end-stage renal disease
circulation_biomarker_diagnosis_up	hsa-mir-204	Kidney Injury	24641951			S37.0	D058186			Our findings indicate that miR-204/miR-211 downregulation accounts at least partially for the Hmx1 upregulation and the miR-204/miR-211-Hmx1 signaling axis may contribute to immune-suppression in the host thereby the Candidemia-induced kidney dysfunction.
circulation_biomarker_diagnosis_up	hsa-mir-211	Kidney Injury	24641951			S37.0	D058186			Our findings indicate that miR-204/miR-211 downregulation accounts at least partially for the Hmx1 upregulation and the miR-204/miR-211-Hmx1 signaling axis may contribute to immune-suppression in the host thereby the Candidemia-induced kidney dysfunction.
circulation_biomarker_diagnosis_up	hsa-mir-125a	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-125a: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia	27619068			C95	D007938	613065	HP:0001909	MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.
circulation_biomarker_diagnosis_up	hsa-mir-196b	Leukemia	18923441			C95	D007938	613065	HP:0001909	the expression of miR-196b was 500-fold higher in MLL-rearranged and 800-fold higher in 5 of 15 T-ALL cases as compared with the expression level in the remaining precursor B-ALL cases (P<0.001).
circulation_biomarker_diagnosis_up	hsa-mir-339	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-339: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_up	hsa-mir-660	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-660: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_up	hsa-mir-663a	Leukemia	19022373			C95	D007938	613065	HP:0001909	miR-663: upregulated during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal
circulation_biomarker_diagnosis_up	hsa-mir-126	Leukemia, B-Cell	27300437			C91.31	D015448	151430		miRNA-126 is highly expressed in a subset of human B-ALL
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, B-Cell	16466964			C91.31	D015448	151430		overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, B-Cell	17940623			C91.31	D015448	151430		miR-155 is encoded by nucleotides 241-262 of BIC, which was originally identified as a transcript derived from an integration site for the avian leucosis virus and found to be overexpressed in B-cell lymphomas. The role of miR-155 is not restricted to B cell lymphomas, however. Recent studies have reported that miR-155 is upregulated in breast, lung, colon, and thyroid cancers.
circulation_biomarker_diagnosis_up	hsa-mir-17	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-17	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-18a	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-18a	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-19a	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-19a	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-20a	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-20a	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Leukemia, B-Cell	16224045			C91.31	D015448	151430		Overexpression
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Leukemia, B-Cell	16736018			C91.31	D015448	151430		upregulation of miR-155 and the miR-17-92 cluster
circulation_biomarker_diagnosis_up	hsa-mir-125b	Leukemia, Lymphoblastic	22335948	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		These three subtypes of leukemia could be identified by unsupervised hierarchical cluster analysis of microRNA expression and had specific up-regulation of miR-335, miR-126 and miR-125b, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-126	Leukemia, Lymphoblastic	22335948	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		These three subtypes of leukemia could be identified by unsupervised hierarchical cluster analysis of microRNA expression and had specific up-regulation of miR-335, miR-126 and miR-125b, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-128a	Leukemia, Lymphoblastic	18056805	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML.
circulation_biomarker_diagnosis_up	hsa-mir-128b	Leukemia, Lymphoblastic	18056805	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML.
circulation_biomarker_diagnosis_up	hsa-mir-181c	Leukemia, Lymphoblastic	27535859	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL.
circulation_biomarker_diagnosis_up	hsa-mir-335	Leukemia, Lymphoblastic	22335948	disease of cellular proliferation	DOID:1037	C91.0	D007945	613065		These three subtypes of leukemia could be identified by unsupervised hierarchical cluster analysis of microRNA expression and had specific up-regulation of miR-335, miR-126 and miR-125b, respectively.
circulation_biomarker_diagnosis_up	hsa-mir-128b	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-15a	Leukemia, Lymphoblastic, Acute	26434860	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The results of our study indicate that resveratrol induces apoptosis in a time and dose-dependent manner in CCRF-CEM cells. Also, increased expression level of miR 16-1 and miR 15a by means of resveratrol in CCRF-CEM
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Leukemia, Lymphoblastic, Acute	26434860	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The results of our study indicate that resveratrol induces apoptosis in a time and dose- dependent manner in CCRF-CEM cells. Also, increased expression level of miR 16-1 and miR 15a by means of resveratrol in CCRF-CEM
circulation_biomarker_diagnosis_up	hsa-mir-17	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-18	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-181b-1	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-19a	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-204	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-20a	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-218	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-29b	Leukemia, Lymphoblastic, Acute	22456238	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	BCR-ABL1 positive cases, in contrast to negative ones, were characterized by slightly, but still significantly, higher expression levels of miR-29b.
circulation_biomarker_diagnosis_up	hsa-mir-331	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-92-1	Leukemia, Lymphoblastic, Acute	17934639	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	The miR-17-92 cluster was also found to be up-regulated in ALL, as previously reported for some types of lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-146b	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-148a	Leukemia, Lymphocytic, Chronic, B-Cell	20504344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-148a:miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	upregulation
circulation_biomarker_diagnosis_up	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-181a-2	Leukemia, Lymphocytic, Chronic, B-Cell	19717645	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	high expression
circulation_biomarker_diagnosis_up	hsa-mir-195	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-21	Leukemia, Lymphocytic, Chronic, B-Cell	20393129	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival
circulation_biomarker_diagnosis_up	hsa-mir-21	Leukemia, Lymphocytic, Chronic, B-Cell	20504344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-21:miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients
circulation_biomarker_diagnosis_up	hsa-mir-221	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-222	Leukemia, Lymphocytic, Chronic, B-Cell	20504344	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-222:miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients
circulation_biomarker_diagnosis_up	hsa-mir-23b	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-24-1	Leukemia, Lymphocytic, Chronic, B-Cell	16251535	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-342	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-342-3p upregulation
circulation_biomarker_diagnosis_up	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	21408091	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	upregulation
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	28407516	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression.
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_up	hsa-mir-195	Leukemia, Lymphocytic, Chronic, B-Cell	17934639	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-21	Leukemia, Lymphocytic, Chronic, B-Cell	17327404	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases
circulation_biomarker_diagnosis_up	hsa-mir-29a	Leukemia, Lymphocytic, Chronic, B-Cell	17934639	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-29c	Leukemia, Lymphocytic, Chronic, B-Cell	17934639	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-331	Leukemia, Lymphocytic, Chronic, B-Cell	17934639	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-34a	Leukemia, Lymphocytic, Chronic, B-Cell	17934639	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	The five most highly expressed miRNAs were miR-128b, miR-204, miR-218, miR-331, and miR-181b-1 in ALL, and miR-331, miR-29a, miR-195, miR-34a, and miR-29c in CLL.
circulation_biomarker_diagnosis_up	hsa-mir-92a	Leukemia, Lymphocytic, Chronic, B-Cell	28407516	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression.
circulation_biomarker_diagnosis_up	hsa-mir-125b-1	Leukemia, Myeloid	20660734	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-125b:Overexpression of the most advantageous miRNA, miR-125b, caused a dose-dependent myeloproliferative disorder that progressed to a lethal myeloid leukemia in mice
circulation_biomarker_diagnosis_up	hsa-mir-125b-2	Leukemia, Myeloid	20660734	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-125b:Overexpression of the most advantageous miRNA, miR-125b, caused a dose-dependent myeloproliferative disorder that progressed to a lethal myeloid leukemia in mice
circulation_biomarker_diagnosis_up	hsa-mir-17	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-17: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-18a	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-18a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19a	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-19a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-19b: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19b-2	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-19b: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-20a	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-20a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-92a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Leukemia, Myeloid	19155294	disease of cellular proliferation	DOID:8692	C92	D007951		HP:0012324	miR-92a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-10a	Leukemia, Myeloid, Acute	25687041	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The high expression of miR-10a may be closely related to over-proliferation of promyelocyte and drug resistance of acute myeloid leukemia cells, except M3.
circulation_biomarker_diagnosis_up	hsa-mir-10a	Leukemia, Myeloid, Acute	21784052	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation  in intermediate-risk acute myeloid leukemia.
circulation_biomarker_diagnosis_up	hsa-mir-196a-1	Leukemia, Myeloid, Acute	21818844	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements, NPM1 mutations, or FLT3-ITD in a cytogenetically normal background, compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b. Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes.
circulation_biomarker_diagnosis_up	hsa-mir-196a-2	Leukemia, Myeloid, Acute	21818844	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements, NPM1 mutations, or FLT3-ITD in a cytogenetically normal background, compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b. Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes.
circulation_biomarker_diagnosis_up	hsa-mir-196b	Leukemia, Myeloid, Acute	21818844	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements, NPM1 mutations, or FLT3-ITD in a cytogenetically normal background, compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b. Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes.
circulation_biomarker_diagnosis_up	hsa-mir-196b	Leukemia, Myeloid, Acute	26744876	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The expression level of miR-155 was significantly higher in AML patients than in controls.
circulation_biomarker_diagnosis_up	hsa-mir-196b	Leukemia, Myeloid, Acute	28507466	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome.
circulation_biomarker_diagnosis_up	hsa-mir-19b	Leukemia, Myeloid, Acute	29032147	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
circulation_biomarker_diagnosis_up	hsa-mir-210	Leukemia, Myeloid, Acute	26549593	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MiR-210 up-regulation was associated with poor prognosis in AML and it might be useful as a marker for predicting the clinical outcome of AML patients.
circulation_biomarker_diagnosis_up	hsa-mir-221	Leukemia, Myeloid, Acute	23895238	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Overexpression of primary microRNA 221/222 in acute myeloid leukemia.
circulation_biomarker_diagnosis_up	hsa-mir-222	Leukemia, Myeloid, Acute	23895238	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Overexpression of primary microRNA 221/222 in acute myeloid leukemia.
circulation_biomarker_diagnosis_up	hsa-mir-140	Leukemia, Myeloid, Chronic	28197964	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors.
circulation_biomarker_diagnosis_up	hsa-mir-18a	Leukemia, Myeloid, Chronic	26458312	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	up-regulated expression of oncogenic miRNAs (miR-17, miR-18a, miR-20a, miR-21, miR-27a and miR-155)
circulation_biomarker_diagnosis_up	hsa-let-7a-3	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-let-7c	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-let-7d	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-107	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-15a	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-15b	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-223	Leukemia, Promyelocytic, Acute	22053279	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-223	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-342	Leukemia, Promyelocytic, Acute	17260024	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation.
circulation_biomarker_diagnosis_up	hsa-mir-155	Leukemia-Lymphoma, Adult T-Cell	22884882			C91.51	D015459		HP:0005517	The high and low plasma levels of miR-155 and miR-126 changed with ATL stage.
circulation_biomarker_diagnosis_up	hsa-mir-125b	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	28415578	disease of cellular proliferation	DOID:7061	C83.5	D015452			High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia.
circulation_biomarker_diagnosis_up	hsa-mir-142	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	19206004	disease of cellular proliferation	DOID:7061	C83.5	D015452			miR-142-3p: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-222	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	19206004	disease of cellular proliferation	DOID:7061	C83.5	D015452			miR-222: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-339	Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic	19206004	disease of cellular proliferation	DOID:7061	C83.5	D015452			miR-339: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-100	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21242186	disease of cellular proliferation	DOID:5599	C83.5	D054218			aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002).
circulation_biomarker_diagnosis_up	hsa-mir-100	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22099053	disease of cellular proliferation	DOID:5599	C83.5	D054218			A significant association was observed between higher expression levels of miR-196b and T-ALL, miR-100 and patients with low white blood cell count at diagnosis and t(12;21) positive ALL.
circulation_biomarker_diagnosis_up	hsa-mir-125b-1	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21242186	disease of cellular proliferation	DOID:5599	C83.5	D054218			aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002).
circulation_biomarker_diagnosis_up	hsa-mir-125b-2	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21242186	disease of cellular proliferation	DOID:5599	C83.5	D054218			aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002).
circulation_biomarker_diagnosis_up	hsa-mir-196b	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	22099053	disease of cellular proliferation	DOID:5599	C83.5	D054218			A significant association was observed between higher expression levels of miR-196b and T-ALL, miR-100 and patients with low white blood cell count at diagnosis and t(12;21) positive ALL.
circulation_biomarker_diagnosis_up	hsa-mir-223	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	20418243	disease of cellular proliferation	DOID:5599	C83.5	D054218			miR-223:over-expression of miR-223
circulation_biomarker_diagnosis_up	hsa-mir-99a	Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic	21242186	disease of cellular proliferation	DOID:5599	C83.5	D054218			aberrant downregulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to upregulation of oncoprotein c-Myc (P<0.0001). Resistance to vincristine and daunorubicin was characterized by ~20-fold upregulation of miR-125b, miR-99a and miR-100 (P<0.002).
circulation_biomarker_diagnosis_up	hsa-mir-29a	Liver Cirrhosis	21946200	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis.
circulation_biomarker_diagnosis_up	hsa-mir-29b-1	Liver Cirrhosis	21946200	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis.
circulation_biomarker_diagnosis_up	hsa-mir-29b-2	Liver Cirrhosis	21946200	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis.
circulation_biomarker_diagnosis_up	hsa-mir-29c	Liver Cirrhosis	21946200	endocrine system disease	DOID:5082	K74	D008103	215600	HP:0001394	MiR-29 directly suppresses the expression of a variety of extracellular matrix components and regulates signaling pathways associated with fibrosis. The serum level of miR-29 in patients with liver disease is consistent with the degree of liver cirrhosis.
circulation_biomarker_diagnosis_up	hsa-mir-212	Liver Diseases [unspecific]	18162065			K76.9	D008107			increased
circulation_biomarker_diagnosis_up	hsa-mir-192	Liver Injury	22045675			S36.11	D056486			Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients.
circulation_biomarker_diagnosis_up	hsa-mir-122	Liver Neoplasms	21154767	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	in serum, miR-21, miR-122, and miR-223 were significantly higher in patients with HCC than those in healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-223	Liver Neoplasms	21154767	disease of cellular proliferation	DOID:916	C22.0	D008113		HP:0002896	in serum, miR-21, miR-122, and miR-223 were significantly higher in patients with HCC than those in healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-128-2	Lung Neoplasms	18304967	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	increased
circulation_biomarker_diagnosis_up	hsa-mir-132	Lung Neoplasms	17447837	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-155	Lung Neoplasms	21904633	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001).
circulation_biomarker_diagnosis_up	hsa-mir-155	Lung Neoplasms	26867772	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Two miRNAs, miR-21 and miR-155, were found to be significantly upregulated in recurrent tumors compared  to primary tumors.
circulation_biomarker_diagnosis_up	hsa-mir-17	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-17	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-17	Lung Neoplasms	17442096	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The mir-17 cluster is also overexpressed in human lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-182	Lung Neoplasms	21904633	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001).
circulation_biomarker_diagnosis_up	hsa-mir-18a	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-18a	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-197	Lung Neoplasms	21904633	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001).
circulation_biomarker_diagnosis_up	hsa-mir-19a	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19a	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-20a	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-20a	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-21	Lung Neoplasms	26867772	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Two miRNAs, miR-21 and miR-155, were found to be significantly upregulated in recurrent tumors compared  to primary tumors.
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Lung Neoplasms	16266980	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Overexpressed in lung cancers
circulation_biomarker_diagnosis_up	hsa-mir-125a	Lupus Nephritis	27215082	urinary system disease	DOID:0080162	M32.14	D008181			Elevated Serum Inflammatory Cytokines in Lupus Nephritis Patients, in Association with Promoted hsa-miR-125a.
circulation_biomarker_diagnosis_up	hsa-let-7a-1	Lupus Vulgaris	18998140			A18.4	D008177			let-7a: upregulation
circulation_biomarker_diagnosis_up	hsa-let-7a-2	Lupus Vulgaris	18998140			A18.4	D008177			let-7a: upregulation
circulation_biomarker_diagnosis_up	hsa-let-7a-3	Lupus Vulgaris	18998140			A18.4	D008177			let-7a: upregulation
circulation_biomarker_diagnosis_up	hsa-let-7e	Lupus Vulgaris	18998140			A18.4	D008177			let-7e: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-130b	Lupus Vulgaris	18998140			A18.4	D008177			miR-130b: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-134	Lupus Vulgaris	18998140			A18.4	D008177			miR-134: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-142	Lupus Vulgaris	18998140			A18.4	D008177			miR-142-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-184	Lupus Vulgaris	18998140			A18.4	D008177			miR-184: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-185	Lupus Vulgaris	18998140			A18.4	D008177			miR-185: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-195	Lupus Vulgaris	18998140			A18.4	D008177			miR-195: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-197	Lupus Vulgaris	18998140			A18.4	D008177			miR-197: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-198	Lupus Vulgaris	18998140			A18.4	D008177			miR-198: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-200c	Lupus Vulgaris	18998140			A18.4	D008177			miR-200c: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-208b	Lupus Vulgaris	18998140			A18.4	D008177			miR-208: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-23a	Lupus Vulgaris	18998140			A18.4	D008177			miR-23a: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-30a	Lupus Vulgaris	18998140			A18.4	D008177			miR-30a-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-433	Lupus Vulgaris	18998140			A18.4	D008177			miR-433: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-494	Lupus Vulgaris	18998140			A18.4	D008177			miR-494: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-516a-1	Lupus Vulgaris	18998140			A18.4	D008177			miR-516-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-516a-2	Lupus Vulgaris	18998140			A18.4	D008177			miR-516-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-516b-1	Lupus Vulgaris	18998140			A18.4	D008177			miR-516-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-516b-2	Lupus Vulgaris	18998140			A18.4	D008177			miR-516-5p: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-518c	Lupus Vulgaris	18998140			A18.4	D008177			miR-518c*: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-575	Lupus Vulgaris	18998140			A18.4	D008177			miR-575: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-583	Lupus Vulgaris	18998140			A18.4	D008177			miR-583: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-600	Lupus Vulgaris	18998140			A18.4	D008177			miR-600: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-601	Lupus Vulgaris	18998140			A18.4	D008177			miR-601: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-608	Lupus Vulgaris	18998140			A18.4	D008177			miR-608: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-612	Lupus Vulgaris	18998140			A18.4	D008177			miR-612: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-622	Lupus Vulgaris	18998140			A18.4	D008177			miR-622: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-638	Lupus Vulgaris	18998140			A18.4	D008177			miR-638: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-657	Lupus Vulgaris	18998140			A18.4	D008177			miR-657: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-658	Lupus Vulgaris	18998140			A18.4	D008177			miR-658: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-662	Lupus Vulgaris	18998140			A18.4	D008177			miR-662: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-150	Lymphoma	18348159	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Three of 15 miRNAs (miR-16, miR-21, and miR-150) showed a high expression level in both blood and lymph node samples. 
circulation_biomarker_diagnosis_up	hsa-mir-16	Lymphoma	18348159	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Three of 15 miRNAs (miR-16, miR-21, and miR-150) showed a high expression level in both blood and lymph node samples. 
circulation_biomarker_diagnosis_up	hsa-mir-17	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-18a	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-19a	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-20a	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-21	Lymphoma	18348159	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Three of 15 miRNAs (miR-16, miR-21, and miR-150) showed a high expression level in both blood and lymph node samples. 
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Lymphoma	16885332	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Primary transcripts overexpressed in lymphomas
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, B-Cell	15738415	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-181a	Lymphoma, B-Cell	27535859	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	The expression of hsa-miR-29a , hsa-miR-126 and has-miR-181 family were significantly different in B-ALL.
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Burkitt	14695998	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Burkitt	16195701	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	overexpression
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Burkitt	16466964	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Burkitt	16940181	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	Increased expression of the precursor of Mir-155has been detected in pediatric Burkitt lymphoma.
circulation_biomarker_diagnosis_up	hsa-let-7a-1	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	let-7a: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-let-7a-2	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	let-7a: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-let-7a-3	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	let-7a: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Hodgkin	16466964	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-155: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-16: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-16-2	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-16: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-17	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-17: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-18a	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-18a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19a	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-19a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-19b: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19b-2	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-19b: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-20a	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-20a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-21	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-21: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-24-1	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-24: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-24-2	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-24: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-9-1	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-9: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-mir-9-2	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-9: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-92a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Lymphoma, Hodgkin	19177201	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-92a: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-9-3	Lymphoma, Hodgkin	18583325	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	miR-9: overexpressed, down-regulation of PRDM1/Blimp-1
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Large B-Cell, Diffuse	17487835	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		DLBCL cases over-expressed miR-21, miR-155 and miR-221 by an average of 9.3, 4.6 and 2.3-fold respectively compared to normal peripheral blood B cells.
circulation_biomarker_diagnosis_up	hsa-mir-21	Lymphoma, Large B-Cell, Diffuse	17487835	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		DLBCL cases over-expressed miR-21, miR-155 and miR-221 by an average of 9.3, 4.6 and 2.3-fold respectively compared to normal peripheral blood B cells.
circulation_biomarker_diagnosis_up	hsa-mir-221	Lymphoma, Large B-Cell, Diffuse	17487835	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		DLBCL cases over-expressed miR-21, miR-155 and miR-221 by an average of 9.3, 4.6 and 2.3-fold respectively compared to normal peripheral blood B cells.
circulation_biomarker_diagnosis_up	hsa-mir-155	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-155:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-17	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-17:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-18a	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-18a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-19a	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-19a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-19b:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-19b-2	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-19b:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-20a	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-20a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-92a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Lymphoma, Large-Cell, Anaplastic	20805506	disease of cellular proliferation	DOID:0050744	C84.70	D017728	105590	HP:0012193	miR-92a:Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL
circulation_biomarker_diagnosis_up	hsa-mir-21	Lymphoma, Non-Hodgkin	22487708	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	B-cell activation induced microRNA-21 is elevated in circulating B cells preceding the diagnosis of AIDS-related non-Hodgkin lymphomas.
circulation_biomarker_diagnosis_up	hsa-mir-92a	Lymphoma, Non-Hodgkin	25236768	disease of cellular proliferation	DOID:0060060	C85.9	D008228	605027	HP:0012539	MiR-92a was decreased exclusively in HBV-/HCV- B-NHLs, while miR-30b was increased in HBV+ and HCV+ samples, though only the HCV+ achieved full statistical significance.
circulation_biomarker_diagnosis_up	hsa-mir-148a	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-182	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-183	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-193a	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-193b	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-224	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-452	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-mir-96	Medulloblastoma	21358093	disease of cellular proliferation	DOID:0050902	C71.6	D008527	155255	HP:0002885	A number of miRNAs like miR-193a, miR-224/miR-452 cluster, miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive activity were found to be overexpressed in the WNT signaling associated medulloblastomas.
circulation_biomarker_diagnosis_up	hsa-let-7d	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	let-7d:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-1249	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-1249:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-125a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-125a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-1280	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-1280:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-142	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-142-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-145	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-145:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-146a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-146a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-146a	Melanoma	27895580	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Increased Levels of miRNA-146a in Serum and Histologic Samples of Patients with Uveal Melanoma.
circulation_biomarker_diagnosis_up	hsa-mir-151a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-151-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-181a-2	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-181a-2*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-183	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-183*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-186	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-186:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-18a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-18a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-199a-1	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-199a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-199a-2	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-199a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-22	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-22*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-221	Melanoma	21273047	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Malignant melanoma patients had significantly higher miR-221 levels than healthy controls in serum.
circulation_biomarker_diagnosis_up	hsa-mir-30a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-30a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-30e	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-30e*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-328	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-328:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-342	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-342-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-361	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-361-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-362	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-362-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-365a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-365:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-365b	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-365:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-378a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-378*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-422a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-422a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-501	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-501-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-550a-1	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-550*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-550a-2	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-550*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-584	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-584:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-625	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-625:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-664	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-664:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-99a	Melanoma	20529253	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	miR-99a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients
circulation_biomarker_diagnosis_up	hsa-mir-103a-1	Mesothelioma	22253921	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR-103 was identified as a potential biomarker for malignant mesothelioma
circulation_biomarker_diagnosis_up	hsa-mir-103a-2	Mesothelioma	22253921	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	miR-103 was identified as a potential biomarker for malignant mesothelioma
circulation_biomarker_diagnosis_up	hsa-mir-625	Mesothelioma	22617246	disease of cellular proliferation	DOID:1790	C45.9	C562839	156240	HP:0100001	Increased circulating miR-625-3p is a potential biomarker for patients with malignant pleural mesothelioma.
circulation_biomarker_diagnosis_up	hsa-mir-132	Mild Cognitive Impairment	25589731			G31.84	D060825	614306		circulating miR-206 and miR-132 as novel miRNAs upregulated in MCI patient were potential biomarkers for diagnosis of MCI.
circulation_biomarker_diagnosis_up	hsa-mir-206	Mild Cognitive Impairment	25589731			G31.84	D060825	614306		circulating miR-206 and miR-132 as novel miRNAs upregulated in MCI patient were potential biomarkers for diagnosis of MCI.
circulation_biomarker_diagnosis_up	hsa-mir-451	Mountain Sickness	25948209			T70.29	D000532	616182		There is a certain level of microRNA-451 in healthy people, the expression of microRNA-451 in CMS patients is significantly higher than that in healthy people. MicroRNA-451 may play an important role in the process of chronic mountain sickness.
circulation_biomarker_diagnosis_up	hsa-mir-130a	Moyamoya Disease	25093848	cardiovascular system disease	DOID:13099	I67.5	D009072	PS252350	HP:0011834	In  an independent MMD cohort, real-time PCR confirmed that miR-106b, miR-130a and miR-126 were significantly upregulated while miR-125a-3p was significantly downregulated in serum.
circulation_biomarker_diagnosis_up	hsa-mir-148a	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.High levels of miR-20a and miR-148a were related to shorter relapse-free survival.
circulation_biomarker_diagnosis_up	hsa-mir-181a-1	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.
circulation_biomarker_diagnosis_up	hsa-mir-181a-2	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.
circulation_biomarker_diagnosis_up	hsa-mir-202	Multiple Myeloma	24048721	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	The relative expression of serum miR-202 in MM patients was significantly higher than that in healthy controls, and therefore it may prove to be useful in the auxiliary diagnosis of MM.
circulation_biomarker_diagnosis_up	hsa-mir-20a	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.
circulation_biomarker_diagnosis_up	hsa-mir-21	Multiple Myeloma	26909911	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	We found that the expression level of serum mir-21  in the MM group was significantly higher than the MGUS group and the NC group
circulation_biomarker_diagnosis_up	hsa-mir-221	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.High levels of miR-20a and miR-148a were related to shorter relapse-free survival.
circulation_biomarker_diagnosis_up	hsa-mir-4449	Multiple Myeloma	27155004	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	The expression levels of serum miR-4449 in MM patients were significantly higher than in healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-625	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.
circulation_biomarker_diagnosis_up	hsa-mir-99b	Multiple Myeloma	22447484	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Plasma level was significantly upregulated in MM.
circulation_biomarker_diagnosis_up	hsa-mir-126	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-146a	Multiple Sclerosis	21875645	nervous system disease	DOID:2377	G35	D009103	PS126200		In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Multiple Sclerosis	21875645	nervous system disease	DOID:2377	G35	D009103	PS126200		In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-155	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-196a	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-21	Multiple Sclerosis	21875645	nervous system disease	DOID:2377	G35	D009103	PS126200		In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls.
circulation_biomarker_diagnosis_up	hsa-mir-21	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-22	Multiple Sclerosis	22231906	nervous system disease	DOID:2377	G35	D009103	PS126200		Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals.
circulation_biomarker_diagnosis_up	hsa-mir-223	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-326	Multiple Sclerosis	21151203	nervous system disease	DOID:2377	G35	D009103	PS126200		The expression of miRNA-326 in blood cells has been reported to increase during relapses.
circulation_biomarker_diagnosis_up	hsa-mir-326	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-379	Multiple Sclerosis	29325906	nervous system disease	DOID:2377	G35	D009103	PS126200		The upregulation of miR-126-3p, miR-146b-5p, miR-155, miR-196a-5p, miR-21-5p, miR-223-3p, miR-326 and miR-379-5p in remission compared to relapse was observed
circulation_biomarker_diagnosis_up	hsa-mir-422a	Multiple Sclerosis	22231906	nervous system disease	DOID:2377	G35	D009103	PS126200		Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals.
circulation_biomarker_diagnosis_up	hsa-mir-572	Multiple Sclerosis	22231906	nervous system disease	DOID:2377	G35	D009103	PS126200		Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals.
circulation_biomarker_diagnosis_up	hsa-mir-614	Multiple Sclerosis	22231906	nervous system disease	DOID:2377	G35	D009103	PS126200		Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals.
circulation_biomarker_diagnosis_up	hsa-mir-648	Multiple Sclerosis	22231906	nervous system disease	DOID:2377	G35	D009103	PS126200		Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals.
circulation_biomarker_diagnosis_up	hsa-mir-206	Muscular Dystrophy	18827405			G71.0	D009136	310200	HP:0003560	miR-206: miR-206 high expression for muscle regeneration and maturation
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Muscular Dystrophy, Duchenne	21479190	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Muscular Dystrophy, Duchenne	21479190	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased
circulation_biomarker_diagnosis_up	hsa-mir-133a-1	Muscular Dystrophy, Duchenne	21479190	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased
circulation_biomarker_diagnosis_up	hsa-mir-133a-2	Muscular Dystrophy, Duchenne	21479190	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased
circulation_biomarker_diagnosis_up	hsa-mir-206	Muscular Dystrophy, Duchenne	21479190	musculoskeletal system disease	DOID:11723	G71.0	D020388	310200		the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased
circulation_biomarker_diagnosis_up	hsa-let-7	Myasthenia Gravis	26943954	musculoskeletal system disease	DOID:437	G70.0	D009157	254200		Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.
circulation_biomarker_diagnosis_up	hsa-mir-21	Myelodysplastic Syndromes	21649547	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-720	Myelodysplastic Syndromes	21649547	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-1	Myocardial Infarction	25225581	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	the expression of plasma miR-1 was significantly increased in the AMI patients compared with the healthy controls
circulation_biomarker_diagnosis_up	hsa-mir-1	Myocardial Infarction	29150941	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	significantly elevated levels of miRNA-1 in post-MI old heart could be predictive of cardiac injury in older mice as the high risk biomarker for MI in older individuals
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Myocardial Infarction	19245789	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1: Upregulated expression in a rat model
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Myocardial Infarction	21642241	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage.
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Myocardial Infarction	22719221	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased miR-1 and decreased miR-126 in plasma from patients with AMI after the onset of symptoms compared with healthy subjects were found.
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Myocardial Infarction	19245789	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-1: Upregulated expression in a rat model
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Myocardial Infarction	21642241	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage.
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Myocardial Infarction	22719221	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased miR-1 and decreased miR-126 in plasma from patients with AMI after the onset of symptoms compared with healthy subjects were found.
circulation_biomarker_diagnosis_up	hsa-mir-125b	Myocardial Infarction	27176713	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-125b-5p and miR-30d-5p presented a diagnostic value for early diagnosis of AMI, and miR鈥?0d鈥?p may have a higher diagnostic value than cTnI.
circulation_biomarker_diagnosis_up	hsa-mir-133a-1	Myocardial Infarction	21642241	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage.
circulation_biomarker_diagnosis_up	hsa-mir-133a-1	Myocardial Infarction	21881276	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples.
circulation_biomarker_diagnosis_up	hsa-mir-133a-2	Myocardial Infarction	21642241	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage.
circulation_biomarker_diagnosis_up	hsa-mir-133a-2	Myocardial Infarction	21881276	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples.
circulation_biomarker_diagnosis_up	hsa-mir-133b	Myocardial Infarction	21881276	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples.
circulation_biomarker_diagnosis_up	hsa-mir-133b	Myocardial Infarction	26198874	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	The level of miR-133a, miR-133b and miR-499-5p were significantly higher in both STEMI and NSTEMI patients compared to healthy volunteers
circulation_biomarker_diagnosis_up	hsa-mir-206	Myocardial Infarction	19245789	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-206: Upregulated expression in a rat model
circulation_biomarker_diagnosis_up	hsa-mir-208a	Myocardial Infarction	20159880	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Elevated cardiac-specific miR-208a in plasma may be a novel biomarker for early detection of myocardial injury in humans
circulation_biomarker_diagnosis_up	hsa-mir-208a	Myocardial Infarction	24482699	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Serum miR-208a was increased by 36-fold and 51-fold while miR-499 was elevated by 103-fold and 95-fold at 4 h and 24 h after AMI.
circulation_biomarker_diagnosis_up	hsa-mir-208a	Myocardial Infarction	26528525	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miRNA-208a was increased in STEMI patients at the time of admission and  nearly undetectable in CAD patients and controls.
circulation_biomarker_diagnosis_up	hsa-mir-208b	Myocardial Infarction	20921333	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miRs-208b and -499 were highly elevated in acute myocardial infarction plasma
circulation_biomarker_diagnosis_up	hsa-mir-21	Myocardial Infarction	29197221	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Expression of miRNA-21 was upregulated in the serum of elderly patients with AMI, which inhibited TNF-a induced apoptosis in HCM by activating the JNK/p38/caspase-3 signaling pathway
circulation_biomarker_diagnosis_up	hsa-mir-210	Myocardial Infarction	27346801	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miRNA-499 and miRNA-210 expression levels were significantly increased
circulation_biomarker_diagnosis_up	hsa-mir-22	Myocardial Infarction	27484208	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Subsequent validation in an independent patient group confirmed that miR鈥?33b and miR鈥?2鈥?p were significantly up鈥憆egulated in the serum of patients with AMI.
circulation_biomarker_diagnosis_up	hsa-mir-328	Myocardial Infarction	21881276	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-328 levels in plasma and whole blood of AMI patients were markedly increased by 10.9-fold and 16.1-fold, respectively, compared to those in control subjects (p=0.033 and p<0.001).
circulation_biomarker_diagnosis_up	hsa-mir-499	Myocardial Infarction	24482699	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Serum miR-208a was increased by 36-fold and 51-fold while miR-499 was elevated by 103-fold and 95-fold at 4 h and 24 h after AMI.
circulation_biomarker_diagnosis_up	hsa-mir-499	Myocardial Infarction	25922707	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miR-499 was shown to substantially increase the diagnostic accuracy  of CK-MB and cTnI in the diagnosis of AMI
circulation_biomarker_diagnosis_up	hsa-mir-499	Myocardial Infarction	25966174	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	the expression  of microRNA-499 in serum of patients with AMI was significantly higher than in controls
circulation_biomarker_diagnosis_up	hsa-mir-499	Myocardial Infarction	27346801	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miRNA-499 and miRNA-210 expression levels were significantly increased
circulation_biomarker_diagnosis_up	hsa-mir-499a	Myocardial Infarction	20395621	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Plasma microRNA 499 as a biomarker of acute myocardial infarction
circulation_biomarker_diagnosis_up	hsa-mir-499a	Myocardial Infarction	20921333	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	miRs-208b and -499 were highly elevated in acute myocardial infarction plasma
circulation_biomarker_diagnosis_up	hsa-mir-92a-1	Myocardial Infarction	22153007	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	In STEMI (ST-segment elevation myocardial infarction) patients, the expression of circulating miR-92a is up-regulated. PCI therapy may suppress such up-regulation. Survival rate is higher in patients showing down-regulation of miR-92a. Our data suggest that miR-92a might have potential for diagnosis and therapeutic application in the prevention and treatment of STEMI.
circulation_biomarker_diagnosis_up	hsa-mir-92a-2	Myocardial Infarction	22153007	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	In STEMI (ST-segment elevation myocardial infarction) patients, the expression of circulating miR-92a is up-regulated. PCI therapy may suppress such up-regulation. Survival rate is higher in patients showing down-regulation of miR-92a. Our data suggest that miR-92a might have potential for diagnosis and therapeutic application in the prevention and treatment of STEMI.
circulation_biomarker_diagnosis_up	hsa-mir-106a	Neoplasms [unspecific]	20234369			C80.1	D009369			the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls
circulation_biomarker_diagnosis_up	hsa-mir-17	Neoplasms [unspecific]	17060945			C80.1	D009369			overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-17	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-17	Neoplasms [unspecific]	20234369			C80.1	D009369			the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls
circulation_biomarker_diagnosis_up	hsa-mir-184	Neoplasms [unspecific]	26525105			C80.1	D009369			The increase of plasma miR-146a, miR-184 and miR-372 was detectable early in the induction, and it was particularly eminent at the most advanced lesion state.
circulation_biomarker_diagnosis_up	hsa-mir-18a	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-18b	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-191	Neoplasms [unspecific]	17060945			C80.1	D009369			overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-19a	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-19b-1	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-19b-2	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-20a	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-20b	Neoplasms [unspecific]	17189674			C80.1	D009369			Co-expression of a cluster of miRNAs derived from one genomic locus (miR-17, -18, -19, and -20) caused a significant acceleration of tumorigenesis in a c-Myc driven mouse model of lymphomagenesis. The miR-17бзC19 cluster for instance was found to be highly expressed in follicular lymphoma, low grade B cell malignancy , several types of lymphoma and solid tumors and small cell lung cancer.
circulation_biomarker_diagnosis_up	hsa-mir-21	Neoplasms [unspecific]	25098165			C80.1	D009369			Over-expression of mir-21, especially in cancerous tissue, was effectively predictive of worse prognosis in various carcinomas. Non-invasive circulating mir-21, however, exhibited modest ability to discriminate outcomes.Major concerns about mir-21 assay standardization and selection of specimen need to be fully addressed before its practical implementation in management of cancer.
circulation_biomarker_diagnosis_up	hsa-mir-21	Neoplasms [unspecific]	20234369			C80.1	D009369			the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls
circulation_biomarker_diagnosis_up	hsa-mir-210	Neoplasms [unspecific]	29187235			C80.1	D009369			miR-210 was > sixfold higher in the TCC group compared to the control group
circulation_biomarker_diagnosis_up	hsa-mir-31	Neoplasms [unspecific]	26525105			C80.1	D009369			A progressive increase of miR-21, miR-31 and miR-146a in both saliva  and plasma samples was also noted.
circulation_biomarker_diagnosis_up	hsa-mir-372	Neoplasms [unspecific]	26525105			C80.1	D009369			The increase of plasma miR-146a, miR-184 and miR-372 was detectable early in the induction
circulation_biomarker_diagnosis_up	hsa-mir-21	Neurilemmoma	28224282	disease of cellular proliferation	DOID:3192	D36.10	D009442			The plasma levels of miR-24-3p, miR-16-5p,miR-185-5p, and miR-451a were upregulated during noise exposures, and increased levels of miR-21 have been found in vestibular schwannomas and human cholesteatoma
circulation_biomarker_diagnosis_up	hsa-let-7b	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	let-7b: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-139	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-139-5p: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-146a	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-146a: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-328	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-328: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-342	Neurodegenerative Diseases [unspecific]	18987751				D019636		HP:0002180	miR-342-3p: up-regulated
circulation_biomarker_diagnosis_up	hsa-mir-370	Obesity	26223376	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	circulating miR-27 (P鈥?鈥?.032), miR-378 (P鈥?鈥?.001) and miR-370 (P鈥?鈥?.045) in obese children were significantly higher
circulation_biomarker_diagnosis_up	hsa-mir-378	Obesity	26223376	disease of metabolism	DOID:9970	E66	D009765	601665	HP:0001513	circulating miR-27 (P鈥?鈥?.032), miR-378 (P鈥?鈥?.001) and miR-370 (P鈥?鈥?.045) in obese children were significantly higher
circulation_biomarker_diagnosis_up	hsa-mir-146a	Oral Lichen Planus	25779071			L43.9	D017676		HP:0031453	The expressions of PBMC and plasma miRNA-155 and miRNA-146a are higher in OLP patients. The expressions of plasma miRNA-155 and miRNA-146a are associated with OLP severity. The over expression of miRNA-155 and miRNA-146a in OLP may play a role in the pathogenesis of OLP.
circulation_biomarker_diagnosis_up	hsa-mir-155	Oral Lichen Planus	25779071			L43.9	D017676		HP:0031453	The expressions of PBMC and plasma miRNA-155 and miRNA-146a are higher in OLP patients. The expressions of plasma miRNA-155 and miRNA-146a are associated with OLP severity. The over expression of miRNA-155 and miRNA-146a in OLP may play a role in the pathogenesis of OLP.
circulation_biomarker_diagnosis_up	hsa-mir-184	Oral Neoplasms	25784212			C06.9	D009062		HP:0100649	There was a highly significant increase in salivary miRNA-21 and miRNA-184 in OSCC and PMD
circulation_biomarker_diagnosis_up	hsa-mir-223	Oral Neoplasms	27441818			C06.9	D009062		HP:0100649	circulating miR-223 levels were significantly higher (~2-fold, P< 0.05) in patients with oral cancer (n = 31) than in those without cancer (n = 31).
circulation_biomarker_diagnosis_up	hsa-mir-140	Osteoarthritis	22143896	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	the expression of both miR-140-5p and miR-455-3p was increased in OA cartilage.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Osteoarthritis	28785809	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA
circulation_biomarker_diagnosis_up	hsa-mir-155	Osteoarthritis	28785809	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA
circulation_biomarker_diagnosis_up	hsa-mir-181a	Osteoarthritis	28785809	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA
circulation_biomarker_diagnosis_up	hsa-mir-223	Osteoarthritis	28785809	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	MBT can modify the expression of miR-155, miR-181a, miR-146a, and miR-223, which are upregulated in OA
circulation_biomarker_diagnosis_up	hsa-mir-455	Osteoarthritis	22143896	musculoskeletal system disease	DOID:8398	M19.9	D010003	165720	HP:0002758	the expression of both miR-140-5p and miR-455-3p was increased in OA cartilage.
circulation_biomarker_diagnosis_up	hsa-mir-191	Osteosarcoma	26406942	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Our data provide new insights for the involvement of miR-191 in osteosarcoma and suggest that the increased expression of miR-191 may be associated with aggressive tumor progression and adverse outcome. Of note, serum miR-191 quantification may be a promising biomarker for the diagnosis and prognosis in osteosarcoma.
circulation_biomarker_diagnosis_up	hsa-mir-200a	Ovarian Neoplasms	23272653	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer
circulation_biomarker_diagnosis_up	hsa-mir-200b	Ovarian Neoplasms	23272653	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer
circulation_biomarker_diagnosis_up	hsa-mir-200c	Ovarian Neoplasms	23272653	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer
circulation_biomarker_diagnosis_up	hsa-mir-21	Ovarian Neoplasms	29373877	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-21 may be used as a diagnostic biomarker for human ovarian cancer
circulation_biomarker_diagnosis_up	hsa-mir-143	Pancreatic Adenocarcinoma	26807325	disease of cellular proliferation	DOID:4074	C25.3				Three miRNAs (miR-143, miR-223, and  miR-30e) were significantly over-expressed in patients with Stage I cancer when compared with age-matched healthy individuals
circulation_biomarker_diagnosis_up	hsa-mir-196a-1	Pancreatic Adenocarcinoma	19723895	disease of cellular proliferation	DOID:4074	C25.3				uperegulated
circulation_biomarker_diagnosis_up	hsa-mir-196a-2	Pancreatic Adenocarcinoma	19723895	disease of cellular proliferation	DOID:4074	C25.3				uperegulated
circulation_biomarker_diagnosis_up	hsa-mir-193b	Pancreatic Endocrine Carcinoma	24778027	disease of cellular proliferation	DOID:1798	C25.4	D018273			Evaluation of microRNAs appears to be promising in the assessment of pNEN. In particular, miR-193b, which is also increased in serum, may be a potential new biomarker of pNEN.
circulation_biomarker_diagnosis_up	hsa-mir-106a	Pancreatic Neoplasms	17442096	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Indeed, in human solid tumors, mir-106a expression is increased in colon, pancreas, and prostate tumors.
circulation_biomarker_diagnosis_up	hsa-mir-132	Pancreatic Neoplasms	17447837	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-18a	Pancreatic Neoplasms	22045190	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		The expression of miR-18a was significantly higher in pancreatic cancer tissues (P=0.012) and pancreatic cancer cell lines (P=0.015) than in normal tissues and fibroblasts. Plasma concentrations of miR-18a were significantly higher in pancreatic cancer patients than in controls (P<0.0001). The value of the area under the receiver-operating characteristic curve (AUC) was 0.9369. Plasma levels of miR-18a were significantly lower in postoperative samples than in preoperative samples (P=0.0077).
circulation_biomarker_diagnosis_up	hsa-mir-191	Pancreatic Neoplasms	29385987	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker
circulation_biomarker_diagnosis_up	hsa-mir-192	Pancreatic Neoplasms	25894267	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our data shows that miR-21, miR-192 and miR-200 could be used as new  diagnostic markers for pancreatic cancer.
circulation_biomarker_diagnosis_up	hsa-mir-196a	Pancreatic Neoplasms	24956938	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Serum levels of miR-196a and -196b were significantly higher in mice with PanIN2/3 lesions (n = 10) or PC (n = 8) as compared to control mice (n = 10) or mice with PanIN1 lesions (n = 10; P = .01).
circulation_biomarker_diagnosis_up	hsa-mir-200	Pancreatic Neoplasms	25894267	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our data shows that miR-21, miR-192 and miR-200 could be used as new  diagnostic markers for pancreatic cancer.
circulation_biomarker_diagnosis_up	hsa-mir-205	Pancreatic Neoplasms	25258651	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A marked difference in the profiles of four circulating miRNAs (miR-205, miR-210, miR-492, and miR-1427) was observed in pancreatic juice collected from patients with PDAC and those without  pancreatic disease.
circulation_biomarker_diagnosis_up	hsa-mir-21	Pancreatic Neoplasms	25384963	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
circulation_biomarker_diagnosis_up	hsa-mir-21	Pancreatic Neoplasms	25894267	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Our data shows that miR-21, miR-192 and miR-200 could be used as new  diagnostic markers for pancreatic cancer.
circulation_biomarker_diagnosis_up	hsa-mir-21	Pancreatic Neoplasms	29385987	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker
circulation_biomarker_diagnosis_up	hsa-mir-210	Pancreatic Neoplasms	20360935	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer
circulation_biomarker_diagnosis_up	hsa-mir-210	Pancreatic Neoplasms	25258651	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A marked difference in the profiles of four circulating miRNAs (miR-205, miR-210, miR-492, and miR-1427) was observed in pancreatic juice collected from patients with PDAC and those without  pancreatic disease.
circulation_biomarker_diagnosis_up	hsa-mir-25	Pancreatic Neoplasms	25991015	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		A combination of six serum miRNAs (miR-483-5p, miR-19a, miR-29a,  miR-20a, miR-24, miR-25) was selected by qRT-PCR as a biomarker for PaC-DM.
circulation_biomarker_diagnosis_up	hsa-mir-451a	Pancreatic Neoplasms	29385987	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker
circulation_biomarker_diagnosis_up	hsa-mir-483	Pancreatic Neoplasms	25384963	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
circulation_biomarker_diagnosis_up	hsa-mir-195	Parkinson Disease	26631952	nervous system disease	DOID:14330	G20	D010300	PS168600		miR-195 was up-regulated, and miR-185, miR-15b, miR-221 and miR-181a were down-regulated.
circulation_biomarker_diagnosis_up	hsa-mir-122	Polycystic Ovarian Syndrome	26860517	syndrome	DOID:11612	E28.2	D011085	184700		relative expression of miR-122, miR-193b, and miR-194 was up-regulated in PCOS patients
circulation_biomarker_diagnosis_up	hsa-mir-193b	Polycystic Ovarian Syndrome	26860517	syndrome	DOID:11612	E28.2	D011085	184700		relative expression of miR-122, miR-193b, and miR-194 was up-regulated in PCOS patients
circulation_biomarker_diagnosis_up	hsa-mir-194	Polycystic Ovarian Syndrome	26860517	syndrome	DOID:11612	E28.2	D011085	184700		relative expression of miR-122, miR-193b, and miR-194 was up-regulated in PCOS patients
circulation_biomarker_diagnosis_up	hsa-mir-223	Polycystic Ovarian Syndrome	26582398	syndrome	DOID:11612	E28.2	D011085	184700		In conclusion, circulating miRNA-93 and miRNA-223 were higher in women with PCOS compared to age and weight matched controls independent of insulin resistance and testosterone levels, and miR-93 may represent a novel diagnostic biomarker for PCOS.
circulation_biomarker_diagnosis_up	hsa-mir-93	Polycystic Ovarian Syndrome	26582398	syndrome	DOID:11612	E28.2	D011085	184700		In conclusion, circulating miRNA-93 and miRNA-223 were higher in women with PCOS compared to age and weight matched controls independent of insulin resistance and testosterone levels, and miR-93 may represent a novel diagnostic biomarker for PCOS.
circulation_biomarker_diagnosis_up	hsa-mir-143	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_up	hsa-mir-145	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_up	hsa-mir-16-1	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_up	hsa-mir-16-2	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_up	hsa-mir-182	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_up	hsa-mir-21	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_up	hsa-mir-223	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_up	hsa-mir-26b	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_up	hsa-mir-26b	Polycythemia Vera	18508790	hematopoietic system disease	DOID:8997	D45	D011087	263300		We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes.
circulation_biomarker_diagnosis_up	hsa-mir-451a	Polycythemia Vera	17976518	hematopoietic system disease	DOID:8997	D45	D011087	263300		Comparative analyses of control and PV EPs suggested increased levels of miR-451, miR-16, miR-21, and miR-26b and decreased levels of miR-150 and miR-221 in PV group, Expression of miR-150 progressively declined with erythroid differentiation, its expression decreased ninefold (p < 0.05) from days 7 to 11.
circulation_biomarker_diagnosis_up	hsa-mir-103a-1	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-103a-2	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-103b-1	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-103b-2	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-130b	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-181a-1	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-181a-2	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-210	Preeclampsia	22095477	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Serum expression level of miR-210 was up-regulated in preeclampsia patients.
circulation_biomarker_diagnosis_up	hsa-mir-24-1	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-24-2	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-26a-1	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-26a-2	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-342	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-574	Preeclampsia	22187671	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis.
circulation_biomarker_diagnosis_up	hsa-mir-885	Preeclampsia	26853698	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	miR-885-5p is increased in plasma from pre-eclampsia compared with healthy pregnant women, and it is released into circulation mainly inside exosomes.
circulation_biomarker_diagnosis_up	hsa-mir-342	Prion Diseases	19712440	nervous system disease	DOID:649	A81.9	D017096			upregulated
circulation_biomarker_diagnosis_up	hsa-mir-494	Prion Diseases	19712440	nervous system disease	DOID:649	A81.9	D017096			upregulated
circulation_biomarker_diagnosis_up	hsa-mir-106a	Prostate Neoplasms	17442096	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Indeed, in human solid tumors, mir-106a expression is increased in colon, pancreas, and prostate tumors.
circulation_biomarker_diagnosis_up	hsa-mir-132	Prostate Neoplasms	17447837	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	miR-132, previously shown to be differentially upregulated in six solid cancer types (breast, colon, lung, pancreas, prostate, and stomach carcinomas)
circulation_biomarker_diagnosis_up	hsa-mir-141	Prostate Neoplasms	21274675	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the miRNA levels in patient blood were higher than that of the controls
circulation_biomarker_diagnosis_up	hsa-mir-141	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-141	Prostate Neoplasms	23377530	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	serum;An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions
circulation_biomarker_diagnosis_up	hsa-mir-21	Prostate Neoplasms	21274675	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the miRNA levels in patient blood were higher than that of the controls
circulation_biomarker_diagnosis_up	hsa-mir-21	Prostate Neoplasms	27434290	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	The expression levels of miR-21 in PCa group were increased compared to  BPH and control group
circulation_biomarker_diagnosis_up	hsa-mir-221	Prostate Neoplasms	21274675	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	the miRNA levels in patient blood were higher than that of the controls
circulation_biomarker_diagnosis_up	hsa-mir-223	Prostate Neoplasms	22892455	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	An increase in serum miR-223 and a decrease in miR-125b and miR-146a were observed in group B.
circulation_biomarker_diagnosis_up	hsa-mir-375	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378a	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378b	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378c	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378d-1	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378d-2	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378e	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378f	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378g	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378h	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-378i	Prostate Neoplasms	22887127	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue.
circulation_biomarker_diagnosis_up	hsa-mir-1266	Psoriasis	22133505	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Increased serum levels of miR-1266 in patients with psoriasis vulgaris.
circulation_biomarker_diagnosis_up	hsa-mir-1266	Psoriasis	27371164	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Increased MicroRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Psoriasis	17965831	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miR-146 is also expressed highly in the skin of psoriasis patients.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Psoriasis	27535005	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Psoriasis	17965831	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	miR-146 is also expressed highly in the skin of psoriasis patients.
circulation_biomarker_diagnosis_up	hsa-mir-155	Psoriasis	27535005	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma.
circulation_biomarker_diagnosis_up	hsa-mir-21	Psoriasis	27535005	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma.
circulation_biomarker_diagnosis_up	hsa-mir-223	Psoriasis	27535005	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma.
circulation_biomarker_diagnosis_up	hsa-mir-369	Psoriasis	24135466	integumentary system disease	DOID:8893	L40.9	D011565	PS177900	HP:0003765	The expression of miR-369-3p is increased in both serum samples and skin tissues from psoriasis patients, and its level in the skin positively correlates with disease severity. Further studies are needed to clarify the role of miR-369-3p in the pathogenesis of psoriasis.
circulation_biomarker_diagnosis_up	hsa-mir-134	Pulmonary Embolism	21943159	cardiovascular system disease	DOID:9477	I26	D011655			Plasma miRNA-134 (miR-134) level was significantly higher in the APE patients than in the healthy controls or non-APE patients. The ROC curve showed that plasma miR-134 was a specific diagnostic predictor of APE with an area under the curve of 0.833 (95% confidence interval, 0.737 to 0.929; P<0.001). The findings indicated that plasma miR-134 could be an important biomarker for the diagnosis of APE.
circulation_biomarker_diagnosis_up	hsa-mir-1-1	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-1: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-1-2	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-1: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-133b	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-133: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-142	Retinal Degeneration	18834879	nervous system disease	DOID:8466	H35.40	D012162	605670	HP:0000546	miR-142: upregulation
circulation_biomarker_diagnosis_up	hsa-mir-206	Rhabdomyosarcoma	20696132	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	miR-206:miR-206, as landmark biomarkers for RMS
circulation_biomarker_diagnosis_up	hsa-mir-125b	Rheumatoid Arthritis	28738524	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Elevated microRNA-125b promotes inflammation in rheumatoid arthritis by activation of NF-κB pathway.
circulation_biomarker_diagnosis_up	hsa-mir-139	Rheumatoid Arthritis	29191214	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The expression levels of  miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents
circulation_biomarker_diagnosis_up	hsa-mir-146a	Rheumatoid Arthritis	24120842	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Elevated expression of specific microRNAs (miRNA) in peripheral blood-derived mononuclear cells (PBMC), particularly miR-146a and miR-155, is associated with rheumatoid arthritis (RA).
circulation_biomarker_diagnosis_up	hsa-mir-155	Rheumatoid Arthritis	24120842	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	Elevated expression of specific microRNAs (miRNA) in peripheral blood-derived mononuclear cells (PBMC), particularly miR-146a and miR-155, is associated with rheumatoid arthritis (RA).
circulation_biomarker_diagnosis_up	hsa-mir-204	Rheumatoid Arthritis	29191214	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The expression levels of  miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents
circulation_biomarker_diagnosis_up	hsa-mir-214	Rheumatoid Arthritis	29191214	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The expression levels of  miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents
circulation_biomarker_diagnosis_up	hsa-mir-223	Rheumatoid Arthritis	26164649	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	MiR-16, miR-146a/b, miR-150, miR-155, and miR-223 described here were shown to be overexpressed at the systemic level: in both the periphery  and RA joints.
circulation_biomarker_diagnosis_up	hsa-mir-760	Rheumatoid Arthritis	29191214	musculoskeletal system disease	DOID:7148	M06.9	D001172	180300	HP:0001370	The expression levels of  miR-139-3p, miR-204, miR-214, and miR-760 increased in RA patients receiving biologic agents
circulation_biomarker_diagnosis_up	hsa-mir-106b	Schizophrenia	27489379	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Schizophrenia patients showed statistically significant upregulation of  five microRNAs: miR9-5p (p=0.002), miR29a-3p (p锛?.001), miR106b-5p (p=0.002), miR125a-3p (p锛?.001), and miR125b-3p (p=0.018).
circulation_biomarker_diagnosis_up	hsa-mir-130b	Schizophrenia	26183697	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The up-regulation of miR-130b and miR-193a-3p is a state-independent biomarker for schizophrenia, and these two miRNAs could be used to develop a diagnostic tool for schizophrenia.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Schizophrenia	26173148	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p).
circulation_biomarker_diagnosis_up	hsa-mir-15a	Schizophrenia	19721432	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-15b	Schizophrenia	19721432	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-193a	Schizophrenia	26183697	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	The up-regulation of miR-130b and miR-193a-3p is a state-independent biomarker for schizophrenia, and these two miRNAs could be used to develop a diagnostic tool for schizophrenia.
circulation_biomarker_diagnosis_up	hsa-mir-23a	Schizophrenia	26173148	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p).
circulation_biomarker_diagnosis_up	hsa-mir-29a	Schizophrenia	27489379	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	Schizophrenia patients showed statistically significant upregulation of  five microRNAs: miR9-5p (p=0.002), miR29a-3p (p锛?.001), miR106b-5p (p=0.002), miR125a-3p (p锛?.001), and miR125b-3p (p=0.018).
circulation_biomarker_diagnosis_up	hsa-mir-34	Schizophrenia	26173148	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p).
circulation_biomarker_diagnosis_up	hsa-mir-4449	Schizophrenia	26173148	disease of mental health	DOID:5419	F20	D012559	181500	HP:0100753	a nominally significant increase in the expression of several miRNAs was found in the 22q11.2 neurons that were previously found to be differentially expressed in autopsy samples and peripheral blood in SZ and autism spectrum disorders (e.g.,miR-34, miR-4449, miR-146b-3p, and miR-23a-5p).
circulation_biomarker_diagnosis_up	hsa-mir-142	Scleroderma, Systemic	21883400	musculoskeletal system disease	DOID:418	M34	D012595	181750		Serum miR-142-3p levels in patients with SSc (systemic sclerosis) were significantly higher than in patients with SSD (scleroderma spectrum disorder), SLE (systemic lupus erythematosus) or DM (dermatomyositis), and healthy control groups. Patients with increased miR-142-3p levels tended to have a short sublingual frenulum.
circulation_biomarker_diagnosis_up	hsa-mir-133a	Sepsis	27434558			A41.9	D018805		HP:0100806	The mRNA expressions of serum miR-155-5p and miR-133a-3p were gradually increased with the aggravation of sepsis.
circulation_biomarker_diagnosis_up	hsa-mir-143	Sepsis	27225861			A41.9	D018805		HP:0100806	Serum miR-143 levels were significantly higher in patients with sepsis
circulation_biomarker_diagnosis_up	hsa-mir-146a	Sepsis	24680405			A41.9	D018805		HP:0100806	The expression levels of miR-146a and miR-223 in plasma in pediatric patients with sepsis was significantly upregulated, and had a positive correlation with IL-10 and IL-10/TNF-α, which may be used as early diagnostic markers and can reflect the severity of condition to a certain degree.
circulation_biomarker_diagnosis_up	hsa-mir-155	Sepsis	27434558			A41.9	D018805		HP:0100806	The mRNA expressions of serum miR-155-5p and miR-133a-3p were gradually increased with the aggravation of sepsis.
circulation_biomarker_diagnosis_up	hsa-mir-223	Sepsis	24680405			A41.9	D018805		HP:0100806	The expression levels of miR-146a and miR-223 in plasma in pediatric patients with sepsis was significantly upregulated, and had a positive correlation with IL-10 and IL-10/TNF-α, which may be used as early diagnostic markers and can reflect the severity of condition to a certain degree.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Sjogren Syndrome	24931100	immune system disease	DOID:12894	M35.00	D012859	270150		Our results demonstrated miR-146a overexpression and miR-155 underexpression in the peripheral mononuclear blood cells of the patients with pSS. Furthermore, the expression levels of these miRNAs correlated with the patients' clinical features. Our data suggest that miR-146a and miR-155 might play important roles in the pathogenesis of pSS and that their expression levels may be useful for diagnosing pSS and for predicting disease activity and therapeutic responses.
circulation_biomarker_diagnosis_up	hsa-mir-181a	Sjogren Syndrome	25128511	immune system disease	DOID:12894	M35.00	D012859	270150		Together, these observations suggested that an elevated miRNA-181a level is a general phenomenon  in Chinese patients with pSS.
circulation_biomarker_diagnosis_up	hsa-mir-100	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-16	Squamous Cell Carcinoma, Esophageal	26221263	disease of cellular proliferation	DOID:3748		C562729			Levels of four of the selected miRNAs were found to be significantly higher in ESCC patients than in controls; namely, miR-16, miR-21, miR-185, and miR-375 (P < 0.050).
circulation_biomarker_diagnosis_up	hsa-mir-193	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-194	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-21	Squamous Cell Carcinoma, Esophageal	21673684	disease of cellular proliferation	DOID:3748		C562729			the plasma level of miR-21 was significantly higher (P=0.0218) and that of miR-375 (P=0.0052) was significantly lower in ESCC patients than controls. (2) The high plasma miR-21 levels reflected tumour levels in all cases (100%). The plasma level of miR-21 was significantly reduced in postoperative samples (P=0.0058). (3) On validation analysis, the plasma level of miR-21 tended to be higher in ESCC patients (P=0.0649), while that of miR-375 was significantly lower (P<0.0001) and the miR-21/miR-375 ratio was significantly higher (P<0.0001) in ESCC patients than in controls. The value of the area under the receiver-operating characteristic curve (AUC) was 0.816 for the miR-21/miR-375 ratio assay. Patients with a high plasma level of miR-21 tended to have greater vascular invasion (P=0.1554) and to show a high correlation with recurrence (P=0.0164).
circulation_biomarker_diagnosis_up	hsa-mir-223	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-25	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-337	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-483	Squamous Cell Carcinoma, Esophageal	24651474	disease of cellular proliferation	DOID:3748		C562729			Seven serum miRNAs were found to be significantly higher in ESCC than in controls; namely, miR-25, miR-100, miR-193-3p, miR-194, miR-223, miR-337-5p and miR-483-5p
circulation_biomarker_diagnosis_up	hsa-mir-210	Squamous Cell Carcinoma, Head and Neck	20187102	disease of cellular proliferation	DOID:5520	C76.0	C535575			Expression of hsa-miR-210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis
circulation_biomarker_diagnosis_up	hsa-mir-21	Squamous Cell Carcinoma, Laryngeal or Hypopharyngeal	27067271	disease of cellular proliferation	DOID:2876					Compared with controls, miR-21 levels in tissue and plasma were significantly higher for both PLL and LSCC groups
circulation_biomarker_diagnosis_up	hsa-mir-181a-1	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-181a-2	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-181b-1	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-181b-2	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-181c	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-181d	Squamous Cell Carcinoma, Oral	21244495	disease of cellular proliferation	DOID:0050866					miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.miR-181 may enhance lymph-node metastasis through regulating migration, which could potentially be exploited as a putative biomarker for patients with OSCC.
circulation_biomarker_diagnosis_up	hsa-mir-122	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity: illustrated liver and muscle toxicity
circulation_biomarker_diagnosis_up	hsa-mir-124-1	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity:illustrated injuries in liver, muscle, and brain
circulation_biomarker_diagnosis_up	hsa-mir-124-2	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity:illustrated injuries in liver, muscle, and brain
circulation_biomarker_diagnosis_up	hsa-mir-124-3	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity:illustrated injuries in liver, muscle, and brain
circulation_biomarker_diagnosis_up	hsa-mir-133a-1	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity: illustrated liver and muscle toxicity
circulation_biomarker_diagnosis_up	hsa-mir-133a-2	Stroke	19745058			I64	D020521	601367	HP:0001297	diagnostical sensitivity: illustrated liver and muscle toxicity
circulation_biomarker_diagnosis_up	hsa-mir-146b	Stroke	29402769			I64	D020521	601367	HP:0001297	upregulated serum miR-146b in acute ischemic stroke might be a potential biomarker for AIS evaluation
circulation_biomarker_diagnosis_up	hsa-mir-21	Stroke	27288814			I64	D020521	601367	HP:0001297	The stroke with SAI group had significantly higher miRNA-21 expression
circulation_biomarker_diagnosis_up	hsa-mir-144	Stroke, Ischemic	26175178			I63.9			HP:0002140	In conclusion, hyperglycemia may activate platelets through miR-144 and miR-223 to downregulate IRS-1 and upregulate P2Y12 expression in the platelets of T2DM patients through an IRS-1-PI3K-Akt signaling.
circulation_biomarker_diagnosis_up	hsa-mir-223	Stroke, Ischemic	26175178			I63.9			HP:0002140	In conclusion, hyperglycemia may activate platelets through miR-144 and miR-223 to downregulate IRS-1 and upregulate P2Y12 expression in the platelets of T2DM patients through an IRS-1-PI3K-Akt signaling.
circulation_biomarker_diagnosis_up	hsa-let-7e	Synovial Sarcoma	21140508	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-125a	Synovial Sarcoma	21140508	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	miR-125a-3p: upregulated
circulation_biomarker_diagnosis_up	hsa-mir-99b	Synovial Sarcoma	21140508	disease of cellular proliferation	DOID:5485		D013584	300813	HP:0012570	upregulated
circulation_biomarker_diagnosis_up	hsa-mir-126	Systemic Lupus Erythematosus	22683424	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-126 was specifically enriched only in the blood of the SLE patients
circulation_biomarker_diagnosis_up	hsa-mir-142	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_up	hsa-mir-146a	Systemic Lupus Erythematosus	21529448	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Increased Expression in Peripheral Blood Mononuclear Cells in Patients with Systemic Lupus Erythematosus.
circulation_biomarker_diagnosis_up	hsa-mir-181	Systemic Lupus Erythematosus	23401079	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203,and miR-92a was decreased
circulation_biomarker_diagnosis_up	hsa-mir-21	Systemic Lupus Erythematosus	24659142	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Plasma miR-21 in SLE patients from Central China is overexpressed.Since circulating miR-21 is aberrantly expressed in many diseases, the applying of it as a disease biomarker should be considered carefully.
circulation_biomarker_diagnosis_up	hsa-mir-21	Systemic Lupus Erythematosus	27510529	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	miR-21 was  high expressed in SLE patients compared to their first-degree relatives and controls.
circulation_biomarker_diagnosis_up	hsa-mir-224	Systemic Lupus Erythematosus	23199328	musculoskeletal system disease	DOID:9074	M32.9	D008180	152700	HP:0002725	Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis
circulation_biomarker_diagnosis_up	hsa-mir-516a	Systemic Lupus Erythematosus, With Pericarditis	24687380			M32.12				High expression levels of microRNA-629, microRNA-525-5p and microRNA-516a-3p in paediatric systemic lupus erythematosus.
circulation_biomarker_diagnosis_up	hsa-mir-525	Systemic Lupus Erythematosus, With Pericarditis	24687380			M32.12				High expression levels of microRNA-629, microRNA-525-5p and microRNA-516a-3p in paediatric systemic lupus erythematosus.
circulation_biomarker_diagnosis_up	hsa-mir-629	Systemic Lupus Erythematosus, With Pericarditis	24687380			M32.12				High expression levels of microRNA-629, microRNA-525-5p and microRNA-516a-3p in paediatric systemic lupus erythematosus.
circulation_biomarker_diagnosis_up	hsa-mir-372	Testicular Neoplasms	17189674	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	The relevance to human tumorigenesis was shown when it was found that these miRNAs are hyper-expressed in Testicular Germ Cell Tumors, a tumor type characterized by its prevalence of wild type p53.
circulation_biomarker_diagnosis_up	hsa-mir-373	Testicular Neoplasms	17189674	disease of cellular proliferation	DOID:2998		D013736	273300	HP:0010788	The relevance to human tumorigenesis was shown when it was found that these miRNAs are hyper-expressed in Testicular Germ Cell Tumors, a tumor type characterized by its prevalence of wild type p53.
circulation_biomarker_diagnosis_up	hsa-let-7e	Thyroid Neoplasms	22472564	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Thyroid Neoplasms	16885332	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-146a	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146.
circulation_biomarker_diagnosis_up	hsa-mir-146a	Thyroid Neoplasms	17965831	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Thyroid Neoplasms	16885332	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-146b	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146.
circulation_biomarker_diagnosis_up	hsa-mir-146b	Thyroid Neoplasms	17965831	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation.
circulation_biomarker_diagnosis_up	hsa-mir-151a	Thyroid Neoplasms	22472564	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage.
circulation_biomarker_diagnosis_up	hsa-mir-151b	Thyroid Neoplasms	22472564	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage.
circulation_biomarker_diagnosis_up	hsa-mir-200a	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Three of these upregulated miRNAs showed significantly higher fold change than the other upregulated miRNAs, these are mir-200a, mir-200b and mir-141.
circulation_biomarker_diagnosis_up	hsa-mir-200b	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Three of these upregulated miRNAs showed significantly higher fold change than the other upregulated miRNAs, these are mir-200a, mir-200b and mir-141.
circulation_biomarker_diagnosis_up	hsa-mir-22	Thyroid Neoplasms	17965831	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation.
circulation_biomarker_diagnosis_up	hsa-mir-221	Thyroid Neoplasms	16885332	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	It was shown that miR-221, highly overexpressed in papillary thyroid tumors, is also overexpressed in normal thyroid tissue adjacent to tumors but not in normal thyroid tissues from individuals without clinical thyroid disease.
circulation_biomarker_diagnosis_up	hsa-mir-221	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146.
circulation_biomarker_diagnosis_up	hsa-mir-221	Thyroid Neoplasms	17965831	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Numerous miRNAs are also up-regulated in papillary thyroid carcinoma, including miR-221, miR-22 and miR-146. This up-regulation was associated with a downregulation in the expression of the oncogene KIT, a tyrosine kinase important for the control of cell proliferation.
circulation_biomarker_diagnosis_up	hsa-mir-222	Thyroid Neoplasms	16885332	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	up-regulation
circulation_biomarker_diagnosis_up	hsa-mir-222	Thyroid Neoplasms	17355635	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	Recent studies in miRNA deregulation PTC found an aberrant miRNA expression profile in PTCs compared to normal thyroid tissues. In particular, a significant increase in mir-222, mir-221, mir-146.
circulation_biomarker_diagnosis_up	hsa-mir-222	Thyroid Neoplasms	22472564	disease of cellular proliferation	DOID:1781	C73	D013964	188550	HP:0100031	The expression of serum let-7e, miR-151-5p, and miR-222 was significantly increased in PTC (papillary thyroid carcinomas ) cases relative to benign cases and healthy controls. Serum let-7e, miR-151-5p, and miR-222 levels were found to be well correlated with certain clinicopathological variables, such as nodal status, tumor size, multifocal lesion status, and Tumor-Node-Metastasis stage.
circulation_biomarker_diagnosis_up	hsa-mir-184	Tongue Neoplasms	19219377	gastrointestinal system disease	DOID:8649	C01	D014062		HP:0100648	miR-184: overexpressed
circulation_biomarker_diagnosis_up	hsa-mir-191	Traumatic Brain Injury	26756543			S06.2	D000070642			Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury.
circulation_biomarker_diagnosis_up	hsa-mir-499	Traumatic Brain Injury	26756543			S06.2	D000070642			Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury.
circulation_biomarker_diagnosis_up	hsa-mir-93	Traumatic Brain Injury	26756543			S06.2	D000070642			Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury.
circulation_biomarker_diagnosis_up	hsa-mir-223	Tuberculosis	26316141	disease by infectious agent	DOID:399	A15-A19	D014376			Leukocyte recruitment, measured as the expression of microRNA-223 was increased in pulmonary TB patients compared to LTBI
circulation_biomarker_diagnosis_up	hsa-mir-155	Tuberculosis, Pulmonary	22037148	disease by infectious agent	DOID:2957	A15	D014397			Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis.
circulation_biomarker_diagnosis_up	hsa-mir-183	Urinary Bladder Cancer	21166959	urinary system disease	DOID:11054	C67	D001749	109800		MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology.
circulation_biomarker_diagnosis_up	hsa-mir-96	Urinary Bladder Cancer	21166959	urinary system disease	DOID:11054	C67	D001749	109800		MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology.
circulation_biomarker_diagnosis_up	hsa-mir-21	Vascular Disease [unspecific]	28464406	cardiovascular system disease	DOID:178	I72.9	D000783			miR-21 and miR-92 levels increased, but did not reach the level of significance
circulation_biomarker_diagnosis_up	hsa-mir-92	Vascular Disease [unspecific]	28464406	cardiovascular system disease	DOID:178	I72.9	D000783			miR-21 and miR-92 levels increased, but did not reach the level of significance
circulation_biomarker_diagnosis_up	hsa-mir-223	Viral Infectious Disease	27226534	disease by infectious agent	DOID:934	A94	D001102			vesicular stomatitis virus (VSV) infection induced significant up-regulation of miR-223 in murine macrophages.
circulation_biomarker_diagnosis_up	hsa-mir-208b	Viral Myocarditis	20921333			B33.2	D009205			a milder but significant elevation of miRs-208b and -499 were highly elevated in Viral Myocarditis plasma
circulation_biomarker_diagnosis_up	hsa-mir-499a	Viral Myocarditis	20921333			B33.2	D009205			a milder but significant elevation of miRs-208b and -499 were highly elevated in Viral Myocarditis plasma
circulation_biomarker_diagnosis_up	hsa-mir-9-1	Wounds and Injuries [unspecific]	21538484				D014947			Upregulated in in serum
circulation_biomarker_diagnosis_up	hsa-mir-9-2	Wounds and Injuries [unspecific]	21538484				D014947			Upregulated in in serum
circulation_biomarker_diagnosis_up	hsa-mir-9-3	Wounds and Injuries [unspecific]	21538484				D014947			Upregulated in in serum
circulation_biomarker_prognosis_down	hsa-mir-1	Acute Heart Failure	26580972			I50				admission levels of miR-1 were lower in AHF and stable CHF patients compared to non-AHF patients
circulation_biomarker_prognosis_down	hsa-mir-34a	Adenocarcinoma, Pancreatic Ductal	27458977	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		A loss of expression of miR-34a, but not of miR-150, is associated with disease progression and poor prognosis in PDAC patients, and may be involved in the chemoresistance of PDAC cells.
circulation_biomarker_prognosis_down	hsa-mir-126	Arteriosclerosis Obliterans	27497911	cardiovascular system disease	DOID:5160		D001162		HP:0002634	Furthermore, plasma miR-126-5p levels were significantly down-regulated in CAD patients with multi-vessel disease, higher SYNTAX score, rather than isolated LMCA and low SYNTAX score.
circulation_biomarker_prognosis_down	hsa-mir-21	Atrial Fibrillation	29676832	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF
circulation_biomarker_prognosis_down	hsa-mir-100	Bladder Neoplasms	26662386			C67	D001749	109800	HP:0009725	The present study demonstrated that the downregulation of miR-100 was associated with advanced clinical features and poor prognosis for bladder cancer patients, suggesting that miR-100 downregulation may be used as an unfavorable prognostic biomarker in bladder cancer.
circulation_biomarker_prognosis_down	hsa-mir-195	Breast Neoplasms	20134314	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	circulating levels of miR-195 and let-7a decreased in cancer patients postoperatively
circulation_biomarker_prognosis_down	hsa-mir-19a	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_down	hsa-mir-19b	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_down	hsa-mir-99a	Carcinoma, Breast	27706621			D05	D001943	114480	HP:0003002	Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer.
circulation_biomarker_prognosis_down	hsa-mir-1300	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Low expression of miR-1300 and miR-939 was significantly correlated with shorter distant metastasis-free survival (DMFS) in Cox univariate analysis (p.adjusted = 0.049).
circulation_biomarker_prognosis_down	hsa-mir-939	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	Low expression of miR-1300 and miR-939 was significantly correlated with shorter distant metastasis-free survival (DMFS) in Cox univariate analysis (p.adjusted = 0.049).
circulation_biomarker_prognosis_down	hsa-mir-145	Carcinoma, Gastric	27460730	disease of cellular proliferation	DOID:5517	C16.9	D013274		HP:0012126	MiR-145-5p is down-expressed in GC, and can be used as a marker of poor prognosis in GC patients.
circulation_biomarker_prognosis_down	hsa-mir-1	Carcinoma, Hepatocellular	26554254	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Low miR-1 expression is associated with shortened survival time.MiR-1 may act as a potential prognostic biomarker for HCC patients.
circulation_biomarker_prognosis_down	hsa-mir-100	Carcinoma, Hepatocellular	23842624	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma.
circulation_biomarker_prognosis_down	hsa-mir-218	Carcinoma, Hepatocellular	26586116	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Consequently, our findings revealed that serum miR-218 levels were remarkably underexpressed in HCC patients as compared to BLD patients and healthy controls.
circulation_biomarker_prognosis_down	hsa-mir-29c	Carcinoma, Hepatocellular	27525839	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Our findings demonstrate that miR-29c expression is significantly downregulated in HCC patients and that miR-29c can act as an independent predictor of unfavorable clinical outcome.
circulation_biomarker_prognosis_down	hsa-mir-135a	Carcinoma, Lung, Non-Small-Cell	27525941			C34.90	D002289		HP:0030358	the serum miR-135a level was downregulated in NSCLC patients, and was associated with poor prognosis.
circulation_biomarker_prognosis_down	hsa-mir-30c	Carcinoma, Lung, Non-Small-Cell	27506865			C34.90	D002289		HP:0030358	MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer.
circulation_biomarker_prognosis_down	hsa-mir-153	Carcinoma, Lung, Non-Small-Cell	26339455			C34.90	D002289		HP:0030358	Decreased expression of miR-153 might be a potential unfavorable prognostic factor for patients with NSCLC, and further studies would be needed to prove our findings.
circulation_biomarker_prognosis_down	hsa-mir-204	Carcinoma, Lung, Non-Small-Cell	26497897			C34.90	D002289		HP:0030358	Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
circulation_biomarker_prognosis_down	hsa-mir-200a	Choriocarcinoma	27081702	disease of cellular proliferation	DOID:3594	C58	D002822		HP:0100768	Eleven miRNAs were significantly different between R and NR (miR-154, miR-409-3p, miR-127-3p, miR-214*, miR-299-5p and miR-125b overexpressed in NR; miR-33a, miR-30e, miR-338-3p, miR-200a and miR-378 decreased).
circulation_biomarker_prognosis_down	hsa-mir-296	Colon Neoplasms	22892953			D12.6	D003110		HP:0100273	Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.
circulation_biomarker_prognosis_down	hsa-mir-16	Colorectal Carcinoma	26934556	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-16 levels were significantly lower in the high blood glucose patients
circulation_biomarker_prognosis_down	hsa-mir-126	Coronary Artery Disease	27497911	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Furthermore, plasma miR-126-5p levels were significantly down-regulated in CAD patients with multi-vessel disease, higher SYNTAX score, rather than isolated LMCA and low SYNTAX score.
circulation_biomarker_prognosis_down	hsa-mir-146a	Coronary Artery Disease	28050558	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Reduced Plasma miR-146a Is a Predictor of Poor Coronary Collateral Circulation in Patients with Coronary Artery Disease.
circulation_biomarker_prognosis_down	hsa-mir-148a	Gastric Neoplasms	27529338	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down-regulation of miR-26a and miR-148a was significantly associated with shorter OS of GC patients
circulation_biomarker_prognosis_down	hsa-mir-26a	Gastric Neoplasms	27529338	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Down-regulation of miR-26a and miR-148a was significantly associated with shorter OS of GC patients
circulation_biomarker_prognosis_down	hsa-mir-34a	Gastric Neoplasms	24232982	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Decreased miR-34a expression and increased FOXP1, p53, and BCL2 coexpression to predict a poor OS for MALT lymphoma and DLBCL patients could become very important prognostic markers in daily clinical work. Further investigation of these changes may be of prognostic significance in clinical practice.
circulation_biomarker_prognosis_down	hsa-mir-30c	Human Papilloma Virus Infection	27506865			B97.7	D027383			MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer.
circulation_biomarker_prognosis_down	hsa-mir-150	Hypertension	23220912	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	Reduced miR-150 is Associated with Poor Survival in Pulmonary Arterial Hypertension
circulation_biomarker_prognosis_down	hsa-mir-124-1	Leukemia, Myeloid, Acute	24135052	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	These findings suggest that miR-124-1 underexpression is a common event and might have a favorable impact on prognosis in AML.
circulation_biomarker_prognosis_down	hsa-mir-204	Leukemia, Myeloid, Acute	26126974	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	We showed low miR-204 expression in AML and found it to be an independent prognostic factor in this patient population.
circulation_biomarker_prognosis_down	hsa-mir-215	Leukemia, Myeloid, Acute	26802165	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Our study demonstrates that reduced microRNA-215 expression is a common event and is associated with poor clinical outcome in acute myeloid leukemia.
circulation_biomarker_prognosis_down	hsa-mir-328	Leukemia, Myeloid, Acute	26185105	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.
circulation_biomarker_prognosis_down	hsa-let-7i	Leukemia, Myeloid, Chronic	28512058	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression.
circulation_biomarker_prognosis_down	hsa-mir-224	Leukemia, Myeloid, Chronic	28512058	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression.
circulation_biomarker_prognosis_down	hsa-mir-451	Leukemia, Myeloid, Chronic	27825294	disease of cellular proliferation	DOID:8552	C92.1	D015464		HP:0005506	Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance.
circulation_biomarker_prognosis_down	hsa-let-7a-1	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7a-2	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7a-3	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7b	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7c	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7d	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7e	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7f-1	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7f-2	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7g	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-let-7i	Lung Neoplasms	17940623	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Studies by Takamizawa et al. and Yanaihara et al. have presented evidence that transcripts of certain let-7 homologs are significantly downregulated in human lung cancer and that low levels of let-7 correlate with poor prognosis.
circulation_biomarker_prognosis_down	hsa-mir-129-1	Lymphoma, Large B-Cell, Diffuse	23463124	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)
circulation_biomarker_prognosis_down	hsa-mir-129-2	Lymphoma, Large B-Cell, Diffuse	23463124	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)
circulation_biomarker_prognosis_down	hsa-mir-146b	Lymphoma, Large B-Cell, Diffuse	24931464	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine,and prednisone.
circulation_biomarker_prognosis_down	hsa-mir-320d	Lymphoma, Large B-Cell, Diffuse	24931464	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine,and prednisone.
circulation_biomarker_prognosis_down	hsa-mir-19a	Myeloma	25220540			C90.0	D009101	254500		Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.
circulation_biomarker_prognosis_down	hsa-mir-126	Myocardial Infarction	27497911	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Furthermore, plasma miR-126-5p levels were significantly down-regulated in CAD patients with multi-vessel disease, higher SYNTAX score, rather than isolated LMCA and low SYNTAX score.
circulation_biomarker_prognosis_down	hsa-mir-150	Myocardial Infarction	23967079	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	We enrolled 150 patients after AMI. Blood samples were obtained at discharge for determination of N-terminal pro-brain natriuretic peptide (Nt-proBNP) and levels of miR-16, miR-27a, miR-101 and miR-150.
circulation_biomarker_prognosis_down	hsa-mir-218	Neoplasms [unspecific]	27631228			C80.1	D009369			Prognostic significance of low microRNA-218 expression in patients with different types of cancer: Evidence from published studies.
circulation_biomarker_prognosis_down	hsa-mir-199a	Ovarian Neoplasms	26951510	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Expression of miR-199a was found to be significantly downregulated in comparison with matched normal controls.
circulation_biomarker_prognosis_down	hsa-mir-17	Preeclampsia	26339600	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	ur data indicate that short-term exposure of 3A villous first trimester trophoblasts to H2O2 significantly alters miRNA profile and mRNA expression of genes implicated in defective placental development. Our data, which indicate that oxidative stress alters miRNAs and RNAs expression, could partially explain some of the early changes in gene expression profiles and miRNA observed in PE.
circulation_biomarker_prognosis_down	hsa-mir-128	Prostate Neoplasms	26339409	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our data suggest that the decreased expression of miR-128 in both tissue and serum samples of PCa patients may be associated with tumor malignant progression and BCR-free survival. Particularly, serum miR-128 may be developed as a novel noninvasive biomarker for PCa diagnosis and prognosis.
circulation_biomarker_prognosis_down	hsa-let-7g	Squamous Cell Carcinoma, Head and Neck	25677760	disease of cellular proliferation	DOID:5520	C76.0	C535575			decreased expressions of miR-153, miR-200c, miR-363, miR-203, miR-17, miR-205, miR-Let-7d, Let-7g, miR-34a, miR-126a, miR-375, miR-491-p5, miR 218, miR-451 and miR-125b were associated with poor prognosis.
circulation_biomarker_prognosis_down	hsa-mir-100	Urinary Bladder Cancer	23173870	urinary system disease	DOID:11054	C67	D001749	109800		Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer
circulation_biomarker_prognosis_down	hsa-mir-9-1	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-9*: decreased expression
circulation_biomarker_prognosis_down	hsa-mir-9-2	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-9*: decreased expression
circulation_biomarker_prognosis_down	hsa-mir-9-3	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-9*: decreased expression
circulation_biomarker_prognosis_ns	hsa-mir-29a	Acquired Immunodeficiency Syndrome	27232693	disease by infectious agent	DOID:635	B20	D000163	609423		the expression level of miR-29a was found to be inversely correlated with HIV viral load
circulation_biomarker_prognosis_ns	hsa-mir-145	Adenocarcinoma, Lung	25192889	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	miRNA-145 is strongly associated with overall survival
circulation_biomarker_prognosis_ns	hsa-mir-210	Adenocarcinoma, Lung	25733977	disease of cellular proliferation	DOID:3910	C78.00	C538231	211980	HP:0030078	Significant correlations were found between miR-210 expression and lymph node metastasis, late disease stages, and poor prognosis in patients with adenocarcinoma.
circulation_biomarker_prognosis_ns	hsa-mir-31	Adenocarcinoma, Pancreatic Ductal	24289824	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		In a cohort of 70 patients, the high expression of miR-21 (p=0.018, HR=2.610; 95% CI=1.179-5.777) and miR-31 (p=0.039, HR=2.735; 95% CI=1.317-6.426), the low expression of miR-375 (p=0.022, HR=2.337; 95% CI=1.431-5.066) were associated with poor overall survival following resection, independent of clinical covariates.
circulation_biomarker_prognosis_ns	hsa-mir-1	Atrial Fibrillation	28422282	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery.
circulation_biomarker_prognosis_ns	hsa-mir-23a	Atrial Fibrillation	28422282	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery.
circulation_biomarker_prognosis_ns	hsa-mir-26a	Atrial Fibrillation	28422282	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery.
circulation_biomarker_prognosis_ns	hsa-mir-122	Autoimmune Hepatitis	26575387	immune system disease	DOID:2048	K75.4	D019693			Alternations of miR-21 and miR-122 serum levels could reflect their putative roles in the mediation of inflammatory processes in AIH.
circulation_biomarker_prognosis_ns	hsa-mir-21	Autoimmune Hepatitis	26575387	immune system disease	DOID:2048	K75.4	D019693			Alternations of miR-21 and miR-122 serum levels could reflect their putative roles in the mediation of inflammatory processes in AIH.
circulation_biomarker_prognosis_ns	hsa-let-7c	Breast Neoplasms	24866763	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.
circulation_biomarker_prognosis_ns	hsa-mir-106b	Breast Neoplasms	25619461	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-106b was found to be associated with a high risk of recurrence of breast cancer, and miR-106b is a putative plasma marker for risk assessment in patients with breast cancer.
circulation_biomarker_prognosis_ns	hsa-mir-10b	Breast Neoplasms	25369070	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Moreover, miR-10b, miR-21 and miR-182 were significantly associated to lymph node metastases occurrence in triple negative breast carcinoma while only miR-10b was associated with grade III in non triple negative breast cancer cases.
circulation_biomarker_prognosis_ns	hsa-mir-139	Breast Neoplasms	24866763	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.
circulation_biomarker_prognosis_ns	hsa-mir-141	Breast Neoplasms	25885099	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miR-200c and miR-141 were deregulated in BC comparing with controls. Furthermore, miR-200c and miR-141 were independent prognostic factors and associated with distinct outcomes of BC patients.
circulation_biomarker_prognosis_ns	hsa-mir-182	Breast Neoplasms	25369070	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Moreover, miR-10b, miR-21 and miR-182 were significantly associated to lymph node metastases occurrence in triple negative breast carcinoma
circulation_biomarker_prognosis_ns	hsa-mir-19a	Breast Neoplasms	25137071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Breast Neoplasms	25885099	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating miR-200c and miR-141 were deregulated in BC comparing with controls. Furthermore, miR-200c and miR-141 were independent prognostic factors and associated with distinct outcomes of BC patients.
circulation_biomarker_prognosis_ns	hsa-mir-202	Breast Neoplasms	24983365	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Based on their cancer-specific increase in breast cancer patients,circulating MAGE-A and BORIS mRNAs may be further explored for early detection of breast cancer and monitoring of MAGE-directed immunotherapies. Moreover, serum miR-202 is associated with prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-205	Breast Neoplasms	25137071	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-208a	Breast Neoplasms	26046768	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
circulation_biomarker_prognosis_ns	hsa-mir-21	Breast Neoplasms	25086636	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy
circulation_biomarker_prognosis_ns	hsa-mir-210	Breast Neoplasms	25086636	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy
circulation_biomarker_prognosis_ns	hsa-mir-320d	Breast Neoplasms	24866763	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.
circulation_biomarker_prognosis_ns	hsa-mir-373	Breast Neoplasms	25086636	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy
circulation_biomarker_prognosis_ns	hsa-mir-4728	Breast Neoplasms	26406406	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	MiR-4728-3p had better ability in distinguishing patients with different status of HER2 than miR-4728-5p. And plasma miR-4728-3p might act as a non-invasive biomarker in predicting HER2 status.
circulation_biomarker_prognosis_ns	hsa-mir-516a	Breast Neoplasms	27528030	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Finally, we show that a combination of 2 miRNAs (miR-190b and miR-516a-5p) exhibiting altered expression in TamR cell lines were predictive of  treatment outcome in a cohort of ER+ breast cancer patients receiving adjuvant tamoxifen mono-therapy.
circulation_biomarker_prognosis_ns	hsa-mir-567	Breast Neoplasms	24866763	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.
circulation_biomarker_prognosis_ns	hsa-let-7i	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-103a	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-140	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-21	Carcinoma, Breast	27696295			D05	D001943	114480	HP:0003002	Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.
circulation_biomarker_prognosis_ns	hsa-mir-21	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-25	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-30a	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-30c	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-320a	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-34a	Carcinoma, Breast	27561942			D05	D001943	114480	HP:0003002	Human serum miR-34a as an indicator of exposure to ionizing radiation.
circulation_biomarker_prognosis_ns	hsa-mir-361	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-374b	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-651	Carcinoma, Breast	27959953			D05	D001943	114480	HP:0003002	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
circulation_biomarker_prognosis_ns	hsa-mir-1296	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS
circulation_biomarker_prognosis_ns	hsa-mir-135b	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS.
circulation_biomarker_prognosis_ns	hsa-mir-185	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS.
circulation_biomarker_prognosis_ns	hsa-mir-539	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS.
circulation_biomarker_prognosis_ns	hsa-mir-572	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression signature of five miRNAs (miR-1296, miR-135b, miR-539, miR-572 and miR-185) was found to be prognostic [p = 1.28E-07, HR 8.4 (95 % CI: 3.81-18.52)] for DMFS.
circulation_biomarker_prognosis_ns	hsa-mir-592	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of miR-592 was significantly associated with the MMR status (p.adjusted <0.01).
circulation_biomarker_prognosis_ns	hsa-mir-6826	Carcinoma, Colon	27878288	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer.
circulation_biomarker_prognosis_ns	hsa-mir-6875	Carcinoma, Colon	27878288	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Carcinoma, Esophageal	23838916	disease of cellular proliferation	DOID:1107	C15.9	D004938	133239	HP:0011459	The serum level of miR-200c can be useful for predicting the response to chemotherapy and the prognosis of patients with esophageal cancer who receive neoadjuvant chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-122	Carcinoma, Hepatocellular	27074850	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	HCC and/or histological components of NASH affected serum miR-122 levels, independently.
circulation_biomarker_prognosis_ns	hsa-mir-125b	Carcinoma, Hepatocellular	28814883	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma
circulation_biomarker_prognosis_ns	hsa-mir-125b	Carcinoma, Hepatocellular	27267832	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	serum miR-125b can serve as a biomarker to reliably predict microvascular invasion
circulation_biomarker_prognosis_ns	hsa-mir-128-2	Carcinoma, Hepatocellular	25642945	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma.
circulation_biomarker_prognosis_ns	hsa-mir-148a	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-16	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Also, miR-16, miR-34a, and miR-221 serum levels would have a prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-192	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-21	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-210	Carcinoma, Hepatocellular	24935355	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-210 may represent a novel biomarker for predicting efficacy of transarterial chemoembolization and overall survival for patients with HCC.
circulation_biomarker_prognosis_ns	hsa-mir-221	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Also, miR-16, miR-34a, and miR-221 serum levels would have a prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-224	Carcinoma, Hepatocellular	25688365	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-224 might be BCLC stage dependent. It can reflect the status of tumor and liver damage. It was an independent predictor for the survival of HCC patients.
circulation_biomarker_prognosis_ns	hsa-mir-224	Carcinoma, Hepatocellular	29291025	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	tissue miR-9, miR-21, miR-22, miR-29c, miR-34a, miR-34c, miR-155, miR-199a, miR-200a, miR-203, miR-221 and blood miR-21, miR-148a, miR-192, miR-224 demonstrate significantly prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-34a	Carcinoma, Hepatocellular	29333940	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Also, miR-16, miR-34a, and miR-221 serum levels would have a prognostic value
circulation_biomarker_prognosis_ns	hsa-mir-718	Carcinoma, Hepatocellular	25584485	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Circulating miRs in serum exosomes have potential as novel biomarkers for predicting HCC recurrence.
circulation_biomarker_prognosis_ns	hsa-mir-16-1	Carcinoma, Lung, Non-Small-Cell	23774211			C34.90	D002289		HP:0030358	MiR-16 exhibited the most statistically significant association: high expression of miR-16 was associated with a significantly better survival
circulation_biomarker_prognosis_ns	hsa-mir-29a	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Ten miRNA's were significantly associated with OS, with hsa-miR-29a being the strongest prognostic marker (HR=6.44, 95%-CI 2.39-17.33).
circulation_biomarker_prognosis_ns	hsa-mir-33a	Carcinoma, Lung, Non-Small-Cell	28141816			C34.90	D002289		HP:0030358	Association of microRNA-33a Molecular Signature with Non-Small Cell Lung Cancer Diagnosis and Prognosis after Chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-376a	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS.
circulation_biomarker_prognosis_ns	hsa-mir-424	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS.
circulation_biomarker_prognosis_ns	hsa-mir-500a	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS.
circulation_biomarker_prognosis_ns	hsa-mir-502	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS.
circulation_biomarker_prognosis_ns	hsa-mir-542	Carcinoma, Lung, Non-Small-Cell	24928469			C34.90	D002289		HP:0030358	Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS.
circulation_biomarker_prognosis_ns	hsa-mir-125b-1	Carcinoma, Lung, Non-Small-Cell	22806310			C34.90	D002289		HP:0030358	Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-125b-2	Carcinoma, Lung, Non-Small-Cell	22806310			C34.90	D002289		HP:0030358	Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-146a	Carcinoma, Lung, Non-Small-Cell	24531034			C34.90	D002289		HP:0030358	Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer.
circulation_biomarker_prognosis_ns	hsa-mir-19b	Carcinoma, Lung, Non-Small-Cell	24531034			C34.90	D002289		HP:0030358	Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer.
circulation_biomarker_prognosis_ns	hsa-mir-22	Carcinoma, Lung, Non-Small-Cell	23794259			C34.90	D002289		HP:0030358	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.
circulation_biomarker_prognosis_ns	hsa-mir-24	Carcinoma, Lung, Non-Small-Cell	23794259			C34.90	D002289		HP:0030358	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.
circulation_biomarker_prognosis_ns	hsa-mir-34a	Carcinoma, Lung, Non-Small-Cell	23794259			C34.90	D002289		HP:0030358	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.
circulation_biomarker_prognosis_ns	hsa-mir-103	Carcinoma, Nasopharyngeal	24563490	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Differentially expressed plasma miRNAs as identified by next-generation sequencing can be helpful for predicting survival in NPC patients.
circulation_biomarker_prognosis_ns	hsa-mir-29a	Carcinoma, Nasopharyngeal	24563490	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Differentially expressed plasma miRNAs as identified by next-generation sequencing can be helpful for predicting survival in NPC patients.
circulation_biomarker_prognosis_ns	hsa-mir-483	Carcinoma, Nasopharyngeal	24563490	disease of cellular proliferation	DOID:9261	C11	C538339	607107	HP:0100630	Differentially expressed plasma miRNAs as identified by next-generation sequencing can be helpful for predicting survival in NPC patients.
circulation_biomarker_prognosis_ns	hsa-mir-1274a	Carcinoma, Ovarian	28293063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
circulation_biomarker_prognosis_ns	hsa-mir-141	Carcinoma, Ovarian	28293063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
circulation_biomarker_prognosis_ns	hsa-mir-200b	Carcinoma, Ovarian	28293063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Carcinoma, Ovarian	28293063	endocrine system disease	DOID:4001	C56.9	C538090	167000	HP:0025318	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
circulation_biomarker_prognosis_ns	hsa-mir-192	Carcinoma, Periampullary	28351309	disease of cellular proliferation	DOID:8110					Plasma microRNA192 in combination with serum CA19-9 as non-invasive prognostic biomarker in periampullary carcinoma.
circulation_biomarker_prognosis_ns	hsa-mir-484	Carcinoma, Thyroid, Follicular	27473101	disease of cellular proliferation	DOID:3962	C73	C572845	188470	HP:0006731	The best two-miRNA classifier (miR-484/miR-148b-3p) identified thyroid malignancy with a sensitivity of 89鈥? and a specificity of 87鈥?.
circulation_biomarker_prognosis_ns	hsa-mir-192	Carcinoma, Urothelial	28928837	disease of cellular proliferation	DOID:4006				HP:0030409	hsa-mir-7705, hsa-mir-192 and hsa-mir-518b can be applied as independent prognostic markers for bladder urothelial carcinoma
circulation_biomarker_prognosis_ns	hsa-mir-518b	Carcinoma, Urothelial	28928837	disease of cellular proliferation	DOID:4006				HP:0030409	hsa-mir-7705, hsa-mir-192 and hsa-mir-518b can be applied as independent prognostic markers for bladder urothelial carcinoma
circulation_biomarker_prognosis_ns	hsa-mir-7705	Carcinoma, Urothelial	28928837	disease of cellular proliferation	DOID:4006				HP:0030409	hsa-mir-7705, hsa-mir-192 and hsa-mir-518b can be applied as independent prognostic markers for bladder urothelial carcinoma
circulation_biomarker_prognosis_ns	hsa-mir-126	Cardiovascular Diseases [unspecific]	23391580				D002318			Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra.
circulation_biomarker_prognosis_ns	hsa-mir-21	Central Nervous System Embryonal Tumor	23832112			C72.9	D009373			Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma.
circulation_biomarker_prognosis_ns	hsa-let-7	Chronic Hepatitis C	27227815			B18.2	D019698	609532		reduced levels of let-7a/7c/7d-5p (let-7s) in plasma were correlated with advanced histological hepatic fibrosis stage
circulation_biomarker_prognosis_ns	hsa-mir-122	Chronic Hepatitis C	28401565			B18.2	D019698	609532		Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
circulation_biomarker_prognosis_ns	hsa-mir-199a	Chronic Hepatitis C	28401565			B18.2	D019698	609532		Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
circulation_biomarker_prognosis_ns	hsa-let-7i	Colorectal Carcinoma	25663689	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
circulation_biomarker_prognosis_ns	hsa-mir-106a	Colorectal Carcinoma	26250939	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The present study reveals novel serum-miRNA-based biomarkers for monitoring tumor dynamics as well as for predicting disease recurrence in patients with stage II/III CRC.
circulation_biomarker_prognosis_ns	hsa-mir-10b	Colorectal Carcinoma	25663689	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
circulation_biomarker_prognosis_ns	hsa-mir-130	Colorectal Carcinoma	24304648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-143	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-145	Colorectal Carcinoma	24304648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-145	Colorectal Carcinoma	26250939	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The present study reveals novel serum-miRNA-based biomarkers for monitoring tumor dynamics as well as for predicting disease recurrence in patients with stage II/III CRC.
circulation_biomarker_prognosis_ns	hsa-mir-155	Colorectal Carcinoma	25528214	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the detection of miR-155 levels in the serum might serve as a new tumor biomarker in the diagnosis and assessment of prognosis of CRC.
circulation_biomarker_prognosis_ns	hsa-mir-17	Colorectal Carcinoma	26250939	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The present study reveals novel serum-miRNA-based biomarkers for monitoring tumor dynamics as well as for predicting disease recurrence in patients with stage II/III CRC.
circulation_biomarker_prognosis_ns	hsa-mir-19a	Colorectal Carcinoma	24460313	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Colorectal Carcinoma	23982750	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
circulation_biomarker_prognosis_ns	hsa-mir-20a	Colorectal Carcinoma	24304648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-21	Colorectal Carcinoma	23970420	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Our results suggest that circulating serum miR-21 is a promising prognostic tumour marker, and they highlight the potential clinical utility of miR-21 expression as a prognostic marker for CRC prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-216	Colorectal Carcinoma	24304648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-221	Colorectal Carcinoma	25663689	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
circulation_biomarker_prognosis_ns	hsa-mir-320a	Colorectal Carcinoma	25663689	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
circulation_biomarker_prognosis_ns	hsa-mir-324	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-345	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-34a	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-372	Colorectal Carcinoma	24304648	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-628	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-885	Colorectal Carcinoma	25663689	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We discovered a metastasis-specific miRNA signature in pCRCs and discovered novel tissue- and serum-based CRC metastasis-specific miRNA biomarkers through intensive validation. These unique miRNAs may be clinically applicable to predict prognosis and distant metastasis in CRC.
circulation_biomarker_prognosis_ns	hsa-mir-886	Colorectal Carcinoma	24940606	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		We identified miR-345 in whole blood as a potential biomarker for clinical outcome. MiR-345 was a single prognostic biomarker for both OS and PFS in all patients and also in the non-KRAS mutant population.
circulation_biomarker_prognosis_ns	hsa-mir-197	Coronary Artery Disease	26720041	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Serum-derived circulating miRNA-197 and miRNA-223 were identified as predictors for cardiovascular death in a large patient cohort with CAD. These results reinforce the assumption that circulating miRNAs are promising biomarkers with prognostic value with respect to future cardiovascular events.
circulation_biomarker_prognosis_ns	hsa-mir-223	Coronary Artery Disease	26720041	cardiovascular system disease	DOID:3393	I20-I25	D003324	608320		Serum-derived circulating miRNA-197 and miRNA-223 were identified as predictors for cardiovascular death in a large patient cohort with CAD. These results reinforce the assumption that circulating miRNAs are promising biomarkers with prognostic value with respect to future cardiovascular events.
circulation_biomarker_prognosis_ns	hsa-let-7a	Diabetes Mellitus	24937531	disease of metabolism	DOID:9351	E10-E14	D003920	222100	HP:0000819	Treatment-naïve, poorly controlled diabetic patients show a significant dysregulation of miRNAs involved in the regulation of the adiponectin pathway, a phenomenon that may be reversed, at least in part, by improved glycemic control.
circulation_biomarker_prognosis_ns	hsa-mir-106b	Ependymoma	27390862	disease of cellular proliferation	DOID:5074	C71.0	D004806		HP:0002888	Three miRNAs were shown to efficiently differentiate between grade II and III ependymomas: miR-17-5p, miR-19a-3p, and miR-106b-5p.
circulation_biomarker_prognosis_ns	hsa-mir-21	Esophageal Neoplasms	22519435			C15.9	D004938	133239	HP:0100751	Circulating miR-21 and miR-375 could be reliable prognostic markers for ESCC.
circulation_biomarker_prognosis_ns	hsa-mir-375	Esophageal Neoplasms	22519435			C15.9	D004938	133239	HP:0100751	Circulating miR-21 and miR-375 could be reliable prognostic markers for ESCC.
circulation_biomarker_prognosis_ns	hsa-mir-34a	Fatty Liver, Non-Alcoholic	28853202	disease of metabolism	DOID:0080208	K75.81	D065626	613282		Potentially pro-apoptotic miR-34a was reduced in the vesicle-free fraction in serum but not in liver after UDCA treatment
circulation_biomarker_prognosis_ns	hsa-mir-100	Gastric Neoplasms	23975664	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
circulation_biomarker_prognosis_ns	hsa-mir-17	Gastric Neoplasms	22406928	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The concentrations of plasma miR-17-5p/20a were significantly associated with the differentiation status and TNM stages of gastric cancer. Kaplan-Meier curve analysis revealed that high expression levels of miR-17-5p/20a were significantly correlated with poor overall survival. Cox regression analysis demonstrated that the level of plasma miR-20a was an independent risk predictor for prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-196a	Gastric Neoplasms	27420607	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Taken together, we propose that circulating miR-196a/b  serve as a more sensitive and specific novel biomarker than carbohydrate antigen  19-9 for GC monitor, diagnosis and prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-196b	Gastric Neoplasms	27420607	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Taken together, we propose that circulating miR-196a/b  serve as a more sensitive and specific novel biomarker than carbohydrate antigen  19-9 for GC monitor, diagnosis and prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Gastric Neoplasms	26662382	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Serum miR-200c expression level as a prognostic biomarker for gastric cancer.
circulation_biomarker_prognosis_ns	hsa-mir-20a	Gastric Neoplasms	22406928	disease of cellular proliferation	DOID:10534	C16	D013274	137215		The concentrations of plasma miR-17-5p/20a were significantly associated with the differentiation status and TNM stages of gastric cancer. Kaplan-Meier curve analysis revealed that high expression levels of miR-17-5p/20a were significantly correlated with poor overall survival. Cox regression analysis demonstrated that the level of plasma miR-20a was an independent risk predictor for prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-21	Gastric Neoplasms	24460332	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Plasma post-operative miR-21 expression in the prognosis of gastric cancers.
circulation_biomarker_prognosis_ns	hsa-mir-21	Gastric Neoplasms	26063956	disease of cellular proliferation	DOID:10534	C16	D013274	137215		Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer.
circulation_biomarker_prognosis_ns	hsa-mir-218	Gastric Neoplasms	24944481	disease of cellular proliferation	DOID:10534	C16	D013274	137215		miR-218 is deregulated in gastric cancer patients and is strongly correlated with tumor stage, grade and metastasis. Serum expression of miR-218 may be a prognostic marker.
circulation_biomarker_prognosis_ns	hsa-mir-106a	Glioblastoma	28284220				D005909		HP:0100843	Serum microRNA profiling in patients with glioblastoma: a survival analysis.
circulation_biomarker_prognosis_ns	hsa-mir-145	Glioblastoma	28284220				D005909		HP:0100843	Serum microRNA profiling in patients with glioblastoma: a survival analysis.
circulation_biomarker_prognosis_ns	hsa-mir-182	Glioblastoma	28284220				D005909		HP:0100843	Serum microRNA profiling in patients with glioblastoma: a survival analysis.
circulation_biomarker_prognosis_ns	hsa-mir-20a	Glioblastoma	28284220				D005909		HP:0100843	Serum microRNA profiling in patients with glioblastoma: a survival analysis.
circulation_biomarker_prognosis_ns	hsa-mir-222	Glioblastoma	28284220				D005909		HP:0100843	Serum microRNA profiling in patients with glioblastoma: a survival analysis.
circulation_biomarker_prognosis_ns	hsa-mir-15a	Glioma	25575767	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	the expression of miR-15a is significantly correlated with prognosis in glioma patients, suggesting that the miR-15a may serve as independent prognostic marker.
circulation_biomarker_prognosis_ns	hsa-mir-21	Glioma	25279461	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Moreover, in the GBM dataset miR-21 and miR-210 were predictors  of worse prognosis in both univariable and multivariable Cox regression analyses
circulation_biomarker_prognosis_ns	hsa-mir-454	Glioma	25190548	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Plasma miR-454-3p as a potential prognostic indicator in human glioma.
circulation_biomarker_prognosis_ns	hsa-mir-224	Graves Ophthalmopathy	25588771			E05.00	D049970			baseline serum miR-224-5p was associated with GC sensitivity in GO and in vitro overexpression of miR-224-5p restored GC sensitivity in a resistant cell model. A parameter combined serum miR-224-5p and TRAb could effectively predict GC ensitivity in GO patients.
circulation_biomarker_prognosis_ns	hsa-mir-30d	Heart Failure	28214846			I50	D006331		HP:0001635	Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure.
circulation_biomarker_prognosis_ns	hsa-mir-101	Heart Transplant Rejection	28125729			T86.31				Association of Serum MiR-142-3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation.
circulation_biomarker_prognosis_ns	hsa-mir-142	Heart Transplant Rejection	28125729			T86.31				Association of Serum MiR-142-3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation.
circulation_biomarker_prognosis_ns	hsa-mir-122	Hepatitis C Virus Infection	25811198	disease by infectious agent	DOID:1883	B19.2	D006526	609532		The expression levels of miR-21 and miR-122 were significantly different between the SVR and NR groups.
circulation_biomarker_prognosis_ns	hsa-mir-29a	Human Immunodeficiency Virus Infection	27232693			B20	D015658	609423		the expression level of miR-29a was found to be inversely correlated with HIV viral load
circulation_biomarker_prognosis_ns	hsa-mir-155	Idiopathic Pulmonary Fibrosis	23822889	respiratory system disease	DOID:0050156	J84.112	D054990	178500		These findings suggest that serum miR-21 is associated with IPF and the degree of damage indicated by FVC and radiologic examinations could correlate with miR-21 and miR-155 expression in serum. From another perspective, our study confirmed serum miRNA can be stable and detectable in serum of patients with IPF,which could prove useful as it could be considered as a new biomarker in serum for diagnosis and assessment of prognosis of IPF in the future.
circulation_biomarker_prognosis_ns	hsa-mir-21	Idiopathic Pulmonary Fibrosis	23822889	respiratory system disease	DOID:0050156	J84.112	D054990	178500		These findings suggest that serum miR-21 is associated with IPF and the degree of damage indicated by FVC and radiologic examinations could correlate with miR-21 and miR-155 expression in serum. From another perspective, our study confirmed serum miRNA can be stable and detectable in serum of patients with IPF,which could prove useful as it could be considered as a new biomarker in serum for diagnosis and assessment of prognosis of IPF in the future.
circulation_biomarker_prognosis_ns	hsa-mir-126	Intermittent Claudication	26116711	cardiovascular system disease	DOID:3669	I73.9	D007383		HP:0004417	Whole blood expression of pro-angiogenic microRNA-126 increased after maximal exercise in the PLA session, but treatment with NAC prevented this response.
circulation_biomarker_prognosis_ns	hsa-mir-223	Intestinal Schistosomiasis	24330517	disease by infectious agent	DOID:0050597	B65.1	D012554	181460		This study suggested that the circulating miR-223 could serve as a potential new biomarker for the detection of schistosome infection and the assessment of the response to chemotherapy.
circulation_biomarker_prognosis_ns	hsa-mir-15a	Ischemia	23233752	cardiovascular system disease	DOID:326		D007511	601367		MicroRNA-15a and MicroRNA-16 Impair Human Circulating Proangiogenic Cell Functions and Are Increased in the Proangiogenic Cells and Serum of Patients With Critical Limb Ischemia
circulation_biomarker_prognosis_ns	hsa-mir-155	Leukemia	22209839			C95	D007938	613065	HP:0001909	These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML.
circulation_biomarker_prognosis_ns	hsa-mir-16	Leukemia	19195700			C95	D007938	613065	HP:0001909	Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation.
circulation_biomarker_prognosis_ns	hsa-mir-181a	Leukemia	22209839			C95	D007938	613065	HP:0001909	These results support that miR-128, let-7b, miR-223 and miR181a have a diagnosis value in AL, while miR-181a and miR-155 are of great prognostic significance in AML.
circulation_biomarker_prognosis_ns	hsa-mir-92a-1	Leukemia	21182798			C95	D007938	613065	HP:0001909	The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients
circulation_biomarker_prognosis_ns	hsa-mir-92a-2	Leukemia	21182798			C95	D007938	613065	HP:0001909	The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients
circulation_biomarker_prognosis_ns	hsa-mir-150	Leukemia, Lymphocytic, Chronic, B-Cell	25584781	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Cellular and serum levels of miR-150 are associated with opposite clinical prognoses and could be used to molecularly monitor disease evolution as a new prognostic factor in CLL.
circulation_biomarker_prognosis_ns	hsa-mir-181a-2	Leukemia, Lymphocytic, Chronic, B-Cell	20487546	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-181a:Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and sensitive patients before treatment
circulation_biomarker_prognosis_ns	hsa-mir-221	Leukemia, Lymphocytic, Chronic, B-Cell	20487546	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-221:Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and sensitive patients before treatment
circulation_biomarker_prognosis_ns	hsa-mir-29a	Leukemia, Lymphocytic, Chronic, B-Cell	20487546	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	miR-29a:Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and sensitive patients before treatment
circulation_biomarker_prognosis_ns	hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	28599250	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia.
circulation_biomarker_prognosis_ns	hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	28599250	disease of cellular proliferation	DOID:1040	C91.1	D015451	151400	HP:0005550	Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia.
circulation_biomarker_prognosis_ns	hsa-mir-10	Leukemia, Myeloid, Acute	26134365	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia.
circulation_biomarker_prognosis_ns	hsa-mir-181a	Leukemia, Myeloid, Acute	29166738	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Expression characteristics and prognosis significance of miRNA-181a in acute myeloid leukemia with normal karyotype
circulation_biomarker_prognosis_ns	hsa-mir-146a	Leukemia, Promyelocytic, Acute	25161335	disease of cellular proliferation	DOID:0060318	C92.4	D015473	612376	HP:0004836	These findings indicated that miR-146a played an important role in the development of APL in part through the repression on Smad4 protein expression. miR-146a functioned as an oncogene and may be a novel prognostic biomarker in APL.
circulation_biomarker_prognosis_ns	hsa-mir-16-1	Leukemia-Lymphoma, Adult T-Cell	23260326			C91.51	D015459		HP:0005517	Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia
circulation_biomarker_prognosis_ns	hsa-mir-16-2	Leukemia-Lymphoma, Adult T-Cell	23260326			C91.51	D015459		HP:0005517	Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia
circulation_biomarker_prognosis_ns	hsa-let-7	Lung Neoplasms	27133539	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Patients with a high level of baseline serum let-7 expression level had significantly better overall survival
circulation_biomarker_prognosis_ns	hsa-let-7a-1	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7a-2	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7a-3	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7b	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7c	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7d	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7e	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7f-1	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7f-2	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7g	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-let-7i	Lung Neoplasms	16885332	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	let-7a-1 expression correlates with poor survival of lung cancer patients
circulation_biomarker_prognosis_ns	hsa-mir-197	Lung Neoplasms	26078336	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Especially hsa-miR-197 could be validated by qRT-PCR as prognostic marker.
circulation_biomarker_prognosis_ns	hsa-mir-16	Lymphoma	24447552	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	Significance of microRNA-16 and bcl-2 expression in T lymphoblastic lymphoma/leukemia and its relation with prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-221	Lymphoma	25430553	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	serum miR-221 expression level has prognostic value in patients with CMM.
circulation_biomarker_prognosis_ns	hsa-mir-224	Lymphoma	26301883	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	MiR-224 expression level is implicated as a prognostic marker for DLBCL patients treated with R-CHOP.
circulation_biomarker_prognosis_ns	hsa-mir-150	Lymphoma, B-Cell	22936066	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-155 and miR-150 expression levels were associated with progression-free survival .
circulation_biomarker_prognosis_ns	hsa-mir-155	Lymphoma, B-Cell	22936066	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	miR-155 and miR-150 expression levels were associated with progression-free survival .
circulation_biomarker_prognosis_ns	hsa-mir-122	Lymphoma, Hodgkin	28377796	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.
circulation_biomarker_prognosis_ns	hsa-mir-144	Lymphoma, Hodgkin	28377796	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.
circulation_biomarker_prognosis_ns	hsa-mir-212	Lymphoma, Hodgkin	28377796	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.
circulation_biomarker_prognosis_ns	hsa-mir-23b	Lymphoma, Hodgkin	28377796	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.
circulation_biomarker_prognosis_ns	hsa-mir-510	Lymphoma, Hodgkin	28377796	disease of cellular proliferation	DOID:8567	C81	D006689	236000	HP:0012189	Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas.
circulation_biomarker_prognosis_ns	hsa-mir-1236	Lymphoma, Large B-Cell, Diffuse	24858372	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen.
circulation_biomarker_prognosis_ns	hsa-mir-214	Lymphoma, Large B-Cell, Diffuse	25723320	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
circulation_biomarker_prognosis_ns	hsa-mir-223	Lymphoma, Large B-Cell, Diffuse	22932402	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		As a potential prognostic biomarker, overexpression of miR-223 correlates with a longer OS of patients with DLBCL (diffuse large B cell lymphoma).
circulation_biomarker_prognosis_ns	hsa-mir-224	Lymphoma, Large B-Cell, Diffuse	24858372	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen.
circulation_biomarker_prognosis_ns	hsa-mir-224	Lymphoma, Large B-Cell, Diffuse	25052605	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		miR-224 expression may play an important role in the development and progression of DLBCL and could be prognostic significance.
circulation_biomarker_prognosis_ns	hsa-mir-28	Lymphoma, Large B-Cell, Diffuse	25723320	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
circulation_biomarker_prognosis_ns	hsa-mir-339	Lymphoma, Large B-Cell, Diffuse	25723320	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
circulation_biomarker_prognosis_ns	hsa-mir-33a	Lymphoma, Large B-Cell, Diffuse	24858372	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen.
circulation_biomarker_prognosis_ns	hsa-mir-455	Lymphoma, Large B-Cell, Diffuse	24858372	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen.
circulation_biomarker_prognosis_ns	hsa-mir-520d	Lymphoma, Large B-Cell, Diffuse	24858372	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		novel prognostic biomarkers to predict the clinical outcome of DLBCL patients treated with R-CHOP regimen.
circulation_biomarker_prognosis_ns	hsa-mir-5586	Lymphoma, Large B-Cell, Diffuse	25723320	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
circulation_biomarker_prognosis_ns	hsa-mir-200c	Malignant Neoplasms [unspecific]	26556949			C80.1	D009369			Our findings indicated that, compared to their tissue counterparts, the expression level of miR-200c and miR-141 in peripheral blood may be more effective for monitoring cancer prognosis. High miR-141 expression was better at predicting tumor progression than survival for malignant tumors.
circulation_biomarker_prognosis_ns	hsa-mir-210	Melanoma	25749524	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
circulation_biomarker_prognosis_ns	hsa-let-7b	Multiple Myeloma	28213378	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Prognostic role of circulating exosomal miRNAs in multiple myeloma.
circulation_biomarker_prognosis_ns	hsa-mir-18a	Multiple Myeloma	28213378	disease of cellular proliferation	DOID:9538		D009101	254500	HP:0006775	Prognostic role of circulating exosomal miRNAs in multiple myeloma.
circulation_biomarker_prognosis_ns	hsa-mir-15b	Multiple Sclerosis	27725128	nervous system disease	DOID:2377	G35	D009103	PS126200		Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
circulation_biomarker_prognosis_ns	hsa-mir-223	Multiple Sclerosis	27725128	nervous system disease	DOID:2377	G35	D009103	PS126200		Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
circulation_biomarker_prognosis_ns	hsa-mir-23a	Multiple Sclerosis	27725128	nervous system disease	DOID:2377	G35	D009103	PS126200		Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
circulation_biomarker_prognosis_ns	hsa-let-7a-1	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7a-2	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7a-3	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7b	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7c	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7d	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7e	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7f-1	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7f-2	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7g	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-let-7i	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-181a-1	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-181a-2	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-181b-2	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-181c	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-181d	Myelodysplastic Syndromes	21332710	disease of cellular proliferation	DOID:0050908	D46.9	D009190	614286	HP:0002863	dysregulated
circulation_biomarker_prognosis_ns	hsa-mir-133a-1	Myocardial Infarction	23137501	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction
circulation_biomarker_prognosis_ns	hsa-mir-133a-2	Myocardial Infarction	23137501	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction
circulation_biomarker_prognosis_ns	hsa-mir-499	Myocardial Infarction	24461971	cardiovascular system disease	DOID:5844	I21	D009203	608557	HP:0001658	Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction.
circulation_biomarker_prognosis_ns	hsa-mir-149	Neoplasms [unspecific]	24180461			C80.1	D009369			The regression analysis identified tumour stage and miR-31 and miR-149 expression as independently associated with tumour progression and tumour stage and miR-149 expression as independently associated with cancer-specific survival.
circulation_biomarker_prognosis_ns	hsa-mir-200	Neoplasms [unspecific]	28321402			C80.1	D009369			Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis.
circulation_biomarker_prognosis_ns	hsa-mir-21	Neoplasms [unspecific]	24076132			C80.1	D009369			Our findings suggest that circulating miR-21 may not suitable to be a diagnostic biomarker, but it has a prognostic value in patients with cancer.
circulation_biomarker_prognosis_ns	hsa-mir-21	Neoplasms [unspecific]	24664585			C80.1	D009369			The present meta-analysis suggests that circulating miR-21 expression is associated with poor survival in patients with cancer and could be a prognostic biomarker for those patients.
circulation_biomarker_prognosis_ns	hsa-mir-221	Neoplasms [unspecific]	24319365			C80.1	D009369			Lack of significant association between plasma/serum miR-221 expression and poor survival of carcinoma: a meta analysis.
circulation_biomarker_prognosis_ns	hsa-mir-133b	Osteosarcoma	25120799	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma.
circulation_biomarker_prognosis_ns	hsa-mir-206	Osteosarcoma	25120799	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma.
circulation_biomarker_prognosis_ns	hsa-mir-21	Osteosarcoma	23321165	disease of cellular proliferation	DOID:3347		D012516	259500	HP:0002669	Identification of Serum MicroRNA-21 as a Biomarker for Chemosensitivity and Prognosis in Human Osteosarcoma
circulation_biomarker_prognosis_ns	hsa-let-7a-1	Ovarian Neoplasms	21571355	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	let-7a is a potential marker for selection of paclitaxel in ovarian cancer management.
circulation_biomarker_prognosis_ns	hsa-let-7f	Ovarian Neoplasms	24223734	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our findings indicate that plasma miR-205 and let-7f are biomarkers for ovarian cancer detection that complement CA-125; let-7f may be predictive of ovarian cancer prognosis.
circulation_biomarker_prognosis_ns	hsa-mir-141	Ovarian Neoplasms	25636451	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200c and miR-141 may be predictive biomarkers for ovarian cancer prognosis. Further large-scale studies are still needed to confirm our findings.
circulation_biomarker_prognosis_ns	hsa-mir-200a	Ovarian Neoplasms	26063644	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients.
circulation_biomarker_prognosis_ns	hsa-mir-200b	Ovarian Neoplasms	26063644	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Ovarian Neoplasms	25636451	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	miR-200c and miR-141 may be predictive biomarkers for ovarian cancer prognosis. Further large-scale studies are still needed to confirm our findings.
circulation_biomarker_prognosis_ns	hsa-mir-200c	Ovarian Neoplasms	26063644	endocrine system disease	DOID:2394	C56	D010051	167000	HP:0100615	Our findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients.
circulation_biomarker_prognosis_ns	hsa-mir-181d	Pancreatic Neoplasms	27380024	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		serum miR-181d was significantly associated with the presence of metastasis in patients with PDA
circulation_biomarker_prognosis_ns	hsa-mir-105	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-132	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-135a	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-142	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-147	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-155	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-223	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-298	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-299a	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-325	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-410	Pelvic Inflammatory Disease	24961692	reproductive system disease	DOID:1003	N70-N77	D000292			Early microRNA expression profile as a prognostic biomarker for the development of pelvic inflammatory disease in a mouse model of chlamydial genital infection.
circulation_biomarker_prognosis_ns	hsa-mir-101	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-191	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-223	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-25	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-26b	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-29a	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-335	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-433	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-516	Pleural Mesothelioma	26262875	disease of cellular proliferation	DOID:7474	C45.0	D054363		HP:0100002	In conclusion, we suggest that miRNA signature A is predictive of sarcomatoid histotype and of worse prognosis in MPM.
circulation_biomarker_prognosis_ns	hsa-mir-21	Preeclampsia	28694210	cardiovascular system disease	DOID:10591	O14	D011225	PS189800	HP:0100602	Circulating microRNA expression as predictor of preeclampsia and its severity.
circulation_biomarker_prognosis_ns	hsa-let-7	Prostate Neoplasms	23798998	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
circulation_biomarker_prognosis_ns	hsa-mir-18a	Retinoblastoma	27574784	nervous system disease	DOID:768	C69.20	D012175	180200	HP:0009919	Downregulation of inhibitor of apoptosis proteins, tumor miRNA-18a, altered serum cytokines, and serum miRNA-18a levels were observed upon NCL-APT treatment
circulation_biomarker_prognosis_ns	hsa-mir-122	Sepsis	25672224			A41.9	D018805		HP:0100806	Serum miR-122 correlates with short-term mortality in sepsis patients.
circulation_biomarker_prognosis_ns	hsa-mir-15a	Sepsis	26683209			A41.9	D018805		HP:0100806	The plasma levels of miRNA are altered in patients with severe sepsis complicated by shock and may offer prognostic value as well as insights into the mechanisms of endothelial dysfunction in sepsis.
circulation_biomarker_prognosis_ns	hsa-mir-27a	Sepsis	26683209			A41.9	D018805		HP:0100806	The plasma levels of miRNA are altered in patients with severe sepsis complicated by shock and may offer prognostic value as well as insights into the mechanisms of endothelial dysfunction in sepsis.
circulation_biomarker_prognosis_ns	hsa-mir-16	Squamous Cell Carcinoma, Esophageal	26692950	disease of cellular proliferation	DOID:3748		C562729			the level of miR-16 in the patients with good outcome was significantly higher than that in the patients with poor outcome
circulation_biomarker_prognosis_ns	hsa-mir-223	Squamous Cell Carcinoma, Esophageal	24390317	disease of cellular proliferation	DOID:3748		C562729			miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC.
circulation_biomarker_prognosis_ns	hsa-mir-25	Squamous Cell Carcinoma, Esophageal	24390317	disease of cellular proliferation	DOID:3748		C562729			miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC.
circulation_biomarker_prognosis_ns	hsa-mir-375	Squamous Cell Carcinoma, Esophageal	24390317	disease of cellular proliferation	DOID:3748		C562729			miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC.
circulation_biomarker_prognosis_ns	hsa-mir-455	Squamous Cell Carcinoma, Head and Neck	27109697	disease of cellular proliferation	DOID:5520	C76.0	C535575			miR-193b-3p and miR-455-5p were positively associated with survival, and miR-92a-3p and miR-497-5p were negatively associated with survival in OPSCC.
circulation_biomarker_prognosis_ns	hsa-mir-124	Toxic Epidermal Necrolysis	26394757	disease by infectious agent	DOID:9063	L51.2	D013206	608579		The serum miR-124 concentration can be used as a disease activity marker for severe drug eruptions, reflecting the severity of keratinocyte apoptosis.
circulation_biomarker_prognosis_up	hsa-mir-155	Acute Myocardial Infarction	22995291	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Real-time RT-PCR confirmed that the serum levels of miR-155 and miR-380* were approximately 4- and 3-fold higher, respectively, in patients who experienced cardiac death within 1 year after discharge.
circulation_biomarker_prognosis_up	hsa-mir-380	Acute Myocardial Infarction	22995291	cardiovascular system disease	DOID:9408	I21	D056989	608446	HP:0001658	Real-time RT-PCR confirmed that the serum levels of miR-155 and miR-380* were approximately 4- and 3-fold higher, respectively, in patients who experienced cardiac death within 1 year after discharge.
circulation_biomarker_prognosis_up	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	26705427	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Upregulation of these microRNAs was associated with a significantly shorter overall survival and recurrence-free survival
circulation_biomarker_prognosis_up	hsa-mir-21	Adenocarcinoma, Pancreatic Ductal	26969625	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Our meta-analysis indicated that elevated miR-21 expression level can predict poor prognosis in patients with PDAC.
circulation_biomarker_prognosis_up	hsa-mir-210	Adenocarcinoma, Pancreatic Ductal	26705427	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Upregulation of these microRNAs was associated with a significantly shorter overall survival and recurrence-free survival
circulation_biomarker_prognosis_up	hsa-mir-483	Adenocarcinoma, Pancreatic Ductal	26124009	disease of cellular proliferation	DOID:3498	C25.3	D021441	260350		Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
circulation_biomarker_prognosis_up	hsa-mir-210	Aortic Stenosis	24626394	cardiovascular system disease	DOID:1712	I35.0	D001024	109730	HP:0001650	Circulating miR-210 levels are increased in patients with AS and provide independent prognostic information to established risk indices.Analytical characteristics were also excellent supporting the potential of micro-RNAs as novel CV biomarkers.
circulation_biomarker_prognosis_up	hsa-mir-133b	Atrial Fibrillation	29676832	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF
circulation_biomarker_prognosis_up	hsa-mir-328	Atrial Fibrillation	29676832	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF
circulation_biomarker_prognosis_up	hsa-mir-499	Atrial Fibrillation	29676832	cardiovascular system disease	DOID:0060224	I48.0	D001281	PS608583	HP:0005110	The miRNAs had different expression profiles dependent on the AF condition, with higher expression in the acute new-onset AF than well-controlled AF
circulation_biomarker_prognosis_up	hsa-mir-21	B-cell Childhood Acute Lymphoblastic Leukemia	28253825	disease of cellular proliferation	DOID:0080146					Upregulation of microRNA-21 is a poor prognostic marker in patients with childhood B cell acute lymphoblastic leukemia.
circulation_biomarker_prognosis_up	hsa-mir-155	Bladder Neoplasms	25918190			C67	D001749	109800	HP:0009725	We found that elevated expression of miR-155 is correlated with a poor outcome for patients with bladder cancer; this suggests that miR-155 is a potential biomarker for bladder cancer prognosis.
circulation_biomarker_prognosis_up	hsa-mir-21	Brain Neoplasms	25790954	disease of cellular proliferation	DOID:1319	C71	D001932	603688	HP:0030692	microRNA-21 is associated with the prognosis of patients with brain tumors,  and high expression of microRNA-21 can predict poor prognosis in patients with brain tumors.
circulation_biomarker_prognosis_up	hsa-mir-10b	Breast Neoplasms	24416156	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High levels of miR-21 and miR-10b were present in the serum of patients with non-metastatic and metastatic HER2(+) breast cancer, respectively. High levels of serum miR-19a may represent a biomarker for IBC that is predictive for favorable clinical outcome in patients with metastatic HER2(+) IBC.
circulation_biomarker_prognosis_up	hsa-mir-146b	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_up	hsa-mir-155	Breast Neoplasms	25503185	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a possible involvement of miR-155 in surgery-induced angiogenesis and potential prognostic significance of high postoperative levels of circulating miR-195 in patients with breast cancer.
circulation_biomarker_prognosis_up	hsa-mir-15a	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_up	hsa-mir-16	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_up	hsa-mir-181b	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_up	hsa-mir-195	Breast Neoplasms	25503185	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a possible involvement of miR-155 in surgery-induced angiogenesis and potential prognostic significance of high postoperative levels of circulating miR-195 in patients with breast cancer.
circulation_biomarker_prognosis_up	hsa-mir-19a	Breast Neoplasms	24416156	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High levels of miR-21 and miR-10b were present in the serum of patients with non-metastatic and metastatic HER2(+) breast cancer, respectively. High levels of serum miR-19a may represent a biomarker for IBC that is predictive for favorable clinical outcome in patients with metastatic HER2(+) IBC.
circulation_biomarker_prognosis_up	hsa-mir-203	Breast Neoplasms	28351024	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer
circulation_biomarker_prognosis_up	hsa-mir-21	Breast Neoplasms	24416156	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	High levels of miR-21 and miR-10b were present in the serum of patients with non-metastatic and metastatic HER2(+) breast cancer, respectively. High levels of serum miR-19a may represent a biomarker for IBC that is predictive for favorable clinical outcome in patients with metastatic HER2(+) IBC.
circulation_biomarker_prognosis_up	hsa-mir-21	Breast Neoplasms	25503185	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	a possible involvement of miR-155 in surgery-induced angiogenesis and potential prognostic significance of high postoperative levels of circulating miR-195 in patients with breast cancer.
circulation_biomarker_prognosis_up	hsa-mir-21	Breast Neoplasms	18812439	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	miR-21: miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis
circulation_biomarker_prognosis_up	hsa-mir-21	Breast Neoplasms	25277099	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	Women with metastatic breast cancer, especially CSII, presented up-regulated levels of miR-183, miR-494 and miR-21, which were associated with a  poor prognosis.
circulation_biomarker_prognosis_up	hsa-mir-34a	Breast Neoplasms	29189128	thoracic disease	DOID:1612	C50	D001943	114480	HP:0100013	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin
circulation_biomarker_prognosis_up	hsa-mir-18b	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-302a	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-423	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-523	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-582	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-888	Carcinoma, Colon	27485175	gastrointestinal system disease	DOID:1520	D01.0	C028885		HP:0003003	The expression of several novel miRNAs were found to be tumour specific, e.g. miR-888, miR-523, miR-18b, miR-302a, miR-423-5p, miR-582-3p (p < 0.05).
circulation_biomarker_prognosis_up	hsa-mir-101	Carcinoma, Hepatocellular	27498785	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High miR-101 expression, vascular invasion, tumor  size 鈮? cm and late pathological stage were the risk factors of recurrence-free survival rate.
circulation_biomarker_prognosis_up	hsa-mir-122	Carcinoma, Hepatocellular	25636448	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	high serum miR-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients, and it is a good biomarker of better prognosis in patients with hepatocellular carcinoma.
circulation_biomarker_prognosis_up	hsa-mir-122	Carcinoma, Hepatocellular	26129878	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High plasma microRNA-122 expression was associated with poor OS in patients with HBV-related hepatocellular carcinoma who underwent RFA.
circulation_biomarker_prognosis_up	hsa-mir-17	Carcinoma, Hepatocellular	23108086	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma
circulation_biomarker_prognosis_up	hsa-mir-221	Carcinoma, Hepatocellular	21295551	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Serum miR-221, upregulated in HCC, can provide predictive significance for prognosis of HCC patients.
circulation_biomarker_prognosis_up	hsa-mir-522	Carcinoma, Hepatocellular	27466991	disease of cellular proliferation	DOID:684	C22.0	D006528	114550	HP:0001402	Upregulation of miR-522 is associated with poor outcome of hepatocellular carcinoma.
circulation_biomarker_prognosis_up	hsa-mir-221	Carcinoma, Lung, Non-Small-Cell	25466375			C34.90	D002289		HP:0030358	High serum miR-155 and miR-221 during the first 2 weeks of CRT were  associated with the development of severe RIET
circulation_biomarker_prognosis_up	hsa-mir-211	Carcinoma, Oral	18946016	gastrointestinal system disease	DOID:0050610					miR-211: Association between high miR-211 microRNA expression and the poor prognosis
circulation_biomarker_prognosis_up	hsa-mir-221	Carcinoma, Renal Cell	24379138	disease of cellular proliferation	DOID:4450		D002292	144700	HP:0005584	Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients.
circulation_biomarker_prognosis_up	hsa-mir-21	Carcinoma, Urothelial	27383043	disease of cellular proliferation	DOID:4006				HP:0030409	miR-21 may be a prognostic marker for cancer progression.
circulation_biomarker_prognosis_up	hsa-mir-21	Cervical Neoplasms	27101583	disease of cellular proliferation	DOID:4362	C53.9	D002583	603956	HP:0030159	Increased circulating miR-21 expression in serum is associated with lymph node metastasis in patients with cervical cancer.
circulation_biomarker_prognosis_up	hsa-mir-181c	Cholangiocarcinoma	27533020	disease of cellular proliferation	DOID:4947	C22.1	D018281	615619	HP:0030153	Down-regulation of NDRG2 and overexpression of miR-181c or LIF are significantly associated with a poorer overall survival (OS) in CCA patients.
circulation_biomarker_prognosis_up	hsa-mir-1260b	Colorectal Carcinoma	27399918	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		The high expression level of miR-1260b is an independent prognostic biomarker that indicates a worse prognosis for patients with CRC.
circulation_biomarker_prognosis_up	hsa-mir-183	Colorectal Carcinoma	25629978	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the elevated miR-183 in the plasma could be a promising biomarker for predicting the risk of tumor recurrence and poor survival in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-203	Colorectal Carcinoma	26701878	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Serum miR-203 levels were significantly upregulated in a stage-dependent manner, and high miR-203 expression was associated with poor survival in patients with CRC in both patient cohorts.
circulation_biomarker_prognosis_up	hsa-mir-203	Colorectal Carcinoma	28351024	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer
circulation_biomarker_prognosis_up	hsa-mir-141	Colorectal Carcinoma	21445232	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		High levels of plasma miR-141 predicted poor survival in both cohorts and that miR-141 was an independent prognostic factor for advanced colon cancer.
circulation_biomarker_prognosis_up	hsa-mir-17	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-18	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-19a	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-19b-1	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-20a	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-92-1	Colorectal Carcinoma	26057451	disease of cellular proliferation	DOID:0080199	C19	D015179	114500		Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
circulation_biomarker_prognosis_up	hsa-mir-126	Diabetic Foot	27623390			E10-11.621	D017719			Increasing the miR-126 expression in the peripheral blood of patients with diabetic foot ulcers treated with maggot debridement therapy.
circulation_biomarker_prognosis_up	hsa-mir-29c	Diabetic Nephropathy	27279796			E10-11.21	D003928			miR-21, miR-29a/b/c and miR-192 could reflect DN pathogenesis
circulation_biomarker_prognosis_up	hsa-let-7d	Glioblastoma	22722712				D005909		HP:0100843	miR-181b, miR-153, miR-145, miR-137, and let-7d were significantly upregulated after treatment with both TMZ (temozolomide ) and OLE (Olea europaea leaf extract).
circulation_biomarker_prognosis_up	hsa-mir-21	Glioblastoma	27531352				D005909		HP:0100843	Further subgroup analysis indicated that increased expression of miRNA-21 was also associated with OS in GBM patients.
circulation_biomarker_prognosis_up	hsa-mir-21	Glioma	27531352	disease of cellular proliferation	DOID:3070		D005910	PS137800	HP:0009733	Our analysis  revealed that the high expression of miRNA-21 is associated with the worse OS in  gliomas.
circulation_biomarker_prognosis_up	hsa-mir-1	Heart Failure	23079087			I50	D006331		HP:0001635	Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction.
circulation_biomarker_prognosis_up	hsa-mir-133a	Hypertension	27514547	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The hypertensive ocean seamen had significantly higher expression levels of microRNA21 and MicroRNA133a than the healthy ocean seamen.
circulation_biomarker_prognosis_up	hsa-mir-21	Hypertension	27514547	cardiovascular system disease	DOID:10763	I10	D006973	145500	HP:0000822	The hypertensive ocean seamen had significantly higher expression levels of microRNA21 and MicroRNA133a than the healthy ocean seamen.
circulation_biomarker_prognosis_up	hsa-mir-183	Kidney Neoplasms	26091793	disease of cellular proliferation	DOID:263	C64	D007680			High serum miR-183 level is associated with poor responsiveness of renal cancer to natural killer cells.
circulation_biomarker_prognosis_up	hsa-mir-24	Leukemia, Acute	25672522	disease of cellular proliferation	DOID:12603	C95.0		308960	HP:0002488	High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia.
circulation_biomarker_prognosis_up	hsa-mir-221	Leukemia, Lymphoblastic, Acute	23566596	disease of cellular proliferation	DOID:9952	C91.0	D054198	247640	HP:0006721	Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia
circulation_biomarker_prognosis_up	hsa-mir-100	Leukemia, Myeloid, Acute	23055746	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia
circulation_biomarker_prognosis_up	hsa-mir-126	Leukemia, Myeloid, Acute	25759982	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The results of the present study demonstrated that higher expression levels of miR-126-5p/3p in patients with AML resulted in a poorer prognosis. Furthermore, miR-126-5p elevated the phosphorylation of Akt.
circulation_biomarker_prognosis_up	hsa-mir-146b	Leukemia, Myeloid, Acute	28473658	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	high expression of  hsa-miR-146b was independent poor prognostic factor
circulation_biomarker_prognosis_up	hsa-mir-155	Leukemia, Myeloid, Acute	27511899	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	High miR-155 expression is an adverse prognostic factor in pediatric NK-AML patients.
circulation_biomarker_prognosis_up	hsa-mir-155	Leukemia, Myeloid, Acute	27531760	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	The high expression of miR-155 is an poor prognostic  factor for patients with AML.
circulation_biomarker_prognosis_up	hsa-mir-181c	Leukemia, Myeloid, Acute	28473658	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	high expression of hsa-miR-181c and hsa-miR-4786 appeared to be favorable factors
circulation_biomarker_prognosis_up	hsa-mir-375	Leukemia, Myeloid, Acute	23864342	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia.
circulation_biomarker_prognosis_up	hsa-mir-551b	Leukemia, Myeloid, Acute	26108690	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia.
circulation_biomarker_prognosis_up	hsa-mir-663a	Leukemia, Myeloid, Acute	21518431	disease of cellular proliferation	DOID:9119	C92.0	D015470		HP:0004820	Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663
circulation_biomarker_prognosis_up	hsa-mir-155	Lung Neoplasms	17028302	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	A high expression of miR-155 has been suggested to be significantly associated with unfavorable prognosis in lung adenocarcinoma patients.
circulation_biomarker_prognosis_up	hsa-mir-155	Lung Neoplasms	17028596	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	High mir-155 associated with poor prognosis in lung cancer (Yanaihara et al., 2006).
circulation_biomarker_prognosis_up	hsa-mir-183	Lung Neoplasms	21920043	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression levels of members of the miR-183 family in lung cancer tumor and sera were higher than that of their normal counterparts. The miR-96 expression in tumors was positively associated with its expression in sera. Log-rank and Cox regression analyses demonstrated that high expression of tumor and serum miRNAs of the miR-183 family were associated with overall poor survival in patients with lung cancer.
circulation_biomarker_prognosis_up	hsa-mir-200c	Lung Neoplasms	21516486	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer
circulation_biomarker_prognosis_up	hsa-mir-21	Lung Neoplasms	21516486	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer
circulation_biomarker_prognosis_up	hsa-mir-96	Lung Neoplasms	21920043	disease of cellular proliferation	DOID:1324	C34.1-.3	D008175		HP:0100526	Expression levels of members of the miR-183 family in lung cancer tumor and sera were higher than that of their normal counterparts. The miR-96 expression in tumors was positively associated with its expression in sera. Log-rank and Cox regression analyses demonstrated that high expression of tumor and serum miRNAs of the miR-183 family were associated with overall poor survival in patients with lung cancer.
circulation_biomarker_prognosis_up	hsa-mir-18b	Lymphoma	25736311	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
circulation_biomarker_prognosis_up	hsa-mir-21	Lymphoma	22541087	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The expression of miR-21 in plasma of lymphoma patient group significantly correlated with their serum LDH level. The expressions of miR-21 and miR-210 in plasma of previously untreated lymphoma patient group were higher than those of the patients treated for 6 or more courses
circulation_biomarker_prognosis_up	hsa-mir-210	Lymphoma	22541087	disease of cellular proliferation	DOID:0060058	C85.9	D008223		HP:0002665	The expression of miR-21 in plasma of lymphoma patient group significantly correlated with their serum LDH level. The expressions of miR-21 and miR-210 in plasma of previously untreated lymphoma patient group were higher than those of the patients treated for 6 or more courses
circulation_biomarker_prognosis_up	hsa-mir-34a	Lymphoma, B-Cell	26854484	disease of cellular proliferation	DOID:707		D016393	109565	HP:0012191	High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
circulation_biomarker_prognosis_up	hsa-mir-17	Lymphoma, Burkitt	27044389	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis.
circulation_biomarker_prognosis_up	hsa-mir-20a	Lymphoma, Burkitt	27044389	disease of cellular proliferation	DOID:8584	C83.7	D002051	113970	HP:0030080	We  found that upregulated expression of miR-17 and miR-20a correlates with lack of pro-apoptotic Bim expression.
circulation_biomarker_prognosis_up	hsa-mir-125b	Lymphoma, Large B-Cell	26870228			C83.3	D016403	109565		high miR-125b indicated poor prognosis
circulation_biomarker_prognosis_up	hsa-mir-200c	Lymphoma, Large B-Cell, Diffuse	23232598	disease of cellular proliferation	DOID:0050745	C83.3	D016403	109565		High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma
circulation_biomarker_prognosis_up	hsa-mir-141	Malignant Neoplasms [unspecific]	26556949			C80.1	D009369			Our findings indicated that, compared to their tissue counterparts, the expression level of miR-200c and miR-141 in peripheral blood may be more effective for monitoring cancer prognosis. High miR-141 expression was better at predicting tumor progression than survival for malignant tumors.
circulation_biomarker_prognosis_up	hsa-mir-15b	Melanoma	25155861	disease of cellular proliferation	DOID:1909	C43.9	D008545	155601	HP:0002861	Serum miR-15b levels significantly increased over time in recurrent patients
circulation_biomarker_prognosis_up	hsa-mir-206	Myotonic Muscular Dystrophy	25915631			G71.11	D009223	160900		Specifically, miR-1, miR-133a, miR133b and miR-206 serum levels were found elevated in DM1 patients with progressive muscle wasting compared to disease stable DM1 patients.
circulation_biomarker_prognosis_up	hsa-mir-200c	Neoplasms [unspecific]	24870778			C80.1	D009369			Low expression of microRNA 200c in tumor tissue and high expression of microRNA 200c in serum are associated with worse survival in solid tumors. Further study is needed to elucidate this contradiction.
circulation_biomarker_prognosis_up	hsa-mir-27a	Neoplasms [unspecific]	24122958			C80.1	D009369			miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer.
circulation_biomarker_prognosis_up	hsa-mir-10b	Pancreatic Adenocarcinoma	27456015	disease of cellular proliferation	DOID:4074	C25.3				We conclude that elevated miRNA-10b levels in station 8 lymph nodes could be utilized to assess risk for early disease progression in patients with periampullary tumors.
circulation_biomarker_prognosis_up	hsa-mir-21	Pancreatic Neoplasms	21139804	disease of cellular proliferation	DOID:1793	C25.0-.2	D010190	260350		upregulated and correlated with worse survival
circulation_biomarker_prognosis_up	hsa-mir-146b	Prostate Neoplasms	23846169	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Multivariate analysis revealed that miR-146b-3p possessed prognostic information beyond standard clinicopathological parameters. 
circulation_biomarker_prognosis_up	hsa-mir-194	Prostate Neoplasms	23846169	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Analysis of tissue cohorts revealed that miR-194 was robustly expressed in the prostate, elevated in metastases, and its expression in primary tumours was associated with a poor prognosis.
circulation_biomarker_prognosis_up	hsa-mir-21	Prostate Neoplasms	26247873	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Our study demonstrates that high miR-21 expression levels in PBMCs were correlated with the presence, recurrence, and metastasis of PCa and that this may be a useful biomarker for screening PCa and monitoring the risk of Pca recurrence and metastasis.
circulation_biomarker_prognosis_up	hsa-mir-221	Prostate Neoplasms	24760272	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies.
circulation_biomarker_prognosis_up	hsa-mir-7	Prostate Neoplasms	24760272	disease of cellular proliferation	DOID:10283	C51	D011471	176807	HP:0100787	Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies.
circulation_biomarker_prognosis_up	hsa-mir-125b-1	Rectal Neoplasms	18695884	disease of cellular proliferation	DOID:1984		D012004			miR-125b: frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer
circulation_biomarker_prognosis_up	hsa-mir-125b-2	Rectal Neoplasms	18695884	disease of cellular proliferation	DOID:1984		D012004			miR-125b: frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer
circulation_biomarker_prognosis_up	hsa-mir-137	Rectal Neoplasms	18695884	disease of cellular proliferation	DOID:1984		D012004			miR-137: frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer
circulation_biomarker_prognosis_up	hsa-mir-125b	Rectum Adenocarcinoma	27081702	disease of cellular proliferation	DOID:1996	C20				High miR-125b expression in tissue and serum were associated with a poor treatment response in LARC patients
circulation_biomarker_prognosis_up	hsa-mir-206	Rhabdomyosarcoma	28834127	disease of cellular proliferation	DOID:3247	M62.82	D012208	268220	HP:0002859	Serum microRNA-206 levels were elevated and remained high after three cycles of vincristine, dactinomycin, and cyclophosphamide (VAC)
circulation_biomarker_prognosis_up	hsa-mir-18a	Squamous Cell Carcinoma, Head and Neck	25677760	disease of cellular proliferation	DOID:5520	C76.0	C535575			significant elevated expressions of  miR-21, miR-18a, miR-134a, miR-210, miR-181a, miR-19a, and miR-155 were associated with poor survival in human HNSCC.
circulation_biomarker_prognosis_up	hsa-mir-183	Tuberculosis	25755759	disease by infectious agent	DOID:399	A15-A19	D014376			High serum miR-183 level is associated with the bioactivity of macrophage derived from tuberculosis patients.
circulation_biomarker_prognosis_up	hsa-mir-155	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-155: increased expression
circulation_biomarker_prognosis_up	hsa-mir-184	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-184: increased expression
circulation_biomarker_prognosis_up	hsa-mir-206	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-206: increased expression
circulation_biomarker_prognosis_up	hsa-mir-363	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-363*: increased expression
circulation_biomarker_prognosis_up	hsa-mir-494	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-494: increased expression
circulation_biomarker_prognosis_up	hsa-mir-542	Waldenstrom Macroglobulinemia	19074725			C88.0	D008258	153600	HP:0005508	miR-542-3p: increased expression